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Summary
This thesis describes the use of mathematical modelling in studying the kinetics and
dynamics of the anti-cancer agent topotecan (TPT), a semi-synthetic derivative of the
natural extract camptothecin (CPT), which has been found to act as an inhibitor of the
DNA enzyme topoisomerase I in a specific and reversible fashion. The drug undergoes
reversible hydrolysis from the pharmacologically active parent lactone form (TPTL) to an
inactive hydroxy acid form (TPTH). In the cytoplasm the irreversible inactivation of TPTL
is catalysed by the enzyme aldehyde dehydrogenase (ALDH). Over-expression of the
human breast cancer resistance protein (BCRP/ABCG2) has been linked to high levels of
resistance to the anti-cancer agent TPT by promoting an active efflux pump mechanism.
The expressions of both ALDH and BCRP have been experimentally identified in a large
number of solid tumours and thus play an important role in clinical drug resistance of
cancers. To investigate the catalytic reaction and efflux pump mechanism, a state-space
model for the in vitro uptake kinetics of TPT has been extended to better describe the drug
activity and delivery of TPTL to the DNA target as well as the catalysis by ALDH and the
elimination of drug from the cytoplasm via the efflux pump. All unknown model
parameters were uniquely estimated to a high level of confidence. Model simulations have
been compared with live human breast cancer cells data and found to give good qualitative
agreement. In addition, a cell cycle model has been extended to include the inhibition
effect of the protein p21CIP1/WAF1 on the cell cycle traverse and the kinetic model has then
been linked to the cell cycle model, which facilitates analysis of the response of the growth
of single cells in the presence and absence of TPT. All unknown model parameters were
uniquely determined by the output structure corresponding to the experiment. Parameter
estimation was performed using green fluorescent protein tagged Cyclin B1 data for the
osteosarcoma cell line U-2 OS. The novel coupling of both models allows the study of drug
perturbation to the cell cycle as well as in silico estimation and prediction of the
relationship between the target binding and the dose, also permitting the effects of different
levels of expression of the drug resistance protein and the ALDH enzyme. Such a coupled
kinetic/dynamic model, once fully validated, has the potential for enhancing the design of
optimal dosing regimens.
11 Introduction
1.1 Problem statement and motivation
Drug discovery and development is a time-consuming and expensive process, with very
few novel drug compounds getting approved [1, 2]. The cost of bringing a new drug to the
market is about $1 billion and the overall development process takes an average of 12-15
years [3]. This process has a low success rate, particularly during clinical trials, due to
reasons including lack of understanding of the pharmacokinetic1/pharmacodynamic2 (dose-
response) relationship in addition to unexpected safety events [4-6].
One of the major goals in pharmacology is the quantitative prediction of the response to
drugs (i.e., exploring drug effects). In recent years, predicting and optimising drug
kinetic/dynamic properties along the discovery process (i.e., in vitro) rather than at the
final stages (i.e., in vitro), has become increasingly important. In addition, predictive
modelling tools can provide key information to enhance and speed-up the drug discovery
and development process. Therefore, several in vitro and in silico approaches have been
devised to predict invaluable drug kinetic/dynamic properties [1] and to greatly assist the
decision-making process [7].
In vitro drug kinetics/dynamics modelling establishes a mathematical and theoretical link
between these two processes and helps better understand and predict drug action [8]. This
modelling approach is being incorporated into several drug discovery and development
projects and is having a growing impact [9-11]. Numerous anti-cancer agents require
interaction with DNA or chromatin components of cancer cells to achieve therapeutic
activity [12]. Accordingly, investigation and quantification of drug targeting dynamics can
be greatly informative in the design of therapeutic regimens and in the field of drug
discovery.
1 Pharmacokinetics (PK): the study that characterises the absorption, distribution, metabolism and elimination
(ADME) properties of a drug.
2 Pharmacodynamics (PD): biological and physiological response to an administered drug.
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The ultimate aim of this thesis is to develop a coupled (joint) mathematical model that is
capable of describing the in vitro drug kinetics of the anti-cancer agent topotecan (TPT) for
single live human osteosarcoma cells linked to primary biological responses (i.e., cell
cycle). This coupling has been achieved by extending a previously published model by
Evans et al. [13] for the in vitro uptake kinetics of TPT in order to account for cell
transporters and drug resistance proteins. In addition, a cell cycle model has been extended
from the model developed by Pomerening et al. [14] to include the inhibition effect of the
protein p21CIP1/WAF1 on the cell cycle process. The extended models (i.e., the drug kinetics
model and the cell cycle model) have been linked to demonstrate both the dynamics and
temporal interactions of the pharmacologically active form of the drug to its DNA-
associated molecular target. By linking the models in this way, it is possible to demonstrate
the response of the growth of single human cells in the presence and absence of the anti-
cancer agent TPT.
1.2 Thesis structure
This thesis is divided into seven chapters. Chapter 2 contains the preliminary material on
model development using state-space modelling techniques in addition to the analytical
and numerical methods that will be used in this thesis. The mathematical tools discussed in
Chapter 2 are fundamental in understanding the models, results and concluding remarks in
Chapters 4, 5 and 6.
In Chapter 3 the background biology of the anti-cancer agent TPT, drug resistance
mechanisms and a review of the cell cycle process shall be described to assist in building
the mathematical models (in Chapters 4, 5 and 6) presented in this thesis. The biological
background is not in great detail, however, it should be adequate for the reader to
understand how the models were developed in the subsequent chapters.
The mathematical modelling begins in Chapter 4. The extended drug kinetics model is
presented in this chapter (i.e., Chapter 4). The modelling starts with the basic building
block for the full cell-based model presented in this thesis. That is, the reversible
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hydrolysis of TPT which has been modelled by Evans et al. [15]. The following section in
Chapter 4 describes the extended mathematical model for the in vitro uptake kinetics of
TPT based on the assumptions related to drug resistance mechanisms discussed in Chapter
3. This is followed by structural identifiability analysis and parameter estimation
techniques which are explained in Chapter 2. Parameter estimation in Chapter 4 was
performed using data collected via two-photon laser-scanning microscopy (TPLSM) from
live human breast cancer cells. These data were provided by the biological collaborators at
Cardiff University. Heterogeneity across two different kinds of cells (a high loading cell
and a low loading cell) has been addressed and compared to the average response of cells.
The extended cell cycle model for human cells is presented in Chapter 5. The cell cycle
model described in Chapter 5 is a novel extension of a previously published cell model by
Pomerening et al. [14] (for Xenopus laevis embryos) to describe the response of the growth
of single human cells in the absence of the anti-cancer agent TPT. The novel extension of
this model includes the inhibitory action of a protein involved in the cell cycle, the
p21CIP1/WAF1. This component has been added to the extended cell cycle model, based on
the background biology discussed in Chapter 3. Similar to the mathematical techniques
applied in Chapter 4, structural identifiability analysis of the extended cell cycle model was
performed in addition to parameter estimation. Parameter estimation was performed using
Cyclin B1 (cell cycle regulator) fluorescence data for single human osteosarcoma cells
provided by the biological collaborators at Cardiff. In Chapter 5, the model was compared
to live-cell data in the absence of TPT (i.e., for an untreated cell).
In Chapter 6, both the extended drug kinetics model (presented in Chapter 4) and the
extended cell cycle model (presented in Chapter 4) are coupled by introducing an effect
component (dynamics). This coupling is based on biological assumptions (given in Chapter
3) of the cell cycle perturbations induced by TPT. Before estimating the unknown model
parameters a formal structural identifiability analysis was performed for the full drug
kinetics/cell cycle response model. Similar to the type of data used in Chapter 5, parameter
estimation (in the presence of two treatment regimens of TPT) was performed using live-
cell Cyclin B1 fluorescence data in addition to DNA damage data. The results obtained
from this Chapter were compared to the results from Chapter 5 (i.e., in the absence of
TPT). To investigate how cells respond to the action of TPT.
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To assist in comprehension, each chapter will close with a summary of the key results and
findings in addition to the important features developed in it. In Chapter 7 (the final
chapter) a summary of the main conclusions from the work presented in this thesis will be
outlined. In addition, the chapter will close with possibilities for extending the models in
this thesis as well as avenues for future research.
52 Systems modelling in biology
2.1 Introduction
The importance of the role that Systems Engineers have in biomedical research has
increased considerably in recent years. This thesis describes how relatively
straightforward, but very powerful, mathematical modelling techniques such as state-space
modelling based on compartmental modelling (Section 2.2) can be used to describe
biological processes in order to provide a practical and meaningful outcome. As a result
this also allows further targeted research. The need for highly effective collaboration with
biologists and mathematicians is demonstrated, where real data are generated to validate
the mathematical models, and then predictions from models can be tested in the laboratory
and clinic. This collaboration has blossomed to become a highly important niche,
commonly termed as mathematical biology or for more complex systems, systems biology;
mathematical biology is the application of mathematical modelling techniques to solve
problems in biology and physiology [16]. Systems biology is the field of science that aims
at system-level understanding of biology and exploring the interactions between biological
systems and how these interactions give rise to functional biological properties of these
systems [17].
A mathematical model (or model for short), irrespective of domain or application, is an
abstract description of the behaviour of a system (in a real-world situation) in terms of
mathematical equations [18]. A model of a particular system is constructed based on
scientific (physical) laws that the elements of the system and their inter-connections (inter-
relations) are believed to obey. The model type depends on the objective of the Systems
Engineer (or Biological Modeller) as well as the tools for analysing the system. The tools
that will be used in exploring the kinetic and dynamic models in this thesis are described in
this chapter.
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Building mathematical models involves imagination and skill. The following summary is
an outline of the modelling process [19]:
 Formulating the problem: the nature of the selected model depends on what one
seeks to find as well as the objective of developing it;
 Outlining the model: the parts of the system must be divided into unimportant
(elements that have no effects and can be neglected), exogenous variables (also
called parameters, inputs or independent variables) and endogenous (output or
dependent) variables. In addition, the inter-relations (which constitute the
assumptions of the model) between variables must be specified;
 Verifying usefulness: in this step, it is essential to check the possibility of
obtaining the needed data that are then used in the model to make the expected
predictions. If this is not possible, then the problem and/or the model should be
reformulated.
 Testing the model: at this stage, the model is examined against data or hypotheses.
However, relying on common sense alone is not advisable as it may well be wrong.
If the predictions are not acceptable (with no mathematical errors) then adjustments
should be made to steps one and/or two. If the predictions are less accurate than
expected, then is it important to understand the reason behind that as there might be
implicit or false assumptions.
The rationale behind biological systems modelling is to proceed with the quantitative
understanding of biological functions as well as to improve medical science and practice
by employing quantitative or qualitative knowledge [20]. In modelling biological
processes, the objective is to summarise the available experimental evidence about the key
(functional) characteristics of biological processes by deriving mathematical relations
among variables of biological significance. The resulting mathematical models are
expected to imitate the observed functional behaviour of the biological system.
In an ideal world, such a biological model should be compact (encompass the minimum
computational and mathematical complexity), globally accurate (reproduce precisely the
observed data from experiments under all natural operating conditions) and interpretable
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(be consistent with biological investigation and analysis that advances the underlying
mechanisms assisting the function of the biological process) [20]. Robustness of the
biological model is another important attribute in modelling a system. That is, the
mathematical model should provide stable behaviour against internal and/or external
random perturbations (including noise). Therefore, the modelling approach can possibly be
formed in a stochastic context to account for such perturbations. Developing a global
biological model presumes the ability to measure (observe) the instantaneous activity of
the variables of interest accurately with a high sampling resolution over time intervals.
However, in practice, the modelling process has been subject to restrictions in the ability to
physically access functional characteristics of biological systems. In many engineering and
scientific applications, the examined system can sometimes be studied and analysed
entirely through invasive methods. In biological applications, invasive and non-invasive
techniques can sometimes be employed to gather the required data; however, this is not
always possible or ethical due to the delicate nature of such structures, particularly in
humans. Therefore, one must rely on in vitro and animal studies which can sometimes be
misleading if the physiology with respect to drug kinetics and dynamics is quite different
compared to that in humans [21]. In addition to data acquisition problems, mathematical
models describing biological systems are composed of sets of non-linear ordinary or partial
differential equations which must be solved numerically by using digital computers.
Advanced models that describe biological processes may require extensive computer
services, and hence, the modelling process can be constrained due to the limited
availability of computational (software packages) and analytical methods. This leads to the
development of models that are “less than ideal” in the sense defined above. That is, an
inability to achieve the desired features of global accuracy, compactness and
interpretability.
Once a mathematical model of a biological process has been developed (built), it can be
used in exploring and studying the response to various differing perturbations. One
advantage of mathematical modelling is to infer from the model information relating to
parts of the biological system that are not directly measured. Another advantage for using
such models is the flexibility to perform simulations (using software packages) over
different time intervals, this allows predictions about future (possibly long-term) behaviour
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of the underlying biological system. Therefore, mathematical models can significantly
reduce the resources (i.e., the cost) required to examine complex biological systems. This
can be achieved by re-running the tests or multiple scenarios using powerful computing
facilities, since repeating experiments using real-world facilities would incur considerable
cost. On other occasions, recreating some experiments in the real-world is not possible due
to multiple reasons including danger of recovery that might result from testing a drug on
humans. Accordingly, mathematical modelling of biological processes in vitro to validate
clinical methods is an important prerequisite to moving into further stages in drug trials to
reduce the effects on living organisms to a minimum. Therefore, mathematical modelling
has the potential to maximise the outcomes of biomedical and biological research. The
methodology of mathematical modelling of systems is discussed comprehensively in [18,
19].
The models (Chapters 4-6) described in this thesis are based on underlying biological
assumptions in which biochemical mechanisms are translated into systems of non-linear
ordinary differential equations (ODEs) by the Law of Mass Action which describes the rate
at which chemicals interact in reactions. Consider the following general chemical reaction:
kaA bB zZ P   
where A, B, …, Z are chemical reactants to form a product chemical P, k is a
proportionality constant known as a rate constant of the reaction, and a, b, …, z represent
the number of moles of A, B, …, Z, respectively. The Law of Mass Action states that the
rate of this chemical process is proportional to the product of the activities (or
concentrations) of the reactants [22]. Mathematically, this is described by the following
rate equation:
d [ ] [ ] [ ]
dt
a b zP k A B Z  .
The sum of the exponents, i.e., ( )a b z   , in the rate equation determine the order of
the chemical reaction. That is, the order corresponds to the molecularity3 of the reaction.
Accordingly, the chemical reaction kA P is an example of a first-order (or
3 Molecularity: is the number of molecular entities that simultaneously collide in a chemical reaction.
Chapter 2: Systems modelling in biology 9
unimolecular) reaction, whereas 2 kA P and kA B P  are examples of second-
order (or bimolecular) reactions.
The ODEs are used to analyse the qualitative and quantitative behaviour of the underlying
system to bridge the gap between mechanisms and theoretical biology. Numerical solution
(using software packages) of the ODEs can then be compared with experimental data
(observations) to determine unknown parameters of the models presented in this thesis.
The experimental data used in this thesis have been provided by the project collaborators
(Wales College of Medicine, Cardiff University). The first data set which was used in the
model development and parameter estimation of the drug kinetics model and the coupled
drug kinetics/dynamics model (see Chapters 4 and 6) was collected from an in vitro study
on the interaction of a culture of live human breast cancer cells (MCF-7 cell line) and TPT
using two-photon laser-scanning microscopy (TPLSM). The second data set that was used
in the model development and parameter estimation of the cell cycle model (see Chapter 5)
and the coupled drug kinetics/dynamics model (see Chapter 6) was obtained from in vitro
experiments on the cell cycle response using high-resolution Cyclin B1 fluorescence data
from live human osteosarcoma cells (U-2 OS cell line) in the absence and presence of the
anti-cancer agent TPT, respectively. The third data set that was used in the model
development and parameter estimation of the coupled drug kinetics/dynamics model (see
Chapter 6) was obtained from in vitro experiments (on U-2 OS cells) for the detection of
H2AX phosphorylation foci (using high-content imaging) for determining the action of
TPT that induces DNA damage (i.e., DNA damage data, see Chapter 6). Therefore, given
the data available, the state-space modelling approach (based on compartmental modelling
techniques) was used in this thesis to provide realistic mathematical models that describe
biological processes, i.e., the in vitro kinetics and dynamics of the anti-cancer agent TPT.
State-space modelling techniques are applied extensively in biology using available
computational and analytical mathematical tools to mathematicians and engineers.
Applications extend from cell based (microscopic level) models up to the macroscopic
level. Developed models are applied for predictive purposes, i.e., to assist in analysing and
diagnosing treatment applications. Developing kinetic systems in addition to analysing and
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simulating drug release into the body is essential in studying dynamic effects leading to
drug discovery.
2.2 Compartmental modelling
A compartmental model (Figure 2.1) consists of a finite number of macroscopic
subsystems (subunits) called compartments or pools, each of which is assumed to consist
of homogenous and well-mixed material [23, 24]. The compartments interact by material
flowing from one compartment to another and they can also exchange material with the
environment. The basic law governing the flow into and out of compartments in such
systems is the Law of Mass Balance which states that the matter can neither be created nor
destroyed. That is, if quantity enters the system it either leaves or it accumulates within the
system. The rate of change of quantities of materials within the compartments can be
described by first-order ODEs. The most general form of compartmental equations for a
(linear or nonlinear) system of n compartments is given by the mass balance equation:
0 0
1 1
d
dt
n n
i
i ij ji i
j j
j i j i
x f f f f
 
 
     (2.1)
where xi (i = 1, …, n) is the quantity of material in compartment i, fij is the flow rate to
compartment i from compartment j, and the environment is denoted by the subscript 0. A
compartmental system can be used to model the kinetics of one substance, in which case
the compartments occupy different physical spaces and the inter-compartment transfers
represent the flow of material from one location to another. Moreover, such systems may
also be used to model the kinetics of two or more substances, examples include a drug and
its metabolites in which case different compartments may occupy the same physical space
and some of the inter-compartment transfers represent the chemical transformation from
one substance to another [25]. Compartmental models are applied extensively both in the
physical and life sciences such as biomedicine/biomedical control (tumour targeting),
chemical reaction systems (enzyme chains) in addition to pharmacokinetics and
anaesthesia (drug kinetics).
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State-space modelling falls under two broad headings: the forward problem and the inverse
problem [23]. In the former, i.e. the forward problem, the structure of the system is known,
that is the number of variables, their connectivities and the values of the non-zero transfer
coefficients. Using this information, the behaviour of the system can be examined by
simulating the state-space model. However, in real applications (experimental sciences),
that is not the way state-space systems are generally applied. Therefore, the second
approach, i.e. the inverse problem approach was applied in this thesis. That is, given some
of the behaviour of a real system, infer the structure of the model and estimate the values
of its unknown parameters using data from experiments.
Figure 2.1: Two general compartments of a compartmental system, as described by
Equation (2.1).
In biological/biomedical applications, systems models can be divided into main types
based on the technique employed to construct the model; these models can be models of
data or models of process or a mixture of both [26]. Models of data are chosen to fit
particular data sets without considering the underlying mechanisms (basic processes) at
work, i.e., there are no interpretations for the processes involved in material exchange
between compartments in models of data. Examples of such models are linear and
polynomial regression models of statistics [23]. The second type encompasses models of
process, these models are built from models of the underlying mechanisms (or processes)
at work in a biological system. Non-mechanistic models are less informative than
mechanistic models since it is more difficult to address the issues of enhancement and
optimisation in the former type of models (i.e., models of data). That is, in non-mechanistic
models, there is no clear understanding for the compartments and/or the processes involved
in exchanging material between the compartments. For these reasons, the state-space
i j
to/from other
compartments
to/from other
compartments
fi0
f0i
fj0
f0j
fji
fij
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models (see Chapters 4-6) derived in this thesis are models of processes based on the
biological mechanisms explained in Chapter 3.
2.3 Applications of state-space models in biology
Many of the most common processes arising in biological and biomedical applications are
non-linear and can be described by non-linear state-space models that are relatively
complicated and require numerical simulation studies as analytical solutions are rarely
available (see Section 2.1). Examples include the modelling of metabolic pathways,
transport across membranes, pharmacokinetics and pharmacodynamics [23, 24]. In non-
linear state-space models, the transfer rate coefficients between compartments (from
compartment j to compartment i) can be a function of the amounts in all compartments,
time, and a vector of rate constants k. Therefore, based on Equation (2.1), the rate of
change of the amount in compartment i (xi (i = 1, …, n)) is given by:
0 0
1 1
d ( ( ), , ) ( ) ( ( ), , ) ( ( ), , ) ( ).
dt
x k x k x k
n n
i
i ij j ji i i
j j
j i j i
x f f t t x t f t t f t t x t
 
 
            
  (2.2)
A non-linear state-space model is autonomous if none of the transfer rate coefficients
depend explicitly on time (i.e., of the form fij(x(t), k)), otherwise the state-space model is
non-autonomous (i.e., of the form fij(x(t), k, t)). Moreover, if the rate of transfer of material
from compartment i to any other compartment or the environment depends only on the
amount or concentration of that compartment (xi) and that is true for all i, then the model is
said to be a donor-controlled state-space model [23]. Otherwise, the state-space model is
said to be a donor-acceptor controlled model. The state-space models (see Chapters 4-6)
describing the biological processes (Chapter 3) in this thesis are autonomous, non-linear
state-space models. Moreover, the kinetics and dynamics of TPT in addition to the cell
cycle response involve enzymatic reactions as well as transfers across the cell membrane;
the transfer rates in such processes depend on the concentration of other compartments.
Therefore, the models described in this work are donor-acceptor controlled systems.
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2.3.1 Enzyme kinetics
Enzyme mediated reactions are important biological processes that take place in cells and
can be described mathematically using state-space models. The simplest form of enzymatic
reaction is the irreversible conversion of substrate s into the product p by an enzyme e in a
homogeneous reaction in a well-stirred reaction vessel of fixed volume. The standard form
of an irreversible chemical reaction is given by [27]:
1 2
1
k k
k
s e c p e

   . (2.3)
The substrate (s) combines with the free enzyme (e) to form an intermediate complex (c).
The complex c can break down in two ways: it may release the free enzyme and substrate,
or it may release the free enzyme and product. Let S(t) be the concentration of the
substrate, P(t) be the concentration of the product, C(t) is the concentration of the enzyme-
substrate (intermediate) complex and E(t) is the concentration of the free enzyme. The
concentrations of S(t), P(t), C(t) and E(t) are measured in molar (M). The rate at which the
substrate (s) binds to the enzyme (e) is proportional (with the association rate constant k1)
to the product of substrate and free enzyme E(t). Dissociation of bound substrate
(intermediate complex) occurs at a first-order rate as either substrate (s), with rate constant
k-1 or product (p), with rate constant k2. The rate constants k1, k-1 and k2 have the units of s-1
M-1, s-1 and s-1, respectively. Using Law of Mass Action, the equations for the rate of
change of each concentration are:
1 1
1 1 2
1 1 2
2
d
dt
d ( )
dt
d ( )
dt
d
dt
S k SE k C
E k SE k k C
C k SE k k C
P k C



  
   
  

. (2.4)
The state-space model describing the irreversible enzyme kinetics (in Equation (2.4)) is
non-linear due to the product terms (2nd order terms) in the concentrations. Note that,
d d 0,
dt dt
E C
  (2.5)
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that is, E(t) + C(t) is constant for a closed system. In addition,
d d d 0,
dt dt dt
S C P
   (2.6)
that is, S(t) + P(t) + C(t) is also constant for a closed system. Chemically, the enzyme
appears in two forms, as free enzyme (e) or as the intermediate complex (c). The complex
c plays a double role as far as the conservation of substance is concerned [23]; that of the
substrate (s) in the form of c and that of the enzyme (e) in the form c.
The initial conditions for the model are:
S(0) = S0, E(0) = E0, C(0) = 0 and P(0) = 0. (2.7)
If E0 is the total concentration of available (free) enzyme, therefore, integrating Equation
(2.5) with respect to time t subject to Equation (2.7), the concentration of E(t) is the
difference between E0 and the intermediate complex (bound substrate), that is:
E(t) = E0 - C(t). (2.8)
Taking the rates of change of S(t), C(t) and P(t) in Equation (2.4) and substituting from
Equation (2.8) gives:
1 0 1 1
1 0 1 1 2
2
d ( )
dt
d ( )
dt
d
dt
S k SE k S k C
C k SE k S k k C
P k C


   
   

. (2.9)
Equation (2.9) represents the new state-space model describing the irreversible conversion
of the substrate s to the product p where E(t) has been eliminated to reduce the number of
state variables. This technique has been applied in the extended drug kinetics model (see
Chapter 4) to mathematically describe the irreversible conversion of the active form of the
drug to the inactive form which is catalysed by the enzyme aldehyde dehydrogenase
(ALDH, see Chapter 3).
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2.3.2 Pseudo-steady state approximation
The purpose of this subsection is to derive Michaelis-Menten kinetics [28]. Pseudo-steady
state approximation (PSSA) is a standard approximation that is widely applied to models in
pharmacokinetics, biology and biomedicine. This technique is based on the following
assumptions (using the state-space model of enzyme kinetics in Section 2.3.1 as the
exemplar) [27]: enzyme (e) is present in a relatively small concentration in comparison to
the substrate (s), that is, E(t) << S(t) and/or the binding affinity of the enzyme is much
lower than unity, that is, (k-1 + k2)/k1 << 1. According to these assumptions, the
intermediate compound (enzyme-substrate complex c) reaches an equilibrium state very
rapidly, i.e., d 0
dt
C
 , very shortly after the start of the reaction. Solving for C in Equation
(2.9) results in:
1 0
1 1 2
k SEC
k S k k

 
. (2.10)
Using the relation in Equation (2.10) and substituting in the state-space model for
irreversible enzymatic reactions, Equation (2.9) can be reformulated and simplified to
Michaelis-Menten approximation:
d
dt
d
dt
m
m
m
m
V SS
S k
V SP
S k





(2.11)
where km = (k-1 + k2)/k1 and Vm = k2E0. In Equation (2.11) Vm is the relevant maximum
reaction rate and km is the relevant Michaelis-Menten constant at which the reaction rate is
one-half of Vm [23]. The PSSA presented in this subsection will be used to reduce the
number of unknown parameters in the extended drug kinetics model (see Chapter 4) by
applying Michaelis-Menten Law to the catalytic reaction of the enzyme ALDH (see
Chapters 3 and 4) and to the efflux pumping mechanism via the breast cancer resistance
protein (BCRP)/ABCG2 drug transporter (see Chapters 3 and 4).
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2.3.3 Transport across membranes
The cell membrane (plasma membrane) is a lipid barrier that physically separates the
interior of all cells and the environment (exterior of cells). Due to the lipid nature of the
plasma membrane it is highly impermeable to both charged4 and polar5 solutes, therefore,
this biological membrane is able to regulate what enters and exits the cell. However,
important solutes are either charged (such as amino acids as well as ions) or polar (such as
glucose). There are several types of transport mechanisms across the cell membrane, that
is, cells have developed highly selective mechanisms that facilitate either the entry or exit
of important metabolites, by active transport (against the concentration gradient) by
moving them up free energy gradients [23]. All of the selective mechanisms utilise proteins
that are in the cell membrane which have special binding sites for the transported (solutes)
molecules. Once the solute is bound to the binding site of its transporter (carrier), the
complex can change conformation so that the bound solute can be discharged (released) on
the other side of the membrane. The transporting mechanism (Figure 2.2) that is modelled
in this subsection is a simplified active pumping mechanism for transporting a solute
across a cell membrane. Additionally, in this thesis, it is assumed that the transported
solute is not metabolised in the cell membrane.
Figure 2.2: Schematic of symmetric carrier model for active transport.
The membrane contains a carrier (transporter), c, that can combine with a specific solute
(substrate), s, to form a transporter-substrate complex (intermediate complex) cs. Both, the
4 Charged solute: having an electric charge
5 Polar solute: a solute in which there is some separation of charge in the chemical bonds. Hence, one part of
the molecule has a slight positive charge and the other has a slight negative charge. That is, the solute has a
permanent electric dipole.
IntracellularCell membraneExtracellular
s+c
cs
c
cs
+s
ka
ka
kb
kb
k1
k2
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free transporter, c, and the transporter-substrate complex, cs, exist in two states: one in
which the binding reaction is with the substrate in the intracellular region, the other in
which the transporter dissociates the substrate to the extracellular region. For the
transporter (c) and the transporter-substrate complex (cs), there are transition rates between
the two states (see Figure 2.2). Similar to the approach used by Jacquez [23], it is assumed
that the model in Figure 2.2 is a symmetric active transporter model, i.e., the rate constants
for the transition between the two states for the transporter are equal (denoted by ka) and
rate constants for the transition between the two states of the transporter-substrate complex
are equal (denoted by kb). The intermediate complex (cs) breaks down in one direction to
release the substrate at the extracellular region (see Figure 2.2).
Let S1(t) be the concentration of the substrate in the intracellular region, S2(t) be the
concentration the substrate in the extracellular region, CS(t) is concentration of the
transporter-substrate complex and C(t) is the concentration of the free transporter. The rate
at which the substrate (s) binds to the transporter (c) is proportional (with association rate
constant k1) to the product of substrate and free transporter C(t). Dissociation of bound
substrate (intermediate complex) occurs at a first-order rate as substrate (s) in the
extracellular region, with rate constant k2.
If C0 denotes the total concentration of available transporter (see Subsection 2.3.1), then
the concentration of free transporter is the difference between C0 and the concentration of
the transporter-substrate complex (CS), that is C(t) = C0 – CS(t). If the volumes of the
extracellular region, cell membrane and intracellular region are denoted by Va, Vb and Vc,
respectively, the mathematical model for the active transport mechanism (described in this
subsection) is given by the following system of differential equations given that v1 = Vb/Vc
and v2 = Va/Vb.
1
1 1 0
1 1 0
2
1
2 2
2
d ( )
dt
( )d
dt
d
dt
S k S C CS
k S C CSCS k CS
v
S k CS
v
  

 

. (2.12)
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Assuming that the concentration of the transporter is much lower than the concentration of
associated substrate (i.e., the transporter is saturable), PSSA can be applied to the model
described by Equation (2.12), see Subsection 2.3.2. The transporter (c) is present in a
relatively small concentration in comparison to the substrate (s) in the intracellular region,
that is, CS(t) << S1(t) and/or the binding affinity of the transporter is much lower than
unity, that is, k2/k1 << 1. According to these assumptions, the intermediate compound
(transporter-substrate complex cs) reaches an equilibrium state very rapidly, i.e., d 0
dt
CS
 ,
very shortly after the start of the active transport. Solving for CS in Equation (2.12) results
in:
1 1 0
1 1 2 1
k S CCS
k S k v


. (2.13)
Using the relation in Equation (2.13) and substituting in the state-space model (Equation
(2.12)), the equations for S1 and S2 can be reformulated and simplified to Michaelis-
Menten approximation (see Subsection 2.3.2):
1 11
1 1
12
2 1 1
d
dt
d
dt ( )
m
m
m
m
V S vS
S k v
V SS
v S k v





(2.14)
where km = k2/k1 and Vm = k2C0. In Equation (2.14) Vm is the relevant maximum reaction
rate and km is the relevant Michaelis-Menten constant at which the reaction rate is one-half
of Vm [23]. This technique is applied in the extended drug kinetics model (see Chapter 4) to
mathematically describe active pumping via the drug transporter.
2.3.4 The relationship between response and drug concentration
Wagner [29] proposed that the intensity of a pharmacologic response (i.e. the
pharmacological effect), R (at time t), is related to the concentration of a drug (in the
vicinity of the receptor), C (at time t), by the following Hill equation:
max
n
n
R C
R K C


(2.15)
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where Rmax is the maximum intensity of the pharmacologic response possible; R → Rmax as
C → ∞. K is a constant and the superscript n is a positive constant. A plot of the function R
versus logC produces a sigmoidal shape which is approximately linear over the range
0.2Rmax < R < 0.8Rmax and therefore, the relationship between the intensity of a
pharmacologic response (R(t)) and the drug concentration (C(t)) becomes [24]:
logR m C e  (2.16)
where m and e are constants. The relationship in Equation (2.16) between R(t) and C(t) is
normally suitable over a wide proportion of the therapeutic range. In order to obtain the
response-time curve, Equation (2.16) (or Equation (2.15) if a wide therapeutic range is
covered) is applied to the drug concentration-time curve (C(t)). As the concentration C(t)
becomes closer to a single exponential, the more nearly the intensity of the pharmacologic
response R(t) approximates to a straight line. Hence, for a one-compartment model, R(t) is
a straight line over a large proportion of the therapeutic range (for a single rapid
intravascular drug administration) and approximates a straight line for relatively large
values of t (for extra-vascular drug administration).
Figure 2.3: Two-compartment drug kinetic model with response (effect) compartment (R)
to model the pharmacological response (redrawn from Reference [24]).
Finding the appropriate curve for C(t), in multi-compartment drug kinetics models, is
generally not an easy task. For example, taking an n-compartment model (n > 1) it is often
found that the substitution of either C1(t), …, or Cn(t) (i = 1, …, n) into Equations (2.15) or
(2.16) gives a poor estimation of the pharmacologic response-time curve R(t) [24]. This
1 2
Bolus injection D
kR1
k21
k12
k0R R
k01
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problem has been overcome by two methods: The first method is to extend the drug
kinetics model by introducing a response (effect) compartment denoted by the variable
R(t), as shown in Figure 2.3. The idea of adding a response (drug effect) compartment was
introduced to the field of pharmacokinetics by Sheiner et al. [30] and to the field of
anaesthetics by Hull et al. [31]. The response compartment R has a negligible effect on the
drug kinetics model, that is, the rate constant kR1 is relatively small in comparison to the
other rate constants, namely, k01, k12 and k21, i.e., x1(t) is unchanged [24]. Accordingly, if
compartments 1 and 2 are denoted by the variables x1(t) and x2(t), respectively, then the
rate of change of the quantity in the response compartment is given by (using Equation
(2.1)):
0 1 1
d
dt R R
R k R k x  . (2.17)
In this particular example, the order of the response (effect) compartment has increased by
one (the response compartment is third-order) and, according to Godfrey [24], enables the
dynamic data (response data) to be fitted more closely in comparison to the approach
described in Equations (2.15) and (2.16). The second method is to model the response as a
sum of contributions from the compartments of the drug kinetics model (see the text by
Godfrey [24] and the paper by Whiting and Kelman [32]); this method is not within the
scope of this thesis. Modelling the dynamic effect of the anti-cancer agent on live human
osteosarcoma cells is described in Chapter 6 using the first method in Equation (2.17).
2.4 Identifiability of model parameters
2.4.1 Structural identifiability
The major techniques for the inverse problem (see Section 2.2) involve the determination
of the structure of the underlying model and parameter estimation. An important objective
is to estimate the unknown parameters of the postulated system and often it is difficult to
observe all of the state-space variables (compartments) of the state-space model. In
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possible experiments (especially for biological systems) one is often restricted so that only
a small subset of the system can be observed. When developing a parametric state-space
model of a given physical system, such as drug kinetics, the basic question of whether the
parameters can be identified (uniquely or otherwise) from a specified input-output
experiment (Figure 2.4) arises. The question concerns whether there is enough information
in the observations (measurements) to uniquely determine the unknown parameters of the
system. Structural identifiability analysis (see, for example, [33] and the papers in [34])
can be applied to try to resolve this question in the theoretical situation of perfect, noise-
free and continuous observations. This is a question relating to the structure of the state-
space model, and deals with whether different combinations of parameters give rise to the
same (ideal) measurement data (observations) [35]. Moreover, this problem is independent
of the actual experimental data (measurements) collected. It should be noted that structural
identifiability is an a priori analysis, i.e. it can be performed before obtaining experimental
data (measurements). However, in practice, data are noisy and never perfect and therefore,
it is essential to analyse the effect of errors in experimental data (observations). Hence, the
question of identifiability in such data is known as the numerical or a posteriori problem
(see Section 2.5).
Figure 2.4: Input-output system.
Structural identifiability analysis is an important step in the modelling process and the
output structure has to uniquely determine the unknown parameters in a postulated model
in order to approach the estimation of the unknown model parameters with greater
confidence. If the unknown parameters are unidentifiable by the input-output behaviour,
the proposed experiment should be redesigned (if possible) in order to obtain an output
structure that uniquely determines the unknown parameters (globally or locally). This
would involve changing which functions of the states are observed (the
observations/output structure) and/or changes can also include how input(s) enter the
system (the input structure). In some cases, it is not possible to achieve an identifiable
model after redesigning the input-output structure and that is due to the limitation of the
process being modelled [36]. Therefore, any subsequent estimation of the unknown model
State-space
System
Input Output
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parameters should be viewed with less confidence. The main objective of identification
problems in industry and biosciences is to combine a priori knowledge with experimental
data [33]. Accordingly, a structural identifiability analysis is a prerequisite for experiment
design, system identification and parameter estimation.
To formally define structural identifiability in mathematical terms, it is necessary to
introduce a general class of parametric models for which the state-space models derived in
this thesis are particular examples. Consider a postulated parametric model given by:
0
( , ) ( ( , ), )
(0, ) ( )
( , ) ( ( , ), )
x p f x p p
x p x p
y p h x p p
t t
t t




(2.18)
where p = (p1, …, pq)T is a q-dimensional vector representing the unknown model
parameters and lies in some open subset q  of feasible vectors. The n-dimensional
vector x(t, p) = (x1(t, p), …, xn(t, p))T is the state vector and represents the information
required by the system to evolve in time, where xi(t, p) are the model variables. Solutions
to Equation (2.18) are assumed to lie in M(p) which is the largest connected open subset of
n (i.e., all n components are real numbers) such that x(t, p)M(p) for all t ≥ 0. It is 
assumed that both f(·, p) and h(·, p) are rational functions in both x and p. The vector
y(t, p) = (y1(t, p), …, yr(t, p))T is the response function or the observation function
(functions of the state that are measured in experiments), where y(t, p) .r It is also
assumed that the initial condition x0(p) is a rational function of p.
The inputs in the experiments considered in this thesis consist of a single impulse, i.e.
injection of the anti-cancer drug TPT into the system, therefore, the corresponding
amounts, are included in the initial conditions x0(p). Otherwise, there are no external inputs
to the system and no further input terms are included in Equation (2.18). According to the
proposed experiments (see Chapter 4), r linear combinations of the variables of the model
are measured, ci1(p)x1(t, p) + ··· + cin(p)xn(t, p), (i = 1, …, r). Thus the following equation
represents the output structure of the model for the systems considered in this thesis:
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c c
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(2.19)
Definition 2.1: If a parameter (pi) can take any of a distinct (countable) number of
values for a given observation function, y(t, p), then the parameter (pi) is locally
identifiable (a priori).
Definition 2.2: If the parameter (pi) can only take a unique value (in the entire parameter
space) for the given observation function, then the parameter (pi) is globally/uniquely
identifiable (a priori) for that particular experiment.
Definition 2.3: Otherwise, the parameter (pi) is unidentifiable (a priori).
Definition 2.4: A state-space model of the form in Equations (2.18) is said to be
structurally globally/uniquely identifiable if all the unknown parameters of the model are
globally/uniquely identifiable.
Definition 2.5: A state-space model of the form in Equations (2.18) is said to be
structurally locally identifiable if all the unknown parameters of the model are locally
identifiable and at least one parameter (pi) is not globally identifiable.
Definition 2.6: Otherwise, a model of the form in Equations (2.18) is said to be
unidentifiable if at least one of the unknown parameters (pi) of the model is unidentifiable.
The definitions above are all based on the uncontrolled structure including the form of the
input, the form of the input-output experiments as well as all the information about the
parameter vector (p), others also consider classes of inputs [25]. These definitions apply to
linear and non-linear state-space models in general.
The structural identifiability of the parameters for analysing linear, time-invariant systems
expressed in state-space form is a well-established concept. There are many techniques
discussed in Walter [34], particularly in the tutorial paper published by Godfrey and
DiStefano III [25]. Among the most commonly used structural identifiability techniques
are those based on the uniqueness properties of the Laplace transform (transfer function
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approach) of the output (or outputs) [23, 25] or on the existence of a similarity
transformation [15, 23-25]. In this thesis, the Laplace transform approach will be explained
in detail (see Section 2.4.2). However, for non-linear state-space models, relatively few
techniques are available, the similarity transformation technique [37, 38], differential
algebra techniques [39, 40] and the most commonly used is the Taylor series approach
[41]. The Taylor series approach (see Section 2.4.3), which will be used in this thesis, can
be applied to state-space models where the drug administration is via a bolus injection
(impulsive input) and performed by expanding the output (observations/measurements) as
a Taylor series around time t = 0 [41]. This technique, i.e. Taylor series approach, can
however be computationally intractable [24]. For non-linear models, significant problems
still need to be resolved, for example, a problem that results from the consideration that
global identifiability be sought with respect to a specific input [42] (including bolus
injection input) of drug in pharmacokinetics.
2.4.2 The Laplace transform approach
In this subsection, linear compartmental systems with constant coefficients are studied to
analyse the two-compartment model developed by Evans et al. [15] (see Section 4.2).
Jacquez [23] considers the Laplace transform (or the transfer function) method as the
easiest approach to use. In addition, this technique, is the most readily comprehended
which immediately specifies the observational parameters (parameters that are
incorporated in the observations) as functions of the basic parameters [23]. Bellman and
Åström [33] indicated that for linear compartmental systems, if a model is identifiable
from any input, the system is also identifiable from the impulse response. Accordingly, one
can examine the transfer function for impulsive inputs at t = 0 for a compartmental system
that starts with zero initial conditions (nothing in the compartments).
Consider a linear deterministic system with constant coefficients, zero initial conditions,
and state-space representation of the following vector-matrix form:
( , ) ( ) ( , ) ( ) ( ); (0, ) 0
( , ) ( ) ( , )
x p A p x p B p u x p
y p C p x p
t t t
t t
  


. (2.20)
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The above is a state-space system of n first-order linear ODEs, similarly, p = (p1, …, pq)T
is a constant q-dimensional vector representing the unknown (constant) model parameters
and the n-dimensional vector x(t, p) = (x1(t, p), …, xn(t, p))T is the state vector (n state
variables of the state-space model). The vector u(t) = (u1(t), …, up(t))T is the input (or
control) vector, where u(t) .p The vector y(t, p) = (y1(t, p), …, yr(t, p))T is the vector of
r known output (observations) variables of the model . In Equation (2.20) A(p) is the
matrix of transfer coefficients which includes the structural (basic) parameters of the
model, B(p) is the input matrix and C(p) is the observational matrix. The matrices A(p),
B(p) and C(p) are constants, each consisting of some or all of the unknown parameters and
their dimensions are (n × n), (n × p), and (r × n), respectively.
Parameters can be classified into observational parameters and basic parameters [23, 43,
44]. The observational parameters are determined by the experimental design and are
functions of a basic parameter set [23]. The basic parameter set consists of the kinetic
parameters of the system (system invariants) in addition to other parameters that may also
be introduced by an experiment.
The Laplace transform [18] provides a means of transforming f(t) from the time domain to
the complex-frequency domain. The defining equation for the Laplace transform of f(t),
i.e., F(s), is given by:
0
( ) ( ) stF s f t e dt

 
where the complex variable s is written as:
s = σ + jω.
Taking Laplace transform of Equations (2.20) and rearranging equations for further
analysis of the identifiability properties of linear constant coefficients models gives:
sX(s) = A(p)X(s) + B(p)U(s) (2.21)
and rearranging for X(s) results in:
X(s) = (sI - A(p))-1B(p)U(s). (2.22)
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The Laplace transform of the observation function is:
Y(s) = C(p)(sI - A(p))-1B(p)U(s). (2.23)
Recall that C(p)(sI - A(p))-1B(p) is the transfer function for the model of experiment. If
D(s) = adj(sI - A(p)), where adj(M) is the adjoint of matrix M, then,
1
1
1
( ) ( )( ( )) ,
( ) ...
D DI A p
I A p n n n
s ss
s s s 


  
   
where i , i = 1, …, n are the observational parameters and the transfer function G(s) can
be written as,
1
1
( ) ( ) ( )( ) .
...
C p D B pG n n
n
ss
s s 

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(2.24)
The next step is to examine the observation (output) function given by:
1
1
( ) ( ) ( ) ( )( ) ( ) ( ) .
...
C p D B p U pY G U p n n
n
ss s
s s 
 
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(2.25)
For each of the observation function components (Yi(s)), the numerator is also a
polynomial in s but of degree less than or equal to n – 1. Writing the numerators and
denominators in factored form can possibly result in observation functions (i.e. Y(s)) that
have common factors in numerator and denominator which should be cancelled before
writing Y(s) in the following standard form:
1
1 2
1
1
...( ) .
...
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n
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n n
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(2.26)
The polynomial in the denominator will be of degree n (the coefficient of sn is 1 in the
denominator) and the polynomial in the numerator will be of a lower degree except for the
possibility of cancellation of common factors in numerators and denominators [23]. If
some of the coefficients are not independent, the determinant of the Jacobian matrix
( / , where , 1,... are the basic parameters)i j j j     will be zero. The observational
parameters (the coefficients, which are often called moment invariants) that appear in the
numerator and denominator of Y(s) have a particular structure of interest. That is, each
observational parameter is homogeneous in the basic parameters. The highest degree
coefficient ( )n is of degree n in the basic parameters, in addition, n is non-zero unless
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there is a zero eigenvalue. There may be more than one  of each degree in the numerator
and the denominator except for that of the highest degree n, i.e., there is only one n .
Moreover, the lowest degree coefficients in both, the numerator and denominator are linear
in the basic parameters that appear in them. Therefore, Equations (2.27) represent the set of
equations for the resulting moment invariants (observational parameters) associated with
Equation (2.26)
1
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i
i j
i j
i j k
i j k
 
  
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
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(2.27)
The identifiability properties are established by examining the information available about
the vector of unknown model parameters (p) as well as the expressions in the powers of s
in the numerators and denominators of Y(s). The Laplace transform method presented in
this section will be applied to perform the structural identifiability analysis for the two-
compartment hydrolysis model in Chapter 4.
The model in Figure 2.5 is used to illustrate structural identifiability analysis using the
Laplace transform approach. The following are the state-space equations for that model
with x(0, p) = 0:
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Using Equation (2.23) and rearranging gives:
 
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where Y(s) is the Laplace transform of y(t, p). The coefficients are the observational
parameters. Therefore, determining Y(s) means that the values for all coefficients are
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determined. The equations for the observational parameters in terms of the basic
parameters are:
1 01 12
2 01 12
3 12
a a
a a
bca



 


.
The observational parameters 1 2 3, and   are unique; 1 2and  yield two possible
solutions for a01 and a12. In addition, if the basic parameter b (or c) is known, using 3
yields two possible solutions for c (or b) and hence, the model is structurally locally
identifiable. If both basic parameters b and c are known, from 3 , a12 is determined and
finally from 1 2or  , a01 is determined and therefore, the model is structurally globally
identifiable. If neither b nor c are known, the model is unidentifiable.
Figure 2.5: Two-compartment model to illustrate the Laplace transform approach.
2.4.3 Taylor series expansion of the observations
As mentioned earlier in this chapter, there are relatively few techniques available for
testing the structural identifiability of non-linear state-space models expressed in the form
of Equations (2.18) and (2.19). Deterministic identifiability for non-linear models presents
even more of a problem than it did for linear models. For example, the superposition
property no longer holds nor do relationships such as the step response being the integral
of the impulse response [24]. Therefore, the transfer function (Laplace transform) method
presented in the previous subsection no longer works for non-linear systems. However, the
output structure (observation) is still available and contains all information about the
x1
I = bu(t)
a12
x2
a01
y = cx1
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parameters of the state-space model that is available from the experiment. Thus an
alternative approach of processing the observation is needed. The method that will be used
in this thesis for testing the structural identifiability of non-linear state-space models
(Sections 4.4, 5.4 and 6.4) is the Taylor series approach of Pohjanpalo [41]. This method
has been applied extensively in models and experiments of interest in pharmacokinetics
[45] and pharmacodynamics.
The Taylor series approach is in particular applicable to systems for which the
administration is through bolus injection (impulsive input). An important condition to
perform this test is that the observation must be analytic in a neighbourhood of t = 0, that
is, the observation function y(t, p) is infinitely differentiable with respect to time t on this
neighbourhood [42]. The Taylor series approach involves expanding the components of
y(t, p), the observation function, and its successive derivatives are evaluated in terms of the
model parameters and initial conditions x0(p) as Taylor series around t = 0+. For the system
described in Equations (2.18) and (2.19), the Taylor series approach is used to verify that
the system is structurally globally identifiable. Mathematically, the Taylor series expansion
of the components of the observation function, y(t, p), about t = 0+ is given by:
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The coefficients in the Taylor series expansion are unique (identifiable/measurable)
functions of the basic parameters and therefore are observational parameters (i.e., they
contain information about the unknown model parameters) [23, 42]. That is, uniqueness of
the coefficients in the Taylor series expansions of yi(t, p) entails the following, if p Ω is
such that y(t, p) = y(t, p ) for all t ≥ 0, then, for each i = 1, …, r and k = 1, 2, 3, …
yi(k)(0, p) = ( ) (0, )kiy p where, yi
(0)(0, p) = yi(0, p). (2.28)
In applying the Taylor series approach to non-linear systems there is usually an infinite set
of coefficients, that is, the upper bound on the number of equations required for this set is
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not easily determined. However, a certain number of equations are independent. For linear
systems, by applying the Cayley-Hamilton theorem [46], the upper limit is 2n – 1 (where n
is the dimension of the state space) independent equations in this set. For bilinear state-
space systems the upper bound (maximum number of independent equations) is 22n – 1
[46] and for non-linear systems of homogenous polynomial form the corresponding upper
bound is (q2n – 1)/(q – 1), where q is the degree of the polynomial [47], one selects (as a
minimum) as many non-zero coefficients as there are basic parameters.
In summary, the procedure to apply the Taylor series approach for a general state-space
model, involves the following main stages [42]:
(a) successive differentiation of y(t, p),
(b) evaluation of yi(k)(0, p) for each i = 1, …, r by substitution of parameters already known
from lower derivatives (< k) in addition to yi(0, p) and,
(c) a check on the parameters (from the parameter vector p) that can be identified at each
stage of the differentiation as well as a check on the independence of the algebraic
equations in the successive derivatives.
In this thesis, the Taylor series approach is applied to the kinetic model in Chapter 4, the
cell cycle model in Chapter 5 and the coupled drug kinetics/dynamics model in Chapter 6.
2.5 Parameter estimation
The main concern in the inverse problem is determining the system structure in addition to
estimating the unknown parameters (p) of the system. Estimating the values of the
unknown parameters can also be considered to be part of verifying the structure of a state-
space system. Once it has been ensured that the parameters in a model are identifiable
(globally or locally) with respect to an experiment performed to collect data, one then must
consider the problem of estimating the unknown parameters in the state-space model from
these data. The effects of measurement errors, noise and imperfect data on parameter
estimates have to be considered when performing parameter estimation. Additionally, it
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has to be emphasised that there is no guarantee that globally (uniquely) identifiable
parameters will be accurately estimated with high confidence from experimental data.
Moreover, the precision (accuracy) of the estimated (fitted) values must be considered as a
separate problem with respect to the experimental data.
There are many possible techniques for performing parameter estimation. Examples of
such techniques include graphical methods (which are widely used) for estimating the
components of exponential decay curves. However, graphical techniques work well only
under three main conditions [23]; the underlying state-space model behaves in a linear
fashion (or a linearised system), there are only a few exponential terms and the exponential
decay constants, the eigenvalues (λi), are separated by factors of at least three. In graphical
techniques, the accuracy of parameter estimates depends on the number of compartments
in the model, if there are more than three exponentials (components), the possibility of
obtaining accurate values is low. This method works well if there are no errors in the
observations y(t, p), however, in real applications (i.e. parameter estimation from real
data), there are always experimental errors. Hence, graphically derived parameter estimates
have proven very good initial estimates for more powerful fitting algorithms including
non-linear least squares techniques and direct estimation of basic parameters.
One of the most commonly used parameter estimation techniques for linear and non-linear
state-space models is the direct estimation of basic parameters using software packages.
This is performed by estimating the unknown model parameters directly by integrating the
rate equations to obtain values of the observation function (output) using an initial estimate
of the parameter values and then comparing the calculated values of the observation
function (the output y(t, p)) with the available data (measurements) at the sample points.
Following that is moving in the parameter space in order to optimise the objective
function. For each new set of parameter values, the rate equations have to be integrated, to
generate the observation functions for this set of parameter values.
Parameter estimation in this thesis was performed using the commercial simulation
software package FACSIMILE (MCPA Software, U.K.), which employs the VA05 routine
from the Harwell Subroutine Library (a hybrid method combining features from the
Newton-Raphson, Steepest descent and Levenberg-Marquardt techniques) [48]. This
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software package is designed to numerically solve differential equations (rate equations),
with specific focus on modelling the kinetics of physical and chemical models. A particular
advantage of this computer-modelling tool is the robust (implicit) and reliable numerical
integrator that is able to handle extremely stiff systems efficiently for both small and large
dimensional problems. Stiffness is a property of the models presented in this thesis, that is,
systems with widely varying rate constants, in other words, this problem appears when the
system has some solutions that change very rapidly in comparison to other solutions or
when solutions change very rapidly at some times compared with other times. The
numerical integrator in FACSIMILE can solve all initial-valued ordinary differential
equations within the given model simultaneously (where derivatives are approximated by
differences over a finite time step) and uses the parameter-fitting option available to
determine the unknown parameter values which best fit the simulated output to the
measurements (experimental data). This computer-modelling tool uses a predictor-
corrector method, in which the solution vector at the end of each time step is first predicted
and then corrected using the hybrid method above, to satisfy the differential equations. The
result of this optimisation method is the estimation of the unknown parameters of the
model.
The parameter fitting is treated as an optimisation problem in which the set of unknown
model parameters that minimises a weighted least-squares performance index is sought.
That is, the performance of the optimisation process involves minimising the closeness of
fit. This closeness (a measure of how well the calculated value fits the experimental data)
is measured by the total weighted residual sum of squares (RSS), that is, the sum of the
squared errors between a calculated value (model) and its corresponding data (observed)
value divided by the standard error (error estimate for the data value) [49]. The parameter-
fitting procedure involves a series of runs of the numerical integration process for the
differential equations. The first run is conducted using the declared initial estimates for all
unknown model parameters and then each unknown parameter is varied in turn (iteratively)
and a statistical analysis is carried out to determine how well the calculated solution fits the
observation data (experimental results). Simulations are carried out to vary the parameters
until a set of unknown parameter values is estimated which gives a calculated solution that
is qualitatively and quantitatively close to the experimental results. The integration process
terminates when the highest value of the independent variable (in this case time t) has been
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reached and when the fitting procedure has been completed, further simulation runs of the
integration process are carried out to perform statistical analysis of the fitted parameters. In
FACSIMILE the RSS is given by:
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where Ni is the number of actual observations used for the data curves i = 1, …, r; yi(tj) is
the ith output of the model at the jth sampling time (tj); and the corresponding experimental
data point is denoted by di(j) for each set of experimental data points (data curves). The
estimated standard error associated with the data series di = (di(1),…, di(Ni)) is denoted by
σi [49]. The standard error of the output (σi) in FACSIMILE is equal to the product of e
(estimate of the overall accuracy of the data) and Ri (range for the experimental data
points) for each data curve, i.e., σi = eRi. This approach is referred to as the weighted least-
squares criterion since the random error at each sampling time (tj) is multiplied by a
constant weight ( 21/ i ). This results in normalised residuals if the standard error of the
output (σi) can be chosen to be the standard deviation (SD) for the random errors.
FACSIMILE estimates a range within which the RSS should fall (given that the number of
data points is known), assuming that the model is accurate and the residual values are due
to random errors in the experiment. If the final RSS is significantly smaller than the
estimated (expected) range, then the fit is unpredictably good and therefore, the
experimental errors might have been over-estimated. If the final RSS is remarkably greater
than the estimated range, then the errors in the data might have been under-estimated or the
model does not fit the experimental data very well (i.e., the fit is not close).
FACSIMILE performs other statistical tests to measure the quality of the fits including a
correlation index for the residuals (CORI). This value for each data curve (i = 1, …, r) is
given by [49, 50]:
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If a good fit has been obtained, then the data values should be evenly distributed above and
below the calculated values, i.e., the residuals are as likely to be positive as negative. If
that is true, then │CORIi│ ≈ 1, otherwise, if the magnitude of CORIi is far greater than 1.0
(i.e., │CORIi│ >> 1) the residuals of the fit for data curve i are one-sided. Another
statistical value that is calculated by FACSIMILE is the mean absolute correlation index
(CORImean) which is given by:
mean
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1CORI CORI
r
i
ir 
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The method that FACSIMILE uses in estimating parameters involves the natural logarithms
of the model parameters. During the fitting procedure, a statistical analysis is performed to
detect parameters that are not well-determined (NWD) by the data. Once detected, NWD
parameters are treated as unknowns in subsequent tests. The default standard deviation of
the natural logarithm (SDLN) of each of the remaining fitted parameters, P0, is estimated
from the variance-covariance matrix of P - P0 [13]. The 5% and 95% confidence limits are
estimated for each of the well-determined parameters, assuming a normal distribution for
the natural logarithms of these parameters. The confidence limits are calculated using the
SDLN value for each fitted parameter which are values such that the probability of the true
parameter being smaller is 5% and 95% respectively [50]. If the 5% and 95% confidence
limits for a particular parameter are reasonably close, this indicates that this parameter is
well-determined. In addition, if the sampling errors are normally distributed, the weighted
least-squares parameter estimate P0 is a maximum-likelihood estimate. Properties of
maximum-likelihood estimators are discussed in [51], they are often unbiased, and if they
are unbiased, maximum-likelihood estimators have minimum variance in comparison to all
unbiased estimators [23]. However, if they are not unbiased, they become asymptotically
unbiased as the size of the sample increases. FACSIMILE also calculates the components of
the correlation matrix to show how the fitted parameters are related to each other.
Normal probability plots are used to test whether the weighted residuals (the weighted
errors between the data points and the simulated output of the model), are normally
distributed with standard deviation of 1 and zero mean [52]. To do this, the residuals are
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listed in an ascending numerical order R1 < R2 <  < RN×r (the smallest value is numbered 1
and the largest is numbered N×r), and
zm = (m – 0.5)/(N×r) (2.32)
where (m = 1, …, N×r), N is the number of sample points in each data curve and r is the
number of data curves in each parameter-fitting process. Next, data tables for the normal
distribution are used to obtain a Zm value from the standard normal distribution
corresponding to the cumulative probability (zm) given in the previous step. Finally, the
resulting graph from the Zm values plotted against the ordered residuals Rm (horizontal
direction) is the normal probability plot. If the residuals are normally distributed then the
normal probability plot should be linear.
2.6 Summary
State-space modelling provides a framework under which drug kinetic and dynamic
models can be described and analysed. This chapter provides the mathematical tools and
techniques that will be used in the entire thesis for model development, model
identification and parameter estimation. Structural identifiability analysis was performed in
this thesis to estimate unknown model parameters with greater confidence. In addition, for
each of the models described in this thesis, structural identifiability analysis was performed
using MATHEMATICA, with the exception of the TPT hydrolysis model. In all models
presented in this thesis, parameter estimation was performed using the software tool
FACSIMILE.
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3 Background biology and literature review
3.1 The anti-cancer agent topotecan
3.1.1 Introduction
Camptothecin (CPT), an ethanolic extract of the Chinese plant Camptotheca acuminata
(Decaisne, Nyssaceae) [53, 54], which is also known as the Xi Shu tree, has revealed a
noticeable anti-neoplastic activity, i.e., it inhibits or prevents the growth or development of
malignant cells [55]. The anti-tumour action of CPT was established using experimental
models during research conducted by the National Cancer Institute during a cytotoxic drug
screening [56]. During clinical trials, CPT was tested in the form of water soluble
carboxylate due to its limited solubility in water, in addition, undesirable side effects
including myelosuppression (decrease in the activity of bone marrow) and hemorrhagic
cystitis (infection of the bladder) have appeared during the trials [57]. However, the
nuclear enzyme DNA topoisomerase I (Section 3.1.2) was discovered as the main CPT
molecular target [58-62]. This finding re-initiated further development of CPT and its
analogues as anti-cancer drugs [63-66]. Improved versions of the drug were developed
using structure-activity data on CPT. Examples include topotecan (TPT), a water-soluble
derivative [53, 54, 67], which has been clinically approved for use as a second-line therapy
for small lung and advanced ovarian cancers [15, 68-70]. In addition, TPT has shown
promising activity against haematological malignancies [67].
3.1.2 DNA topoisomerase I enzyme
A number of topological problems arise as a result of the intertwining of the two strands of
the DNA helix [71]. Therefore, the cell must overcome such obstacles for it to be able to
re-generate, re-combine and express its genetic information [72-74]. Topoisomerase I (or
type I) is one of the two ubiquitous nuclear enzymes that modulate the topological
Chapter 3: Background biology and literature review 37
structure of DNA in eukaryotic cells; in effect, it interconverts different topological forms
of DNA [71]. This enzyme has essential roles in cellular functions including chromatin
organisation [75], DNA replication [76-79], recombination [80-82], mitosis [83] and
transcription [78, 84-88]. In some types of tumours, the topoisomerase I enzyme is
produced in excess when compared with corresponding non-malignant cells [70]. As
mentioned in the previous section, topoisomerase I (Figure 3.1) is linked to the treatment
of human cancers; type I is a primary cellular target for several types of anti-cancer drugs
including CPT and its analogues.
Figure 3.1: Human DNA topoisomerase I cDNA. The amino acid residues listed represent
sites of mutation that can lead to CPT resistance (redrawn from Reference [53]).
Figure 3.2: Super-coiled DNA and its relaxation by mammalian DNA topoisomerase I
(redrawn from Reference [53]).
Excessive DNA supercoiling resulting from replication and transcription is removed by a
relaxation reaction (Figure 3.2) of both positively charged and negatively charged
supercoils [79, 89]. This function is catalysed by the topoisomerase I enzyme [53]. The
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eukaryotic type I enzyme triggers a transient single-stranded nick in the nucleic acid
backbone and passes the other DNA strand through the nick, and reseals the original
scission [54, 72-74].
Figure 3.3: The topoisomerisation reaction during the cell cycle in the absence of TPT (redrawn
from Reference [54]).
The schematic diagram in Figure 3.3 represents the reaction of the topoisomerase I enzyme
with a DNA oligonucleotide. The catalytic cycle, which is also known as
topoisomerisation, begins with the binding of the type I enzyme to the double-stranded
DNA (dsDNA) resulting in a covalent 3’-phosphorotyrosyl adduct known as the cleavable
complex [54]. As a result, the separated ends of the single-strand breaks are kept in
proximity while the other DNA strand is passed through the break [90]. At this instant, the
reaction is mainly controlled by the complementarity of the charge and surface of both
species, i.e., the enzyme and the dsDNA. The shape adaptation of both partners results in
the so-called kissing complex by which the tyrosine hydroxyl (OH) group at site Y723 [64]
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on the human topoisomerase I enzyme is brought into a favourable position for attacking
the phosphate group of the phosphodiester linkage forming an enzyme-linked single-strand
DNA break (covalent adduct) [91]. The bite of the enzyme topoisomerase I stimulates
swivelling (the release of torsional stress in supercoiled DNA) in a process known as
controlled rotation [92]. Next, the rejoining process begins by the 5’ hydroxyl group
attacking the tyrosol phosphate bond. As a result, the tyrosine residue is released from the
phosphate and the single-strand break is re-ligated and the topoisomerase I enzyme
dissociates from DNA, thus restoring the discontinuity of the DNA backbone and leaving
the active site tyrosine ready for a later kiss and bite catalytic cycle. Single-strand breaks
catalysed by topoisomerase I are barely detectable and are not lethal to cells since they can
be well repaired.
3.1.3 TPT mechanism of action
CPT analogues including, but not limited to, TPT (Hycamtin®, GlaxoSmithKline)
represent a new class of anti-cancer drugs that have been approved clinically for battling
human cancers. These analogues have better water solubility and lower toxicities. In this
project, the kinetics and dynamics of TPT will be discussed and studied. TPT has
demonstrated clinical activity in human malignancies and it is one of the most widely used
CPT analogues [69]. In addition, clinical trials are in progress to define its use in
combination with other chemotherapeutic agents. Moreover, experiments are ongoing to
better mark and describe its spectrum of clinical activity as well as to determine its optimal
schedules of administration.
All CPT active analogues (including the active form of TPT) contain the chemically
unstable lactone ring. Additionally, CPT analogues with more chemically stable rings are
inactive (this includes the inactive form of TPT) [68]. Several studies have indicated that
the administration of the closed ring lactone is essential for both topoisomerase I inhibition
and maximal anti-tumour activity [93-96]. In aqueous media, the ring-closed (Figure
3.4(a)), parent lactone form (TPTL) is chemically unstable at physiological pH and
undergoes reversible hydrolysis to an open-ring hydroxy acid (hydroxyl carboxylate,
Figure 3.4(b)) form (TPTH), as shown in Figure 3.4, which is devoid of topoisomerase I
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inhibitory activity [15, 97]. This conversion is pH-dependent, and under a high-acidic
medium pH (≤4) the parent lactone structure predominates, whereas the hydroxy acid form 
is exclusively present in a high-basic medium pH (≥10) [98-100]. The pH has an effect on 
both, the lactone-to-carboxylate ratio at equilibrium as well as the conversion rate between
TPTL and TPTH [98]. The study conducted by Yao et al. [101] has shown that a pH of 6.28
(at 25°C) resulted in an approximate 50:50 mixture of the two TPT species (TPTL and
TPTH) and this agrees with the results obtained by Underberg et al. [98]. In addition, the
rate of interconversion is increased with temperature rise without affecting the equilibrium
itself in vitro and in vivo. In the latter, the equilibrium also depends on the binding process
to albumin [102]. The reversible hydrolysis of TPT has been modelled by Evans et al. [15]
(see Section 4.2) and forms the basic building block of the extended drug kinetics model
presented in this thesis (see Chapter 4).
(a) (b)
Figure 3.4: Chemical structures of TPT (a) TPTL and (b) TPTH undergoing pH-dependent
reversible hydrolysis (taken from Reference [103]).
The two forms of the anti-cancer drug TPT, i.e. TPTL (lactone form) and TPTH (hydroxy
acid form), are two completely different chemical entities with significant differences in
their physical properties. Therefore, they have different molecular interaction behaviours
with target macromolecules including DNA, topoisomerase I and the topoisomerase I-
DNA complex [101].
TPTL is the pharmacologically active form of the drug that acts as a specific and reversible
inhibitor of topoisomerase I [59, 96]. According to experiments, the lactone form (TPTL) is
much more cytotoxic than the carboxylate form (TPTH) and the parent form also appears to
be an important structural pre-requisite for passive diffusion of the anti-cancer agent into
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malignant cells [104]. Therefore, it is essential for anti-tumour activity [93, 94, 96, 105].
The active form of the drug (TPTL) targets the nuclear DNA-relaxing enzyme,
topoisomerase I, and converts it into a cell poison by inhibiting the breakage-rejoining
reaction of the enzyme. TPTL covalently binds to DNA-topoisomerase I enzyme cleavable
complex and stabilises it, specifically in the DNA re-joining (re-sealing) step of the
reaction causing a delay (or blocking the re-joining step) [60, 106]. This results in
accumulation of a reversible intermediate complex consisting of topoisomerase
I + TPTL + DNA as a ternary complex (cleavable complex, see Figure 3.5) [53]. The drug-
induced single strand breaks are reversible upon drug removal. Such lesions are non-
poisonous (non-toxic) as they can be reversed (repaired) [107]. TPTL arrests the replication
fork by stabilising the DNA-enzyme complex, and hence, causing double-strand breaks
and terminating RNA-synthesis [108], this damage is responsible for the primary cytotoxic
effects of TPT. The extent of DNA cleavage is reduced or increased depending on the
point of the reaction cycle at which the anti-cancer drug TPT will act, whether it is before
or after the bite.
It has been suggested that TPTL only binds to the topoisomerase I-DNA complex and not
to DNA alone nor to the topoisomerase I enzyme by itself as described by Chappell et al.
[107]. However, the data published by Yang et al. [109] show that the active form of TPT
is stabilised through direct interactions with dsDNA. In addition, the presence of dsDNA
was found to promote the conversion of TPTH to TPTL (within the cell nucleus) in the
absence of topoisomerase I enzyme. This suggests that TPT, upon reaching chromosomal
DNA, may interact directly with DNA prior to the action of the topoisomerase I enzyme
even if the drug binding site on DNA is not necessarily at the site of the enzyme’s
(topoisomerase I) action [109]. In the study published by Yao et al. [101] it was observed,
for the first time, that only TPTL binds directly and non-covalently to both dsDNA and
single-stranded DNA (ssDNA) structures in the absence of the topoisomerase I enzyme.
Binding to dsDNA and ssDNA is selective. Additionally, it has been demonstrated that
TPTL exhibits specificity for dT-containing sequences in dsDNA and exhibits a
characteristic binding pattern to ssDNA polymers [101].
Some malignant tissues contain higher topoisomerase I levels of expression than their
normal counterparts [110, 111]. In addition, different tumour types have different
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expression levels of the enzyme, for example, higher expression of topoisomerase I has
been detected in colon and cervical cancers than in lung and breast tumours [112]. The
level of topoisomerase I is relatively constant in between the cell cycle phases [108].
Moreover, the level of type I enzyme is regulated at transcriptional, translational and post-
translational levels [113, 114]. However, this requirement for replication fork movement to
produce cytotoxicity implies that TPT is a cell cycle specific drug for killing cells in
synthesis (S) phase and causing extensive chromosomal disruptions and chromatid
exchanges [108, 115, 116]. This property has significant implications for the clinical use of
this anti-cancer agent, because optimal therapeutic efficacy of S phase-specific cytotoxic
drugs (including TPT) requires protracted exposure of the tumour to drug concentrations
exceeding a minimum threshold [67]. In fact, studies involving in vitro and in vivo
experiments suggest that for efficacy (anti-tumour activity or cytotoxicity), prolonged
administration of the anti-cancer drug TPT is of greater significance than short-term
exposure to high concentration [117].
Figure 3.5: The topoisomerisation reaction during the cell cycle in the presence of TPT (redrawn
from Reference [54]).
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3.2 Drug resistance mechanisms
3.2.1 The BCRP/ABCG2 drug efflux pump
One of the major forms of cancer treatment is chemotherapy. In general, cancers are either
resistant to chemotherapy or obtain resistance during treatment, thereby leading to
ineffective chemotherapy [118]. Several resistance mechanisms to topoisomerase I-
targeted anti-cancer agents have been characterised in vitro, however, their significance in
the clinical setting has not been fully identified until now. These mechanisms involve pre-
target events such as drug accumulation, metabolism, intracellular drug distribution, or
drug-target interactions [67]. Post-target events, including DNA synthesis or repair, cell
cycle progression as well as cell death regulation, have also been demonstrated to play a
significant role in the sensitivity to these drugs [67].
Numerous mechanisms have been described in cancer cells able to reduce accumulation of
cytotoxic drugs by up-regulating cell membrane located adenosine triphosphate (ATP)-
dependent efflux pumps [119]. Examples of drugs to which resistance has been observed
or for which resistance is acquired during treatment include topoisomerase inhibitors (e.g.,
TPT), anthracyclines (e.g., doxorubicin), the Vinca alkaloids (e.g., vincristine) and the
taxanes (e.g., paclitaxel) [118]. The model in this thesis assumes that a resistance to TPT is
a result of the over-expression of efflux transport proteins in the plasma membrane of
cancer cells. Examples of such mechanisms include the two transmembrane xenobiotic
transporter proteins, P-glycoprotein (P-gp) which has been reported in hamster ovarian
cells [120, 121], and the multidrug resistance protein 1 (MRP1) [122]. More recently, other
human ATP-binding cassette (ABC) transporters that are involved in the resistance of anti-
cancer drugs have been discovered. The most important of these, a novel protein, is the
breast cancer resistance protein (BCRP) [123] also known as the placenta-specific ABC
protein (ABCP) [124] or mitoxantrone-resistance protein (MXR) [125].
Following immunoblotting analysis with BCRP-specific antibodies, it has been suggested
that BCRP is a 72 kDa membrane protein [126, 127]. It has been shown from various
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studies on drug efflux mechanisms that BCRP is mostly localised at the plasma membrane
of the drug-resistant cells over-expressing the transporter instead of at internal vesicular
membranes [123, 128, 129]. Therefore, BCRP is presumably involved in active transport
from the cell rather than in transport into internal vesicles. Following experimental studies
by Maliepaard et al. [130] and Ishii et al. [131] it has been observed that TPT
accumulation in resistant cell lines was reduced by enhanced drug efflux. The actual efflux
pumping mechanism is explained in detail in Chapter 4. Transfection studies conducted in
various laboratories have verified that enforced expression of BCRP complementary DNA
(cDNA) in different types of cells caused resistance to multiple anti-cancer drugs and
reduced drug accumulation in the cell [128, 129, 132]. Such experiments provide strong
evidence that BCRP is a main cause of drug resistance in tissue culture models for certain
types of chemotherapeutic drugs including TPT. This protein is significantly expressed in
organs central for absorption (the small intestine), distribution (the placenta and blood-
brain barrier), and elimination (the liver and small intestine) [118]. Further investigations
have come to the conclusion that BCRP plays a significant role in drug disposition.
The ABC transporter is the largest protein superfamily identified to date [133]. ABC
transporters are widely spread in all organisms (including mammals and bacteria) and are
responsible for transporting a wide range of compounds across the plasma membranes
against concentration gradient (active pumping mechanism) with ATP hydrolysis as the
source of energy for the process of substrate translocation. ABC transporters are involved
in multiple physiological processes. Examples of this include, transporting drug
(xenobiotics) or drug conjugates in addition to the excretion of endogenous metabolites or
physiological substrates [134]. A number of human genetic diseases have been found to be
associated with defects in ABC transporter genes such as CFTR in cystic fibrosis [135],
MRP2 in Dubin-Johnson syndrome [136] and ABCR in Stargardt disease [137]. Typically,
the structure (Figure 3.6) of the majority of mammalian ABC transporters contains two
types of structural domains (homologous halves) each containing two parts as follows: the
hydrophilic intracellular nucleotide binding domain (NBD) and the hydrophobic
membrane spanning domain (MSD) which is putatively arranged into six α-helices [118, 
138]. P-gp is arranged in two tandem repeated halves of two domains: one hydrophobic
MSD followed by one hydrophilic NBD [120, 134]. The two repeated halves are connected
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by a polypeptide linker sequence. The great majority of ABC transporters have such a 4-
domain structural organisation.
Figure 3.6: A membrane topology model of BCRP. BCRP contains one NBD followed by
one MSD with six predicted transmembrane α-helices. Two or three putative N-
glycosylation sites (N418, N557, or N596) are predicted to be in the extracellular loops as
indicated (taken from Reference [118]).
BCRP belongs to the sub-family G of the large ABC transporter superfamily. BCRP, also
known as ABCG2, is the second member of the sub-family G of the human ABC
transporter. This transporter has been described in drug-resistant ovary, breast, colon,
gastric cancer in addition to fibrosarcoma cell lines [123-125, 130, 139]. Moreover, BCRP
has only one ATP-binding cassette and six putative transmembrane domains, suggesting
that BCRP is a half-transporter, which may work as a homodimer or heterodimer [140,
141], unlike P-gp and MRP1 which are arranged in two repeated halves. Another unique
feature is the configuration of the (BCRP/ABCG2) protein in which the NBD is followed
by the MSD as illustrated in Figure 3.6, whereas P-gp and MRP1 have an opposite domain
arrangement, in that the MSD precedes the NBD. Therefore, this unique domain
organisation implies that the transport mechanism of ABCG proteins (including
BCRP/ABCG2) may be different from those of other ABC transporters.
CPT derivatives are the second most important class of anti-cancer agents that are
transported by the (BCRP/ABCG2) transporter [118]. A wide range of BCRP-over-
expressing cell lines reveal resistance to CPT derivatives including TPT [131, 142]. The
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study carried out by Rabindran et al. [143] demonstrates that MCF-7 cells transfected with
BCRP cDNA display significant resistance to TPT in comparison to the vector control
cells, this is additional evidence that CPT derivatives (including TPT) are BCRP
substrates. In a study published by Rajendra et al. [144], it has been reported that the
important factors for substrate recognition (i.e. effective efflux pumping) are the
hydrophilic groups in the chemical structure of CPT. It has been shown by Yoshikawa et
al. [145] that BCRP prefers to transport CPT derivatives with high polarity over the low
polarity CPT analogues [118]. Accordingly, polarity is also essential for recognition of the
CPT analogues by BCRP. All such information is essential in designing clinically useful
CPT analogues that are not transported by BCRP/ABCG2. Based on the advice of the
project collaborators at Cardiff University and according to these observations, it is
assumed that in the drug kinetics model (see Chapter 4) the BCRP/ABCG2 transporter
carries TPTH (high polarity) from the cytoplasm through the cell membrane to the
extracellular region irreversibly.
3.2.2 The enzyme ALDH
Aldehyde dehydrogenases (ALDHs) [aldehyde: NAD(P)+ oxidoreductase] are an enzyme
group that catalyse the conversion of aldehydes to the corresponding acids irreversibly by
means of an NAD(P)+-dependent reaction [146]. ALDHs are distinguished based on
properties including physicochemical characteristics, enzymological, subcellular
localisation and tissue distribution [147]. ALDH enzymes demonstrate high activity in
oxidising aldophosphamide and detoxifying anti-cancer agents. It has been proven that this
drug resistance was associated with the transcriptional activation of ALDH expression in
cancer cells [148].
ALDH isozymes6 (or isoenzymes) including ALDH1A1, are important for multiple
biological activities including drug resistance [149, 150]. It has been demonstrated by the
project collaborators at Cardiff University that the uptake of TPT in cells exposed to an
ALDH inhibitor (disulfiram) is enhanced (unpublished; data not shown). Moreover, kinetic
6 Isozymes: are enzymes that vary in the amino acid sequence but catalyse the same chemical reaction.
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analysis of TPT uptake also suggests that the change in charge upon ring hydrolysis would
favour exclusion via the ABCG2 pump, and this is the overriding process to remove TPT
from the cellular environment [151]. Therefore based on these studies, the active drug
(TPTL) in the cytoplasm is assumed to bind irreversibly to the enzyme ALDH (in the
extended drug kinetics model) where it is converted to the form favoured by the efflux
pump (TPTH).
3.2.3 Fluorescence spectral properties of TPT
TPT is a naturally fluorescent agent which can be excited using ultra-violet wavelengths
(350-430 nm) [100] and detected at a visible wavelength with peak emission at 540 nm.
This property of TPT has been exploited to study the interaction of this anti-cancer drug
with biological macromolecules and most importantly to evaluate drug resistance in
differentially derived cell lines using confocal microscopy [152]. This approach is
commonly used to compute the amount of drug in human plasma and cellular extracts [15]
using HPLC [103]. The binding characteristics of drug to DNA have been determined
using the high two-photon absorption property (demonstrated by TPT) during spectroscopy
studies [100].
Figure 3.7: The fluorescence intensity of TPT in live human breast cancer cells (MCF-7 cell
line) plotted against the concentrations of TPTL and TPTH (taken from Reference [48]).
Chapter 3: Background biology and literature review 48
The anti-cancer drug TPT is also infrared two-photon excitable; the basic principle of two-
photon excitation of fluorescence is that two photons of longer wavelength light are
absorbed (simultaneously) by a fluorochrome (a chemical entity that exhibits fluorescence)
that would generally be excited by a single photon with a shorter wavelength. Accordingly,
the excitation of fluorochrome is limited to the focus point by the non-linear optical
absorption property of two-photon excitation. Advantages of such a method (i.e., non-
linear excitation) include the following: images obtained have relatively high contrast and
are free of out-of-focus light. In addition, this technique is beneficial to live cell imaging
since the light is restricted to the focal plane. Accordingly, this decreases the photo-
damage to the cells as well as photo-bleaching of the indicator. This method is however not
capable of differentiating between both forms of the drug, i.e. TPTL (active form) and
TPTH (inactive form) as demonstrated in Figure 3.7. In the experiments conducted at
Cardiff, delivery and localisation of the drug in single MCF-7 cells (live human breast
cancer cells) are examined using TPLSM (see Subsection 4.5.1).
3.3 The cell cycle
3.3.1 Introduction
Recent studies have examined tumours and tumour cell lines for the presence of mutations
in the genes encoding cell cycle-related regulatory proteins [153]. The results of these
studies demonstrate that mutations in the cell cycle genes are the most common genetic
alterations in cancer cells [154]. Therefore, the cell cycle has been studied extensively in
cancer research (oncology). This research has led to techniques useful for determining the
effects (pharmacodynamics) of anti-cancer drugs on the cell cycle progression. Hence, the
cell cycle response (by mathematically modelling the dynamics of anti-cancer drugs)
should be considered in the design of chemotherapeutics. In this thesis, a model describing
the response of the growth of single human cells in the absence (see Chapter 5) and
presence (see Chapter 6) of the anti-cancer agent TPT is presented.
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The cell cycle is probably the most essential process that occurs in eukaryotic cells [155].
It is a ubiquitous, complicated process engaged in proliferation and growth of cells. The
cell cycle is also involved in organism development, regulation of DNA damage repair,
tissue hyperplasia (hypergenesis) as response to chronic inflammations and injuries [156].
In addition, this process is associated in life-threatening diseases such as cancer.
Figure 3.8: Schematic of the cell cycle showing the main phases and the Start and Finish
transitions (redrawn from Reference [107]).
The cell cycle (cell division cycle) is the series of events by which a growing cell replicates
all its essential constituents (components) and divides into two daughter cells. Each of the
two distinct cells contains adequate machinery and information to repeat the process [157].
The most important components are the chromosomes of the cell which contain linear
DNA molecules associated with proteins. Each DNA molecule must be precisely
duplicated and the two copies accurately partitioned to the two daughter cells at division
[158]. In mammalian somatic cells, these processes occur in temporally distinct phases as
shown in Figure 3.8. The cell cycle comprises four stages (phases) referred to as G1 (Gap
1), S (Synthesis), G2 (Gap 2) and M (Mitotic) phases. The two milestones in this process
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are DNA synthesis and mitosis (which also make up the chromosome cycle of the cell),
and the gaps (G1 and G2) of the cycle occur between these two landmarks.
In G1 stage, the chromosomes are unreplicated and the cell is not committed to division,
moreover, cells in this phase start preparing for DNA synthesis. During transition to S
phase, the cell commits to replication if the integrity of DNA is not compromised; that is,
the cell undergoing the cycle confirms that the internal and external conditions are suitable
for a new round of DNA synthesis. In S phase, the cell starts synthesising DNA and
therefore, it includes aneuploid (between 2N and 4N) DNA content. The two identical
DNA molecules are referred to as sister chromatids. This is followed by the G2 stage
during which the cell prepares for the mitotic process (M phase) where the chromosomal
material is prepared by the surveillance of its integrity before committing to mitosis. For
example, in the G2 phase, the cell checks that the DNA synthesis and repair are complete
before committing to the M phase. Additionally, persistence of double strand breaks that
might be caused by an anti-cancer drug (see Section 3.1) are sensed at the cell cycle
checkpoints.
(a) (b) (c) (d) (e)
Figure 3.9: The four stages of the M phase. (a) Prophase, (b)
metaphase, (c) anaphase (d) telophase followed by (e)
cytokinesis (taken from Reference [159]).
The mitotic (M) phase in the cell cycle includes mitosis and cytokinesis (the true division
of cells into two identical daughter cells). The M phase can be subdivided into four stages:
prophase, metaphase, anaphase and telophase, which are followed by cytokinesis [159,
160]. The mitotic process [161] as shown in Figure 3.9, begins with prophase; during this
stage, the nucleoli gradually disappear and chromatin (the chromosomal material) begins to
coil into dense, recognisable chromosomes. Each replicated chromosome consists of two
chromatids, which both carry identical genetic information. Also during this phase (in
some texts it is referred to as prometaphase), the nuclear membrane (envelope) fades away
and the nucleus becomes unrecognisable. Moreover, the spindle fibres start forming;
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spindle fibres are fibrelike processes that extend from the poles toward the equatorial plate
of the cell. Some fibres elongate from centrosomes and fasten to kinetochores (complex
protein structures located at the centromere region in the chromosomes that specify the
attachment between the two sister chromatids and the spindle fibre microtubules [162]).
Other spindle fibres elongate and overlap each other at the centre of the cell instead of
attaching to the chromosomes.
In metaphase, the next mitotic phase, chromosomes are aligned in one plane along the
polar axis as a result of the tension applied by the spindle fibres. Anaphase follows
metaphase, and is characterised by the shortening of the mitotic spindle fibres and
separation of the kinetochores so that the chromosomes (formerly chromatids) are pulled
apart and begin moving to opposite poles of the cell along the direction established by the
spindle fibres. The attachment of kinetochores to the spindle fibres is essential for the
movement to take place in the anaphase stage. If the kinetochore is lost, the sister
chromatids will not be able to orient on the spindle fibres, and as a result, the separation
fails to occur. The next stage is the telophase; during this phase, the daughter chromosomes
(formerly sister chromatids) arrive at the poles and the mitotic spindle fibres that have
pulled them apart fade away. The final phase is cytokinesis in which spindle fibres not
attached to chromosomes disappear and the cell also undergoes the furrowing process in
which the cell squeezes-in on all sides until two daughter cells are formed. In addition, a
nuclear membrane is reformed, the chromosomes uncoil and disappear (under the light
microscope) as discrete structures and the cell returns to the interphase (G1) state.
Cells in the G0 (resting or quiescent) state are not actively cycling. The resting state is used
to indicate cells not in the cycle except with the potential for division; examples include
hepatocytes (cells in the liver involved in protein synthesis, protein storage and other vital
activities). G0 state occurs at a certain point in the G1 phase, in this state, most of the cell
functions are halted (including proliferation).
The growth cycle runs parallel to the cell cycle, whereby the components of the cell
(including proteins, (ribonucleic acid) RNA, carbohydrates and phospholipid bilayers) are
also replicated and partitioned (after cytokinesis) more-or-less evenly between the two
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daughter cells. These two cycles (i.e., the cell cycle and growth cycle) turn at the same rate
during normal cell proliferation, so that each round of DNA synthesis and mitosis is
balanced by duplicating all other macromolecules in the cell. Therefore, the
nucleocytoplasmic ratio (ratio of nuclear size to the cell size) is kept within advantageous
limits. However, there are exceptions to this rule, for example, fertilised eggs divide
rapidly without growing and oocytes grow largely without dividing [163]. Nonetheless,
balanced growth and division determine the long-term viability of a cell line.
The major processes of the cell cycle are tightly regulated. In most eukaryotic cells this
coordination is carried out at three checkpoints [158]. A checkpoint (regulatory
mechanism) is a stage of the cell cycle process where the progress is stopped until the
appropriate relay signals (surveillance mechanism) confirm suitable conditions for
progress throughout the cycle. For example in G1 phase, cells explore their internal state
(nucleocytoplasmic ratio) and external environment (for nutritional conditions and growth
factors [158]) and this is known as the G1/S checkpoint. That is, for the Start transition (see
Figure 3.8) to happen, cells must grow to a critical size before they can commit to DNA
synthesis and division to achieve balanced growth and division. However, this requirement
can be compromised by mutations and as a result, cells may become morbidly large or
small [164]. In G2 phase, the cell checks DNA synthesis and repair and that the size is
large enough to commit to the M phase; this surveillance mechanism is known as the G2/M
checkpoint. In M phase (particularly at metaphase), cells ensure that all chromosomes are
properly aligned on the metaphase plate and that there are no problems with DNA
replication before issuing the command to segregate sister chromatids to opposite poles of
the mitotic spindle. This is a crucial regulatory constraint, if there have been any problems,
the Finish (see Figure 3.8) transition is held off at the third checkpoint (mitotic
checkpoint). If anaphase commences without fulfilling the conditions of the mitotic
checkpoint, a fatal mistake might happen and the daughter nuclei would not receive a full
complement of chromosomes [165].
For modelling purposes, according to Tyson and Novak [157] the cell cycle can be
subdivided into two alternative states, G1 and S-G2-M separated by Start and Finish as in
Figure 3.8. Start (the transition from G1 phase to S phase) is defined as when the cell
begins replication, the decision is irreversible, i.e. once DNA synthesis begins, it goes to
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completion [157]. The second irreversible transition (i.e., Finish) is triggered when the
DNA replication is complete. The anti-cancer agent TPT is believed to be S phase specific,
this implies that many cells may resist the effects of the drug by not attempting to replicate
DNA (i.e., failing to enter the S phase) during a finite exposure to TPT [166]. Blocking
entry to S phase results in suppressing cellular growth and expansion (i.e., cytostasis) and
under some conditions can cause apoptosis (i.e. cell death).
3.3.2 Cell cycle regulation
Cyclin B1 is a protein involved in the regulation of the cell cycle. In this thesis, a
mathematical model of Cyclin B1 dynamics is extended from a previously published
model by Pomerening et al. [14] describing the growth of human osteosarcoma cells (U2-
OS cell) in the absence (see Chapter 5) and presence (see Chapter 6) of the anti-cancer
agent TPT. The model accounts for the inhibition dynamics of the cyclin-dependent kinase
inhibitor (CKI) p21CIP1/WAF1 on Cyclin B1.
Numerous regulatory proteins are involved in the cell cycle; in fact, they direct the cell
through specific series of events as well as terminating in mitosis and producing two
daughter cells. The cell cycle progression is regulated (controlled) by cyclin-dependent
kinases (CDKs) and their activating partner proteins, cyclins [167]. CDKs are critical for
the cell cycle progression because their inactivation prevents mitosis [168-170]. The
activation of CDKs necessitates binding to a cyclin. Moreover, CDKs are targeted to the
nucleus when bound to cyclins, since CDKs lack nuclear localisation signals that are
contained in cyclins [171]. Some CDKs attach more than one cyclin, hence this provides
some substrate specificity. The expression of cyclins during the cell cycle process is cyclic,
that is why they were so named. Therefore, CDKs are activated at specific times during the
cell cycle as a result of this cyclic expression.
There are several CDKs in eukaryotic cells; CDK1, also known as CDC2 (this designation
used to name cell division cycle genes and proteins), is the prototype CDK. Cyclin B1 is
one of the most extensively characterised cell cycle regulators in human and other
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eukaryotic cells [159]. In the G1 phase, CDK1 activity is relatively low because the
relevant partner cyclin protein (Cyclin B1) is missing. Cyclin B1 is missing during G1
because Cyclin B1 mRNA production is inhibited and Cyclin B1 protein is degraded. At
Start (late G1) Cyclin B1 synthesis is promoted and Cyclin B1 degradation is inhibited
causing a remarkable rise in the activity of CDK1. CDK1/Cyclin B1 complex activity
remains high throughout S, G2 and M phases of the cell cycle. High activity of
CDK1/Cyclin B1 dimer is necessary for DNA replication, chromosome condensation and
spindle assembly.
At Finish (late G2) the anaphase-promoting complex (APC) is activated. APC consists of a
group of proteins that targets proteins such as Cyclin B1 for degradation by attaching a
destruction label. The target proteins are degraded by proteolysis (digestion of proteins by
cellular enzymes). The core complex of APC is made up of about a dozen polypeptides in
addition to two auxiliary proteins, namely CDC20 and CDH1. The main roles of CDC20
and CDH1 are to recognise specific target proteins including the CDK1/Cyclin B1 dimer
and present them to the core complex to be labelled for destruction [172, 173].
There are other complexities in the CDK network and these proteins (i.e., CDKs) are in
turn regulated by numerous proteins such as the CKIs including p53 and p21CIP1/WAF1. The
cell cycle is often dysregulated in tumour cells (neoplasia) as a result of alterations in
tumour suppressor genes or oncogenes that have a direct affect on cell cycle regulation
such as p53 in addition to oncogenes that indirectly impact the cell cycle process [156].
p53 is a tumour suppressor gene and mutations of this gene have been identified in many
types of malignancies including osteosarcomas [174-177]. This tumour suppressor gene
controls multiple cell cycle checkpoints that regulate mammalian response to DNA
damage. Following DNA damage, the tumour suppressor gene is stabilised and initiates the
transcription of the p21CIP1/WAF1 protein resulting in cell cycle arrest (or apoptosis) in the
G1 stage of the cell cycle. That is, p53 halts G1/S (Start) transition in cells exposed to
DNA-damaging agent by causing accumulation of p21CIP1/WAF1 [178, 179], a protein that
binds to CDK/cyclin complexes (including CDK/Cyclin B1 complex) [180] to inhibit their
activity for initiating DNA synthesis [181]. p53 is also involved in regulating a mitotic
spindle checkpoint that prevents DNA synthesis prior to chromosome segregation [182].
The CKI p21CIP1/WAF1 can also bind to proliferating cell nuclear antigen and inhibit its
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function in replication, this process also results in G1 arrest. Moreover, p21CIP1/WAF1 can
prevent G2/M transition (under the transcriptional control of p53) in human cell lines [183-
185] by decreasing the intracellular levels of Cyclin B1 protein (the regulatory subunit of
CDK1) which is required for mitotic initiation [186]. As a result, p53 (by expressing
p21CIP1/WAF1) arrests the cell cycle process in G2 phase [187]. The ability of the tumour
suppressor gene p53 to control mitotic initiation (by inducing the expression of
p21CIP1/WAF1) by regulating the intracellular levels of Cyclin B1 protein suggests that
Cyclin B1-dependent G2 checkpoint is involved in preventing growth of malignancies, i.e.
preventing cells with damaged DNA from entering the M phase of the cell cycle [186].
Since the progression of the cell cycle is tightly regulated by several proteins, including
Cyclin B1, for that reason, Cyclin B1 protein tracking provides information on the cell
cycle progression and the dynamics of the cell regulators. In this work, the monitoring of
the cell cycle progression was achieved by the project collaborators (Wales School of
Medicine, Cardiff University) using the green fluorescent protein (GFP)-probe (see
Chapter 5) which has expression, localisation and destruction description that shadow
Cyclin B1 dynamics in living cells [159].
The cell cycle regulation is also determined by phosphorylation state [156].
Phosphorylation on threonine and tyrosine residues is one of the methods in which the
CDKs are regulated. CDK1 has specific phosphorylation sites that are both stimulatory and
inhibitory depending on the location of phosphorylation on CDK1 residues. For example,
CDK1 phosphorylation on threonine 161 (T161) by cdk-activating kinase (CAK) is
essential for CDK1 kinase activity, and this is a stimulatory function [188]. In addition,
threonine 14 (T14) and tyrosine 15 (Y15) are located in the active site of the kinase and
their phosphorylation prevents kinase activity. This phosphorylation is performed by
Wee1, Mik1 and Myt1 protein kinases [169, 189-194]. The Wee1 kinase phosphorylates
and inactivates CDK1/Cyclin B1 complex upon its entry into the nucleus, in order to
protect the nucleus from premature exposure to an active mitotic kinase [190]. When the
cell becomes ready to divide, CDC25 dephosphorylates CDK1 at T14 and Y15, and
therefore activating CDK1 kinase [195-198]. Wee1 kinase and CDC25 phosphatase are in
turn regulated by phosphorylation, therefore forming an activation cascade [199-201].
Moreover, CDK1 phosphorylates both Wee 1 and CDC25, thereby forming positive- and
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negative-feedback loops as shown in Figure 3.10. These feedback components are
incorporated in the extended cell cycle model presented in Chapter 5.
Figure 3.10: Schematic diagram of proposed Wee1 kinase and CDC25 phosphatase
interactions with CDK1-Cyclin B1 complexes (redrawn from Reference [156]).
3.4 Summary
This chapter provides a summary of the relevant and necessary biological background in
addition to the underlying assumptions that were used in this thesis to develop the extended
drug kinetics model, the extended cell cycle model and the coupled drug kinetics/dynamics
model.
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4 The in vitro kinetic model
4.1 Introduction
The state-space modelling approach to drug kinetics can provide a mathematical
description of drug stability and delivery to a specified target [15]. For this purpose, a
state-space model for the in vitro uptake kinetics of the anti-cancer agent TPT has been
extended from a previously published model by Evans et al. [13] to account for drug
resistance mechanisms in cancer cells. That is, the extended model describes the drug
activity and delivery of the pharmacologically active form to the nuclear DNA target as
well as the catalysis of the ALDH enzyme and the elimination of drug from the cytoplasm
via the efflux pump (see Chapter 3). The extended model is based on underlying biological
assumptions, and the unknown parameters of the proposed model are estimated from two-
photon laser-scanning microscopy (TPLSM) data, which provide concentrations of TPT
(lactone plus hydroxy acid forms) in the extracellular region containing live human breast
cancer cells (MCF-7 cell line), the cytoplasm and the nucleus.
High performance liquid chromatography (HPLC) provides a means by which the levels
(concentrations) of TPTL and TPTH can be measured from medium and cellular extracts.
Data collected by project collaborators (Wales College of Medicine, Cardiff University)
from in vitro cell experiments using HPLC provide information about the respective
concentrations of TPTL and TPTH in the medium and cellular pools. These data have been
used to drive model development and to estimate unknown parameters in corresponding
state-space models [15].
The reversible hydrolysis (see Section 3.1) of TPTL was modelled by Evans et al. [15]
using a simple linear two-compartment model with parameter estimation from HPLC data
in buffers at different pH levels in order to characterise the pH dependency of the
reversible conversion between TPTL and TPTH. According to the results obtained from the
live cell experiments, differential reversible hydrolysis of TPT occurs in the medium in
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comparison to the cellular pools. This occurs due to the difference between intracellular
and extracellular pH levels as well as due to less well-defined properties of the drug in the
cell.
Figure 4.1: Schematic of the five-compartment model (proposed by Evans et al.
[15]) used to investigate the effect on TPT of injecting a dose (system
concentration 10 μM) of TPTL into a culture medium containing human
lymphoma cells (SU-DHL-4 cell line).
Based on the two-compartment model, Evans et al. [15] developed a non-linear five-
compartment model (Figure 4.1) describing the uptake kinetics of TPT in a medium
enclosing human lymphoma cells (SU-DHL-4 cell line). This was achieved by combining
compartmental models for both the intracellular and extracellular pools. In addition,
cellular influx and efflux terms were included to partially demonstrate the stability of TPTL
in solutions containing live cells. Finally, a compartment was added to represent the
cellular target, which is the pharmacologically active form of the drug (TPTL) bound to
nuclear DNA. To complete the mathematical model which describes the drug (TPTL)
activity and delivery to DNA target, appropriate non-linear association and linear
dissociation pathways were included. The non-linear model characterises the kinetics of
TPT in the entire cell population. Similar to the two-compartment model in Evans et al.
[15], the unknown parameters for the five-compartment model were estimated from HPLC
data. Before estimating the unknown model parameters from the in vitro data, a structural
identifiability analysis was performed which demonstrated that all of the unknown model
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parameters are uniquely determined by the output structure corresponding to the
experiment. HPLC allows the direct measurement of the concentrations of TPTL and TPTH
(separately) in the extracellular medium as well as the concentrations of TPTL and TPTH
(separately) in the cellular pool (i.e., the cytoplasm and the nucleus).
Figure 4.2: Schematic of the mathematical model (developed by Evans et al. [13]) used to
investigate the uptake kinetics of TPT in a culture medium containing human breast cancer
cells (MCF-7 cell line) in suspension.
The five-compartment model (Figure 4.1) does not allow for heterogeneity in the medium;
that is, the model does not define the region within the medium pool from which the active
form of the drug (i.e., TPTL) may flow into the cells, since the extracellular compartments
are assumed to be homogeneous and well-mixed (by definition) [15]. If the influx of TPTL
to the cell were from a smaller region of the medium (that is not well-mixed with the rest)
then the ratio of TPTL to TPTH in this region might seem more favoured to TPTH, however,
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this does not match expectations from the pH buffer experiments (see Evans et al. [15]).
For this reason, the five-compartment model was further developed to a seven-
compartment system (Figure 4.2) by Evans et al. [13], by splitting the medium into two
separate pools (regions): a region into which the drug is added and a region from which
drug can flow into the cells (see Section 4.3). Similarly, the seven-compartment model
describes the drug activity and delivery of the pharmacologically active form TPTL to the
DNA target. The unknown model parameters (of the seven-compartment model in Figure
4.2) are uniquely identifiable by the output structure corresponding to the experiments and
were estimated from two-photon laser-scanning microscopy data from live human breast
cancer cells (MCF-7 cell line).
4.2 TPT reversible hydrolysis model
The reversible hydrolysis of TPT is an important aspect of the kinetics of this particular
drug and forms the basic building block for the full cell-based model presented in this
thesis (Section 4.3). The inactivation of TPTL and subsequent activation of TPTH has been
modelled by Evans et al. [15] using a simple two-compartment model. Figure 4.3 provides
a schematic diagram of the two-compartment model developed by Evans et al. [15] where
L(t) stands for the concentration of parent form of the drug (TPTL) in solution at time t
after an initial dose of TPTL and H(t) denotes the corresponding concentration of the
inactive form of the drug (TPTH). The ring opening (inactivation) of TPTL occurs with a
first order rate constant ko to give TPTH and the first order rate constant kc is for the
activation (ring closing) of TPTH to give TPTL. The following coupled linear differential
equations describe the dynamics of the concentrations of the active form (TPTL) and
inactive form (TPTH) of TPT:
d ( ) ( ) ( )
dt
d ( ) ( ) ( )
dt
o c
o c
L t k L t k H t
H t k L t k H t
  
 
. (4.1)
In all of the experiments considered in this thesis, TPT is administered as a single bolus
input (impulsive input) of TPTL (active/lactone form) to yield an initial concentration D for
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L(0). Since the drug concentrations are zero before administration (i.e. at t = 0), the
corresponding initial conditions for the two-compartment model Equation (4.1) are given
by:
L(0) = D and H(0) = 0. (4.2)
In Evans et al. [15] the values of the unknown model parameters ko and kc were estimated
from HPLC data collected at Cancer Research Wales Laboratories (Velindre NHS Trust,
Cardiff) for different pH values consistent with physiological conditions (pH 6.8-8.0).
However, in this thesis, the values for the constants (ko and kc) will only be estimated at
pH = 7.2 since the MCF-7 cells (cell-based model in Section 4.3) were placed in a medium
with pH = 7.2 in the TPLSM experiments. The experiment carried out to collect HPLC
data allows separate sampling of the concentrations of TPTL and TPTH, accordingly, there
are two model outputs (observations), L(t) and H(t). In the pH buffer, concentrations were
measured in μM, the initial dose was D = 10 μM. Before estimating the unknown model 
parameters from the HPLC data, a structural identifiability analysis (using the Laplace
transform) for the model was performed.
Figure 4.3: Schematic of the simple two-compartment model (developed by Evans et al.
[15]) used to investigate TPT hydrolysis in buffers at different pH values.
4.2.1 Structural identifiability analysis for the hydrolysis model
The Laplace transform method presented in Section 2.4 is applied to perform the structural
identifiability analysis for the two-compartment hydrolysis model developed by Evans et
al. [15]. The dose D is assumed to be known and is therefore not included in the parameter
vector p, which is given by p = (ko, kc)T. Since the parameters must be real and positive,
HL
Dose
kc
ko
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the set of feasible vectors is taken to be Ω = {(p1, p2)T : pi > 0 and real}f. The state vector
x(t, p) (n = 2) and output vector y(t, p) (r = 2) are the same and are given by
( , )
( , ) ( , ) .
( , )
L t
t t
H t
 
   
 
p
y p x p
p
The state takes values in the connected open subset M(p) which is taken to be 2 (i.e., the
set of all 2-vectors (L(t), H(t))T. Notice that for a unit impulse input (a bolus injection) at
t = 0 into a zero initial state system, one can write the equations without input as shown in
Equations (2.18) and (2.19). Therefore, the initial state x(0, p) is given by x0(p) = (D, 0)T
which is independent of the vector of unknown model parameters p (since D is assumed to
be known). To obtain the equations similar to the form of Equations (2.18) and (2.19), i.e.
non-zero initial state without further input, the following is defined:
,o c
o c
k k LL
k k HH
    
        


where (L, H)T is an arbitrary vector in M(p), the matrix
( ) o c
o c
k k
k k
 
  
 
A p
is the matrix of transfer coefficients which contains the basic (structural) components of
the compartmental model, and the output matrix
1 0
( )
0 1
 
  
 
C p
is independent of the vector of unknown model parameters p.
Taking Laplace transforms of Equations (4.1) and (4.2) and rearranging gives:
( ) ( ) ( )
( ) ( ) ( ) 0
L H
L H
o c
o c
s k s k s D
k s s k s
  
   
(4.3)
where L(s) and H(s) are the Laplace transforms of L(t) and H(t), respectively. Solving for
L(s) and H(s) results in:
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Therefore, the Laplace transform of the observation function is:
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(4.5)
The coefficients are the moment invariants (observational parameters), therefore,
determining Y1(s) and Y2(s) means that values for all of the coefficients are determined.
Looking at the coefficients of individual outputs, the equations for the observational
parameters in terms the model basic parameters are:
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. (4.6)
The coefficient 2 0  as a result of a zero eigenvalue. The coefficient 4 determines kc
since the value of D is a measurable constant, and from 1 , ko is determined. Accordingly,
the two basic parameters (ko and kc) of the model are uniquely determined by the output
structure corresponding to the proposed experiment. Therefore, the two-compartment
hydrolysis model is structurally globally (uniquely) identifiable. The structural
identifiability analysis was performed in this section to estimate the unknown model
parameters with greater confidence.
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4.2.2 Parameter estimation for the hydrolysis model
Parameter estimation (Appendix B) was performed using the commercial software package
FACSIMILE (MCPA Software, U.K.) for HPLC data consisting of values of both forms of
TPT (i.e., TPTL and TPTH) at times t = 1, 2, 5, 10, 15, 30, 45, 60 and 120 min following
drug administration (via a bolus injection). Phosphate buffer saline (PBS) solutions made
to the required pH levels (6.8, 7.0, 7.2, 7.4, 7.6, 7.8 and 8.0) were used in the experiments.
PBS is an isotonic buffer solution (i.e., the solution has the same ion concentration and
osmolarity as the human body) widely used in the field of biological research to maintain
constant pH levels during experiments. This buffer solution contains sodium chloride
(NaCl), sodium phosphate (Na2HPO4) and, in some chemical formulations, it may also
include potassium chloride (KCl) and potassium phosphate (KH2PO4). Table 4.1 represents
data from the HPLC experiments (at pH = 7.2) which were performed in duplicate (i.e.,
two experiments at each pH level) and Figure 4.4 is the graphical representation of the data
in Table 4.1. The unknown parameters (ko and kc) for the hydrolysis model were estimated
at pH = 7.2 since MCF-7 cells were placed in a medium with pH = 7.2 in the microscopy
experiments used to collect data from live cells.
Table 4.1: HPLC data for TPTL and TPTH from two different sets (A and B) of TPT
hydrolysis experiments at pH = 7.2. Time is given in minutes (min) and concentrations in
micromolar (μM). 
Time (mins) Set A: TPTL (μM) Set A: TPTH (μM) Set B: TPTL (μM) Set B:TPTH (μM)
1.00 9.99 0.00 9.93 0.05
2.00 9.89 0.09 9.85 0.11
5.00 9.71 0.27 9.63 0.29
10.00 9.36 0.60 9.26 0.71
15.00 8.98 1.10 8.91 1.02
30.00 7.96 2.01 8.40 1.52
45.00 7.47 2.48 7.34 2.61
60.00 7.10 3.07 6.86 3.08
120.00 6.79 3.11 6.83 3.12
The parameter estimation was performed simultaneously using the two HPLC data sets
(four data curves) in Table 4.1. The fitted (estimated) parameter values with estimates for
their respective confidence intervals are presented in Table 4.2, where it is seen that the
two parameters (ko and kc) are well-determined by the HPLC data. In addition, the
confidence limits for both parameters (ko and kc) are reasonably close, which gives further
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confidence that the parameter values are well-determined. In addition, the value of
CORImean = 0.61467 indicates that the residuals are acceptable and evenly distributed
above and below the (simulated) output of the model and therefore, the resulting fit is
good.
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Figure 4.4: Graphical presentation of HPLC data for TPTL and TPTH from two different
sets (A and B) of TPT hydrolysis experiments at pH = 7.2.
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Figure 4.5: The plot represents the model output (lines) for TPTL (yellow) and TPTH (black)
fitted to the HPLC data sets A (circles and pentagrams for TPTL and TPTH respectively)
and B (triangles and squares for TPTL and TPTH respectively) at pH = 7.2.
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Table 4.2: The parameter values ko and kc for the model
Equations (4.1) and (4.2) obtained from HPLC data (set A and
set B).
Parameter Value SDLN 5% 95%
ko (min-1) 9.36×10-3 0.0507 8.611×10-3 1.0174×10-2
kc (min-1) 1.8×10-2 0.0935 1.5435×10-2 2.0992×10-2
RSS = 2.7118×10+1
In Figure 4.5, the simulated output of the model, given by Equations (4.1)–(4.2), is plotted
together with the experimental data. From this plot, it is seen that there is close
reproduction of the collected data by the simulated output from the hydrolysis model with
parameters taking values from Table 4.2. The correlation coefficient for the two parameters
is 0.903 showing high linear covariation between the estimates for ln(ko) and ln(kc).
Accordingly, only a linear combination of the two parameters that is well estimated, and
that they are not being estimated separately [23]. The results obtained from the parameter
estimation of the unknown parameters of the hydrolysis model, namely, ko and kc at
pH = 7.2, agree with the parameter estimates reported in Evans et al. [15]. The results in
Table 4.2 were used in the extended model (cell based model) in the following section
(Section 4.3).
From the results obtained by Evans et al. [15], it is shown that as the value of pH increases,
the long term value of TPTL decreases and the initial slope of the TPTL time curve
becomes steeper. Thus indicating that at higher pH levels, the initial dose (D) of the active
form of the drug (TPTL) undergoes hydrolysis to the inactive form (TPTH) more rapidly. In
addition, the equilibrium concentration of TPTL decreases. However, TPTH is formed more
rapidly at higher pH levels with an increased concentration at equilibrium. As expected
(see Section 3.1.3), this indicates that TPTL predominates (i.e., becomes more stable) at
lower pH levels. Evans et al. [15] have also concluded the estimates for the parameter ko
vary linearly with pH (the estimated value of ko increases with pH), however, there is not a
clear relationship between kc and pH.
Figure 4.6 is a normal probability plot for the residuals in the weighted non-linear least-
squares fit of the hydrolysis model to HPLC data. The residuals are plotted in ascending
numerical order on the horizontal axis, against cumulative probabilities in N(0, 1)
transformed to a linear scale. The figure suggests that the residuals are normally distributed
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(with approximately zero mean) since the graph is approximately linear. This is an
indicator of the appropriateness of the standard error σi used for each observation yi.
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Figure 4.6: A normal probability plot for the residuals in the weighted non-linear least-
squares fit of the hydrolysis model to HPLC data. The residuals are plotted in ascending
numerical order on the horizontal axis, against cumulative probabilities in N(0, 1)
transformed to a linear scale.
4.3 The cell-based model
The simple two-compartmental model for the reversible hydrolysis of TPTL (Figure 4.3) in
buffers was used as the main building block to construct the five- and seven-compartment
models developed by Evans et al. [13, 15] as well as the extended model in this thesis;
these models are based on the kinetics of TPT in live cell experiments. Similar to the
previous cell-based models, the extended model yields quantitative predictions (through
simulations) of the concentrations of both forms of TPT (i.e., TPTL and TPTH) in the
various experimental pools.
The new single-cell state-space model is a model of processes based on mass balance
principles. The model is represented by first order ODEs describing the reactions and
transfer of both forms of TPT, within the system. Accordingly, the simulation results
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obtained from the model are compared with real experimental data (live human breast
cancer cells using two-photon laser-scanning microscopy) for parameter estimation.
4.3.1 Mathematical model
The original single-cell compartmental model (the seven-compartment model in Figure
4.2) proposed by Evans et al. [13] allows for heterogeneity by dividing the medium into
two separate pools: the medium region into which the drug is added and the extracellular
region in which the cells are located. Figure 4.7 demonstrates the response of a single cell
for which the data were collected during the two-photon laser-scanning microscopy
experiments on MCF-7 cells, and it is evident from Figure 4.7(a) that the mixing takes
place in the medium. The drug exchange between the cells and medium takes place only
through the extracellular region. In this model, the cellular pool that contains all of the
individual cells has been extended to include the cell membrane. Therefore, this leads to a
model with five physical regions: the medium, the extracellular region, the cell membrane,
the cytoplasm, and the nucleus which are denoted by subscripts m, e, cm, c, and n,
respectively. Assumptions about the kinetics of TPT (see Chapter 3) on a single cell basis
were made. In addition, the Law of Mass Action was used to model all the chemical
reactions within the extended system.
The extended model (Figure 4.8) is made up of nine compartments, each compartment
represents a well-mixed homogenous subsystem. These subsystems represent the
concentration of the anti-cancer drug in its active (TPTL) or inactive (TPTH) forms, in a
particular (physical) location with respect to time. The arrows in the model represent
transfers between compartments. These flows can be as a result of the reversible hydrolysis
of TPT (Section 4.2), the rate of flow of drug (TPTL or TPTH) from one physical location
to another physical location, the association/dissociation of the drug to/from the drug
transporter, the association/dissociation of the drug to/from the ALDH enzyme or the
association/dissociation of the drug to/from the nucleus. Figure 4.8 provides a schematic
diagram of the extended state-space model, where L and H stand for the concentrations of
TPTL and TPTH, respectively. Therefore, Lm(t), Le(t), Lc(t), and Ln(t), denote the
concentrations of TPTL in the medium, extracellular region, cytoplasm and nucleus
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respectively, at time t following the addition of drug. The corresponding variables for
TPTH are Hm(t), He(t), and Hc(t). The concentration of TPTH bound to the efflux pump is
denoted by THcm(t), and the variable T(t) represents the total concentration of available
ABCG2 (drug transporter) binding sites at time t. TPTH (the form favoured by the efflux
pump) in the cytoplasm (Hc) binds to the drug transporter (T) to form an intermediate
complex (THcm) which breaks in one direction to release free drug transporter (T0) and
TPTH in the extracellular region (He). That is, 1 2 .k kc cm eH T TH T H   
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Figure 4.7: The total concentration of TPT (TPTL + TPTH) against time in (a) the
extracellular pool (b) nucleus (blue line) and cytoplasm (green line). The drug was
administered at t = 97.532 seconds.
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Figure 4.8: Schematic of the extended mathematical model used to investigate the uptake
kinetics of TPT in a culture medium containing human breast cancer cells in suspension.
In Evans et al. [13, 15] , it is assumed that all drug in the nucleus is bound and only TPTL
binds to DNA. The latter assumption is supported by current knowledge from DNA studies
in free solution (see Chapter 3). The former assumption is a simplification of the real case
in which the nucleus may contain unbound drug as well; therefore, this postulation requires
further experimental investigation. Therefore, in the model, there is no direct pathway for
the inactive form of the drug (TPTH) to enter the nucleus. In the three experimental pools,
i.e. medium, extracellular region and cytoplasm, TPT undergoes reversible and pH
dependent hydrolysis, as considered in Section 4.2, which has been modelled by a simple
two-compartment model [15]. The rate constants for the ring closing of TPTH and ring
opening of TPTL are identical in the medium and extracellular pools; assuming
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homogeneity in pH and/or any other factors that might have an effect on the hydrolysis, the
rate constants are kcm and kom for the ring closing of TPTH and ring opening of TPTL,
respectively, for both the medium and the extracellular region. The corresponding rate
constants for the cytoplasm are kcc and koc.
The active drug (TPTL) in the cytoplasm is assumed to bind irreversibly (see Chapters 2
and 3) to the enzyme ALDH where it is converted to the form favoured by the efflux pump
(TPTH). In accordance with the Law of Mass Action, the rate at which TPTL binds to
ALDH is assumed to be proportional, with the association rate ka, to the product of the
concentrations of TPTL in the cytoplasm, Lc(t), and free enzyme, E(t). Additionally,
dissociation of drug bound to ALDH occurs at a first-order rate as either TPTL, with rate
constant k-a, or TPTH, with rate constant kd. If E0 denotes the total concentration of
available ALDH, then the concentration of free ALDH (by applying suitable conservation
laws) is E(t) = E0 – ELc(t), where ELc(t) is the concentration of enzyme-drug complex.
Mixing between the medium and extracellular pools can be modelled by first-order flows
between them. Assuming that the rate constants are the same for the lactone and hydroxy
acid forms, kmi denotes the flow from the medium to the extracellular pool and kmo denotes
the flow out of the extracellular pool to the medium. Flow between the extracellular region
and the cellular pool, including the cell membrane and cytoplasm, takes place
simultaneously via two distinct processes. The first process is the efflux pumping
mechanism (see Chapter 2) in which the BCRP/ABCG2 transporter carries TPTH through
the cell membrane to the extracellular region irreversibly. According to the Law of Mass
Action, the rate at which TPTH in the cytoplasm binds to the efflux pump is assumed to be
proportional, with association rate constant k1, to the product of the concentrations of the
inactive drug in the cytoplasm, Hc(t), and free transporter, T(t). The dissociation of drug
bound to the efflux pump (THcm) is assumed to be first order with rate constant k2. If T0
denotes the total concentration of available (BCRP/ABCG2) drug transporter, then the
concentration of free transporter (by applying suitable conservation laws) is the difference
between T0 and the concentration of bound drug (THcm), that is T(t) = T0 – THcm(t). The
second process is the diffusion between the cytoplasm and the extracellular region, which
is also modelled via a first-order process. Note however, that only TPTL diffuses across the
cell membrane, based on previous experimental observations [15, 48] and physical
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properties of TPTH with respect to the lipid bilayer traverse [202]. The rate constant for
influx of Le(t) into the cytoplasm is ki and the rate constant for the efflux of Lc(t) into the
extracellular pool is ke. Similarly, the binding rate of TPTL to DNA is assumed to be
proportional (with constant kb) to the product of the concentrations of TPTL in the
cytoplasm and free binding sites, BF(t). Let BT denote the total concentration of available
DNA binding sites, therefore, the concentration of free sites, BF(t), is the difference
between BT and the concentration of bound drug, Ln(t), that is BF(t) = BT – Ln(t).
Dissociation of bound drug is assumed to occur at a first-order rate as either TPTL, with
rate constant kdl, or TPTH, with rate constant kdh. That is, TPTL may bind to DNA in a
reversible manner and can then, once bound, be converted to TPTH, as suggested by
Streltsov [203].
If the volumes of the medium, extracellular region, cytoplasm, cell membrane and nucleus,
are denoted by Vm, Ve, Vc, Vcm, and Vn, respectively, then the postulated mathematical
model for the uptake kinetics of TPT is given by the following system of differential
equations:
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where, v0 = Ve/Vm, v1 = Ve/Vc, v2 = Vn/Vc, v3 = Vcm/Vc, and v1/v3 = Ve/Vcm. Time t = 0
corresponds to the (first) addition of drug as a bolus injection. The corresponding initial
conditions for the model are given by:
Hm(0) = Le(0) = He(0) = Lc(0) = Hc(0) = Ln(0) = ELc(0) = THcm(0) = 0, (4.8)
and
Lm(0) = (1 + v0)D, (4.9)
where D is the concentration of dose in the full physical medium (i.e. 2 ml or 2×1012 μm3).
According to Evans et al. [13, 15], the estimates obtained for the volumes, using data
collected from optical sectioning using a confocal microscope, are: Vc + Vcm = 829 μm3
(SD=232 μm3) for the average volume of cytoplasm and cell membrane in single cell; the
volume of the nucleus in a single cell (Vn) is 326 μm3 (SD=85.5 μm3); and therefore, the
total volume of the average cell (Vc + Vcm + Vn) is 1155 μm3. According to the above
values, the radius of the cell can be calculated assuming that the cell is spherical, therefore,
the average radius of a single cell is 6.5 μm and the average radius of the nucleus in a 
single cell is 4.27 μm. The cell membrane thickness is approximately 3-10 nm [204]. There 
is therefore relatively little variation in the plasma membrane thickness between cells. In
this model, the chosen value of the membrane thickness is 7 nm. The resulting calculations
for the average volumes of Vcm, and Vc in a single cell are 8.4 μm3 and 820.5 μm3,
respectively. The culture medium has a volume of 2×1012 μm3, therefore:
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Given that the culture medium contains 1×105 cells in the experiment providing data, the
cellular volume ratios are given by:
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where α = 2.4375×104, v2 = 3.9732×10-1, and v3 = 1.0238×10-2. Cells were placed in a
medium with pH = 7.2 in the experiments used to collect data for estimating the unknown
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parameters in the proposed model. With the assumption that the hydrolysis rate constants
are primarily dependent on pH, the corresponding values for kom, kcm, koc and kcc from
Section 4.2 (i.e., ko and kc) are used, these values are kom = koc = 1.6×10-4 s-1 (9.36×10-3
min-1) and kcm = kcc = 3.0×10-4 s-1 (1.8×10-2 min-1). In the experiment used to collect data
for parameter estimation, concentrations were measured in μΜ, the initial dose was D = 10
μΜ, and time was measured in seconds. 
4.3.2 Pseudo-steady state approximation of the cell-based model
In this subsection, the extended model in Figure 4.8 is reduced by assuming that the
binding kinetics of both the ALDH enzyme and the BCRP/ABCG2 efflux pump are
saturable within the physical volume of space considered. That is, the concentrations of the
enzyme and the transporter are much lower than the concentration of associated substrates.
A structural identifiability analysis (Section 4.4) of the unknown parameters of the system
is performed for the reduced system following a PSSA (see Section 2.3.2) [27]. The
structural identifiability properties of the reduced model will change from those of the
original system [205]. Therefore, fewer system parameters (of the basic model) may be
structurally globally identifiable as they enter in new parameter groupings in the reduced
order model. The assumptions on the relative sizes of the model parameters, are the
following:
 The concentration of the enzyme is much lower than the active form of the drug in
the cytoplasm, that is E0 << Lc and/or the binding affinity of the enzyme ALDH is
much lower than unity, (kd + k-a)/ka << 1.
 The concentration of the transporter (BCRP/ABCG2) is much lower than the
concentration of the inactive form of the drug in the cytoplasm, T0 << Hc and/or the
binding affinity of the transporter is low k2/k1 << 1.
Under these assumptions, following the administration of drug, saturation of the available
binding sites (enzyme and transporter) or equilibrium of bound substances is virtually
instantaneous, whereby a PSSA can be made [205]. Such an approximation yields a
coupled set of algebraic and differential equations. According to the assumptions above,
the intermediate compounds THcm and ELc are formed rapidly and reach an equilibrium
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state (i.e., d d0 and 0
dt dt
cm cTH EL  ). Therefore, solving for THcm and ELc in Equation
(4.7) results in:
0 1 0
2 3 1
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c a c
cm c
c d a a c
T k H E k LTH EL
k v k H k k k L
 
  
. (4.10)
Using the above results and substituting these in the state space system (see Equation
(4.7)), the ODEs for He, Lc and Hc can be reduced to the following:
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(4.11)
where km1 = k2/k1, km2 = (kd + k-a)/ka, Vm1 = k2T0 and Vm2 = kdE0. The kmr values (r = 1, 2)
represent the relevant Michaelis-Menten constants and the Vmr values (r = 1, 2) are the
numerical constants [205] that represent the relevant maximum velocities obtained when
the enzyme and the transporter exist completely in the form THc (r = 1) and ELc (r = 2),
respectively. Such (outer solution) approximations provide accurate results for the
asymptotic (long-time) behaviour of drug uptake [205]. Moreover, the number of unknown
parameters in the model (Figure 4.9) has been reduced by two and the system equations are
reduced to seven. For completeness, the reduced mathematical model is given by:
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(4.12)
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Figure 4.9: Schematic of the reduced mathematical model used to investigate the uptake
kinetics of TPT in a culture medium containing human breast cancer cells (MCF-7 cell line)
in suspension.
In all of the two-photon laser-scanning microscopy experiments (from the MCF-7 cells)
considered in this chapter, concentrations are measured in µM and time t in seconds. For
completeness, the twenty parameters in the drug kinetics model (in Figure 4.9) are:
 kom and kcm, units: s-1 (per second). Rate constants for deactivation/activation of
TPTL/ TPTH, respectively, in the medium and extracellular region;
 kmi and kmo, units: s-1. Rate constants for the flow of TPTL and TPTH to/from the
extracellular region/medium respectively;
 ki and ke, units: s-1. Rate constants for the flow of TPTL into and out of the cell (i.e.,
to/from extracellular region), respectively;
 koc and kcc, units: s-1 (per second). Rate constants for deactivation/activation of
TPTL/ TPTH, respectively, in the cell (cytoplasm);
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 kb, units: (µM s)-1. Rate constant for binding (association) of TPTL (in the
cytoplasm) to DNA;
 kdl and kdh, units: s-1. Rate constants of dissociation of TPTL from DNA to TPTL/
TPTH (in cytoplasm) respectively;
 BT units: µM. Concentration of DNA sites available for TPTL (in cytoplasm) to
bind to;
 km1 and km2, units: µM. Michaelis-Menten constants for the BCRP/ABCG2 drug
transporter and the ALDH enzyme respectively.
 Vm1 and Vm2, units: µM s-1. Numerical constants that represent the maximum
velocity obtained when the transporter and the enzyme exist completely in the form
THc and ELc respectively;
 v0, v1, v2 and v3. The ratios, respectively, of the volumes of extracellular region (Ve)
to medium (Vm), extracellular region to cytoplasm (Vc), nucleus (Vn) to cytoplasm
and cell membrane (Vcm) to cytoplasm.
Thirteen of these parameters (ki, ke, kb, kmi, kmo, kdl, kdh, v0, BT, Vm1, Vm2, km1 and km2) are
unknown and need to be estimated from experimental data. Using TPLSM, it is possible to
directly measure the total concentration of drug within the extracellular region (Le + He),
cytoplasm (Lc + Hc) and nucleus (Ln). The cell membrane (plasma membrane) acts as a
barrier and the drug is transported either passively (TPTL) or actively (TPTH) through it.
Accordingly, there are no measurements obtained from it (i.e., from the cell membrane as a
physical region). Prior to the parameter estimation for the extended drug kinetics model
(presented in this chapter), a structural identifiability analysis has been performed (Section
4.4) to test whether the unknown model parameters are uniquely determined by the output
structure corresponding to the microscopy experiments. In the following section, the
Taylor series approach is used to show that the extended single-cell model (Figure 4.9) is
structurally globally identifiable.
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4.4 Structural identifiability analysis of the single-cell model
In this section, the Taylor series approach (see Section 2.4) is applied to the pseudo-steady
state model (Figure 4.9) described by Equations (4.12) with initial conditions given in
Equations (4.8) and (4.9). The input in this particular experiment is a bolus injection of the
anti-cancer drug TPT into the system. Therefore, the corresponding amounts can be
included as non-zero initial conditions x0(p) for the system with no input. The vector p
comprising the thirteen unknown parameters of the model is given by:
0 1 1 2 2( , , , , , , , , , , , , ) .mi mo i e b dl dh T m m m mk k k k k k k B v V k V kp
T
The unknown model parameters represent flow rate constants (ki, ke, kb, kmi, kmo, kdl and
kdh), Michaelis-Menten constants (km1 and km2), numerical constants (Vm1 and Vm2), volume
ratio (v0) or a concentration (BT) and are therefore, positive. This means that the set of
feasible parameter vectors, Ω, comprises the vectors (p1, …, p13)┬ such that pi > 0
(1 ≤ i ≤ 13). The state space vector x(t, p) is given by:
( , ) ( ( , ), ( , ), ( , ), ( , ), ( , ), ( , ), ( , ))m m e e c c nt L t H t L t H t L t H t L tx p p p p p p p p
T (4.13)
and the set M(p) is 7 . The initial conditions for the state-space representation of the
model (for D = 10 μM) are given by: 
0 0( , ) ((1 ) ,0,0,0,0,0,0) .t v D x p
T
The output function of the extended model is given by:
( , ) ( ( , ) ( , ), ( , ) ( , ), ( , ))e e c c nt L t H t L t H t L t  y p p p p p p
T
thus, in terms of the general mathematical formulation of Equation (2.19), the output
matrix C(p) is given by:
0 0 1 1 0 0 0
0 0 0 0 1 1 0
0 0 0 0 0 0 1
C(p)
 
 
  
 
 
. (4.14)
An arbitrary parameter vector is denoted by p such that:
0 1 1 2 2( , , , , , , , , , , , , )mi mo i e b dl dh T m m m mk k k k k k k B v V k V kp
T
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for which, ( , ) ( , )t ty p y p for all t ≥ 0. In order to perform the Taylor Series method 
(Section 2.4), successive coefficients of the Taylor series expansions of the components of
( , ) and ( , )t ty p y p are computed to determine the relationships that exist between p and
p . Computer algebra systems such as MATHEMATICA [206] have proven helpful for the
symbolic calculation of these coefficients, particularly when they become algebraically
complicated. This software tool was therefore used to perform the following analysis (see
Appendix A).
As explained in Subsection 2.3.3, uniqueness of the coefficients in the Taylor series
expansions of yi(t, p) entails the following, if p Ω is such that y(t, p) = y(t, p ) for all
t ≥ 0, then, for each i = 1, 2, and 3 (for this particular model output), and k = 1, 2, 3, …,
then
yi(k)(0,p) = ( ) (0, )kiy p where, yi
(0)(0, p) = yi(0, p). (4.15)
For k = 0 in Equation (4.15) for i = 1, 2 and 3, no information is gained since each of these
coefficients is 0, i.e., yi(k)(0,p) = 0 for each i = 1, 2, and 3, and k = 0. Now considering the
1st derivative (k = 1) yields:
(1) T0
0
(1 )(0, ) ( ,0,0)y p miDk v
v

 (4.16)
and substituting in Equation (4.15) gives:
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The 2nd derivative terms (k = 2) give:
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and using the relation in Equation (4.17) yields:
0 0 0 0 0 0 0
0 0 0 0 0 0
( ) ( ) ( ) (1 )and .
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(4.19)
Now considering the next derivative (k = 3) in addition to using the relations in Equations
(4.17) and (4.19) it follows that:
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Considering the relations (Equations (4.17), (4.19) and (4.20)) between parameters in p
and p , the following equation must hold to satisfy Equation (4.15) for each i (1, 2 and 3)
and k = 0, …, 3:
0 0, , , , and .T bT e e i i mi mi mo mo
b
B kB k k k k k k k k v v
k
      (4.21)
Calculating the fourth derivative terms (k = 4) and using the relations in Equation (4.21),
yields:
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From the next set of coefficients in the Taylor series expansions (k = 5), as well as using
the relations in Equations (4.21) and (4.22), gives:
2 2
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and .m mdh dh m
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k Vk k V
k
  (4.23)
Considering the relations (Equations (4.21)-(4.23)) between parameters in p and p , the
following relations must hold in order to satisfy Equation (4.15) for each i (1, 2 and 3) and
k = 0, …, 5:
1 1 2 2
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(4.24)
Equating and substituting the parameter relations resulting from evaluating the sixth
derivative (k = 6) in Equation (4.24) gives:
2 2, and .b b m mk k k k  (4.25)
Considering the relations in Equations (4.24) and (4.25) between parameters in p and p ,
the following relations must hold in order to satisfy Equation (4.15) for each i (1, 2 and 3)
and k = 0, …, 6:
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Finally, equating the eighth set of coefficients (k = 7), and combining with the relations in
Equation (4.26), yields:
1 1.m mk k (4.27)
Therefore, the following relations must hold in order to satisfy Equation (4.15) for each
i (1, 2 and 3) and k = 0, …, 7:
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(4.28)
Therefore, for Equation (4.15) to be satisfied p p (for each i and all k). This is true for
generic p , and thus the model is structurally globally identifiable, that is all of the
model parameters are uniquely determined by the output structure corresponding to the
proposed experiments to collect data for the purpose of parameter estimation. In the next
section, the unknown model parameters were estimated from TPLSM data. The structural
identifiability analysis was performed in this section to approach the estimation of the
unknown model parameters with greater confidence.
4.5 Parameter estimation of the single-cell model
4.5.1 Two-photon laser-scanning microscopy experiments
Experimental data used for estimating unknown parameters of the extended single-cell
model were collected (by the project collaborators at Cardiff University) from an in vitro
study on the interaction between the anti-cancer drug TPT and live human breast cancer
cells (MCF-7 cell line). In the experiments conducted at Cardiff, delivery and localisation
of the drug in single MCF-7 cells were examined using TPLSM. The set up of the
instrument was calibrated in order that the fluorescence response was linear for 0-15 µM
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TPT, making the conversion to the concentration of drug from fluorescence intensity
(following background subtraction) simple to calculate. The optical sectioning capacity of
this technique provides high-resolution spatial information representing the fluorescence
intensity in the compartments and, therefore, quantification of the drug concentration in
these compartments, i.e. nucleus (Le), cytoplasm (Lc + Hc) and extracellular (Le + He)
environment, as shown in Figure 4.10. The kinetics of the uptake for each sub-
compartment can be analysed via time-lapse sequences thus providing the primary data for
parameter estimation. During the course of the entire uptake assay the signal-to-noise ratio
ranged from 1 to 10, this is considered a low value for high resolution microscopy [13].
However, this range for physiological imaging is relatively adequate.
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Figure 4.10: Experimental data from TPLSM experiments for total concentration of TPT in
the extracellular region (red circles), nucleus (green circles) and cytoplasm (blue circles).
In the TPLSM experiment [12] to track the delivery to sub-cellular compartments of a
population of live human breast cancer cells, a concentration of 10 µM of TPTL was added
to a culture of 105 adherent cells. Measuring all 105 MCF-7 cells was not feasible and
therefore 104 cells were physically measured. From these, 13 individual cells were selected
as being representative of the entire population in terms of heterogeneity in response to
TPT. The duration of the experiment was 7.5 min (450 seconds) with observations
(measurements) taken every 5 seconds (Figure 4.10). The dynamic fluorescent intensities
representing the drug concentration were derived from the three main cell compartments:
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the nucleus, cytoplasm and extracellular region. Experimental data points were collected
starting from t1 = 5 seconds to t90 = 450 seconds, resulting in a data set of 27 observations
at 90 time points, that is, 1 mutual measurement for all cells from the extracellular region
(Le + He) and 2 measurements per cell (for 13 individual cells) from the cytoplasm
(Lc + Hc) and the nucleus Ln (Figure 4.10).
4.5.2 Parameter estimation
Parameter estimation (Appendix B) was performed using the commercial simulation
software package FACSIMILE (MCPA Software, U.K.). The optimisation method used to
obtain parameter estimates involves the minimisation of the weighted least-squares
criterion (see Section 2.5).
Assuming that TPT hydrolysis is primarily dependent on the level of pH and that there are
no other cellular factors affecting it, the hydrolysis rate constants in the cytoplasm (koc and
kcc) were fixed at values estimated from HPLC data at pH = 7.2, (1.6×10-4 s-1 and 3.0×10-4
s-1, respectively), see Section 4.2. The structural global identifiability of the extended
model demonstrates uniqueness of the model output for given cellular TPT hydrolysis rate
constants, with respect to the unknown parameters.
The response to the anti-cancer drug TPT varies between the 13 individual cells.
Therefore, the impact of a dose D can be measured in terms of the total concentration of
TPTL binding to DNA (Ln) over the first 7.5 minutes (450 seconds) following the drug
administration which can be represented as the area under the time series curve (AUC) for
Ln corresponding to the initial dose D (AUC(Ln, D)). Figure 4.11 shows the measurements
(observations) from the nucleus for the 13 individual cells. With reference to Figure 4.11,
clearly the responses vary across cells. Therefore, to account for this variation, three
different types of curve fitting were conducted for the model represented in Equations
(4.12) (at pH = 7.2):
 The data from the 13 individual cells were averaged and the postulated model fitted
to these averaged data.
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 The model was fitted to data from an individual high loading cell (relatively high
concentration of Ln(t)).
 Data from an individual low loading cell (relatively low concentration of Ln(t))
were used in the fitting.
Table 4.3: Normalised AUC(Ln, D) for Ln
following a bolus injection D = 10 µM
Cell AUC
Cell 1 0.46148
Cell 2 0.89843
Cell 3 0.79741
Cell 4 0.44891
Cell 5 0.69542
Cell 6 0.98369
Cell 7 1
Cell 8 0.94444
Cell 9 0.50931
Cell 10 0.65691
Cell 11 0.79689
Cell 12 0.85242
Cell 13 0.86333
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Figure 4.11: Observations from the nucleus (Ln) for the 13 individual cells that represent
the full range of heterogeneity observed in response to the drug.
Table 4.3 represents normalised AUC(Ln, D), D = 10 µM, values (with respect to the
maximum AUC(Ln, 10 µM)) that correspond to the 13 individual cells. Although Cell 4
has the lowest normalised AUC(Ln, D) value, Cell 1 has been selected as a low loading cell
for parameter estimation due to noise in the measurements in the cytoplasm (i.e., Lc + Hc)
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for Cell 4. Cell 7 has been chosen as a high loading cell as the concentration of TPTL in the
nucleus is relatively high.
Table 4.4: Best parameter estimates for averaged data obtained for the model
Equations (4.12), estimated using TPLSM data. The cellular hydrolysis rate
constants are fixed at values obtained from Table 4.2 (see Subsection 4.2.2) for
pH = 7.2 buffered solution where: kom = koc = 1.6 × 10-4 s-1 and kcm = kcc = 3 × 10-4
s-1.
Parameter Value SDLN 5% 95%
ki (s-1) 2.3599×10-2 0.0531 2.1625×10-2 2.5754×10-2
ke (s-1) 1.0266×10-2 0.0594 9.3106×10-3 1.1321×10-2
kb (s-1 µM-1) 1.9483×10-4 0.8778 4.5975×10-5 8.2564×10-4
kmi (s-1) 1.4539×10-6 0.0374 1.3671×10-6 1.5463×10-6
kmo (s-1) 9.1051×10-2 0.0277 8.7001×10-2 9.5290×10-2
kdl (s-1) 3.5101×10-2 0.1821 2.6015×10-2 4.7360×10-2
kdh (s-1) 2.0000×10-4 1.2927 2.3852×10-5 1.6770×10-3
v0 1.4778×10-5 0.0539 1.3525×10-5 1.6147×10-5
BT (µM) 1.3412×10+2 0.952 2.8015×10+1 6.4209×10+2
Vm1 (s-1 µM) 1.6071×10-2 0.1746 1.2060×10-2 2.1417×10-2
Vm2 (s-1 µM) 4.0086×10-3 0.1465 3.1500×10-3 5.1013×10-3
km1 (µM) 1.1400×10-6 0.3981 5.9221×10-7 2.1945×10-6
km2 (µM) 9.6828×10-6 0.1616 7.4231×10-6 1.2630×10-5
RSS = 2.3423×10+1
The fitted (estimated) parameter values, with estimates for their confidence levels are
presented in Tables 4.4-4.6. These parameter estimates correspond to the averaged data
fitting, high loader fitting and low loader fitting, respectively. In Table 4.4, which
corresponds to the averaged data fitting, it is seen that all parameters are well-determined
by the microscopy data. In addition, ten parameters, namely, ki, ke, kmi, kmo, kdl, v0, Vm1, Vm2,
km1 and km2, have low SDLN values corresponding to high confidence in their values.
However, the estimated parameter values for kb, kdh and BT have high SDLN values due to
the low signal-to-noise ratio in the experimental data. The value of CORImean = 2.00848 (in
the averaged fitting, Table 4.4) indicates that the residuals are acceptable and evenly
distributed above and below the simulated output of the model and therefore, the resulting
fit is considered to be good.
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Table 4.5: Best parameter estimates for high loading cell data obtained for the
model Equations (4.12), estimated using TPLSM data. The cellular hydrolysis
rate constants are fixed at values obtained from Table 4.2 (see Subsection 4.2.2)
for pH = 7.2 buffered solution where: kom = koc = 1.6 × 10-4 s-1 and kcm = kcc =
3 × 10-4 s-1.
Parameter Value SDLN 5% 95%
ki (s-1) 1.7762×10-1 0.1390 1.4130×10-1 2.2327×10-1
ke (s-1) 9.8046×10-3 0.3720 5.3167×10-3 1.8081×10-2
kb (s-1 µM-1) 5.3077×10-4 0.1611 4.0722×10-4 6.9180×10-4
kmi (s-1) 1.3585×10-6 0.0422 1.2674×10-6 1.4561×10-6
kmo (s-1) 1.0108×10-1 0.0521 9.2774×10-2 1.1013×10-1
kdl (s-1) 2.8264×10-2 0.1322 2.2741×10-2 3.5127×10-2
kdh (s-1) 1.1245×10-5 NWD - -
km2 (µM) 5.9031×10-2 0.5286 2.4741×10-2 1.4085×10-1
v0 1.1951×10-5 0.0866 1.0364×10-5 1.3782×10-5
BT (µM) 4.7215×10+1 0.3006 2.8795×10+1 7.7418×10+1
Vm1 (s-1 µM) 1.4157×10+1 0.1075 1.1862×10+1 1.6895×10+1
Vm2 (s-1 µM) 1.4245×10-1 0.1187 1.1717×10-1 1.7317×10-1
km1 (µM) 3.6341 0.2181 2.5387 5.2021
RSS = 3.2520×10+1
Table 4.6: Best parameter estimates for low loading cell data obtained for the
model Equations (4.12), estimated using TPLSM data. The cellular hydrolysis
rate constants are fixed at values obtained from Table 4.2 (see Subsection 4.2.2)
for pH = 7.2 buffered solution where: kom = koc = 1.6 × 10-4 s-1 and kcm = kcc =
3 × 10-4 s-1.
Parameter Value SDLN 5% 95%
ki (s-1) 7.3625×10-2 0.1893 5.3925×10-2 1.0052×10-1
ke (s-1) 7.8178×10-3 0.0478 7.2268×10-3 8.4571×10-3
kb (s-1 µM-1) 1.7577×10-4 0.2127 1.2387×10-4 2.4941×10-4
kmi (s-1) 9.1689×10-7 0.0844 7.9808×10-7 1.0534×10-6
kmo (s-1) 9.0915×10-2 0.0418 8.4878×10-2 9.7381×10-2
kdl (s-1) 4.0550×10-2 0.0832 3.5361×10-2 4.6501×10-2
kdh (s-1) 1.1362×10-5 NWD
km2 (µM) 7.5653×10-2 0.2066 5.3851×10-2 1.0628×10-1
v0 9.3481×10-6 0.1096 7.8054×10-6 1.1196×10-5
BT (µM) 1.2689×10+2 0.2292 8.7040×10+1 1.8500×10+2
Vm1 (s-1 µM) 7.3930 0.1341 5.9293 9.2181
Vm2 (s-1 µM) 6.1983×10-2 0.0615 5.6019×10-2 6.8583×10-2
km1 (µM) 8.4899×10-3 0.1856 6.2558×10-3 1.1522×10-2
RSS = 3.8679×10+1
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In Tables 4.5 and 4.6, which correspond to the high loader fitting and low loader fitting,
respectively, it is seen that the same one of the thirteen parameters (kdh) is not well-
determined (NWD) by the data. That is, small deviations from the obtained estimates for
the parameter kdh result in similar fits. The final estimates for the unknown model
parameter kdh were gained from multiple fits with a range of initial guesses. All well
determined parameters (in Tables 4.5 and 4.6) have low SDLN values corresponding to
high confidence in their estimated values. The one exception is km2 in the high loader
fitting and is due to low signal-to-noise ratio in the experimental data. The values of
CORImean = 0.75542 (in the high loader fitting) and CORImean = 1.61803 (in the low loader
fitting) indicate that the residuals (in both fits) are acceptable and evenly distributed above
and below the simulated output of the model and therefore, the resulting fits are good.
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Figure 4.12: Simulated output for averaged data for the model Equations (4.12), with
parameters taking values in Table 4.4, plotted (solid) against experimental data (circles).
Based on Tables 4.4 and 4.5, the rate constants for the flow of both Le(t) and Lm(t) into the
cytoplasm and extracellular pool (respectively) are higher in the high loader than the low
loader, suggesting that these parameters play important roles in transporting the active
form of the drug (TPTL) to the cellular pool. In addition, the binding constant (kb) at which
TPTL binds to DNA increases for the high loader, which offers another reason why the
cells receive more pharmacologically active drug. The binding affinity of the drug (km1) to
the efflux pump is around 428 times higher in the low loading cell, therefore, the drug
transporter mainly resists the anti-cancer agent TPT. The rate constant for dissociation of
bound drug (kdl) is relatively low for the high loading cell, providing another reason for the
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retention of the active form of the drug bound to DNA for these cells. Although the
concentration of TPTL in the nucleus for the high loader is relatively high compared to that
for the low loader, the value of BT in the low loading cell is larger. This suggests that the
efflux pumping mechanism plays a key role in the resistance of anti-cancer drugs.
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Figure 4.13: Simulated output for high loading cell data for the model Equations (4.12),
with parameters taking values in Table 4.5, plotted (solid) against experimental data
(circles).
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Figure 4.14: Simulated output for low loading cell data for the model Equations (4.12), with
parameters taking values in Table 4.6, plotted (solid) against experimental data (circles).
The plots shown in Figures 4.12-4.14 represent the model fits for the averaged data, high
loader and low loader, respectively. These fits show that there is close reproduction of the
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data by the simulated output from the model with parameters taking values from Tables
4.4-4.6. Figures 4.15-4.17 show normal probability plots of the three fittings, i.e. average,
high loader and low loader, and this is used to test whether or not the weighted residuals
are normally distributed. The residuals are plotted in ascending numerical order on the
horizontal axis, against cumulative probabilities in N(0, 1) transformed to a linear scale.
The figures are consistent with the assumption of normally distributed errors. This is an
indicator for the appropriateness of the standard error σi used for each observation yi.
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Figure 4.15: A normal probability plot for the residuals in the weighted non-linear least-
squares fit (averaged data) of the extended model Equations (4.12) to TPLSM data. The
residuals are plotted in ascending numerical order on the horizontal axis, against
cumulative probabilities in N(0, 1) transformed to a linear scale.
The estimated correlation matrices for the well-determined parameters in each of the fits
are given in Tables 4.7-4.9 (average data, high loader and low loader fittings, respectively).
The parameter pairings that exhibit noticeable (highest) correlation are: ki and kmi (-0.935),
ki and v0 (-0.938), kmi and v0 (0.933), ki and kmo (0.577), kb and BT (-0.995), kb and kdl (-
0.707), BT and kdl (0.774), BT and kdh (0.716), Vm1 and BT (-0.644) and Vm1 and Vm2 (0.631).
The pairs that involve BT and/or kb relate to the association/dissociation of TPTL to/from
DNA target. The pairs that involve Vm1 and/or Vm2 relate to the drug resistance mechanisms
in the cell, namely, ALDH and the BCRP/ABCG2 transporter. The rest of the pairings
relate to the crossing of the medium/extracellular region or extracellular region/cytoplasm
borders in which the modelling of this involves the ratio v0. Therefore, this parameter, i.e.,
v0, is important and other parameters depend on it in the model. The high correlation of the
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logarithms of these parameters indicates the significance of their product or ratio (i.e., drug
affinity) for the fitting procedure.
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Figure 4.16: A normal probability plot for the residuals in the weighted non-linear least-
squares fit (high loading cell data) of the extended model Equations (4.12) to TPLSM data.
The residuals are plotted in ascending numerical order on the horizontal axis, against
cumulative probabilities in N(0, 1) transformed to a linear scale.
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Figure 4.17: A normal probability plot for the residuals in the weighted non-linear least-
squares fit (low loading cell data) of the extended model Equations (4.12) to TPLSM data.
The residuals are plotted in ascending numerical order on the horizontal axis, against
cumulative probabilities in N(0, 1) transformed to a linear scale.
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Table 4.7: The estimated correlation matrix for the well-determined parameters for averaged data fitting
ki ke kb kmi kmo kdl kdh v0 BT Vm1 Vm2 km1 km2
ki 1 0.317 -0.204 -0.838 0.577 0.26 0.491 -0.926 0.233 0.101 -0.234 -0.201 -0.315
ke 0.317 1 -0.529 0 -0.098 -0.088 0.73 0.05 0.47 0.43 0.478 -0.471 0.184
kb -0.204 -0.529 1 0.038 0.023 -0.707 -0.74 0.021 -0.995 0.045 0.183 -0.152 0.104
kmi -0.838 0 0.038 1 -0.22 -0.301 -0.265 0.871 -0.087 0.008 0.401 0.073 0.306
kmo 0.577 -0.098 0.023 -0.22 1 0.158 0.105 -0.67 0.008 -0.149 -0.226 0.011 -0.305
kdl 0.26 -0.088 -0.707 -0.301 0.158 1 0.314 -0.311 0.774 -0.339 -0.562 0.372 -0.251
kdh 0.491 0.73 -0.74 -0.265 0.105 0.314 1 -0.258 0.716 0.017 -0.177 -0.187 -0.251
v0 -0.926 0.05 0.021 0.871 -0.67 -0.311 -0.258 1 -0.074 0.084 0.421 0.049 0.387
BT 0.233 0.47 -0.995 -0.087 0.008 0.774 0.716 -0.074 1 -0.086 -0.242 0.178 -0.127
Vm1 0.101 0.43 0.045 0.008 -0.149 -0.339 0.017 0.084 -0.086 1 0.631 -0.189 0.292
Vm2 -0.234 0.478 0.183 0.401 -0.226 -0.562 -0.177 0.421 -0.242 0.631 1 -0.487 0.638
km1 -0.201 -0.471 -0.152 0.073 0.011 0.372 -0.187 0.049 0.178 -0.189 -0.487 1 -0.4
km2 -0.315 0.184 0.104 0.306 -0.305 -0.251 -0.251 0.387 -0.127 0.292 0.638 -0.4 1
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Table 4.8: The estimated correlation matrix for the well-determined parameters for high loading cell data fitting
ki ke kb kmi kmo kdl km2 V0 BT Vm1 Vm2 km1
ki 1 0.45 -0.481 0.014 0.341 -0.324 -0.043 -0.176 0.259 0.424 0.676 -0.754
ke 0.45 1 -0.794 0.136 -0.138 0.033 -0.693 0.164 0.895 -0.241 0.678 -0.195
kb -0.481 -0.794 1 -0.029 -0.141 -0.104 0.246 0.062 -0.892 0.217 -0.56 0.281
kmi 0.014 0.136 -0.029 1 -0.526 0.113 -0.352 0.869 0.089 0.655 0.642 -0.288
kmo 0.341 -0.138 -0.141 -0.526 1 -0.317 0.529 -0.877 -0.113 -0.228 -0.28 -0.146
kdl -0.324 0.033 -0.104 0.113 -0.317 1 -0.165 0.243 0.362 -0.165 -0.094 -0.21
km2 -0.043 -0.693 0.246 -0.352 0.529 -0.165 1 -0.509 -0.527 0.109 -0.459 -0.002
v0 -0.176 0.164 0.062 0.869 -0.877 0.243 -0.509 1 0.117 0.509 0.534 -0.09
BT 0.259 0.895 -0.892 0.089 -0.113 0.362 -0.527 0.117 1 -0.373 0.521 -0.17
Vm1 0.424 -0.241 0.217 0.655 -0.228 -0.165 0.109 0.509 -0.373 1 0.534 -0.606
Vm2 0.676 0.678 -0.56 0.642 -0.28 -0.094 -0.459 0.534 0.521 0.534 1 -0.591
km1 -0.754 -0.195 0.281 -0.288 -0.146 -0.21 -0.002 -0.09 -0.17 -0.606 -0.591 1
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Table 4.9: The estimated correlation matrix for the well-determined parameters for high loading cell data fitting
ki ke kb kmi kmo kdl km2 v0 BT Vm1 Vm2 km1
ki 1 0.236 0.31 -0.935 0.389 -0.325 -0.365 -0.938 -0.367 0.521 0.65 0.158
ke 0.236 1 -0.431 -0.151 0.033 0.089 -0.542 -0.137 0.411 -0.176 0.126 0.181
kb 0.31 -0.431 1 -0.43 0.058 -0.201 0.383 -0.376 -0.948 0.599 0.131 0.176
kmi -0.935 -0.151 -0.43 1 -0.221 0.276 0.346 0.933 0.456 -0.559 -0.423 -0.331
kmo 0.389 0.033 0.058 -0.221 1 -0.181 0.089 -0.556 -0.109 0.115 0.072 -0.185
kdl -0.325 0.089 -0.201 0.276 -0.181 1 -0.249 0.297 0.501 -0.367 -0.33 0.472
km2 -0.365 -0.542 0.383 0.346 0.089 -0.249 1 0.267 -0.428 -0.146 -0.158 -0.58
v0 -0.938 -0.137 -0.376 0.933 -0.556 0.297 0.267 1 0.416 -0.51 -0.379 -0.218
BT -0.367 0.411 -0.948 0.456 -0.109 0.501 -0.428 0.416 1 -0.644 -0.218 0.005
Vm1 0.521 -0.176 0.599 -0.559 0.115 -0.367 -0.146 -0.51 -0.644 1 0.341 -0.019
Vm2 0.65 0.126 0.131 -0.423 0.072 -0.33 -0.158 -0.379 -0.218 0.341 1 -0.276
km1 0.158 0.181 0.176 -0.331 -0.185 0.472 -0.58 -0.218 0.005 -0.019 -0.276 1
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In order to study the variations across a high loader and a low loader, the extended drug
kinetics model (Equation (4.12)) was fitted to the high loading cell data and low loading
cell data simultaneously as shown in Figures 4.18-4.20. This fitting was performed by
assuming that such variations across cells are only due to differences between the
parameters relating to the ALDH enzyme and the BCRP/ABCG2 drug transporter. That is,
the parameters, ki, ke, kb, kmi, kmo, kdl, kdh, v0 and BT, are fixed in both cells and the
parameters Vm1, Vm2, km1 and km2 vary between both cells.
Table 4.10: Best parameter estimates for simultaneous fitting between high
loading cell data and low loading cell obtained for the model Equations (4.12),
estimated using TPLSM data. The cellular hydrolysis rate constants are fixed at
values obtained from Table 4.2 (see Subsection 4.2.2) for pH = 7.2 buffered
solution where: kom = koc = 1.6 × 10-4 s-1 and kcm = kcc = 3 × 10-4 s-1.
Common parameters
Parameter Value SDLN 5% 95%
ki (s-1) 1.04×10-1 0.152 8.13×10-2 1.34×10-1
ke (s-1) 8.86×10-1 0.2314 6.06×10-1 1.30
kb (s-1 µM-1) 1.34×10-3 0.5855 5.13×10-4 3.52×10-3
kmi (s-1) 2.83×10-6 0.0498 2.61×10-6 3.07×10-6
kmo (s-1) 7.97×10-2 0.0303 7.58×10-2 8.38×10-2
kdl (s-1) 3.57×10-3 0.0745 3.16×10-3 4.03×10-3
kdh (s-1) 1.8331×10-7 NWD
v0 3.43×10-5 0.0679 3.07×10-5 3.84×10-5
BT (µM) 9.28×10+1 0.4708 4.28×10+1 2.01×10+2
Parameters relating to the high loading cell
Parameter Value SDLN 5% 95%
Vm1 (s-1 µM) 2.47×10+1 0.0937 2.12×10+1 2.88×10+1
Vm2 (s-1 µM) 2.70×10-1 0.0859 2.35×10-1 3.11×10-1
km1 (µM) 2.74×10+1 0.1378 2.18×10+1 3.43×10+1
km2 (µM) 9.20×10-4 0.2274 6.33×10-4 1.34×10-3
Parameters relating to the low loading cell
Parameter Value SDLN 5% 95%
Vm1 (s-1 µM) 3.13×10+1 0.0767 2.76×10+1 3.55×10+1
Vm2 (s-1 µM) 5.78×10-1 0.0496 5.33×10-1 6.27×10-1
km1 (µM) 3.16 0.277 2.00 4.98
km2 (µM) 8.39×10-2 0.2263 5.79×10-2 1.22×10-1
RSS = 1.46139×10+2
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The fitted (estimated) parameter values with estimates for their confidences are presented
in Table 4.10, where it is seen that the parameter kdh is NWD by the data. That is, small
deviations from the obtained estimate for the unknown model parameter kdh will result in
similar fits. The estimated parameter values for kb and BT have high SDLN values due to
the low signal-to-noise ratio in the experimental data from the nucleus and cytoplasm,
particularly for the high loader (see Figures 4.19 and 4.20). However, the rest of the
parameter estimates in Table 4.10 have low SDLN values corresponding to high
confidence in their values. The value of CORImean = 4.29423 (in the simultaneous fitting)
indicates that the residuals are acceptable and evenly distributed above and below the
simulated output of the model and therefore, the resulting fit is good.
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Figure 4.18: Simulated output of the extracellular region for simultaneous fitting of the
high loading cell data and the low loading cell data for the model Equations (4.12), with
parameters taking values in Table 4.10, plotted (solid) against experimental data (circles).
Based on Table 4.10, the binding affinity of the inactive form of the drug (km1) to the efflux
pump is higher in the low loading cell, as expected, the efflux pumping mechanism plays a
key role in the resistance of anti-cancer drugs. In addition, the results obtained in the
simultaneous fitting are consistent with the previous results, that is, the drug transporter
(BCRP/ABCG2) is a key factor in resisting TPT. The plots shown in Figures 4.18-4.20
represent the simultaneous model fits for the extracellular region, nucleus and cytoplasm,
respectively. These fits show that there is close reproduction of the data by the simulated
output from the model with parameters taking values from Table 4.10. Figure 4.21 shows a
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normal probability plot of the simultaneous fitting. The residuals are plotted in ascending
numerical order on the horizontal axis, against cumulative probabilities in N(0, 1)
transformed to a linear scale. The figures are consistent with the assumption of normally
distributed errors. This is an indicator for the appropriateness of the standard error σi used
for each observation yi.
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Figure 4.19: Simulated output of the nucleus for simultaneous fitting of the high loading cell
data and the low loading cell data for the model Equations (4.12), with parameters taking
values in Table 4.10, plotted (solid) against experimental data (circles).
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Figure 4.20: Simulated output of the cytoplasm for simultaneous fitting of the high loading
cell data and the low loading cell data for the model Equations (4.12), with parameters
taking values in Table 4.10, plotted (solid) against experimental data (circles).
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Figure 4.21: A normal probability plot for the residuals in the weighted non-linear least-
squares fit (low loading cell and high loading cell data simultaneously) of the extended
model Equations (4.12) to TPLSM data. The residuals are plotted in ascending numerical
order on the horizontal axis, against cumulative probabilities in N(0, 1) transformed to a
linear scale.
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Figure 4.22: Simulated output for Lc and Hc of a high loader and a low loader for the model
Equations (4.12), with parameters taking values in Table 4.10.
An advantage of mathematical modelling is to infer from the model information relating to
state variables of the system (in this case, the extended cell cycle model) that are not
directly measured (i.e., parts of the system that are not accessible) [13]. For example, in the
cytoplasm it is the total concentration of the drug (Lc + Hc) that is directly observed (using
Chapter 4: The in vitro kinetic model 98
microscopy, see Section 4.5.1). However, using the model, it is possible to separately
predict the concentrations of TPTL and TPTH in the cytoplasm (i.e., Lc and Hc,
respectively). Figure 4.22 shows simulated output from the extended drug kinetics model
(with parameters taking values in Table 4.10) for Lc and Hc in a high loader and a low
loader. The concentrations of the active form of the drug in the cytoplasm (Lc) are almost
indistinguishable between the high loader and low loader and converge over time. In
addition, the concentrations of the inactive form of the drug in the cytoplasm (Hc) differ
noticeably between both cells and diverge over time. As expected, the efflux pumping
mechanism resulting from the BCRP/ABCG2 transporter accounts for reducing the
concentration of TPT in the cell.
4.6 Sensitivity analysis
It was shown from the previous section that the main differences between the model
predictions, for the high loader and low loader, using the parameter values in Table 4.10 is
the concentration of TPTH in the cytoplasm (i.e., Hc) and the concentration of TPTL in the
nucleus (Ln). Other predicted output does not seem to be sensitive to the different values
assumed for the binding affinity (km1) of TPTH (in the cytoplasm) to the BCRP/ABCG2
transporter and the binding affinity (km2) of TPTL (in the cytoplasm) to the enzyme ALDH.
In this section the impact of varying the values for km1 and km2 is considered with respect to
individual state variable and predicted dose response at the target (nuclear DNA).
4.6.1 Sensitivity analysis of the single-cell model
The impact of varying the values for the binding affinity of TPTH to the transporter, km1, is
shown in Figure 4.23 Parameters in the single-cell model were assigned values from the
high loader fit (for demonstration purposes) in Table 4.10, and the parameter km1 was
varied in the range of 2.74×10-1-2.74×10+2 µM. The values are: (a) 2.74×10-1 µM, (b) 2.74
µM, (c) 2.74×10+1 µM and (d) 2.74×10+2 µM. The only model variable exhibiting
noticeable variation in simulation was Hc when varying km1. Decreasing the binding
affinity of TPTH to the BCRP/ABCG2 transporter (i.e., increasing the value of the
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parameter km1) results in an increase in the concentration of TPTH in the cytoplasm. This is
not surprising since the drug is retained in the cytoplasm and is not flushed out of the cell
when the binding affinity decreases.
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Figure 4.23: Simulated output for Hc from the model Equations (4.12), with parameters
taking values in Table 4.10, while varying the binding affinity of TPTH to the
BCRP/ABCG2 transporter km1 in the ranges (a) 2.74×10-1 µM to (d) 2.74×10+2 µM.
The impact of varying the values for the binding affinity of TPTL (in the cytoplasm) to the
enzyme ALDH, km2, is shown in Figures 4.24 and 4.25. Parameters in the single-cell model
were assigned values from the high loader fit in Table 4.10, and the parameter km2 was
varied in the range of 9.2×10-4-9.2×10+2 µM. The values are: (a) 9.2×10-4 µM, (b) 9.2×10-2
µM, (c) 9.2 µM and (d) 9.2×10+2 µM. The only model variables exhibiting noticeable
variation in simulation were Hc (Figure 4.24) and Ln (Figure 4.25) when varying km2. As
expected, decreasing the binding affinity of TPTL (in cytoplasm) to the enzyme ALDH
(i.e., increasing the value of the parameter km2) results in a decrease in the concentration of
TPTH in the cytoplasm (Hc), as shown in Figure 4.24. That is, decreasing the binding
affinity results in a decrease in the drug resistance caused by the enzyme ALDH. In
addition, increasing the value of the parameter km2 (i.e., decreasing the binding affinity of
Lc to the enzyme) results in an increase in the drug bound to nuclear DNA (Figure 4.25).
The lack of sensitivity of the state variable Lc to variation in km2 suggests that this is not the
key process for the presence of TPTL in the cytoplasm. However, the passive influx/efflux
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of TPTL across the plasma membrane in addition to its association/dissociation are more
crucial. These results confirm that the enzyme ALDH is another key factor in resisting
TPT.
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Figure 4.24: Simulated output for Hc from the model Equations (4.12), with parameters
taking values in Table 4.10, while varying the binding affinity of TPTL to the enzyme ALDH
km2 in the ranges (a) 9.2×10-4 µM to (d) 9.2×10+2 µM.
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Figure 4.25: Simulated output for Ln from the model Equations (4.12), with parameters
taking values in Table 4.10, while varying the binding affinity of TPTL to the enzyme ALDH
km2 in the ranges (a) 9.2×10-4 µM to (d) 9.2×10+2 µM.
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4.6.2 Sensitivity of dose response
As explained in Section 4.5, the impact of the dose (following the drug administration) can
be measured by calculating the AUC for Ln corresponding to the initial dose D, i.e.,
AUC(Ln, D). Similar to the approach used in Evans et al. [13], the therapeutic impact of a
dose was measured by AUC(Ln, D) over the first hour (3600 s) following drug
administration. Simulations were performed with D taking values from 0.1 μM to 20 μM 
for the high loading cell (Figure 4.26) and low loading cell (Figure 4.27).
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Figure 4.26: AUC for Ln over 3600 seconds (1 hour) against dose D using the parameter
values for the high loader.
For both the high loading cell and low loading cell, at low values for the dose D the impact
is relatively low. As the value of the dose D increases up to 8 μM (in the high loading cell) 
and 10 μM (in the low loading cell) the rate of change of AUC with respect to dose starts 
increasing. In the low loading cell (Figure 4.27) increasing the dose D results in an
increase in the rate of change of AUC with respect to dose, however, in the high loading
cell at around D = 15 μM, the slope of the impact starts decreasing. This suggests that there 
is a maximum damaging effect on cells and further increase in the treatment regimen will
not have further therapeutic impact on cells, as cells might be fully damaged, i.e., all DNA
binding sites are occupied by the drug.
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Figure 4.27: AUC for Ln over 3600 seconds (1 hour) against dose D using the parameter
values for the low loader.
4.7 Summary
In summary, this chapter presents a state-space model for the in vitro uptake kinetics of the
anti-cancer agent TPT has been extended from a previously published model by Evans et
al. [13]. The extended model describes drug activity and delivery of the pharmacologically
active form to the DNA target as well as the catalysis of the ALDH enzyme and the
elimination of drug from the cytoplasm via the efflux pump. Structural identifiability
analysis of the cell-based model was performed using the software tool MATHEMATICA
which demonstrates that all of the unknown model parameters are uniquely determined by
the output structure corresponding to the real experiment. Parameter estimation was
performed using the software tool FACSIMILE. Model simulations have been compared with
MCF-7 cells and found to give good qualitative agreement. This model will be used in the
drug kinetics/dynamics model in Chapter 6.
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5 The cell cycle model
5.1 Introduction
In recent years, molecular biologists have revealed a wealth of information about the
proteins regulating and controlling cell growth and division (i.e., the cell cycle and mitosis)
in eukaryotic cells [157]. Moreover, the dynamic properties of this complex regulatory
system defy intuitive reasoning alone. Quantitative tools using software packages are
necessary to probe, understand and reliably predict the behaviour of such networks (i.e.
cell cycle control). In this thesis, the hypothetical molecular mechanisms (molecular wiring
diagrams) of the cell cycle are converted into sets of non-linear ODEs in computer-
readable form [207]. Numerical solution of the ODEs can then be compared with
experimental results (observations) to determine unknown model parameters (including
kinetic rate constants) and to confirm the adequacy of the mathematical model. The
mathematical model describing the cell cycle events, with mechanistically meaningful
equations and rate constants, is derived with the intention of giving precise simulations of
known observations (experimental results). Such models once validated may also allow
predictions about the behaviour of the system that can be verified experimentally.
This chapter presents a mathematical model describing the growth of single human cells in
the absence of the anti-cancer agent TPT. The cell cycle model described in this thesis is a
novel extension of a previously published model by Pomerening et al. [14] (for Xenopus
laevis embryos) to account for the inhibitory action of the protein p21CIP1/WAF1 (under the
transcriptional control of p53, see Section 3.3) on Cyclin B1. The extended model is based
on underlying biological assumptions of the cell cycle process, and the unknown model
parameters of the proposed model are estimated from high-resolution fluorescence of
Cyclin B1 data (see Section 5.2) from live human osteosarcoma cells (U-2 OS cell line)
provided by the project collaborators at Cardiff University. The analytical and numerical
methods described in Chapter 2 are used to study the cell cycle process presented in this
work.
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5.2 Cyclin B1-GFP experiments
Critical to modelling the sequence of events of the cell cycle process is the ability to
undertake high spatio-temporal resolution monitoring of the cell cycle progression using
green fluorescent protein (GFP) cell cycle phase markers (CCPMs). This monitoring
technique allows the continuous tracking of single cell checkpoint transitions within a
heterogeneous population in a non-destructive (non-invasive) manner. The GFP-based
probe has expression, localisation and destruction characteristics that shadow the dynamic
behaviour of the Cyclin B1 regulator (during the cell cycle) in living cells [159]. That is,
the status of the cell cycle is monitored and reported by dynamic stealth sensors based on
the expression, localisation and degradation of GFP under the control of one of the key
components of the cell cycle regulators, the Cyclin B1 protein. These sensors can precisely
and non-invasively determine the status of the cell cycle in living cells by fluorescence
imaging, i.e., without perturbing the progression of the cell cycle. The performance of the
non-invasive stealth reporter has been validated on high content to high throughput
detection platforms including multi-well high-throughput screen (HTS) imaging, single
cell kinetic-tracking and multi-parameter flow cytometry [107, 159, 208]. HTS is a method
of scientific experimentation used particularly in the field of drug discovery and the related
fields of biology and chemistry. This method allows researchers to rapidly conduct
millions of biochemical and pharmacological tests.
Cyclin B1-GFP tracking provides important sub-phase information about the progression
of the cell cycle, the dynamics of the cell-cycle regulator (Cyclin B1) in parallel with
morphological landmarks and DNA content analysis (Figure 5.1). Moreover, this time-
lapse microscopy provides a means for understanding the subtleties in cell cycle event
patterns such as delayed versus arrested patterns [209, 210]. The continuous progression of
the cell cycle traverse and encoded molecular readouts in bifurcation cell lineages have
been tracked to enable data extraction with subsequent linking to phenotypic cellular
behaviour in both normal conditions (i.e., in the absence of TPT), and in response to
treatment with the anti-cancer drug TPT (Chapter 6). In experimental terms, a cell lineage
is defined as a descent in a line from a mutual progenitor (origin or starting cell) that was
exposed to a given influence for a discrete time period [211]. The behaviour of both the
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progenitor and the descending line of offspring (descendants) demonstrates the time-
integrated cell cycle response (in the absence of the anti-cancer drug TPT) and dynamic
response (in the presence of TPT) [210, 212]. Examples of such responses include changes
in the inter-mitotic time (IMT), i.e., the temporal distance between two consecutive cell
divisions, as well as cell death [211]. The experimental data provide the essential data upon
which the cell cycle model is both developed and validated to a certain degree.
(a) (b)
Figure 5.1: Human osteosarcoma cell (U-2 OS cells): (a) Expressing a Cyclin B1-GFP
stealth reporter. (b) A corresponding transmission image to identify all the cells in the field
of view (taken from Reference [107]).
The parental cell line used in this thesis was a human osteosarcoma cell line (U-2 OS)
derived from a 15 year old Caucasian female. U-2 OS cells were transfected (by the project
collaborators at Cardiff University) with G2M CCPM (GE Healthcare, UK) using the
transfection reagent Fugene (Roche). Tracking cell cycle progression using the high-
resolution fluorescence microscopy was performed with cells seeded into a multi-well
coverslip-bottomed plate. Each well represents a different treatment regimen (a dose range
for the anti-cancer agent TPT of 1-10 µM, see Section 6.2) in addition to a control well
(untreated cells). Cyclin B1-GFP data used for estimating the unknown parameters of the
extended cell cycle model (see Sections 5.3, 5.4 and 5.5) are for untreated single human
osteosarcoma cells. The cultured dishes were placed onto a time-lapse instrument designed
to capture bright-field phase images and Cyclin B1-GFP fluorescence images. Sequences
of images were captured every 20 minutes for 48 hours (h), in triplicate, i.e. three regions
of interest (ROI’s), in the control experiment.
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For the cell of interest, in each image frame, three ROIs are used to extract parameters
from the raw image sequence (using FLUROTRAK, a bespoke software tool by the Cardiff
collaborators) viewed in the image analysis software METAMORPH. The first ROI is
positioned on the nucleus and the other two ROIs are positioned on the cytoplasmic
regions (usually, on the opposite sides of the nucleus of the cell of interest). Once the ROIs
are placed, the cell of interest is tracked frame by frame for 48 h (resulting in a total of 144
frames) starting at frame one. A normal cell division results in two daughter cells, however
in some cases, a progenitor cell can abnormally generate three or four individual daughter
cells, i.e., cells can produce re-fused and/or polyploidy (when cells have more than two
pairs of chromosomes) outcomes. The extended cell cycle model in this thesis looks into
cells that experience normal cytokinesis (see Section 3.3) and such outcomes (i.e. re-fused
or polyploidy) are not in the scope of this work.
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Figure 5.2: Continuous Cyclin B1-GFP intensity profile track extracted from an untreated
G2 cell, three compartments were tracked, the nucleus (blue) and two regions of interest in
the cytoplasm (red and green) respectively.
Continuous cell cycle tracking at the single cell level (i.e., a typical time-lapse microscopy
image sequence) shows cells traversing the cell cycle and fluorescence changes (see Figure
5.2) as the cell progresses to M phase from G1. Individual cells rapidly increase Cyclin B1-
GFP expression (i.e. become brighter) and a translocation event from the cytoplasm to the
nucleus compartment occurs (prior to mitosis) via the cytoplasmic retention signal [213].
That is, the fluorescent G2M CCPM reporter system relies on the control of location and
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levels of expression of GFP (driven by the promoter region and removal via the destruction
box) as cells progress to the later phases of the cell cycle and negotiate entry and exit to the
M phase. This is attained by utilising the functional components from the Cyclin B1
protein to confer switch-like properties to the stealth reporter. Expression levels of Cyclin
B1 are tightly regulated and act as a control switch that is appropriate for transition from S
phase through G2 into mitosis (and cytokinesis). Due to the absence of the cyclin box from
the reporter, the stealth sensor does not interfere or perturb the progression of the cell
cycle.
A typical cell lineage over 48 h illustrates cellular information at two levels: (a) phenotypic
behaviour (cell division represented by M) and (b) Cyclin B1-GFP reporter readout, i.e.,
fluorescence intensities in arbitrary units (a.u.) and hence, position in the cell cycle process
at the single cell level as shown in Figure 5.2. The continuous progression of the cell cycle
traverse between the two landmarks, represented by the mitotic events (M1 and M2) at both
ends was demonstrated for a typical cell in the G2 phase of the cell cycle.
5.3 Mathematical model of the cell cycle
Most molecular elements are affected by the cell cycle, however, this process is controlled
by a very limited set of biochemical interactions containing a few tens of components
[214]. Some of these interactions are essential, while preventing other biochemical
interactions does not prohibit the cell cycle and division process [215]. The cell cycle
process happens as a result of external signalling, however, in the case of tumours, this
tight regulation is absent (both intra- and extracellular) [215], and an internal set of
protein-protein interactions and genetic regulation can result in unconstrained cell cycle
division [216]. Accordingly, it can be assumed that the oscillations in the cell cycle process
can be ascribed to a simple oscillatory core which has also been named an oscillophore by
Goldstein et al. [217]. Such unlimited cell cycles that are not controlled by external
stimulations and/or feedback mechanisms from the size of the cell are frequent [163, 218-
220].
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5.3.1 Cell cycle models
One of the major challenges for theoretical molecular biologists is to describe the
physiology of cell proliferation in a wide assortment of unicellular and multi-cellular
eukaryotes in terms of their underlying molecular control systems. Therefore, such
molecular connections are necessary which will be made by developing mathematical
(computational) models that reflect the complexity of real cell cycle controls [221, 222]. In
order to design such models and understand how they function, the basic control
mechanisms should be well understood.
Within the field of cancer research, significant efforts have been devoted to modelling the
cell cycle process [14, 157, 221, 223-242]. The large number of such mathematical models,
often based on different components and different feedback loops, indicates that the same
biological response can be described using different mathematical techniques [243].
Accordingly, a criterion for selecting an appropriate mathematical description is required.
Most existing ODE-based cell cycle models are based on a hysteresis mechanism, such as
the mathematical models of the cell cycle process developed by Tyson and Novak [157]
(for yeast cells) and Pomerening et al. [14, 244], or on an oscillophore which was proposed
by Goldbeter [224], and later adopted by several research groups including Hatzimanikatis
et al. [223] as well as Tyson and Novak [157], each with different components, but having
the same structure [243]. In the first group of cell cycle models, i.e., the models based on a
hysteresis mechanism, the internal parameters are of no vital importance, since the external
parameters determine both the presence and the length of the cell cycle. However,
oscillophores can be sensitive to parameter changes. The paper by Clyde et al. [245] is an
excellent review on the development of cell cycle models.
5.3.2 The extended cell cycle model
The cell cycle model described in this thesis is an extended version of the model developed
by Pomerening et al. [14] to account for the inhibition dynamics of p21CIP1/WAF1 protein on
Cyclin B1 for mammalian cells. In this model, biochemical mechanisms are translated into
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systems of non-linear ODEs by the law of mass action. That is the mathematical modelling
of the cell cycle process involves the construction of ODEs to describe protein interaction
networks that regulate the cell cycle process. Moreover, dynamical systems theory is used
to analyse the qualitative behaviour of these equations and to bridge the gap between
mechanisms and theoretical molecular biology. The original cell cycle model [14] relies on
a hysteresis mechanism, and therefore, the choice was made on this set of models since the
cell cycle may vary in length as well as in the concentration of its different components,
and the presence of an oscillophore appears not to be sensitive to the precise properties of
the elements used to steer the cell cycle [243].
Nurse [246] proposed that the DNA replication-division cycle in all eukaryotic cells is
regulated by a common set of protein interaction networks (i.e. the key elements and
biochemical interactions are similar in eukaryotes), which has been confirmed by
numerous experimental studies [214, 247]. However, the mix of these proteins and
interactions varies among organisms and therefore, each organism generates its own
idiosyncrasies of cell growth and division. The generic features of the cell cycle control
involve these common genes and regulatory proteins in addition to the general dynamic
principles by which they coordinate the replication and division of the genome from the
mother cell to offspring (two daughter cells). The peculiarities of the cell cycle process
concern exactly which parts of the common mechanisms are functioning in any given cell
type, given the genetic background and developmental stage of an organism [247].
Therefore, given the data available (i.e., Cyclin B1-GFP data, see Figure 5.2), the cell
cycle model in this thesis is adopted from the mathematical model in Pomerening et al.
[14] which was originally derived for the cell cycle of Xenopus laevis (African clawed
frog) embryos to model the cell cycle control systems in mammalian cells.
The original model of Pomerening et al. [14] is similar in many ways to that of Tyson and
Novak [157] (for yeast cells): both rely on a hysteresis mechanism and the governing
equations account for the regulation of CDK1/Cyclin B1. When comparing the simulation
results of the governing equations of Pomerening et al. [14] in Figure 5.3 and Tyson and
Novak [157] in Figure 5.4, the original cell cycle model by Pomerening et al. [14]
reproduces closer qualitative agreement to experimentally observed results in Figure 5.5
(i.e., Cyclin B1-GFP experiments). Accordingly, the choice has been made to extend the
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previously published cell cycle model by Pomerening et al. [14] to mathematically
describe the cell cycle process to account for the effects of CKI p21CIP1/WAF1, using Cyclin
B1-GFP data from high-resolution fluorescence microscopy experiments for live human
osteosarcoma cells.
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Figure 5.3: Simulation of CDC2/Cyclin B1 activity using the cell cycle model of Pomerening
et al. [14] for Xenopus laevis embryos.
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Figure 5.4: Simulation of CDK1/Cyclin B1 activity using the cell cycle model of Tyson and
Novak [157] for yeast cells.
The cell cycle process of the Xenopus laevis embryo is a prominent example of a robust
biological oscillator. In addition, the cycles of CDC2 (or CDK1) activation and
inactivation are quasi-synchronous and rapid with a limited variability among embryos
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[244]. The cycles of the Xenopus laevis embryo continue with relatively normal timing and
amplitude even under conditions when the embryos are enucleated [248] or when cell-
cycle endpoints (such as DNA replication and spindle assembly) are met. According to the
observations, the embryonic cell cycle is driven by an autonomous, modular, clock-like
regulatory circuit centred on CDC2 (or CDK1) and the APC [249, 250].
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Figure 5.5: Average cytoplasmic Cyclin B1-GFP intensity profile track of the untreated G2
cell in Figure 5.2.
The original cell cycle model by Pomerening et al. [14] is based on a simplified model for
the CDC2 (or CDK1)/APC system (see Section 3.3), as shown in Figure 5.6. Synthesis and
gradual accumulation of the major mitotic cyclin (Cyclin B1 protein) drives the cell into
mitosis. This accumulation results in the binding of Cyclin B1 to CDK1 (CDC2), and,
under appropriate conditions, the CDK1/Cyclin B1 dimer becomes active and
phosphorylates mitotic substrates, hence driving the G1/S transition (Start), see Section 3.3.
The transition from M phase back to G1 (Finish) is driven by a negative-feedback loop; the
active CDK1/Cyclin B1 dimer activates the APC, resulting in polyubiquitination7 [251]
and proteolysis (degradation of proteins) of Cyclin B1 [252-254]. The presence of a
negative-feedback loop does not guarantee persistent oscillations of the CDC2/APC
network. The importance of this negative-feedback loop for mitotic oscillations was
demonstrated experimentally when APC-resistant cyclin mutants were added to Xenopus
7 Polyubiquitination: modification of a protein by the addition of one or more ubiquitin monomers.
Ubiquitins are polypeptides involved in modifying and degrading proteins.
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egg extracts in the G1 phase (interphase), the extracts approached a steady state rather than
oscillating [255].
Figure 5.6: At G1, APC negates the activity of CDC2 (or CDK1) by degrading the major
mitotic cyclin (Cyclin B1), while the activity of APC is inhibited by the CDK1/Cyclin B1
dimer (redrawn from Reference [107]).
Figure 5.7: Schematic depiction of the CDC2/APC network by Pomerening et al. [14].
A long negative-feedback loop (in some cases) by itself is sufficient to produce
oscillations. However, the CDC2/APC network in Pomerening et al. [14] contains two
additional elements (i.e., in addition to the long negative-feedback loop) in the circuit
presented in Figure 5.7: a double-negative-feedback loop and a positive-feedback loop
centred on Cyclin B1/CDC2 [14, 244], as shown in Figure 5.7. That is, active Cyclin
B1/CDC2 phosphorylates and activates its activator (represented by the positive-feedback
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loop), the phosphatase CDC25 (Figure 3.10, Section 3.3). Moreover, active Cyclin
B1/CDC2 phosphorylates and inactivates its inhibitors (represented by double-negative-
feedback loop), Wee1 and Myt1 protein kinases (Figure 3.10, Section 3.3).
Figure 5.8: Schematic depiction of the CDC2/APC network in the extended model to
contain an additional circuit element, a negative-feedback loop to account for the inhibitory
action of p21CIP1/WAF1.
In this thesis, the original cell cycle model by Pomerening et al. [14] has been extended to
contain an additional circuit element, a negative-feedback loop, to account for the
inhibitory action of p21CIP1/WAF1 as shown in Figure 5.8. The CKI p21CIP1/WAF1 and Cyclin
B1/CDC2 are antagonist proteins, in fact, tumour cells induce the accumulation of this CKI
under the transcriptional control of p53. The accumulating p21CIP1/WAF1 binds to the Cyclin
B1/CDC2 dimer and therefore inhibiting its activity for initiating DNA synthesis (see
Section 3.3). This results in stabilising the G1 state (G1 arrest in some cases) of the cell
cycle process. These loops could function as a bistable system (switch) [14, 221, 236, 244]
with a hysteretic steady-state stimulus/response relationship [256], toggling between two
discrete steady states, namely, the G1 state and the S-G2-M state. A system is bistable if it
can switch between two discrete alternative states without being able to rest in an
intermediate state (Figure 5.9). In the first case (i.e., G1 phase), CDC2 and CDC25 are
inactive while Wee1, Myt1, APC and p21CIP1/WAF1 are active and in the second stable state
(i.e., S-G2-M state), CDC2 and CDC25 are active while Wee1, Myt1, APC and
p21CIP1/WAF1 are inactive.
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A bistable trigger in the extended cell cycle model and the original model (Figures 5.7 and
5.8, respectively) is critical for the function of a mitotic oscillator by ensuring that a cell
settles in a discrete, mutually exclusive G1 phase and S-G2-M state and not in a continuum
of intermediate states [221, 257]. The system will approach a high activity (S-G2-M state)
of CDC2 above a critical concentration of non-degradable Cyclin B1 and below some
other lower concentration of Cyclin B1, the system will approach a low CDC2 activity (G1
state). At an intermediate concentration of Cyclin B1, the system will approach either the
G1 state or S-G2-M state depending upon the initial conditions, but the system does not
settle in a state with a partially activated pool of CDC2. This property (i.e., bistability of
CDC2 activation) minimises chattering (slipping rapidly back and forth between cell cycle
phases) during the transitions into and out of S-G2-M. The advantage of the bistability
property is to ensure that the mitotic oscillator will never approach a stable steady-state.
Adding a bistable trigger to the negative-feedback loop (i.e., Cyclin B1 destruction and
CDC2 inactivation by APC) as suggested by Pomerening et al. [14] in Figure 5.7, in
addition to the second negative-feedback loop (the inhibition effect by the p21CIP1/WAF1
protein) in the extended model (Figure 5.8) also produces sustained oscillations with
explosive spikes of CDC2 activity, resulting in a relaxation oscillator. This category of
oscillators is suitable as a biological timer [14] and has advantages over simple negative-
feedback oscillators in terms of noise rejection, reliability, spatial propagation and self-
synchronisation [258-260].
Figure 5.9: The bistable response could arise from a combination of ultra-sensitivity and
positive feedback (redrawn from Reference [14]).
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Pomerening et al. [14] have experimentally determined that the CDC2 system is bistable.
That is, the response of CDC2 to active Cyclin B1 protein is temporally abrupt and switch-
like. Moreover, it has been shown in the study by Pomerening et al. [14], that the
activation of CDC2 exhibits hysteresis. The Cyclin B1-GFP data shown in Figure 5.10 (see
Section 5.2) reflect CDC2 activity (Cyclin B1-GFP fluorescence intensities) of two
different daughter cells (labelled Track 1 and Track 3) from the same progenitor cell. The
time course of the activation of CDC2 in response to Cyclin B1 exhibits a temporal lag that
precedes abrupt transition (G2/M) between low and high Cyclin B1-GFP intensity (Figure
5.10), i.e., CDC2 activation. This means that the rate of CDC2 activation increases with
CDC2 activity. Therefore, the activation of CDC2 is bistable, this observed temporal
abruptness (highly switch-like with explosive spikes) is consistent with the predicted
behaviour of bistable systems. Another feature of bistable systems is the discontinuity in
the steady-state level of CDC2 activity as a function of Cyclin B1 concentration. These
observations in Figure 5.10 are consistent with a bistable response, that is, small changes in
Cyclin B1 result in large changes in CDC2 activity.
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Figure 5.10: Average cytoplasmic Cyclin B1-GFP intensity profile along two different
tracks (Track 1 and Track 3) resulting from the same progenitor (untreated) cell of the
exemplar lineage (see Figure 5.2).
Temporal abruptness (between low and high CDC2 activity) and discontinuity in the
steady-state level of CDC2 activity (as function of Cyclin B1 concentration) can also be
detected in a highly switch-like, ultrasensitive, monostable system. A more definitive
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approach to distinguish between monostable and bistable responses is to examine
hysteresis in the response of CDC2 to Cyclin B1. A monostable system will approach the
steady-state level of CDC2 activity for a given fixed Cyclin B1 concentration, in spite of
the history of the system. However, a bistable system will approach either of the two stable
steady states, namely, G1 state and S-G2-M state, depending on the history of the system.
Accordingly, as shown in Figure 5.9, the stimulus-response curve for a bistable system
should exhibit hysteresis, with a relatively low threshold for switching to the G1 state and
with a relatively higher threshold for switching to the S-G2-M state. The CDC2 activity is
bistable, the concentration of Cyclin B1 in Track 3 following the first division (Figure
5.10) is not sufficient to drive the cell from the G1 phase to the S-G2-M state as a result of
the inhibition of the CKI p21CIP1/WAF1 (G1 arrest). However, the concentration of Cyclin B1
in Track 1 following the first division is sufficient to maintain an S-G2-M state for long
periods of time resulting in another cytokinesis (second cell division) before switching
again to the G1 state. Therefore, the Cyclin B1-GFP data confirm that the CDC2 activation
exhibits hysteresis, which is consistent with the predicted behaviour of the cell cycle
process, i.e., the mitotic trigger is bistable.
Figure 5.11 provides a schematic diagram of the structure of the extended cell cycle model
of the CDC2/APC system including the effects of the CKI p21CIP1/WAF1. The biochemical
reactions (processes) of the postulated mathematical model are described by the following
system of non-linear ODEs:
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where the components in the square brackets refer to concentrations. In the extended model
of the CDC/APC system described by Equations (5.1)–(5.10), there are four different
forms of the Cyclin B1/CDC2 dimer: [CDC2CycB], [CDC2CycBYP], [CDC2CycBYPTP]
and [CDC2CycBTP] denote the concentrations (in nM) of the Cyclin B1/CDC2 dimer
forms, namely, non-phosphorylated complex (inactive), Y15-phosphorylated complex
(inactive), Y15- and T161-phosphorylated complex (inactive) and T161-phosphorylated
(active), respectively, at time t of the Cyclin B1-GFP tracking. The time-lapse microscopy
experiments provide intensity profiles of the active form of Cyclin B1/CDC2 complex
(T161-phophorylated complex) in the nucleus and cytoplasm compartments of human
osteosarcoma cells (U-2 OS cell line).
In the extended model, [CycB] and [CDC] are the concentrations (in nM) of free
(unbound) monomers of Cyclin B1 and CDC2 (CDK1), respectively. The APC, the protein
kinase Wee1, the phosphatase CDC25, and the CKI p21CIP1/WAF1 all exist in, active and
inactive forms (Figure 5.11). In the mathematical model described by Equations (5.1)-
(5.10), [APCactive], [Wee1active], [CDC25active] and [p21active] denote the concentrations (in
nM) of the active forms of APC, Wee1 protein kinase, CDC25 phosphatase and
p21CIP1/WAF1, respectively. In addition, their total concentrations (in nM) are denoted by
[APCtotal], [Wee1total], [CDC25total] and [p21total], respectively.
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Figure 5.11: Schematic diagram of the extended CDC2/APC model to account for the
effects of the CKI p21CIP1/WAF1.
In the extended model, the rate at which Cyclin B1 monomer ([CycB]) is synthesised is
modelled via zero-order chemical reaction with constant ksynth. Additionally, the rate at
which Cyclin B1 forms (monomer and dimers) are degraded is assumed to be proportional
(with the rate constant kdest) to the product of the sum of concentrations of the active forms
of APC and p21CIP1/WAF1 ([APCactive] + [p21active]), and their corresponding form of Cyclin
B1 (monomer and dimers). Therefore, the terms in Equations (5.1)-(5.5) that represent
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degradation (destruction) rate of Cyclin B1 (monomer and dimers) are dependent on the
activity of APC and p21CIP1/WAF1. That is, the rates of change of the Cyclin B1 monomer
and Cyclin B1/CDC2 dimers decrease with the activity of APC and/or p21CIP1/WAF1.
The rate at which Cyclin B1 binds to CDC2 (forming the inactive non-phosphorylated
complex) is assumed to be proportional, with the association rate ka, to the product of
concentrations of Cyclin B1 (monomer), [CycB], and free CDC2, [CDC2]. In addition,
dissociation of Cyclin B1 bound to CDC2 (i.e. [CDC2CycB]) occurs at a first-order rate,
with rate constant kd. According to Pomerening et al. [14, 244], the binding affinity of
Cyclin B1 to CDC (kd/ka) should be less than 1 nM. The constant [CDC2total] denotes the
total concentration of available CDC2, therefore, the concentration of free CDC2 is:
2 total YP
YPTP YPTP
[CDC2]( ) [CDC2 ] ([CDC2CycB]( ) [CDC2CycB ]( )
[CDC2CycB ]( ) [CDC2CycB ]( ))
t C t t
t t
  
 
. (5.11)
The parameter kWee1 represents the rate constant for the inactivation of Cyclin B1/CDC2
dimers, namely, the non-phosphorylated complex and the active Cyclin B1/CDC2 complex
(T161-phosphorylated complex) by Wee1 kinase. Therefore, the rate of this inactivation is
assumed to be proportional, with inactivation rate constant kWee1, to the product of the
concentrations of active Wee1 kinase ([Wee1active]) and Cyclin B1/CDC2 complexes
([CDC2CycB] and [CDC2CycBTP]). Moreover, the mechanism through which the progress
of the cell cycle traverse is switched from S-G2-M phase-like state to G1 phase-like state
depends on the basal activity of Wee1 kinase. As suggested by Pomerening et al. [14], it is
assumed that the accumulation of active Cyclin B1/CDC complex and non-phosphorylated
Cyclin B1/CDC2 complex (or inactive Wee1 kinase accumulation) triggers the switch
from S-G2-M phase-like state to G1 phase-like state, because the basal activity of Wee1
kinase is non-zero. Thereby, this accumulation drives the formation of a small amount of
inactive Cyclin B1/CDC2 complexes even in the S-G2-M state. Therefore, given that
[Wee1total] denotes the total concentration of Wee1 kinase (active and inactive forms), the
rates of Wee1 inactivation of active and non-phosphorylated Cyclin B1/CDC2 complexes
are assumed to be proportional, with inactivation rate constant kWee1basal, to the product of
concentrations of inactive Wee1 kinase ([Wee1total] - [Wee1active]) and the Cyclin B1/CDC2
complexes ([CDC2CycBTP] and [CDC2CycB]).
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The parameter kCDC25 represents the rate constant for the activation of Cyclin B1/CDC2
dimers, namely, the Y15-phosphorylated complex (inactive complex) and the Y15- and
T161-phosphorylated complex (inactive complex) by CDC25 phosphatase. Therefore, the
rate of this activation is assumed to be proportional, with inactivation rate constant kCDC25,
to the product of the concentrations of active CDC25 phosphatase ([CDC25active]) and
Cyclin B1/CDC2 complexes ([CDC2CycBYP] and [CDC2CycBYPTP]). Moreover, the
mechanism through which the progress of the cell cycle traverse is switched from G1
phase-like state to S-G2-M phase-like state depends on the basal activity of CDC25
phosphatase. Pomerening et al. [14] suggested that the accumulation of inactive Cyclin
B1/CDC2 complexes (namely, [CDC2CycBYP] and [CDC2CycBYPTP]) and/or the
accumulation of inactive CDC25 phosphatase trigger the switch from G1 phase-like state to
S-G2-M phase-like state, since the basal activity of CDC25 phosphatase is non-zero.
Thereby, this accumulation drives the formation of a small amount of active Cyclin
B1/CDC2 complex and non-phosphorylated complex even in G1 phase. Therefore, given
that [CDC25total] denotes the total concentration of CDC25 phosphatase (active and
inactive forms), the rates of CDC25 activation of inactive Cyclin B1/CDC2 complexes
([CDC2CycBYP] and [CDC2CycBYPTP]) are assumed to be proportional, with inactivation
rate kCDC25basal, to the product of concentrations of inactive CDC25 phosphatase
([CDC25total] - [CDC25active]) and the Cyclin B1/CDC2 complex ([CDC2CycBYP] and
[CDC2CycBYPTP]). The basal activities of Wee1 kinase and CDC25 are given by the
following:
Wee1
Wee1basal
CDC25
CDC25basal
kk
factor
kk
factor


(5.12)
where the parameter factor represents the strength of the feedback from CDC2 to Wee1
and CDC25 which is critical for the bistability of the CDC2/APC system.
In the extended cell cycle model, it is assumed that the dependence of APC, Wee1 kinase
and CDC25 phosphatase on CDC2 activity (T161-phosphorylated complex) is described
by Hill functions with Hill coefficients denoted by nAPC, nWee1 and nCDC25, respectively (see
Equations (5.7)-(5.9)) [14]. The EC50’s are the half maximal effective concentrations in the
Hill functions, and in the extended model, the EC50 concentrations (in nM) in the Hill
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functions relating to the rates of change of APC, Wee1 and CDC25 are denoted by
EC50APC, EC50Wee1 and EC50CDC25, respectively. The rate constants for turning on the
APC, the Wee1 kinase and the CDC25 phosphatase are denoted by kAPCon, kWee1on and
kCDC25on, respectively. The corresponding rate constants for turning them off (i.e., APC,
Wee1 and CDC25) are kAPCoff, kWee1off and kCDC25off, respectively.
In the extended cell cycle model of the CDC2/APC system described in this chapter, it is
assumed that the dependence of p21CIP1/WAF1 on CDC2 activity is described by a Hill
function with Hill coefficient denoted by np21 (Equation (5.10)). The EC50 concentration (in
nM) in the Hill equation relating to the rate of change of p21 is denoted by EC50p21. The
rate constants for turning the CKI p21CIP1/WAF1 on and off are denoted by kAPCon and kAPCoff,
respectively (Equation (5.10)).
Phosphorylation of CDC2 (CDK1) on T161 residue is necessary for CDC2 (CDK1) kinase
activity (activation). This site (i.e. T161) is activated (phosphorylated) by CAK in the
presence of Cyclin B1 (see Section 3.3) [261-263]. This activation (phosphorylation)
process is modelled by a first-order kinetic reaction, where kCAK denotes the rate constant
of the phosphorylation of the Y15-phosphorylated complex ([CDC2CycBYP]) on T161
residue, resulting in Y15- and T161-phosphorylated complex ([CDC2CycBYPTP]). Type 2C
protein phosphatases (PP2Cs) are essential physiological regulators of cellular growth and
of cellular stress signalling [264]. Additionally, it has been demonstrated that PP2Cs are
linked to the cellular stress response (a reaction to the threat of macromolecular damage
[265]) by inhibiting the cellular stress signalling. Moreover, it has been suggested that
PP2Cs dephosphorylate T-loop-activated kinases (i.e. CDC2 or CDK1) that are involved in
DNA damage [266]. This inactivation (dephosphorylation) process is modelled by a first-
order kinetic reaction, where kPP2C denotes the rate constant of the dephosphorylation of
the Y15- and T161-phosphorylated complex ([CDC2CycBYPTP]) on T161, resulting in
Y15-phosphorylated complex ([CDC2CycBYP]).
The original cell cycle model by Pomerening et al. [14] describes the CDC2/APC system
of Xenopus laevis embryos. The model has been extended to account for the effects of the
CKI p21CIP1/WAF1 to describe the cell cycle process of human osteosarcoma cells. Although
Chapter 5: The cell cycle model 123
the key elements and interactions within the cell cycle process are similar in most
eukaryotes, the interaction rate constants may vary significantly among organisms [243].
In addition, these rate constants may also vary widely between different cell types of the
same organism or within the same cell type under different conditions (e.g. cell size,
temperature, pH). Therefore, in the extended mathematical model describing the cell cycle
process, all values for the rate constants (which involve time units in them) have been
appropriately scaled (re-parameterised) with respect to time with the scaling factor C1 (see
Equations (5.1)-(5.11)), according to the live-cell data provided in Cyclin B1-GFP
experiments. The method for calculating the dimensionless constant C1 is described in
Section 5.5. In addition, concentrations of the cell cycle components (i.e. variables) vary
drastically among organisms, among different cell types and under different conditions
(external and internal). Therefore, in the extended cell cycle model, this has been taken
into consideration by appropriately scaling (re-parameterising) all the constant
concentrations with the same scaling factor C2 for simplicity (see Equations (5.1)-(5.11)),
according to the live-cell data provided in Cyclin B1-GFP experiments. In the extended
model, the scaling (by C2) includes the total concentrations of CDC2 ([CDC2total]), APC
([APCtotal]), Wee1 ([Wee1total]), CDC25 ([CDC25total]) and p21CIP1/WAF1 ([p21total]) as well
as EC50’s relating to the Hill functions of APC ([EC50APC]), Wee1 kinase ([EC50Wee1]),
CDC25 phosphatase ([EC50CDC25]) and CKI p21CIP1/WAF1 ([EC50p21]).
In the extended cell cycle model, seven new parameters were added to the original cell
cycle model by Pomerening et al. [14]. Five parameters were added to account for the
effects of the CKI p21CIP1/WAF1, these parameters are, the Hill coefficient np21, the half
maximal effective concentration EC50p21, the total concentration of p21CIP1/WAF1
([p21total]), the rate constant for activating p21CIP1/WAF1 (kp21on) and the rate constant for
switching p21CIP1/WAF1 off (kp21off). Two parameters, the scaling factors C1 (in time) and C2
(in concentration), were added to the extended cell cycle model to account for the
variations among organisms since the extended model presented in this chapter describes
the cell cycle process in mammalian cells (in the absence of TPT).
The corresponding initial conditions (i.e. at time t = 0 min) for the original cell cycle
model in Pomerening et al. [14] are given by:
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YP
YPTP TP active
active active
[CycB](0) 0, [CDC2CycB](0) 0, [CDC2CycB ](0) 0,
[CDC2CycB ](0) 0, [CDC2CycB ](0) 0, [APC ](0) 0,
[Wee1 ](0) 0, [CDC25 ](0) 0 and [CDC2](0) 100
  
  
  
. (5.13)
As a first attempt to determine the initial conditions for the extended cell cycle model, it is
assumed that p21CIP1/WAF1 functions in a similar manner to the APC (for simplicity).
Accordingly, the initial condition (i.e. at time t = 0) for the variable relating to the CKI
p21CIP1/WAF1 in the extended model is given by:
active[p21 ](0) 0 . (5.14)
Figure 5.12 represents the simulated output of the extended model (prior to scaling by C1
or C2), using the initial conditions in Equations (5.13) and (5.14) and assuming that the
parameters relating to the activity of p21CIP1/WAF1, namely, np21, EC50p21, [p21total], kp21on
and kp21off are equal to their corresponding parameter values relating to the activity of the
APC (Table 5.1). Based on the advice of the biological collaborators at Cardiff, the time at
which a new cell cycle starts can be identified in the model (Figure 5.12) as the point in
time, denoted by tG1, when the concentration of active CDC2/Cyclin B1 (i.e.
[CDC2CycBTP]) is the lowest and non-zero in a complete cell cycle process. In this case,
tG1 = 141.75 min (see Figure 5.12), and accordingly, the values of the variables in
Equations (5.1)-(5.11) were evaluated at tG1. Therefore, the corresponding re-parameterised
initial conditions (before scaling by C2) for the extended cell cycle model are given by:
YP YPTP
TP
active active
active
[CycB](0) 0.141396, [CDC2CycB](0) 0.992654,
[CDC2CycB ](0) 1.4763, [CDC2CycB ](0) 11.41023,
[CDC2CycB ](0) 1.64121, [CDC2](0) 84.479606,
[APC ](0) 3.8539,[Wee1 ](0) 15,
[CDC25 ](0) 1.
 
 
 
 
 active54009 and [p21 ](0) 3.8539
. (5.15)
This correction (re-parameterisation) step for the initial conditions has been performed
because in a real case, a small amount of the active form of Cyclin B1/CDC2 (i.e.
[CDC2CycBTP]) is formed even in the G1 phase of the cell cycle since the basal activity of
CDC25 phosphatase is non-zero. To ensure that this re-parameterisation does not affect the
qualitative behaviour of the extended cell cycle model, the output of the model was
simulated (prior to scaling by C1 or C2) using the initial conditions in Equations (5.15) and
assuming that the parameters relating to the activity of p21CIP1/WAF1, namely, np21, EC50p21,
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[p21total], kp21on and kp21off are equal to the corresponding parameters relating to the activity
of the APC (Table 5.1). The simulation results of the extended cell cycle model using the
re-parameterised initial conditions in Equation (5.15) illustrated in Figure 5.15, reproduce
close qualitative agreement to experimentally observed results (i.e. Cyclin B1-GFP
experiments in Figure 5.10).
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Figure 5.12: Simulation results of the extended cell cycle model to determine the conditions
at t = tG1. The horizontal sold red line indicates the lowest point in the activity of CDC.
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Figure 5.13: Simulation results of the extended cell cycle model using the initial conditions
given in Equation (5.14).
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In this chapter, parameter estimation was performed for one complete cell cycle starting at
G1 phase of a new born cell, i.e. at time t = tG1. Accordingly, in this chapter, time t = 0
corresponds to the time when the cell tracking began (at G2 phase cells), i.e. the time when
the first Cyclin B1-GFP fluorescence image was captured (see Section 5.2). This time
point, i.e. t = tG1, can be determined from the experimental data using the software
FLUROTRAK (see Section 5.2), an important feature of this tool is the ability to index any
bifurcating point t = tB, where one cell divides into two daughter cells, as shown in Figure
5.13. Therefore, the time at which a new cell cycle starts, t = tG1, is the data point after
t = tB (Figure 5.14.), where tG1 – tB = 20 min (for each new cycle) since Cyclin B1-GFP
fluorescence images were captured every 20 min (see Section 5.2). Moreover, tG1 varies
among organisms and between different cell types of the same organism or within the same
cell type under different conditions. Therefore, the corresponding values for the extended
cell cycle model variables (scaled by C2 to account for variations among organisms and
cell types) at the start of a new cell cycle, i.e. at time t = tG1 are given by:
G1 2 G1 2
YP G1 2 YPTP G1 2
TP G1 2 G1 2
active G1 2 activ
[CycB]( ) 0.141396 , [CDC2CycB]( ) 0.992654 ,
[CDC2CycB ]( ) 1.4763 , [CDC2CycB ]( ) 11.41023 ,
[CDC2CycB ]( ) 1.64121 , [CDC2]( ) 84.479606 ,
[APC ]( ) 3.8539 , [Wee1
t C t C
t C t C
t C t C
t C
 
 
 
 e G1 2
active G1 2 active G1 2
]( ) 15 ,
[CDC25 ]( ) 1.54009 and [p21 ]( ) 3.8539
t C
t C t C

 
. (5.16)
0 5 10 15 20 25 30 35 40 45 50
0
100
200
300
400
500
600
Time (hours)
C
yc
lin
B
1-
G
FP
In
te
ns
ity
(a
.u
.)
Bifurcating point t = tB
Start of a new cell cycle t = tG1
Figure 5.14: Average cytoplasmic Cyclin B1-GFP intensity profile track of the untreated G2
cell in Figure 5.2, where tB is the bifurcating point and tG1 is the time point at which a new
cell cycle starts.
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Prior to estimating the unknown model parameters (see Section 5.5), the values for the
parameters factor, np21 and EC50p21 (in the extended cell cycle model) which determine the
qualitative features of the output of the extended model were verified by simulating the
model output to ascertain the closest qualitative agreement (explosive spikes represented
by the G2/M transition back to G1) with Cyclin B1-GFP data (see section 5.2). This
qualitative computation is insensitive to changes in the values for the unknown model
parameters.
The impact of varying the values for the feedback strength (i.e. factor) in the extended cell
cycle model is shown in Figures 5.15 and 5.16. The parameter factor was varied in the
range of 1-23. The values are: (a) 1, (b) 5, (c) 7, (d) 10, (e) 15, (f) 20 and (g) 23. If the
value for factor is 1 (weak feedback) the stimulus/response relationship is monostable and
the system reaches a stable steady state. When the level of feedback strength is modestly
increased to factor = 5, the system oscillates, and the steady-state response is monostable.
However, these oscillations are not sustained (i.e., damped oscillations) and the
CDC2/APC system reaches a stable steady-state close to the steady state reached by the
system when the strength of feedback is 1 (factor = 1). Increasing the level of feedback
strength to 7, results in a monostable steady-state response but highly ultrasensitive.
Moreover, at this level of feedback strength (i.e., factor = 7) the system oscillates
sustainably and the amplitude of these oscillations increases with the strength of feedback.
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Figure 5.15: Simulation results of Cyclin B1/CDC2 activity in the extended cell cycle model
by varying the feedback strength, factor = 1 (blue), factor = 5 (green) and factor = 7 (red).
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Figure 5.16: Simulation results of Cyclin B1/CDC2 activity in the extended cell cycle model
by varying the feedback strength, factor = 10 (blue), factor = 15 (green), factor = 20 (red)
and factor = 23 (yellow).
Increasing the level of feedback strength (in the extended cell cycle model) to 10, 15, 20 or
23 (factor = 10, 15, 20 or 23) results in bistable steady-state responses with explosive
spikes of CDC2 activity and more realistic-looking oscillations when compared to Cyclin
B1-GFP data (see Figure 5.14). In addition, the amplitudes of these oscillations increase
with increasing the level of feedback strength up to the value of 20 (factor = 20). Further
increase in the level of feedback strength (i.e. when factor = 23) results in differences in
the amplitudes being indistinguishable. The level of feedback strength also determines the
size of the hysteresis loop. That is, for an increase in the feedback strength (factor), the
hysteresis loop becomes larger [244]. In addition, by increasing the level of feedback
strength, the time required before the abrupt G2/M transition increases. Note that, the exact
level of feedback at which the transition from damped oscillations to sustained oscillations
depends on the parameter values (including concentrations and rate constants) used in the
extended cell cycle model. Setting the level of feedback strength to the value of 20
(factor = 20) or 23 (factor = 23) results in a closer qualitative agreement to Cyclin B1-GFP
data (see Figure 5.14) in comparison to lower levels of feedback strength, particularly in
the abrupt G2/M transition back to G1 phase. However, when the value of the parameter
factor = 20 the slope of the interphase (i.e., G1-S-G2) is steeper than the slope of the
interphase when the value of factor = 23. The steepness of the interphase slope when the
value of level of feedback strength is 20 (i.e., factor = 20) reproduces closer qualitative
agreement to Cyclin B1-GFP data. Therefore, the level of feedback strength used in the
extended cell cycle model in this thesis is 20 (i.e., the value of the parameter factor = 20).
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The impact of varying the values for the Hill coefficient np21 is shown in Figures (5.17).
The parameter np21 was varied in the range of 1-6. The values are: (a) 1, (b) 2, (c) 3, (d) 4,
(e) 5 and (f) 6. If the value for np21 = 1 and 2, the stimulus/response relationship is
monostable (with no oscillations) and the system reaches a stable steady-state. When the
value of np21 is increased to 3 (np21 = 3), the system oscillates, and the steady-state response
is monostable. However, these oscillations are not sustained (i.e., damped oscillations) and
the CDC2/APC system reaches a stable steady-state. Increasing the Hill coefficient to 4, 5
or 6 (np21 = 4, 5 or 6) results in bistable steady-state responses with explosive spikes of
CDC2 activity and more realistic-looking oscillations when compared to Cyclin B1-GFP
data (see Figure 5.14). Moreover, the amplitudes of these oscillations increase with
increasing value of np21 up to np21 = 5. That is, any increase in the Hill coefficient np21
(beyond np21 = 5) has a relatively indistinguishable affect on the dynamical response of the
cell cycle model in comparison to the response of the system when np21 = 5. Therefore
empirically, the value of the parameter np21 chosen in the cell cycle presented in this thesis
is 5 (i.e., np21 = 5).
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Figure 5.17: Simulation results of Cyclin B1/CDC2 activity by varying the Hill coefficient
np21. These values are, np21 = 1 (blue), np21 = 2 (green), np21 = 3 (red), np21 = 4 (magenta),
np21 = 5 (yellow) and np21 = 6 (black).
The impact of varying the values for the half maximal effective concentration EC50p21 is
shown in Figures (5.18). The parameter EC50p21 was varied in the range of 10 nM-50 nM.
The values are: (a) 10 nM, (b) 20 nM, (c) 30 nM, (d) 40 nM and (e) 50 nM. If the value for
EC50p21 = 10 nM, the stimulus/response relationship is monostable (with no oscillations)
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and the system reaches a stable steady-state. Increasing the half maximal effective
concentration EC50p21 to 20 nM, 30 nM, 40 nM and 50 nM (EC50p21 = 20 nM, 30 nM, 40
nM or 50 nM) results in bistable steady-state responses with explosive spikes of CDC2
activity and more realistic-looking oscillations when compared to Cyclin B1-GFP data (see
Figure 5.14). Moreover, the amplitudes of these oscillations (dynamical response) increase
with increasing the value of the half maximal effective concentration parameter EC50p21.
In comparison between the simulation results (dynamical responses) of the CDC2/APC
system shown in Figure 5.18 for the different values of EC50p21, namely, EC50p21 = 30
nM, 40 nM and 50 nM, the steep transition (slope) from S-G2-M phase to G1 phase using
the value of EC50p21 = 30 nM results in a closer qualitative agreement with the transition
from S-G2-M phase to G1 in the Cyclin B1-GFP data (Figure 5.14). Therefore, the value
used for the half maximal effective concentration EC50p21 in the extended cell cycle model
is 30 nM (i.e., EC50p21 = 30 nM).
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Figure 5.18: Simulation results of Cyclin B1/CDC2 activity by varying the half maximal
effective concentration EC50p21. These values are, EC50p21 = 10 (blue), EC50p21 = 20 (green),
EC50p21 = 30 (red), EC50p21 = 40 (black) and EC50p21 = 50 (yellow).
In the extended model, the rate constant for activating (turning on) p21CIP1/WAF1 (kp21on) is
assumed to be equal to the rate constants for activating the APC, Wee1 kinase and CDC25
phosphatase. Therefore, the value used for kp21on is 0.8 min-1. The total concentration of
p21CIP1/WAF1 ([p21total]), and the rate constant for switching p21CIP1/WAF1 off (kp21off) are
unknown parameters in the model which were estimated using the time-lapse microscopy
data (Cyclin B1-GFP fluorescence data). Table 5.1 represents the known parameter values
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of the extended cell cycle model for live human osteosarcoma cells: values for the known
parameters are characterised by those given in Pomerening et al. [14] in addition to the
parameters evaluated for the extended cell cycle model, namely factor, np21, EC50p21, and
kp21on. All extended cell cycle model parameters (known and unknown) have been
implicitly scaled by C1 or C2 in Equations (5.1)-(5.12) and Equation (5.16).
Table 5.1: Table of known parameter values of the extended
cell cycle model for live human osteosarcoma cells.
Parameter Value
ksynth (nM min-1) 1.2
kdest (nM-1 min-1) 0.005
ka (nM-1 min-1) 0.1
kd (min-1) 0.001
Factor 20
kWee1 (nM-1 min-1) 0.1
kCDC25 (nM-1 min-1) 0.1
CDC2total (nM) 100
APCtotal (nM) 50
Wee1total (nM) 15
CDC25total (nM) 15
nAPC 5
nWee1 4
nCDC25 4
np21 5
EC50APC (nM) 30
EC50Wee1 (nM) 25
EC50CDC25 (nM) 25
EC50p21 (nM) 30
kAPCon (min-1) 0.8
kWee1on (min-1) 0.8
kCDC25on (min-1) 0.8
kp21on (min-1) 0.8
kAPCoff (min-1) 0.08
kWee1off (min-1) 0.08
kCDC25off (min-1) 0.08
kCAK (min-1) 0.8
kPP2C (min-1) 0.008
The extended cell cycle model of the CDC2/APC system is similar in many ways to the
model proposed by Novak and Tyson [221] and refined by Marlovits et al. [267].
However, the main difference between the Novak and Tyson model [221] and the model
presented in this thesis is in the assumed source of ultra-sensitivity [14]. Moreover, the
extended CDC2/APC model is also similar to the Tyson and Novak model [157] in that
both rely on a hysteresis mechanism and the governing equations account for the
regulation of CDK1/Cyclin B1.
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Figure 5.19 illustrates a comparison between the simulation results of the extended cell
cycle model of the CDC2/APC system and the original cell cycle model of the CDC2/APC
system model by Pomerening et al. [14], before scaling by C1 or C2. The cell cycle models
(extended and original) were simulated using parameter values in Table 5.1 and the re-
parameterised initial conditions in Equation (5.16). In simulating the extended cell cycle
model, it is assumed that the values for the unknown model parameters p21total and kp21off
are equal to their corresponding parameter values relating to the activity of the APC (see
Table 5.1)
Indeed, the inhibition effect of the CKI p21CIP1/WAF1 plays a significant role in stabilising
the G1 state. The principal effect of adding the negative-feedback loop (inhibition effect of
p21CIP1/WAF1) is an extension between the two mitotic landmarks, and an increase in IMT,
including an extended delay in G1 state. In the extended cell cycle model, the inter-mitotic
time (IMT), denoted by IMT2 is equal to 138.5 min (i.e. IMT2 = 138.5 min) and in the
original cell cycle model, the IMT, denoted by IMT1 is equal to 131.25 min (i.e.,
IMT1 = 131.25 min), this result is consistent with the predicted response to the inhibitor
p21CIP1/WAF1. In addition, the extended cell cycle model reproduces closer qualitative
agreement to experimentally observed results than the original cell cycle model (see Figure
5.14) particularly in the abrupt G2/M transition back to G1 phase (switch-like response).
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Figure 5.19: Simulation results of extended cell cycle model (in red) and the original cell
cycle model (in blue) by Pomerening et al. [14].
Chapter 5: The cell cycle model 133
In all of the time-lapse microscopy experiments (from U-2 OS cell) considered in this
chapter, fluorescence intensities (which reflect the concentrations of the active form of
Cyclin B1, i.e., [CDC2CycBTP]) are measured in arbitrary units (a.u.) and time in minutes
(min). The thirty two parameters considered in the extended cell cycle model are:
 ksynth and kdest, units: nM min-1 (nM per minute) and (nM min)-1, respectively. Rate
constants for Cyclin B1 (monomer) synthesis and Cyclin B1 (monomer and dimers)
destruction, respectively;
 ka and kd, units: (nM min)-1 and min-1, respectively. Rate constants for association
of CDC2 (monomer) to Cyclin B1 (monomer) forming the inactive non-
phosphorylated complex (CDC2CycB) and the dissociation of this complex to the
monomers (i.e., Cyclin B1 and CDC2), respectively;
 factor, dimensionless constant. This parameter represents the strength of the
feedback from CDC2 to Wee1 kinase and CDC25 phosphatase;
 kWee1, units: (nM min)-1. Rate constant for the inactivation of Cyclin B1/CDC2
dimers, namely, the non-phosphorylated complex (CDC2CycB) and the active
Cyclin B1/CDC2 complex (CDC2CycBTP) by Wee1 kinase;
 kCDC25, units: (nM min)-1. Rate constant for the activation of Cyclin B1/CDC2
dimers, namely, the Y15-phosphorylated complex (CDC2CycBYP) and the Y15-
and T161-phosphorylated complex (CDC2CycBYPTP) by CDC25 phosphatase;
 CDC2total, APCtotal, Wee1total, CDC25total and p21total, units: nM. The total
concentrations of CDC2, APC, Wee1 kinase, CDC25 phosphatase and the CKI
p21CIP1/WAF1, respectively;
 nAPC, nWee1, nCDC25, and np21, dimensionless constants. These dimensionless
constants are the Hill coefficients of the Hill functions describing the rates of
change of the active forms of the APC, Wee1 kinase, CDC25 phosphatase and the
CKI p21CIP1/WAF1, respectively;
 EC50APC, EC50Wee1, EC50CDC25, and EC50p21, units: nM. The half maximal
effective concentrations (EC50’s) in the Hill functions describing the rates of
change of the active forms of the APC, Wee1 kinase, CDC25 phosphatase and the
CKI p21CIP1/WAF1, respectively;
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 kAPCon, kWee1on, kCDC25on and kp21on, units: min-1. Rate constants for turning on the
APC, Wee1 kinase, CDC25 phosphatase and the CKI p21CIP1/WAF1, respectively;
 kAPCoff, kWee1off, kCDC25off and kp21off, units: min-1. Rate constants for turning off the
APC, Wee1 kinase, CDC25 phosphatase and the CKI p21CIP1/WAF1, respectively;
 kCAK and kPP2C, units: min-1. The rate constants for phosphorylation/
dephosphorylation of the Y15-phosphorylated complex (CDC2CycBYP)/ Y15- and
T161-phosphorylated complex (CDC2CycBYPTP), respectively.
 C1 and C2, dimensionless constants. Scaling factors to account for the variations in
the interaction rate constants and the variations in the concentrations of the cell
cycle components (among different organisms), respectively.
Three of these parameters are unknown (C2, kp21off and p21total) in addition to two
observational parameters (α and β, see Section 5.4 and Section 5.5) are unknown, and need
to be estimated from experimental data. The time-lapse microscopy experiments allow
direct measurement of the fluorescence intensities (Cyclin B1-GFP) of concentrations of
the active form of Cyclin B1 (Cyclin B1/CDC2) in the nucleus and cytoplasm (see Section
5.2). Prior to the parameter estimation for the extended cell cycle model, a structural
identifiability analysis has been performed (Section 5.4) to test whether the unknown
model parameters are uniquely determined by the observations structure corresponding to
the time-lapse microscopy experiments. In the following section, the Taylor series
approach is used to show that the extended cell cycle model (for a single cell) is
structurally globally identifiable.
5.4 Structural identifiability analysis of the cell cycle model
In this section, the Taylor series approach (see Section 2.4) is applied to the extended cell
cycle model at time t = tG1 (start of a new cell cycle, see Figure 5.14) described by
Equations (5.1)-(5.11). For this study, the output function, y(t, p), of the extended model is
taken to be a linear function of active Cyclin B1 concentration ([CDC2CycBTP]), that is:
TPy( , ) CDC2CycB ( , )t t  p p (5.17)
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where, α and β are the observational parameters estimated from the experimental data. The
state-space model describing cell cycle process for a mammalian cell (in the absence of
TPT) in this chapter is an uncontrolled (referred to as free or autonomous) non-linear
system.
The vector p comprising the five unknown parameters of the model is given by:
2 p21off total( , , , , p21 ) .C k p
T
The unknown model parameters represent observational parameters, a scaling factor, a rate
constant and a concentration, and are therefore positive. This means that the set of feasible
parameter vectors, Ω, comprises the vectors (p1, …, p5)┬ such that pi > 0 (1 ≤ i≤ 5). The 
state space vector x(t, p) is given by:
YP
YPTP TP
active active active active
( , ) (CycB( , ),CDC2CycB( , ),CDC2CycB ( , ),
CDC2CycB ( , ),CDC2CycB ( , ),CDC2( , ),
APC ( , ), Wee1 ( , ),CDC25 ( , ), p21 ( , ))
t t t t
t t t
t t t t
x p p p p
p p p
p p p p T
(5.18)
and the set M(p) is 10 . The values for the state variables of the model at t = tG1 are given
by:
G1 2 2 2 2 2
2 2 2 2 2
( , ) (0.141396 ,0.992654 ,1.4763 ,11.41023 ,1.64121 ,
84.479606 ,3.8539 ,15 ,1.54009 ,3.8539 ) .
t C C C C C
C C C C C
x p
T (5.19)
In this model (i.e., the extended cell cycle model), the values for the state variables at time
t = tG1 are actually dependent on components of the vector of unknown parameters p.
An arbitrary parameter vector is denoted by p such that:
2 p21off total( , , , , p21 )C k p
T
for which, y( , ) y( , )p pt t for all t ≥ 0. Similar to the structural identifiability analysis for 
the cell-based kinetics model in Chapter 4, the computer algebra system MATHEMATICA
[206] was used to perform the following structural identifiability analysis of the extended
cell cycle model (see Appendix A). As explained in Section 2.4, uniqueness of the
coefficients in the Taylor series expansions of y(t, p) entails the following, if p Ω is such
that y(t, p) = y(t, p ) for all t ≥ 0, then, for each k = 1, 2, 3, …
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( ) ( ) (0)
G1 G1 G1 G1( , ) ( , ) where, ( , ) ( , ).
k ky t y t y t y t p p p p (5.20)
Setting k = 0 in Equation (5.20) yields the first Taylor series coefficient given by:
(0)
G1 2( , ) 1.64121y t C   p (5.21)
and substituting in Equation (5.20) gives:
2 21.64121 1.64121 .C C      (5.22)
The 1st derivative term (k = 1) gives:
(1) 2
G1 2( , ) 2.52518y t C p (5.23)
and using the relations in Equation (5.22) yields:
2
2
2
2
.C
C

  (5.24)
Considering the relations (Equations (5.22) and (5.24)) between parameters in p and p , the
following equations must hold to satisfy Equation (5.20) for k = 0, 1:
2 2
2 2
22
2 2
, and 1.64121 1.64121 .C CC
C C
 
       (5.25)
The 2nd derivative term (k = 2) gives:
(2)
G1 2
2
20.107836 0.38890( , ) ( 1 )y t C C p (5.26)
and using the relations in Equations (5.25) and (5.26) yields:
2 2.C C (5.27)
Considering the relations (Equations (5.25) and (5.27)) between parameters in p and p , the
following equations must hold to satisfy Equation (5.20) for k = 0, 1, 2:
2 2 , , and .C C       (5.28)
The 3rd derivative term (k = 3) gives:
(3)
G1 2
2
2 20.0598942( 0.06( , 27616 ) (4.45049) )y t C C C   p (5.29)
and substituting in Equation (5.20) yields no information since none of the remaining
unknown model parameters are present in the 4th coefficient of the Taylor series expansion.
Equating the 4th derivative terms (k = 4) gives:
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2 3 4(4)
G1 2 2 2
2
5
0.00252426 0.0345519 0.171215
0.00922425
( , )y t C C C
C
  

 



p
(5.30)
and substituting in Equation (5.20) yields no information since none of the remaining
unknown model parameters are present in the 5th coefficient of Taylor series expansion.
Equating the 5th derivative terms (k = 5) gives:
2 3
4 2 10
total
(5)
G1 2 2 2
2 2
( , ) ( 0.000310113 2.6964 2.50228
0 0.0542277 5.16.00142062 716 10 p2 ))1(
y t C C C
C C


 
  
p
(5.31)
and using the relations in Equations (5.28) yields:
p21off p21o
7 7
totaf taf l to l1.01719 10 p21 1.01719 10 p21 .k k
    (5.32)
Finally, equating the seventh set of coefficients (k = 6), and using the relations in Equations
(5.28) and (5.32), yields:
total totalp21 p21 . (5.33)
Therefore, the following relations must hold in order to satisfy Equation (5.20) for all
k = 0, …, 6:
tot2 2 p21off p21 al to aoff t lp21 p21 and, , , , .C C k k         (5.34)
Equation (5.20) is therefore satisfied for all k ≥ 0 with p p . This is true for generic
p , thus the model is structurally globally identifiable, that is all of the model
parameters are uniquely determined by the output structure corresponding to the proposed
experiments to collect data for the purpose of parameter estimation. In the next section, the
unknown model parameters are estimated from time-lapse microscopy data (Cyclin B1-
GFP data). The structural identifiability analysis was performed in this section to approach
the estimation of the unknown model parameters with greater confidence.
5.5 Parameter estimation of the cell cycle model
In this chapter, the cell cycle model describes the response of growth of single human
osteosarcoma cells in the absence of the anti-cancer agent TPT. The unknown model
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parameters (as in Section 5.4) were estimated from the Cyclin B1-GFP data of a control
cell (untreated cell) for one complete cell cycle event of a newborn cell starting at time
t = tG1 (see Figures 5.14 and 5.20) to investigate the effects of the CKI p21CIP1/WAF1 on the
progression of the cell cycle traverse. The expression of Cyclin B1 is driven by a cell-
cycle-phase-specific promoter that initiates expression at the end of the S phase of the cell
cycle process and peaks during the G2 phase [268]. Once Cyclin B1 is expressed, it shuttles
between the nucleus and cytoplasm during the G2 phase of the cell cycle traverse.
However, Cyclin B1 localisation is primarily cytoplasmic because the rate of nuclear
export is much greater than its import [159]. Thereafter (i.e., at the start of the M phase),
Cyclin B1 accumulates, in a phosphorylation dependent manner [269, 270]. Accordingly,
the G2/M transition is marked by the localisation of Cyclin B1 in the cell. Since the
unknown model parameters are estimated between two mitotic events, Cyclin B1-GFP data
in the cytoplasm were averaged (i.e., Cyclin B1-GFP data from the two cytoplasmic ROI’s,
see Section 5.2) and used for the curve fitting as shown in Figure 5.20.
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Figure 5.20: Average cytoplasmic Cyclin B1-GFP fluorescence intensities for an untreated
cell.
The spikes in the Cyclin B1-GFP experimental data correspond to morphological changes
in the cell during the M phase of the cell cycle traverse. As cells grow, their shapes change
and round up just before cell division (i.e., bifurcation or cytokinesis) and the spikes in the
Cyclin B1-GFP (at mitosis) are artefacts due to these morphological changes (rounding up
of cells). This is because the light reflected back (measure of the fluorescence) is at its
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maximum intensity at this stage of the cell cycle process and the camera takes full
thickness image, and so for every pixel the volume of cytoplasm increases resulting in a
false peak (see Figure 5.20) in the Cyclin B1-GFP data. The location of the false peak (in
time) can be determined from the experimental data using the software FLUROTRAK.
Therefore, the unknown model parameters were estimated between the two vertical dashed
lines in Figure 5.20 staring from the G1 phase (at time t = tG1) of the cell cycle (newborn
daughter cell) up to the experimental point in time before the false peak, denoted by t2 (see
Figure 5.20).
Parameter estimation was performed using the commercial simulation software package
FACSIMILE (MCPA Software, U.K.). The optimisation method used to obtain parameter
estimates involves the minimisation of the weighted least-squares criterion, see Section
2.5. The unknown parameters of the extended cell cycle model, namely, the observational
parameters (α and β), the concentration scaling factor C2 (specific to cell type and cellular
conditions), total concentration of the CKI p21CIP1/WAF1 ([p21total]) and the rate constant for
turning p21CIP1/WAF1 off (kp21off) are estimated from the experimental data (see Section 5.2).
Live cells are tracked in time and therefore, these parameters (i.e., the unknown model
parameters) are permitted to change (if appropriate) at cell division (cytokinesis), however,
they remain constant during an individual cycle. The parameter values in Table 5.1 are
specific for all cell types and cellular conditions (internal and external) that influence the
cell cycle progression, in addition, these parameters (in Table 5.1) are also permitted to
change implicitly (if appropriate) at cell division since they are scaled by C1 or C2.
However, they remain constant during an individual cell cycle.
For the Cyclin B1-GFP data of the control (untreated) cell shown in Figure 5.20, the
progenitor cell divides into two daughter cells at 280 min (i.e., tB = 280 min, see Figure
5.14) after the start of the experiment, and therefore, in this particular track, tG1 = 300 min
(see Figure 5.20). The false peak is located at time t = 1620 min and therefore, t2 = 1600
min (the experimental data point just before the false peak), since the fluorescence image
sequences were captured every 20 min (see Section 5.2 and Figures 5.14 and 5.20). In
addition, the untreated cell divides again at time t = 1640 min (second cell division).
Therefore, in this particular fitting, the unknown model parameters were estimated
between tG1 = 300 min and t2 = 1600 min. Then, the estimated parameters were used to
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simulate the model from t2 = 1600 min to t3 = 1660 min (which is tG1 of the new cycle) to
ensure that the cell has completed the cycle (i.e., the cell has completely divided into two
daughter cells). The scaling factor C1 is given by:
1
IMT
IMT
a
b
C  (5.35)
where, IMTa is the inter-mitotic time in the extended model before scaling and IMTb is the
inter-mitotic time in the experimental data (i.e., the time for one individual cycle). IMTa is
a constant and is equal to 138.5 min (see Figure 5.19) and in this particular track (Figure
5.20), IMTb = 1360 min (1640 min – 280 min), and therefore, C1 = 0.1017 (Table 5.2).
Table 5.2: Best parameter estimates for control (untreated) cell data obtained
for the model Equations (5.1)-(5.11) and state values at t = tG1 in Equation (5.16),
estimated using live-cell Cyclin B1-GFP data.
Parameter Value
C1 0.1017
Parameter Value SDLN 5% 95%
α (a.u. nM-1) 2.2041×10+1 0.0948 1.8860×10+1 2.5759×10+1
C2 9.2038×10-1 0.0179 8.9363×10-1 9.4793×10-1
β (a.u.) 6.7686×10+1 0.0925 5.8132×10+1 7.8809×10+1
kp21off (min-1) 5.2973×10-2 0.5973 1.9829×10-2 1.4152×10-1
p21total (nM) 5.2179×10+2 0.4153 2.6352×10+2 1.0332×10+3
RSS = 1.5804×10+1
The fitted (estimated) parameter values, with estimates for their confidence levels are
presented in Table 5.2, where it is seen that all parameters are well-determined by the live-
cell data. Additionally, three of the estimated parameters, namely C2, α and β, have low
SDLN values corresponding to high confidence in their values. However, the estimated
parameter values for kp21off and p21total have high SDLN values due to the low signal-to-
noise ratio in the experimental data. Moreover, the value of CORImean = 1.09241 indicates
that the residuals are acceptable and evenly distributed above and below the (simulated)
output of the model and therefore, the resulting fit is good.
The plots shown in Figure 5.21 show a typical trace for the growth of a cell in the absence
of the anti-cancer drug TPT. The live-cell data are denoted by the blue circles and the
simulated data by the solid red curve. The model fit in Figure 5.21 shows that there is close
reproduction of the experimental data by simulated output from the extended cell cycle
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model with parameters taking values from Tables 5.1 and 5.2. In an attempt to minimise
the impact of the artefact of morphological changes (rounding up) during the final stages of
the M-phase of the cell cycle traverse which results in the over-expression of Cyclin B1-
GFP fluorescence intensities (false spikes) in the experimental data, the false peak (spike)
in the data is under-predicted (minimised or capped) by the extended model.
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Figure 5.21: Model fit showing model prediction (solid red line) and Cyclin B1-GFP data
(blue circles) in the absence of TPT. An artefact of morphological changes during the final
stages of mitosis is the over-expression of Cyclin B1 fluorescence giving rise to false peaks in
the experimental data.
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Figure 5.22: A normal probability plot for the residuals in the weighted non-linear least-
squares fit of the extended cell cycle model to Cyclin B1-GFP data. The residuals are
plotted in ascending numerical order on the horizontal axis, against cumulative
probabilities in N(0, 1) transformed to a linear scale.
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Figure (5.22) is a normal probability plot for the residuals in the weighted non-linear least-
squares fit of extended cell cycle model to Cyclin B1-GFP data. The residuals are plotted
in ascending numerical order on the horizontal axis, against cumulative probabilities in
N(0, 1) transformed to a linear scale. The figure suggests that the residuals are normally
distributed (with approximately zero mean) since the graph is approximately linear. This is
an indicator for the appropriateness of the standard error σ used for each observation y.
The estimated correlation matrix for the well-determined parameters is given in Table 5.3.
The parameter pairing that exhibits noticeable (highest) correlation is p21total and kp21off
(0.881). These two parameters (i.e., p21total and kp21off) represent the total concentration of
CKI p21CIP1/WAF1 and the rate at which this CKI is turned off. The high correlation of the
logarithm of these parameters indicates that it is the product of these that is important for
the fitting, that is, the rate at which the inhibitor is activated.
Table 5.3: The estimated correlation matrix for the well-determined parameters for an
untreated (control) cell.
Α C2 β kp21off p21total
α 1 -0.108 -0.687 -0.544 -0.617
C2 -0.108 1 0.44 -0.579 -0.156
β -0.687 0.44 1 -0.135 -0.019
kp21off -0.544 -0.579 -0.135 1 0.881
p21total -0.617 -0.156 -0.019 0.881 1
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Figure 5.23: Simulation results of the extended cell cycle model Equations (5.1)-(5.11) for
the concentration (in nM) of the active form of Cyclin B1/CDC2 complex ([CDC2CycBTP]).
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Figure 5.24: Simulation results of the extended cell cycle model Equations (5.1)-(5.11) for
the concentration (in nM) of the active form of the CKI p21CIP1/WAF1 ([p21active]).
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Figure 5.25: Simulation results of the extended cell cycle model Equations (5.1)-(5.11) for
the concentration (in nM) of the active form of the APC ([APCactive])..
One of the main advantages of mathematical modelling is to infer from the model
information relating to variables of the system (in this case, the extended cell cycle model)
that are not directly measured (i.e., parts of the system that are not accessible) [13]. For
example, it is the fluorescence intensities of the active form of Cyclin B1/CDC2 that are
measured using the time-lapse microscopy experiments, and so one might wish to study the
changes in the actual concentrations of the cell cycle regulators during the cell cycle.
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Figures 5.23, 5.24 and 5.25 represent the concentrations (in nM) of the active forms of
Cyclin B1/CDC2 ([CDC2CycBTP]) in the cytoplasm, the CKI p21CIP1/WAF1 ([p21active]) and
the APC ([APCactive]), respectively, simulated from the extended cell cycle model
(Equations (5.1)-(5.11) and Equation (5.16), with parameters taking values in Tables 5.1
and 5.2) during one complete cell cycle (tG1 = 300 min to t3 = 1660 min) of a newborn cell
see Figure 5.21. Based on the simulation results presented in Figures 5.23-5.25, at G1 (at
time tG1 = 300 min) the concentration of active CDC2 ([CDC2CycBTP]) is low as shown in
Figure 5.23 while the concentrations of both the APC and the CKI p21CIP1/WAF1 are
relatively high. During the cell cycle, particularly in the S-G2-M state (Start), the levels of
Cyclin B1/CDC2 rapidly rise (since Cyclin B1 synthesis is induced) while the activities of
both the APC and the CKI p21CIP1/WAF1 are inhibited by active Cyclin B1/CDC2 protein. At
approximately time t = 1500 min the G2/M transition occurs in cell cycle, and the activities
of both the APC and the CKI p21CIP1/WAF1 start increasing (Figures 5.24 and 5.25).
Towards the end of the cell cycle (i.e. at Finish) this increase in the activities of APC and
p21CIP1/WAF1 starts destroying the activity of CDC2 by degrading Cyclin B1 protein
resulting in the explosive spikes of CDC2 activity (see Sections 3.3 and 5.3). The results
obtained confirm the antagonism between active CDC2 ([CDC2CycBTP]) and the APC as
well as the antagonism between active CDC2 and the CKI p21CIP1/WAF1.
5.6 Sensitivity analysis of the cell cycle model
The impact of varying the values for the rate for turning the CKI p21CIP1/WAF1 off (i.e.
kp21off) for one complete cell cycle starting at t = tG1 of the untreated (control) cell is shown
in Figure 5.26. The parameter kp21off was varied in the range of 1×10-2 min-1-1×10-1 min-1.
These values are: (a) 1×10-2 min-1, (b) 3×10-2 min-1, (c) 5.2973×10-2 min-1 and (d) 1×10-1
min-1. The model variable CDC2CycBTP (the active form of Cyclin B1) exhibits noticeable
variation in simulations illustrated in Figure 5.26 when varying the parameter kp21off. That
is, the activity of Cyclin B1/CDC2 is sensitive to changes in the rate at which the CKI
p21CIP1/WAF1 is switched off (deactivated). Based on the results obtained in Figure 5.26, the
time required to complete a cell cycle decreases with an increase in the parameter kp21off.
This is not surprising since the CKI p21CIP1/WAF1 and active CDC2 (CDC2CycBTP) are
antagonist proteins (see Figures 5.23 and 5.24).
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Figure 5.26: Simulated output from the extended cell cycle model Equations (5.1)-(5.11) and
state value at t = tG1 (Equation (5.16)) by varying rate for turning CKI p21CIP1/WAF1 off,
kp21off = 5.2973×10-2 min-1 (blue), kp21off = 3×10-2 min-1 (red), kp21off = 1×10-2 min-1 (green) and
kp21off = 1×10-1 min-1 (orange).
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Figure 5.27: Simulated output from the extended cell cycle model Equations (5.1)-(5.11) and
state value at t = tG1 (Equation (5.16)) by varying the total concentration of CKI ,
p21total = 1×10+2 nM (blue), p21total = 5.2179×10+2 nM, p21total = 7×10+2 nM and
p21total = 1×10+5 nM.
The impact of varying the values for the total concentration of CKI p21CIP1/WAF1 (i.e.,
p21total) for one complete cell cycle starting at t = tG1 of the untreated (control) cell is
shown in Figure 5.27. The parameter p21total was varied in the range of 1×10+2 nM-1×10+5
nM. These values are: (a) 1×10+2 nM, (b) 5.2179×10+2 nM, (c) 7×10+2 nM and (d) 1×10+5
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nM. The model variable CDC2CycBTP (the active form of Cyclin B1) exhibits noticeable
variation in simulations shown in Figure 5.27 when varying the parameter p21total. That is,
the activity of Cyclin B1/CDC2 is sensitive to changes in the total concentration of CKI
p21CIP1/WAF1. Based on the results obtained in Figure 5.27, the time required to complete a
cell cycle increases with an increase in the parameter p21total. In addition, the activity of
CDC2/Cyclin B1 complex decreases with an increase in the total concentration of CKI
p21CIP1/WAF1. This antagonist relationship between both CDC2 (CDC2CycBTP) and the CKI
can result in cell cycle arrest in the G1 phase of the cell cycle. These results match the
expected biological behaviour of cells undergoing a cell cycle.
5.7 Summary
A state-space model describing the response of growth of single human cells in the absence
of TPT is presented. The cell cycle model described in this chapter is a novel extension of a
previously published model by Pomerening et al. [14] for Xenopus laevis embryos to
account for the inhibition effect of the CKI p21CIP1/WAF1. The structural identifiability
analysis of the extended cell cycle model demonstrates that all of the unknown model
parameters are uniquely determined by the output structure corresponding to the real
experiment. The structural identifiability analysis of the extended cell cycle model was
performed using MATHEMATICA. The unknown model parameters were estimated (using
FACSIMILE) from live human osteosarcoma cells (Cyclin B1-GFP data) of a control
(untreated cell) for one complete cell cycle event of a newborn cell starting at G1 of the
cycle, to investigate the effects of the CKI p21CIP1/WAF1 on the progression of the cell cycle
traverse. The model fit of the untreated cell shows that there is close reproduction of the
experimental data by simulated output from the extended cell cycle model. The extended
cell cycle model is used in the coupled drug kinetics/cell cycle response model.
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6 The coupled drug kinetics/dynamics model
6.1 Introduction
This chapter presents a mathematical model describing the response of the growth of single
human osteosarcoma cells (U-2 OS cells) to the presence of the anti-cancer agent TPT. The
model includes a novel coupling of the extended kinetics model of TPT (described in
Chapter 4) to the extended cell cycle model (described in Chapter 5). That is, the coupled
kinetics/cell cycle response model presented in this thesis describes the effect of the drug
on cell cycle dynamics whilst also accounting for the in vitro kinetics of the drug (i.e., a
description from dose to effect). Coupling the models in this way, rather than studying
them separately, allows examination of how the anti-cancer drug TPT perturbs the cell
cycle.
The main feature of the coupled kinetics/cell cycle response (dynamics) model is the
ability to demonstrate the dynamic interactions of the active form of the drug (TPTL) with
the DNA-associated molecular target (i.e., the topoisomerase I enzyme, see Section 3.1)
and the downstream impact on cell growth (including the cell cycle) and cell death. The
coupling between the kinetics model and the cell cycle response (dynamics) model is based
on underlying biological assumptions of the cell cycle perturbations induced by the anti-
cancer agent TPT. Live-cell data from high-resolution fluorescence imaging of Cyclin B1
(see Sections 5.2 and 6.2) and high-content imaging for quantifying DNA damage (see
Section 6.2) have been used for parameter estimation of the unknown model parameters of
the proposed coupled kinetics/dynamics model. Moreover, these data are used for model
development and parameter estimation in addition to model simulation to further examine
the drug interactions with its DNA target and possible routes of cellular evasion of drug
action (i.e., drug resistance mechanisms) [107]. Ultimately, a robust and validated
kinetics/dynamics model could be used to design and quantitatively predict drug effect (in
silico predictions) and therefore, the consequences and potential failure of drug treatment
regimens (treatment schedules). The analytical and numerical methods described in
Chapter 2 are used to investigate the coupled model presented in this chapter.
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Generally, the relationships between drug kinetics and the effect of the drug on the cell
cycle (i.e., cell cycle response) are exceedingly complicated. In particular, when the
perturbed biological system being modelled expresses discrete responses (events) within a
heterogeneous population of cells [107]. A model developed by Alarcón et al. [271]
considers a method that uses the cell cycle (in normal and cancer cells) as a descriptor of
the biological response to hypoxia (oxygen deprivation). One limitation of the model
described by Alarcón et al. [271] is the difficulty in obtaining model validation or
comparison with experimental data. More recently, Chappell et al. [107] linked the drug
kinetic model (for TPT) developed by Evans et al. [13] with a basic cell cycle model
suggested by Tyson and Novak [157] (for yeast cells). The coupled model (by Chappell et
al. [107]) is similar to the kinetics/cell cycle response model described in this thesis, in that
both models describe the response of the growth of single human osteosarcoma cells (U-2
OS cell line) in the presence of the anti-cancer agent TPT. Moreover, the model developed
by Chappell et al. [107] has been compared to in vitro cell cycle response data similar to
the data used in the coupled model described in this chapter. However, a current limitation
of the coupled model developed by Chappell et al. [107] is that it does not account for drug
resistance as a result of BCRP and the ALDH enzyme which affect drug activity and
delivery to the nuclear target sites (see Chapter 4). In addition, the cell cycle response
model used by Chappell et al. [107] does not take into account the effects of the CKI
p21CIP1/WAF1 which is an important cell cycle regulator in G1 and G2 phases of the cell cycle
traverse. Moreover, the coupled model described by Chappell et al. [107] does not consider
the variations in the interaction rate constants between cells (within the same cell type)
under different conditions (particularly, different treatment regimens).
6.2 Experimental data collection
The ability to undertake high spatio-temporal resolution monitoring of cell cycle
progression is important and crucial to modelling the sequence of events of cell cycle
responses to the action of the anti-cancer agent TPT. This is achieved by the tracking a
single cell (U-2 OS cell line) in a non-destructive (non-invasive) fashion within
heterogeneous populations using GFP (CCPMs) as explained in Section 5.2. This
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monitoring approach also enables continuous tracking of single cell checkpoint transitions
non-invasively in the presence of the anti-cancer drug TPT.
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Figure 6.1: Cyclin B1-GFP intensity profiles extracted from typical G2 cells treated with (a)
1 µM (1×10+3 nM) TPT and (b) 10 µM (10×10+3 nM) TPT. Three compartments were
tracked, the nucleus (blue) and two regions of interest in the cytoplasm (red and green)
respectively.
The behaviour of both the progenitor and the descending line of offspring demonstrate the
time-integrated biological (cell cycle) response to intervention by the anti-cancer drug TPT
including changes in the IMT (illustrated in Figure 6.1) as well as cell death. The time-
lapse microscopy experiments provide essential information (Cyclin B1-GFP) upon which
the coupled drug kinetics/cell cycle response model is both developed and to a certain
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degree validated. These experiments (for tracking cell cycle progression in the presence of
TPT) were performed with cells seeded into a multi-well coverslip-bottomed plate. Each
well represents a different treatment regimen. That is, live human osteosarcoma cells were
treated with 1 µM (1×10+3 nM) or 10 µM (10×10+3 nM) bolus of TPT with 60 min (1 h)
residence and then the drug was washed out and the cell tracking began (see Section 6.3).
Similar to the control experiment explained in Section 5.2, Sequences of the fluorescence
images were captured every 20 mins in triplicate (i.e., three ROIs) per treatment regime
corresponding to one in the nucleus and two in the cytoplasm, as shown in Figure 6.1.
Similar to the lineage of the untreated (control) cell (see Chapter 5), a cell lineage for cells
treated with TPT illustrates cellular information including phenotypic behaviour as well as
fluorescence intensities (Cyclin B1-GFP intensities in a.u.) at the single cell level. Figures
6.1(a) and 6.1(b) show continuous Cyclin B1-GFP tracking extracted for single cells in G2
phase of the cell cycle traverse treated with 1 µM (1×10+3 nM) and 10 µM (10×10+3 nM)
TPT concentrations, respectively. The main effect of treating human osteosarcoma cells
with TPT is the extension between the two mitotic landmarks (mitotic events or spikes).
that is, an increase in the IMT including an extended delay in the G2 phase of the cell cycle
progression for the cell treated with TPT. Cyclin B1-GFP data (for cells treated with TPT)
were used for parameter estimation in Subsection 6.5.2. In addition, the coupled drug
kinetics/cell cycle response model in this chapter looks into cells that undergo normal cell
division, outcomes including re-fused or polyploidy cells are not in the scope of the work
presented in this thesis.
In addition to Cyclin B1-GFP data, the project collaborators at Cardiff University have also
provided DNA damage data (using high-content imaging) for live human osteosarcoma
cells (U-2 OS cell line) treated with a 1 h bolus of 1 µM (1×10+3 nM) and 10 µM (10×10+3
nM) TPT and then washed out (see Sections 6.3-6.5). Histones are water soluble alkaline
proteins around which DNA can wind. These proteins are found in cell nuclei and are
highly involved in gene regulation in eukaryotic cells by packaging and ordering DNA into
the basic structural units called nucleosomes [272]. Histone H2AX is one of several
variants of histone H2A (one of the six histone classes) [273-275], that is immediately
phosphorylated at its C terminus on serine 139 by the Ataxia telangiectasia mutated (ATM)
protein kinase (when activated) in response to damage that induces dsDNA breaks [276,
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277]. Moreover, the phosphorylated H2AX, also termed gamma-H2AX (γH2AX), plays a 
crucial role in safeguarding genome integrity [278].
ATM protein kinase is also required for the maintenance of genome integrity and is the
vital component of the signal transduction pathways that are mobilised by the damage of
DNA structure [278]. In addition to H2AX, the p53 tumour suppressor gene (a
nucleoplasmic substrate) is among the downstream target effectors phosphorylated by
ATM protein kinase. This phosphorylation leads to up-regulation (transcription) of
p21CIP1/WAF1 protein, thereby, causing cell cycle arrest in the G1 stage of the cell cycle
traverse (see Section 3.3). The phosphorylation of the ATM downstream substrates
(including H2AX and p53) is essential for successful DNA repair and suppression of
tumourigenesis (formation of tumours). That is, suppressing cells from further progression
through the cell cycle and/or inducing apoptosis (cell death) and therefore, preventing
transmission of DNA damage to cell progeny that could lead to genome instability (i.e., to
enable cells to accumulate mutations to develop malignancies).
ATM activation and H2AX phosphorylation, consequences of DNA damage, can either be
induced by radiation, anti-cancer drugs or environmental carcinogens/mutagens. However,
the scope of this chapter is to asses the response of the growth (including DNA damage) of
single human cells induced by the DNA topoisomerase I inhibitor TPT. This anti-cancer
agent (i.e., TPT) is involved in stabilising the cleavable complex formed between
topoisomerase I enzyme which collides with a progressing DNA replication fork
generating irreversible dsDNA breaks (see Section 3.1). These breaks in chromatin, (i.e.,
dsDNA breaks) induce a cascade of molecular events to sense, transduce and effect DNA
repair and cellular responses.
Expression of ATM-mediated γH2AX foci act as a reporter of DNA damage that generates 
formation of dsDNA breaks [279, 280]. In addition, the number of induced dsDNA breaks
is reflected by the frequencies of γH2AX foci [281]. Therefore, the detection of γH2AX 
foci by imaging provides a quantitative tool for determining the action of the anti-cancer
agent TPT that induces DNA damage and potentially enables the linking between DNA
damage and repair with the initiation of the cell cycle checkpoints, delay and arrest. The
Chapter 6: The coupled drug kinetics/dynamics model 152
high-content imaging provides the final number (count) of γH2AX foci in single nuclei 
within a heterogeneous population of live human osteosarcoma cells (U-2 OS cell line)
treated with 1 µM (1×10+3 nM) or 10 µM (10×10+3 nM) bolus of TPT for 1 h.
6.3 The coupled drug kinetics/cell cycle model
Figure 6.2 provides a schematic for the coupled drug kinetic/cell cycle model. Separate
models have been developed for the drug kinetics (see Chapter 4) and the cell cycle (see
Chapter 5). These models are: the extended state-space kinetic model that describes the
drug activity and delivery of the pharmacologically active form (TPTL) to the DNA target
as well the catalysis of the ALDH enzyme and the elimination of drug from the cytoplasm
via the efflux pump (BCRP/ABCG2 transporter); and the extended state-space model that
describes the continuous tracking of Cyclin B1 through the cell cycle at the single level, to
account for the inhibition of p21CIP1/WAF1 protein on the dynamics of Cyclin B1.
In this coupled model, relevant basic physiology and biochemical mechanisms are
translated into a system of non-linear ODEs by the law of mass action (see Equations (6.1)-
(6.15)). That is, the mathematical modelling of the coupled drug kinetics/cell cycle model
involves the construction of ODEs to describe protein interaction networks that regulate
the cell cycle as well as the chemical reactions, simple diffusion, active pumping
mechanism (BCRP/ABCG2 transporter) and partitions that take place when the drug
moves to/from the medium, the cytoplasm and nuclear compartments. The coupling of
both models (i.e., the cell cycle model and the drug kinetics model) allows the analysis of
how the drug perturbs and affects cell cycle progression in live human osteosarcoma cells
(the U-2 OS cell line).
The method of modelling the dynamic effect (response) of TPT on human osteosarcoma
cells is based on the approach described in Subsection 2.3.4. The pseudo-steady state
approximated drug kinetics model in Figure 4.9 has been extended by introducing an effect
(response to TPT) compartment denoted by the variable γH2AX(t) with rate constants kTPT
and kdam (see Subsection 2.3.4). The variable Ln(t) remains unchanged by the addition of
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the extra compartment. The new variable, (i.e., γH2AX(t)), represents the number of
γH2AX foci (i.e., foci count) in a single nucleus. The set of ODEs describing the drug 
kinetics part (including the dynamic effect) of the coupled model is given by:
0
0
0 1
3 1
0 1 3 1
1 2
d ( )
dt
d ( )
dt
d ( )
dt
d ( )
dt ( )
d ( ) (
dt
m
om mi m cm m mo e
m
om m cm mi m mo e
e mi m e c
mo om i e cm e
e mi m c
m om e cm mo e
m c
c
i e e oc c cc c dl n b T
L k k L k H k v L
H k L k k H k v H
L k L k Lk k k L k H
v v
H k v V HH k L k k H
v v v k H
L k v L k k L k H k v L k B L
    
   
     
    

      
m2
2
3 1 2
2
3 1 2
2
TPT
)
( )
d
dt ( ) ( )
d ( ) ( )
dt
d 2 2
dt
n c
c
m c
c m c m c
oc c cc c dh n
m c m c
n b
T n c dl dh n
n dam
L
V L
k L
H v V H V Lk L k H k v L
v k H k L
L k B L L k k L
v
H AX k L k H AX 


    
 
   
 
(6.1)
where, v0 = Ve/Vm, v1 = Ve/Vc, v2 = Vn/Vc, v3 = Vcm/Vc, and v1/v3 = Ve/Vcm. The volumes of
the medium, extracellular region, cytoplasm, cell membrane and nucleus, are denoted by
Vm, Ve, Vc, Vcm, and Vn, respectively (see Section 4.3).
In the drug kinetics model described in Chapter 4, the unknown model parameters were
estimated from live human breast cancer cells (MCF-7 cell line) and the coupled model
describes the response of growth of the growth of single human osteosarcoma cells (U-2
OS cells) in the presence of TPT. Therefore, for simplicity, it is assumed that cellular
volumes (Vn + Vc + Vcm) are the same across cell types. In addition, the total volume of the
medium, VT, is equal to the sum of volumes of the medium region and the extracellular
region, that is,
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(1 )e e
T m e e
V V vV V V V
v v

     . (6.2)
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Figure 6.2: Schematic diagram of the coupled drug kinetics/cell cycle response model.
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In the coupled drug kinetics/cell cycle response model, it is assumed that DNA damage
(represented by γH2AX) is only induced in the presence of TPT, i.e., there is no DNA 
damage prior to drug administration. Time t = 0 corresponds to the (first) addition of TPTL
only as a bolus injection to give a concentration of D (nM) with respect to the total volume
of the medium (VT = 2 ml or 2×1012 μm3). The corresponding initial conditions for the drug
kinetics model are given by:
0
(0) (0) (0) (0) (0) (0) 2 (0) 0, and
(0) (1 ) .
m e e c c n
m
H L H L H L H AX
L v D
      
 
(6.3)
Cells were placed in a medium with pH = 7.2 in the experiments used to collect data for
estimating the unknown parameters in the proposed drug kinetics model (see Chapter 4).
The parameter values used in the kinetics component (in this chapter) of the coupled drug
kinetics/cell cycle model are the estimated parameter values for averaged data from the 13
individual cells (see Table 4.4). After 1 h, the medium containing human osteosarcoma
cells is exchanged for drug-free medium. This process is termed washout and the cell
tracking (Cyclin B1-GFP experiment) begins (20 min after the washout event). To model
the washout at t = 1 h the variables relating to the drug (both forms TPTL and TPTH) in the
medium (medium environment and extracellular region) are instantaneously set to 0, that
is:
(1) (1) (1) (1) 0m m e eL H L H    (6.4)
All other variables, i.e. Lc(t), Hc(t), Ln(t) and γH2AX(t) within the model described by
Equations (6.1) are unaffected by the washout event. The values of the variables relating to
the drug (TPTL and TPTH) in the cytoplasm and the nucleus, namely, Lc(t), Hc(t), and Ln(t),
as well as the value of the variable relating to DNA damage, γH2AX(t), at t = 1 h depend
on the treatment regimen (i.e., concentration of the dose D), the method for obtaining these
values is explained in Section 6.5.
The cellular response to DNA damage involves a series of events including cell cycle
arrest (in G1 phase) or apoptosis. γH2AX foci play an important role in the DNA damage 
signalling pathway induced by dsDNA breaks by acting as docking areas for the
recruitment of DNA repair factors by bringing the broken ends of the DNA closer to
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complete the repair. Moreover, Fernandez-Capetillo et al. [282] and Fragkos et al. [283]
have demonstrated the direct significance of γH2AX in cell cycle arrest. That is, γH2AX is 
necessary for p21CIP1/WAF1-induced cell cycle arrest at G1 phase (i.e. up-regulation of
p21CIP1/WAF1) after replication stalling [283]. The loss of the CKI p21CIP1/WAF1 results in
replication defects and this may lead to cell death when cells are treated with anti-cancer
agents, including TPT [284, 285]. Proteosome-dependent degradation of p21 CIP1/WAF1
follows p53/p21CIP1/WAF1-mediated cell cycle arrest (in G1 phase), this process (i.e.,
degradation of the CKI) results in cells progressing to the S phase of the cell cycle process.
Figure 6.3: Schematic depiction of the coupled drug kinetics/cell cycle response model.
The formation of γH2AX (as a result of DNA damage) has been identified across species 
from humans to yeast including Xenopus laevis embryos [283, 286]. Therefore, the drug
kinetics model (presented in Chapter 4) is coupled to the extended cell cycle model
(presented in Chapter 5) as shown in Figures 6.2 and 6.3. The drug kinetics model has been
linked to the CKI and regulator p21CIP1/WAF1 via γH2AX, which is itself driven by the 
kinetic model within the cell cycle constraint. This coupling between the two models
involves an additional circuit element, a negative-feedback component to account for the
regulation between the DNA damage induced by TPT which is represented by γH2AX and 
the CKI p21 CIP1/WAF1. These feedback loops could function as a bistable system (switch)
with a hysteretic steady-state stimulus/response relationship, toggling between two discrete
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steady states, namely, G1 state and S-G2-M state (see Chapter 5). In the model presented in
this chapter, the coupling between γH2AX and bound TPT in the nucleus is constrained to 
only have an effect in the S-G2-M state of the cell cycle process since TPT is believed to be
specific to the S phase (see Section 3.3) and therefore, TPT induced γH2AX acts almost 
exclusively in S phase cells [278].
Figure 6.3 provides a schematic diagram of the structure of the coupled drug kinetic/cell
cycle response model. The model equations are based upon those of the cell cycle model
describing the mechanisms (biochemical reactions) occurring in untreated cells (see
Chapter 5). The system of equations employed in the coupled drug kinetics/cell cycle
response model is a modified version of these based upon the action of TPT and using
appropriate parameter values derived from live-cell data as explained in Section 6.2 (the
human osteosarcoma cells). The equations (processes) governing the biochemical
interactions during the cell cycle process, in the presence of TPT, are given by:
1 1 active active
YPTP 1 1 1
d[CycB] ([APC ] [p21 ])[CycB]
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synth dest
a d
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In the coupled drug kinetics/cell cycle response model, it is assumed that DNA damage
(represented by γH2AX) is only induced in the presence of TPT. The up-regulation of the 
CKI p21CIP1/WAF1 resulting from the increase in γH2AX foci has been incorporated in the 
model by decreasing the rate constant at which p21CIP1/WAF1 is turned off (i.e., kp21off). This
has been employed in the model by multiplying kp21off by the factor of 1/(1 + kdamγH2AX)
as shown in Equation (6.14). Accordingly, this increases the time duration of the CKI’s
activity, in addition, in the absence of TPT, the equation that relates to the activity of
p21CIP1/WAF1 reduces to Equation (5.10) (see Chapter 5) since the number of γH2AX foci 
reduces to zero.
Similar to the cell cycle model described in Chapter 5, the scaling factors C1 and C2
(unknown model parameters) are the scaling factors introduced to account for the
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variations in the rate constants and variations in the concentrations of the cell cycle
components among different organisms, respectively. Table 6.1 represents the values for
the parameters of the coupled drug kinetics/cell cycle response model which are
characterised by those given in Tables 4.4 (with appropriate conversion of units) and 5.1.
In this chapter, time t = 0 min corresponds to the (first) addition of TPTL (only) as a bolus
injection. The medium is exchanged for drug-free medium (i.e., washout event) at time
tw = 60 min. In addition, the corresponding values for the cell cycle response model
variables at the start of a new cell cycle at time t = tG1 are given by (see Section 5.3):
G1 2 G1 2
YP G1 2 YPTP G1 2
TP G1 2 G1 2
active G1 2 activ
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In all of the time-lapse microscopy experiments (from the U-2 OS cell line) considered in
this chapter, fluorescence intensities (which reflect the concentrations of the active form of
Cyclin B1, i.e., [CDC2CycBTP]) are measured in arbitrary units (a.u.) and time in minutes
(min). Moreover, in the high-content screening imaging experiments (used to detect
γH2AX), DNA damage is represented with the number (count) of γH2AX foci (from U-2 
OS cells) and time in minutes. For completeness, the fifty four parameters considered in
the coupled drug kinetics/dynamics model are:
 kom and kcm, units: min-1 (per minute). Rate constants for deactivation/activation of
TPTL/ TPTH, respectively, in the medium and extracellular region;
 kmi and kmo, units: min-1. Rate constants for the flow of TPTL and TPTH to/from the
extracellular region/medium respectively;
 ki and ke, units: min-1. Rate constants for the flow of TPTL into and out of the cell
(i.e., to/from extracellular region), respectively;
 koc and kcc, units: min-1. Rate constants for deactivation/activation of TPTL/ TPTH,
respectively, in the cell (cytoplasm);
 kb, units: (nM min)-1. Rate constant for binding (association) of TPTL (in the
cytoplasm) to DNA;
Chapter 6: The coupled drug kinetics/dynamics model 161
 kdl and kdh, units: min-1. Rate constants of dissociation of TPTL from DNA to TPTL/
TPTH (in cytoplasm) respectively;
 BT units: nM. Concentration of DNA sites available for TPTL (in cytoplasm) to bind
to;
 km1 and km2, units: nM. Michaelis-Menten constants for the BCRP/ABCG2 drug
transporter and the ALDH enzyme respectively.
 Vm1 and Vm2, units: nM min-1. Numerical constants that represent the maximum
velocity obtained when the transporter and the enzyme exist completely in the form
THc and ELc respectively;
 v0, v1, v2 and v3. The ratios, respectively, of the volumes of extracellular region (Ve)
to medium (Vm), extracellular region to cytoplasm (Vc), nucleus (Vn) to cytoplasm
and cell membrane (Vcm) to cytoplasm;
 ksynth and kdest, units: nM min-1 (nM per minute) and (nM min)-1, respectively. Rate
constants for Cyclin B1 (monomer) synthesis and Cyclin B1 (monomer and dimers)
destruction, respectively;
 ka and kd, units: (nM min)-1 and min-1, respectively. Rate constants for association
of CDC2 (monomer) to Cyclin B1 (monomer) forming the inactive non-
phosphorylated complex (CDC2CycB) and the dissociation of this complex to the
monomers (i.e., Cyclin B1 and CDC2), respectively;
 factor, dimensionless constant. This parameter represents the strength of the
feedback from CDC2 to Wee1 kinase and CDC25 phosphatase;
 kWee1, units: (nM min)-1. Rate constant for the inactivation of Cyclin B1/CDC2
dimers, namely, the non-phosphorylated complex (CDC2CycB) and the active
Cyclin B1/CDC2 complex (CDC2CycBTP) by Wee1 kinase;
 kCDC25, units: (nM min)-1. Rate constant for the activation of Cyclin B1/CDC2
dimers, namely, the Y15-phosphorylated complex (CDC2CycBYP) and the Y15-
and T161-phosphorylated complex (CDC2CycBYPTP) by CDC25 phosphatase;
 CDC2total, APCtotal, Wee1total, CDC25total and p21total, units: nM. The total
concentrations of CDC2, APC, Wee1 kinase, CDC25 phosphatase and the CKI
p21CIP1/WAF1, respectively;
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 nAPC, nWee1, nCDC25, and np21, dimensionless constants. These dimensionless
constants are the Hill coefficients of the Hill functions describing the rates of
change of the active forms of the APC, Wee1 kinase, CDC25 phosphatase and the
CKI p21CIP1/WAF1, respectively;
 EC50APC, EC50Wee1, EC50CDC25, and EC50p21, units: nM. The half maximal
effective concentrations (EC50’s) in the Hill functions describing the rates of
change of the active forms of the APC, Wee1 kinase, CDC25 phosphatase and the
CKI p21CIP1/WAF1, respectively;
 kAPCon, kWee1on, kCDC25on and kp21on, units: min-1. Rate constants for turning on the
APC, Wee1 kinase, CDC25 phosphatase and the CKI p21CIP1/WAF1, respectively;
 kAPCoff, kWee1off, kCDC25off and kp21off, units: min-1. Rate constants for turning off the
APC, Wee1 kinase, CDC25 phosphatase and the CKI p21CIP1/WAF1, respectively;
 kCAK and kPP2C, units: min-1. The rate constants for phosphorylation/
dephosphorylation of the Y15-phosphorylated complex (CDC2CycBYP)/ Y15- and
T161-phosphorylated complex (CDC2CycBYPTP), respectively.
 C1 and C2, dimensionless constants (parameters). Scaling factors to account for the
variations in the interaction rate constants and the variations in the concentrations
of the cell cycle components (among different organisms), respectively.
 kTPT and kdam, units: (nM min)-1 and min-1, respectively. Rate constants relating to
the effect (response to TPT) compartment.
Five of these parameters (kTPT, kdam, C2, kp21off and p21total) in addition to two observational
parameters (α and β, see Sections 5.4 and 6.4.2) are assumed to be unknown, and need to
be estimated from experimental data. Using high-content imaging (for cells treated with
1×10+3 and 10×10+3 nM TPT), it is possible to detect and count γH2AX foci in single 
nuclei, and data from these experiments were used to estimate the unknown model
parameters kTPT and kdam prior to the washout event (at t ≤ 1 h). The time-lapse microscopy 
experiments allow direct measurement of the fluorescence intensities (Cyclin B1-GFP) of
concentrations of the active form of Cyclin B1 (Cyclin B1/CDK1) in the cytoplasm and
nucleus. These experiments were used to estimate the unknown model parameters kTPT,
kdam, C2, kp21off and p21total. Prior to the parameter estimation for the coupled drug
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kinetics/cell cycle model, two structural identifiability analyses have been performed (see
Section 6.4) to test whether the unknown model parameters are uniquely determined by the
observations corresponding to the two different experiments. In the following section, the
Taylor series approach is used to show that the coupled drug kinetics/cell cycle response
model is structurally globally identifiable.
Table 6.1: Table of known parameter values in the drug kinetics model (see
Chapter 4) and cell cycle model (see Chapter 5).
Drug kinetics model Cell cycle model
Parameter Value Parameter Value
ki (min-1) 1.4159 ksynth (nM min-1) 1.2
ke (min-1) 0.6160 kdest (nM-1 min-1) 0.005
kb (min-1 nM-1) 1.1690×10-5 ka (nM-1 min-1) 0.1
kmi (min-1) 8.7234×10-5 kd (min-1) 0.001
kmo (min-1) 5.4631 Factor 20
kdl (min-1) 2.1061 kWee1 (nM-1 min-1) 0.1
kdh (min-1) 0.0120 kCDC25 (nM-1 min-1) 0.1
v0 1.4778×10-5 CDC2total (nM) 100
BT (nM) 1.3412×10+5 APCtotal (nM) 50
Vm1 (min-1 nM) 9.6426×10+2 Wee1total (nM) 15
Vm2 (min-1 nM) 2.40516×10+2 CDC25total (nM) 15
km1 (nM) 1.1400×10-3 nAPC 5
km2 (nM) 9.6828×10-3 nWee1 4
kom (min-1) 0.0096 nCDC25 4
kcm (min-1) 0.0180 np21 5
koc (min-1) 0.0096 EC50APC (nM) 30
kcc (min-1) 0.0180 EC50Wee1 (nM) 25
v1 0.3602 EC50CDC25 (nM) 25
v2 3.9732×10-1 EC50p21 (nM) 30
v3 1.0238×10-2 kAPCon (min-1) 0.8
kWee1on (min-1) 0.8
kCDC25on (min-1) 0.8
kp21on (min-1) 0.8
kAPCoff (min-1) 0.08
kWee1off (min-1) 0.08
kCDC25off (min-1) 0.08
kCAK (min-1) 0.8
kPP2C (min-1) 0.008
Chapter 6: The coupled drug kinetics/dynamics model 164
6.4 Structural identifiability analysis
6.4.1 Structural identifiability analysis of the drug kinetics model
including the effect compartment
In this subsection, the Taylor series approach (see Section 2.4) is applied to the drug
kinetics model (including the effect compartment γH2AX) described by Equations (6.1) 
with initial conditions given in Equation (6.2). The input in this particular experiment is a
bolus injection of the anti-cancer drug TPT into the system, therefore, the corresponding
amounts are included in the initial conditions x0(p). The vector p comprising the two
unknown parameters of the model is given by:
TPT( , ) .damk kp
T
The unknown model parameters are positive, therefore, the set of feasible parameter
vectors, Ω, comprises the vectors (p1, p2)┬ such that pi > 0 (i = 1, 2). The state space vector
x(t, p) is given by:
( , ) ( ( , ), ( , ), ( , ), ( , ), ( , ), ( , ),
( , ), 2 ( , ))
x p p p p p p p
p p
m m e e c c
n
t L t H t L t H t L t H t
L t H AX t

T (6.16)
and the set M(p) is 8 . The initial condition for the state space representation of the model
is given by:
0 0( , ) ((1 ) ,0,0,0,0,0,0,0) .t v D x p
T
where D is the known dose and is therefore not included in the unknown parameter vector
p. The output function of the extended model is given by:
( , ) 2 ( , )y p pt H AX t (6.17)
An arbitrary parameter vector is denoted by p such that:
TPT( , )damk kp
T
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for which, y( , ) y( , )p pt t for all t ≥ 0. In order to perform the Taylor Series method 
(Section 2.3), successive coefficients of the Taylor series expansions of the components of
y( , ) and y( , )p pt t are computed to determine the relationship between p and p . Similar
to the structural identifiability analysis for the cell-based drug kinetics model in Chapter 4
and the cell cycle model in Chapter 5, the computer algebra system MATHEMATICA [206]
was used to perform the following structural identifiability analysis of the extended cell-
based drug kinetics model including the effect compartment (see Appendix A). As
explained in Subsection 2.3.3, uniqueness of the coefficients in the Taylor series
expansions of y(t, p) entails the following, if p Ω is such that y(t, p) = y(t, p ) for all t ≥ 
0, then, for each k = 1, 2, 3, …
( ) ( ) (0)(0, ) (0, ) where, (0, ) (0, ).k ky y y y p p p p (6.18)
For k = 0, 1, 2, 3 in Equation (6.18) no information is gained since each of these
coefficients is 0, i.e., y(k)(0,p) = 0 for k = 0, 1, 2, 3. Now considering the 4th derivative
(k = 4) yields:
(4) TPT
2
(0, ) T b i miB Dk k k ky
v

p (6.19)
and substituting in Equation (6.18) gives:
TPT TPTk k . (6.20)
The 5th derivative term (k = 5) gives:
(4) TPT 2 2 2 2
2 2
TPT 2 2 2
2 2
TPT 2 2 2 2
2 2
( )(0, )
( )
( 2 )
T b i mi dam m T b m dh m dl m
m
T b i mi e m i m m mi
m
T b i mi m mo m oc m om m
m
B Dk k k k k k B k k k k k ky
k v
B Dk k k k k k k k k k
k v
B Dk k k k k k k k k k V
k v



   

  




 
p
(6.21)
and using the relation in Equation (6.20) yields:
dam damk k . (6.22)
Therefore, for Equation (6.18) to be satisfied, it is necessary that:
TPT TPT and dam damk k k k  , (6.23)
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that is, p p (for all k ≥ 0). This is true for generic p , thus the model is structurally
globally identifiable, that is all of the unknown model parameters in p are uniquely
determined by the output structure corresponding to the proposed experiments to collect
data for the purpose of parameter estimation. In Section 6.5, the unknown model
parameters are estimated from high-content imaging data for the identification and
counting of γH2AX. The structural identifiability analysis was performed in this section to 
approach the estimation of the unknown model parameters with more confidence.
6.4.2 Structural identifiability analysis of the full drug kinetics/dynamics
model
In this subsection, the Taylor series approach (see Subsection 2.3.3) is applied to the
coupled drug kinetics/cell cycle response (dynamics) model at time t = tG1 (the start of a
new cell cycle, see Sections Chapter 5) described by Equations (6.1) and Equations (6.5)-
(6.14). For this study, the output function, y(t, p), of the coupled drug kinetics/cell cycle
response model is taken to be a linear function of the active Cyclin B1 concentration
([CDC2CycBTP]), that is:
TPy( , ) CDC2CycB ( , )t t  p p (6.24)
where, α and β are unknown observational parameters estimated from the experimental
data (see Section 5.4). The state space model describing how the drug perturbs the cell
cycle process is an uncontrolled non-linear system.
The vector p comprising the five unknown parameters of the model is given by:
2 p21off total( , , , , p21 ) .C k p
T
The unknown model parameters represent observational parameters (α and β), a scaling
factor (C2), a rate constant (kp21off) and a concentration (p21total), and are therefore positive.
This means that the set of feasible parameter vectors, Ω, comprises the vectors (p1, …, p5)┬
such that pi > 0 (1 ≤ i≤ 5). The state space vector x(t, p) is given by:
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YP YPTP TP
active act
( , ) ( ( , ), ( , ), ( , ), ( , ), ( , ), ( , ),
( , ), 2 ( , ),CycB( , ),CDC2CycB( , ),
CDC2CycB ( , ),CDC2CycB ( , ),CDC2CycB ( , ),
CDC2( , ),APC ( , ), Wee1
x p p p p p p p
p p p p
p p p
p p
m m e e c c
n
t L t H t L t H t L t H t
L t H AX t t t
t t t
t t




ive
active active
( , ),
CDC25 ( , ), p21 ( , ))
p
p p
t
t t T
(6.25)
and the set M(p) is 18 . The values for the state variables of the model at t = tG1 are given
by:
G1 1 2 3 4 5 6 7 8 2
2 2 2 2
2 2 2 2 2
( , ) ( , , , , , , , ,0.141396 ,
0.992654 ,1.4763 ,11.41023 ,1.64121 ,
84.479606 ,3.8539 ,15 ,1.54009 ,3.8539 )
t a a a a a a a a C
C C C C
C C C C C



x p
T
(6.26)
where ai (i = 1, …, 8) are the values of the variables in the model described by Equation
(6.1) (i.e., the drug kinetics model including the effect compartment) which depend on the
time point (tG1) at which a new cell cycle starts and on the value of the dose D (treatment
regimen). Determining the values of ai (i = 1, …, 8) is explained in Section 6.5. In this
model (i.e., the coupled drug kinetics/dynamics model), the values for the state variables at
time t = tG1 are actually dependent on components of the vector of unknown parameters p.
An arbitrary parameter vector is denoted by p such that:
2 p21off total( , , , , p21 )C k p
T
for which, y( , ) y( , )p pt t for all t ≥ 0. Similar to the structural identifiability analysis for 
the cell-based kinetics model (Chapter 4) and the extended cell cycle model (Chapter 5),
the computer algebra system MATHEMATICA [206] was used to perform the following
structural identifiability analysis of the extended cell cycle model (see Appendix A). As
explained in Subsection 2.3.3, uniqueness of the coefficients in the Taylor series
expansions of y(t, p) entails the following, if p Ω is such that y(t, p) = y(t, p ) for all
t ≥ 0, then, for each k = 1, 2, 3, …
( ) ( ) (0)
G1 G1 G1 G1( , ) ( , ) where, ( , ) ( , ).
k ky t y t y t y t p p p p (6.27)
Setting k = 0 in Equation (6.27) yields the first Taylor series coefficient given by:
(0)
G1 2( , ) 1.64121y t C   p (6.28)
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and substituting in Equation (6.27) gives:
2 21.64121 1.64121 .C C      (6.29)
The 1st derivative term (k = 1) gives:
(1) 2
G1 2( , ) 2.52518y t C p (6.30)
and using the relations in Equation (6.29) yields:
2
2
2
2
.C
C

  (6.31)
Considering the relations (Equations (6.29) and (6.31)) between parameters in p and p , the
following equations must hold to satisfy Equation (6.27) for k = 0, 1:
2 2
2 2
22
2 2
, and 1.64121 1.64121 .C CC
C C
 
       (6.32)
The 2nd derivative term (k = 2) gives:
(2)
G1 2
2
20.107836 0.38890( , ) ( 1 )y t C C p (6.33)
and using the relations in Equations (6.32) and (6.33) yields:
2 2.C C (6.34)
Considering the relations, in Equations (6.32) and (6.34), between parameters in p and p ,
the following equations must hold to satisfy Equation (6.27) for k = 0, 1, 2:
2 2 , , and .C C       (6.35)
The 3rd derivative term (k = 3) gives:
(3)
G1 2
2
2 20.0598942( 0.06( , 27616 ) (4.45049) )y t C C C   p (6.36)
and substituting in Equation (6.27) yields no information since none of the remaining
unknown model parameters are present in the 4th coefficient of Taylor series expansion.
The 4th derivative term (k = 4) gives:
2 3 4(4)
G1 2 2 2
2
5
0.00252426 0.0345519 0.171215
0.00922425
( , )y t C C C
C
  

 



p
(6.37)
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and substituting in Equation (6.27) yields no information since none of the remaining
unknown model parameters are present in the 5th coefficient of Taylor series expansion.
The 5th derivative term (k = 5) gives:
(5)
G1 2 2 2
2 2
p21o
2 3
4 2 10
tota
ff 2
8
l
4
( , ) ( 0.000310113 2.6964 2.50228
0.00142062 (0.0542277 5.16716 10 ))
0.00507981
(1 )
p21
p
dam
y t C C C
C C
k C
a k




 
 




  (6.38)
and using the relations in Equations (6.35) yields:
7 7
total
7 7
tota
p21off p21off 8
8 l
1.01719 10 1.01719 10 )p21
1.01719 10 +1.01719 10 )p21
(
(
dam
dam
k k a k
a k
 
 
 
  
 
. (6.39)
Finally, calculating the seventh coefficient of Taylor series expansion (k = 6), and using the
relations in Equations (6.37) and (6.41) gives:
total totalp21 p21 . (6.40)
Therefore, the following relations must hold in order to satisfy Equation (6.27) for all
k = 0, …, 6:
to2 tal tot2 p21off p21off al, , p21 p21 and, .C C k k         (6.41)
Equation (6.27) is therefore satisfied for all k ≥ 0 with p p . This is true for generic
p , thus the model is structurally globally identifiable, that is all of the model
parameters are uniquely determined by the output structure corresponding to the proposed
experiments to collect data for the purpose of parameter estimation. In Section 6.5.2, the
unknown model parameters were estimated from time-lapse microscopy data (Cyclin B1-
GFP fluorescence data) at the start of a new cell cycle (i.e., at t = tG1), in the presence of
the anti-cancer agent TPT. The structural identifiability analysis was performed in this
section to approach the estimation of the unknown model parameters with greater
confidence.
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6.5 Parameter estimation of the coupled drug kinetics/cell cycle
model
6.5.1 Parameter estimation before the washout event
In this subsection, the DNA damage data (the number of γH2AX foci in single nuclei) for 
live human osteosarcoma cells (U-2 OS cell line) treated with 1×10+3 and 10×10+3 nM TPT
were used to estimate the unknown model parameters, namely, kTPT and kdam (for the two
treatments regimens) prior to the washout event at time tw = 60 min, see Section 6.3. Figure
6.4 illustrates distinctly different patterns of response for these cells to the different
treatment regimens. The cells were treated with a bolus of TPT and after 60 min of
administration, the number of γH2AX foci per nucleus are quantified for individual cells (1 
data point at tw = 60 min). The average DNA damage (i.e., the dsDNA breaks) induced by
TPT (see Table 6.2), increases with the value of dose administered as shown in Figure 6.4.
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Figure 6.4: The number of γH2AX foci in single nuclei for live human osteosarcoma cells 
treated for one hour with 1×10+3 nM (blue) and 10×10+3 nM (green) TPT.
Using the estimated drug kinetics model parameters in Table 6.1, the FACSIMILE software
(Appendix B) package (MCPA Software, U.K.) was used to estimate the unknown model
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parameters kTPT and kdam for the two treatment regimens (Table 6.2). Data from 25 cells
(for those treated with 1×10+3 nM TPT) and 26 cells (for those treated with 10×10+3 nM
TPT) were averaged as presented in Table 6.2, and the postulated model (Equations (6.1))
fitted to these averaged data. The estimated parameter values and the predicted number of
γH2AX foci per nucleus for each treatment regimen after 60 min are presented in Table 
6.2. The predicted count of γH2AX foci per nucleus show that there is exact reproduction 
of experimental data (in both experiments) by the simulated output from the model taking
parameter values from Tables 6.1 and 6.2.
Table 6.2: Parameter values for the model described by Equations (6.1), estimated using
high-content imaging.
TPT = 1×10+3 nM TPT = 10×10+3 nM
Parameter Value Parameter Value
kTPT (nM min)-1 2.1885×10-3 kTPT (nM min)-1 1.83468×10-4
kdam (min-1) 1.43934×10-2 kdam (min-1) 4.0782×10-3
Average γH2AX foci 
per nucleus
Predicted γH2AX foci 
per nucleus
Average γH2AX foci 
per nucleus
Predicted γH2AX foci 
per nucleus
65 65 108 108
The value of the parameter kTPT decreases with increasing dose. In addition, the value of
this parameter (i.e., kTPT) in both experiments is very small in comparison to the other
parameters relating to compartment Ln (drug bound in the nucleus). Thus the estimated
value for the parameter kTPT is very small in comparison with any of kdl, kdh, in addition to
the product of BT and kb (see Table 6.1). Therefore, extending the drug kinetics model
presented in Chapter 4 (Figure 4.9) by introducing the effect compartment γH2AX (see 
Figures 6.3 and 6.4) has a negligible effect on the drug kinetics model. Moreover, the value
of the parameter kdam decreases with increasing dosage (D), and consequently the intensity
of response to the drug (i.e., the DNA damage induced by the drug) increases.
The drug kinetics model described by Equations (6.1) was simulated for 60 min, with
parameters taking values from Tables 6.1 and 6.2 and treatment regimens D = 1×10+3 and
10×10+3 nM TPT as shown in Figures 6.5-6.8. The average number of γH2AX foci per 
nucleus increases as the concentration of bound drug to the nucleus (Ln) increases (Figures
6.6 and 6.8). Moreover, when cells are treated with 10×10+3 nM TPT, the concentration Ln
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reaches a maximum value of 1.2457×10+4 nM at time t = 13.5 mins (Figure 6.7), and then
starts to gradually decrease. However, the number of γH2AX foci continues to increase; 
this indicates that DNA damage that generates the formation of dsDNA breaks is still
increasing and the DNA repair process does not start immediately once the concentration
of the drug bound to its DNA target decreases.
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Figure 6.5: Simulated output for Ln (blue), Lc (red) and Hc (green) from model Equation
(6.1), with parameters taking values in Tables 6.1 and 6.2 and the initial dose D = 1×10+3
nM TPT for 60 min (until the washout event).
The predicted concentration for the inactive form of the drug (TPTH) in the cytoplasm (Hc)
diverges over time (in both experiments) as shown in Figures 6.5 and 6.7. The pH level at
which the experiments were undertaken was 7.2; the results obtained are consistent with
previous studies [98, 99] that TPTL in the cytoplasm (Lc) is unstable at physiological pH
and undergoes reversible hydrolysis to TPTH (Hc). The enzyme ALDH is also responsible
for the irreversible hydrolysis (inactivation) of TPTL to TPTH (in the cytoplasm) which
brings about the increase in the ratio of TPTH to TPTL in the cytoplasm during the first 60
min (see Chapter 4). In addition, the dissociation of Ln to Hc increases the concentration of
Hc. For both treatment regimens, the predicted concentrations of the active form of the
drug (TPTL) in the cytoplasm (Lc) and in the nucleus (Ln) settle to a steady state, as shown
in Figures 6.5 and 6.7.
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Figure 6.6: Simulated output for the average number of γH2AX foci per nucleus from the 
model Equations (6.1), with parameters taking values in Tables 6.1 and 6.2 and the initial
dose D = 1×10+3 nM TPT for 60 min (until the washout event).
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Figure 6.7: Simulated output for Ln (blue), Lc (red) and Hc (green) from model Equations
(6.1), with parameters taking values in Tables 6.1 and 6.2 and the initial dose D = 10×10+3
nM TPT for 60 min (until the washout event).
Following the washout event at time tw = 60 min, the variables relating to the drug kinetics
model (including the effect compartment) that are unaffected by this event for D = 1×10+3
nM are given by (see Figures 6.5 and 6.6):
3 3
3
(60) 0.45 10 nM, (60) 8.73 10 nM,
(60) 0.833 10 nM and 2 (60) 65
c c
n
L H
L H AX
 

   
  
(6.42)
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and the corresponding values for these variables at time tw = 60 min when D = 10×10+3 nM
are given by (see Figures 6.7 and 6.8):
3 4
4
(60) 6.22 10 nM, (60) 1.27 10 nM,
(60) 1.07 10 nM and 2 (60) 108.
c c
n
L H
L H AX
 

   
  
(6.43)
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Figure 6.8: Simulated output for the average number of γH2AX foci per nucleus from the 
model Equations (6.1), with parameters taking values in Tables 6.1 and 6.2 and the initial
dose D = 10×10+3 nM TPT for 60 min (until the washout event).
6.5.2 Parameter estimation of the coupled model
In this chapter, the coupled drug kinetics/dynamics model describes the response of single
human osteosarcoma cells treated with 1×10+3 nM and 10×10+3 nM TPT. Similar to the
approach used for the control (untreated) cell in Chapter 5, the unknown model parameters
C2, kp21off, p21total, α and β (as in Section 6.4) were estimated using Cyclin B1-GFP data
(see Section 6.2) for one complete cell cycle event of a newborn cell starting at time t = tG1
(see Chapter 5) to study the effects of TPT on cell cycle progression. In addition, the
unknown model parameters were estimated from averaged cytoplasmic Cyclin B1-GFP
data (see Figure 6.9) from the two ROI’s (see Section 6.2). Moreover, due to the artefacts
of morphological changes (rounding up of the cell before cell division) during the M phase
of the cell cycle, which result in a false peak (Figure 6.9) in the data, the parameter
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estimation was performed starting from time t = tG1 (G1 phase of a new cell cycle) for one
complete cell cycle excluding the experimental time point corresponding to the false peak
(see Section 5.2).
In this subsection, the FACSIMILE software package (MCPA Software, U.K.) was used to fit
the coupled drug kinetics/cell cycle response model to Cyclin B1-GFP fluorescence data.
The unknown parameters of the coupled model are the observational parameters (α and β),
the concentration scaling factor C2 (specific to cell type and cellular conditions, see
Chapter 5), total concentration of the CKI p21CIP1/WAF1 ([p21total]) and the rate constant for
turning p21CIP1/WAF1 off (kp21off). Live cells are tracked in time and therefore the unknown
model parameters are permitted to change (if appropriate) at cytokinesis, however, they
remain constant during an individual cycle. The parameter values in Table 6.1 are specific
for all cell types and cellular conditions (internal and external) that influence the cell cycle
progression. These parameters are also permitted to change implicitly (if appropriate) at
cell division since they are scaled by C1 or C2. However, they remain constant during an
individual cell cycle.
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Figure 6.9: Average cytoplasmic Cyclin B1-GFP fluorescence intensity extracted from a
typical G2 cell treated with 1×10+3 nM TPT.
Figure 6.9 represents average cytoplasmic Cyclin B1-GFP intensity profile from a G2 cell
responding to a dose D = 1×10+3 nM of TPT. The high-resolution fluorescence tracking
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begins (i.e. the first image is captured) 20 min after the washout event, that is at time
tstart = 80 min (see Figure 6.9). In this particular experiment, the progenitor cell divides into
two daughter cells (first cell division) at time tB = 260 min (see Chapter 5) and the
complete newborn cell appears at time tG1 = 280 min (the time when a new cycle starts
from the G1 phase). The values for the state variables relating to the cell cycle response
component of the coupled model at time tG1 are given in Equation 5.16 (see Chapter 5). In
order to identify the values for the state variables of the full model (coupled drug
kinetics/cell cycle response model), the drug kinetics model (including the effect
compartment) was simulated to time tG1 = 280 min (i.e., 220 min following the washout
event) as shown in Figures 6.10-6.12.
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Figure 6.10: Simulated output for average number of γH2AX foci per nucleus from the 
model Equation (6.1), with parameters taking values in Tables 6.1 and 6.2 and the initial
dose D = 1×10+3 nM following the washout event until time t = tG1.
The average number of γH2AX foci per nucleus slightly increases and reaches the 
maximum number of γH2AX foci per nucleus at around time t = 62 min. Then, the number
of γH2AX foci starts to exponentially decrease (see Figure 6.10), that is when the cell 
starts the DNA repair mechanism. The concentration of TPTH in the cytoplasm (Hc) also
increases following the washout event (Figure 6.11) and reaches a maximum concentration
of 9.0821×10+3 nM at time t = 65.3333 min as a result of the reversible hydrolysis of Lc to
Hc, the irreversible hydrolysis of Lc to Hc (due to the catalytic reaction of the enzyme
ALDH) and the dissociation of TPTL bound to DNA (i.e., Ln) to Hc. Then, Hc decays to
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zero (i.e., 0 nM, see Figure 6.16) over time as shown in Figure 6.11. The concentrations of
both TPTL in the cytoplasm (Lc) and nucleus (Ln) start rapidly decreasing after the washout
event (Figure 6.12). Therefore, the drug in the cellular compartments flows to the
extracellular region by simple diffusion (only TPTL) or by active pumping (only TPTH
through the BCRP/ABCG2 transporter). These results match expected biological
behaviour.
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Figure 6.11: Simulated output for TPTH in the cytoplasm (Hc) from model Equation (6.1),
with parameters taking values in Tables 6.1 and 6.2 and the initial dose D = 1×10+3 nM TPT
following the washout event until time t = tG1.
The values for the state variables of the full drug kinetics/cell cycle response model
(dynamics) at time tG1 = 280 min when cells are treated with 1×10+3 nM TPT are given by:
2 2
YP 2 YPTP 2
TP 2 2
active 2 activ
[CycB](280) 0.141396 , [CDC2CycB](280) 0.992654 ,
[CDC2CycB ](280) 1.4763 , [CDC2CycB ](280) 11.41023 ,
[CDC2CycB ](280) 1.64121 , [CDC2](280) 84.479606 ,
[APC ](280) 3.8539 , [Wee1
C C
C C
C C
C
 
 
 
 e 2
active 2 active 2
3
](280) 15 ,
[CDC25 ](280) 1.54009 , [p21 ](280) 3.8539 ,
(280) 0.0584, (280) 0.0457, (280) 0.0659,
(280) 5.0496, (280) 0.0106, (280) 6.97 10 ,
(280) 0.0197 and 2 (280) 2.9
m m e
e c c
n
C
C C
L H L
H L H
L H AX


 
  
   
  1
(6.44)
where, the state variable γH2AX is dimensionless and the rest of the state variables are
measured in nM.
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Figure 6.12: Simulated output for Ln (blue) and Lc (green) from model Equation (6.1), with
parameters taking values in Tables 6.1 and 6.2 and the initial dose D = 1×10+3 nM TPT
following the washout event until time t = tG1.
In the track shown in Figure 6.9, the false peak is located at time t = 1860 min and the cell
divides again (second cell division) at time t = 1900 min, therefore, a complete newborn
cell appears at time t3 = 1920 min (the time when a new cycle starts from the G1 phase).
The parameter estimation (for the cell treated with 1×10+3 nM TPT) was performed
starting from time tG1 = 280 min until time t3 = 1920 min (one complete cell cycle)
excluding the experimental data point which includes the false peak. Using Equation
(5.35), the scaling factor C1 is given by (see Section 5.4):
1
IMT
IMT
a
b
C  . (6.45)
where, IMTa is the inter-mitotic time in the extended model before scaling and IMTb is the
inter-mitotic time in the experimental data. IMTa is a constant and is equal to 138.5 min
(see Figure 5.19, Chapter 5) and for this particular track (Figure 6.9) IMTb = 1640 min
(1920 min – 280 min), and therefore, C1 = 0.0845 (see Table 6.3).
The fitted parameter values, and their confidence levels are presented in Table 6.3, where it
is seen that all parameters are well-determined by the Cyclin B1-GFP data. Additionally,
three of the estimated parameters, namely, C2, α and β, have low SDLN values
corresponding to high confidence in their values. However, the estimated parameter values
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for kp21off and p21total have high SDLN values due to the low signal-to-noise ratio in the
experimental data. Moreover, the value of CORImean = 0.62857 indicates that the residuals
are acceptable and evenly distributed above and below the simulated output of the model
and therefore the resulting fit is good (in terms of the residuals).
Table 6.3: Best parameter estimates for the coupled drug kinetics/cell cycle
response model Equation (6.1)-(6.14) and state values at t = tG1 in Equation
(6.44), estimated using live-cell Cyclin B1-GFP data for a cell treated with
1×10+3 nM.
Parameter Value
C1 0.0845
Parameter Value SDLN 5% 95%
α (a.u. nM-1) 2 0.3483 1.13 3.55
C2 9×10-1 0.0275 8.60×10-1 9.42×10-1
β (a.u.) 2.83×10+1 0.1214 2.32×10+1 3.46×10+1
kp21off (min-1) 7.20×10-2 1.4102 7.08×10-3 7.32×10-1
p21total (nM) 1.85×10+2 1.7707 1.00×10+1 3.40×10+3
RSS = 7.1229×10+1
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Figure 6.13: Comparison of model prediction (solid red line) and Cyclin B1-GFP data (blue
circles) in the presence of 1×10+3 nM TPT. An artefact of morphological changes during the
final stages of mitosis is the over-expression of Cyclin B1 fluorescence giving rise to false
peaks in the experimental data.
The plots shown in Figure 6.13 demonstrate a typical trace for the growth of a cell treated
with 1×10+3 nM TPT. The Cyclin B1-GFP data are denoted by the blue circles and the
simulated data by the solid red curve. The model fit in Figure 6.13 does not show that there
is a close reproduction of Cyclin B1-GFP data by simulated output from the coupled model
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(with parameters taking values from Tables 6.1-6.3) due to the noise in the data. However,
the simulated output from the model detects the exact location of the peak (spike) in the
Cyclin B1-GFP data and reproduces the general phenotypic (qualitative) behaviour (i.e.,
position in the cell cycle) of the experimental data. Similar to the extended cell cycle
model presented in Chapter 5, the impact of the false peak (see Figure 6.9) in the
experimental data, due to morphological changes (rounding up) during the M phase of the
cell cycle, is minimised by the coupled drug kinetics/cell cycle response model.
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Figure 6.14: A normal probability plot for the residuals in the weighted non-linear least-
squares fit of the coupled drug kinetics/cell cycle response model to Cyclin B1-GFP data
extracted from typical G2 cell treated with 1×10+3 nM TPT. The residuals are plotted in
ascending numerical order on the horizontal axis, against cumulative probabilities in
N(0, 1) transformed to a linear scale.
Figure 6.14 shows the normal probability plot for the weighted residuals for the fit in
Figure 6.13 of the coupled drug kinetics/cell cycle response model to Cyclin B1-GFP data
of a cell treated with 1×10+3 nM TPT. The residuals are plotted in ascending order on the
horizontal axis, against cumulative probabilities in N(0, 1) transformed to a linear scale.
The figure is consistent with the assumption of normally distributed errors (with
approximately zero mean and standard deviation of 1), since the graph is approximately
linear, which is an indicator for the appropriateness of the standard error σ used for each
observation y.
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The estimated correlation matrix for the well-determined parameters is given in Table 6.4.
From this table the parameter pairings that exhibit the highest correlation are: p21total and
kp21off (0.861) and α and β (-0.916). The first pair represent the total concentration of CKI
p21CIP1/WAF1 and the rate at which this CKI is turned off. The high correlation of the
logarithm of these parameters indicates that it is the product of these that is important for
the fitting, i.e., the rate at which the inhibitor is activated. The second pair relates to the
experimental observations. Accordingly, the high correlation of the logarithm of these
parameters (α and β) indicates that it is the sum of these parameters that is important for
the fitting.
Table 6.4: The estimated correlation matrix for the well-determined parameters for a cell
treated with 1×10+3 nM TPT.
Α C2 β kp21off p21total
α 1 -0.416 -0.916 0.601 0.795
C2 -0.416 1 0.441 -0.946 -0.662
β -0.916 0.441 1 -0.593 -0.729
kp21off 0.601 -0.946 -0.593 1 0.861
p21total 0.795 -0.662 -0.729 0.861 1
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Figure 6.15: Simulated output for the average number of γH2AX foci per nucleus from the 
model Equations (6.1), with parameters taking values in Tables 6.1 and 6.2 and the initial
dose D = 1×10+3 nM during one complete cell cycle.
Figure 6.15 represents the simulated output for the average number of γH2AX foci per 
nucleus during a complete cell cycle event for a cell (Figure 6.9) treated with 1×10+3 nM
TPT, starting at tG1 = 280 (G1 phase of the newborn cell) min up to t3 = 1920 min. The
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dsDNA breaks (induced by TPT) completely disappear at time t ≈ 700 min, that is, the 
DNA is successfully repaired. In addition, at time t ≈ 990 min, the anti-cancer agent TPT 
(in both forms TPTL and TPTH) is totally flushed out of the cell, directly and indirectly via
the BCRP/ABCG2 transporter as illustrated in Figure 6.16, which demonstrates the
significance of this transporter in drug resistance mechanisms (see Chapters 3 and 4).
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Figure 6.16: Simulated output for TPTH in the cytoplasm (Hc) from model Equation (6.1),
with parameters taking values in Tables 6.1 and 6.2 and the initial dose D = 1×10+3 nM TPT
during one complete cell cycle.
Figure 6.17 represents the average cytoplasmic Cyclin B1-GFP intensity profile from a G2
cell responding to a dose D = 10×10+3 nM of TPT. Similar to the previous experiment,
tracking of cells begins 20 min after the washout event, i.e., at time tstart = 80 min (see
Figure 6.17). In this particular experiment, the first cell division takes place at time
tB = 620 min and the complete newborn cell appears at time tG1 = 640 min. The values for
the state variables relating to the cell cycle response component of the coupled model at
time tG1 are given in Equations (5.16), see Chapter 5. In order to identify the values for the
state variables of the full model, the drug kinetics model (including the effect
compartment) was simulated to time tG1 = 640 min (i.e., 580 min following the washout
event) as shown in Figures 6.18-6.20.
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Figure 6.17: Average cytoplasmic Cyclin B1-GFP fluorescence intensity extracted from a
typical G2 cell treated with 10×10+3 nM TPT.
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Figure 6.18: Simulated output for the average number of γH2AX foci per nucleus from the 
model Equations (6.1), with parameters taking values in Tables 6.1 and 6.2 and the initial
dose D = 10×10+3 nM following the washout event until time t = tG1.
The average number of γH2AX foci per nucleus slightly increases (following the washout
event) and reaches the maximum number of γH2AX foci per nucleus at around time 
t = 65.6667 min. Then, the number of γH2AX foci starts to exponentially decrease (see 
Figure 6.18), that is when the cell starts the DNA repair mechanism which does not start
immediately after removing the drug from the medium. The concentration of TPTH in the
cytoplasm (Hc) also increases following the washout event (Figure 6.19) and reaches a
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maximum concentration of 1.3054×10+3 nM at time t = 71.6667 min as a result of the
reversible hydrolysis of Lc to Hc, the irreversible hydrolysis of Lc to Hc (due to the catalytic
reaction of the enzyme ALDH) and the dissociation of TPTL bound to DNA to Hc. Then,
Hc starts to decrease and converges to zero (i.e., 0 nM) over time as shown in Figure 6.19.
Similar to the previous experiment (i.e., when cells are treated with D = 10×10+3), Lc and
Ln start rapidly decreasing after the washout event (Figure 6.20). Therefore, the drug (TPTL
and TPTH) in the cellular compartments (nucleus and cytoplasm) flows to the extracellular
region by simple diffusion (only TPTL) or by the active pumping mechanism (only TPTH
through the BCRP/ABCG2 transporter).
The values for the state variables of the full drug kinetics/cell cycle response model
(dynamics) at time tG1 = 640 min when cells are treated with 10×10+3 nM TPT are given
by:
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(6.46)
where, the state variable γH2AX is dimensionless and the rest of the state variables are 
measured in nM.
In the Cyclin B1-GFP intensity profile shown in Figure 6.17, the false peak is located at
time t = 2860 min and the second cell division occurs at time t = 2880 min, therefore, a
complete newborn cell appears at time t3 = 2900 min. The parameter estimation for the cell
treated with 10×10+3 nM TPT was performed starting from time tG1 = 640 min until time
t3 = 2900 min excluding the experimental data point which includes the false peak at time
t = 2860 min. Using Equation (6.45), the scaling factor C1 = 0.0613.
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Figure 6.19: Simulated output for TPTH in the cytoplasm (Hc) from model Equations (6.1),
with parameters taking values in Tables 6.1 and 6.2 and the initial dose D = 10×10+3 nM
TPT following the washout event until time t = tG1.
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Figure 6.20: Simulated output for Ln (blue) and Lc (green) from model Equations (6.1), with
parameters taking values in Tables 6.1 and 6.2 and the initial dose D = 10×10+3 nM TPT
following the washout event until time t = tG1.
The fitted (estimated) parameter values, with estimates for their confidence levels are
presented in Table 6.5, where it is seen that all parameters are well-determined by the
Cyclin B1-GFP data. In addition, all of the estimated parameters have low SDLN values
corresponding to high confidence in their values. The one exception is the estimated
parameter value for p21total due to the low signal-to-noise ratio in the Cyclin B1-GFP data.
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The value of CORImean = 0.67176 indicates that the residuals are acceptable and evenly
distributed above and below the simulated output of the model and therefore the resulting
fit is good.
Table 6.5: Best parameter estimates for the coupled drug kinetics/cell cycle
response model Equations (6.1)-(6.14) and state values at t = tG1 in Equation
(6.46), estimated using live-cell Cyclin B1-GFP data for a cell treated with
10×10+3 nM.
Parameter Value
C1 0.0613
Parameter Value SDLN 5% 95%
α (a.u. nM-1) 2.21 0.2073 1.57 3.11
C2 9.23×10-1 0.0237 8.87×10-1 9.59×10-1
β (a.u.) 3.52×10+1 0.0592 3.19×10+1 3.88×10+1
kp21off (min-1) 3.08×10-2 0.296 1.89×10-2 5.01×10-2
p21total (nM) 1.08×10+2 0.9677 2.21×10+1 5.33×10+2
RSS = 5.59×10+1
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Figure 6.21: Model fit showing model prediction (solid red line) and Cyclin B1-GFP data
(blue circles) in the presence of 10×10+3 nM TPT. An artefact of morphological changes
during the final stages of mitosis is the over-expression of Cyclin B1 fluorescence giving rise
to false peaks in the experimental data.
The plots shown in Figure 6.21 demonstrate a typical trace for the growth of a cell treated
with 10×10+3 nM TPT. The Cyclin B1-GFP data are denoted by the blue circles and the
simulated data by the solid red curve. The model fit in Figure 6.21 shows that there is a
close reproduction of Cyclin B1-GFP data by simulated output from the coupled drug
kinetics/dynamics model with parameters taking values from Tables 6.1-6.3. In addition,
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the impact of the false peak (see Figure 6.17) in the experimental data is minimised by the
model.
Figure 6.22 shows the normal probability plot for the weighted residuals for the fit in
Figure 6.21 of the coupled drug kinetics/cell cycle response model to Cyclin B1-GFP data
of a cell treated with 10×10+3 nM TPT. The residuals are plotted in ascending order on the
horizontal axis, against cumulative probabilities in N(0, 1) transformed to a linear scale.
The figure is consistent with the assumption of normally distributed errors (with
approximately zero mean and standard deviation of 1), since the graph is approximately
linear, which is an indicator for the appropriateness of the standard error σ used for each
observation y.
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Figure 6.22: A normal probability plot for the residuals in the weighted non-linear least-
squares fit of the coupled drug kinetics/cell cycle response model to Cyclin B1-GFP data
extracted from typical G2 cell treated with 10×10+3 nM TPT. The residuals are plotted in
ascending numerical order on the horizontal axis, against cumulative probabilities in
N(0, 1) transformed to a linear scale.
Table 6.6: The estimated correlation matrix for the well-determined parameters for a cell
treated with 10×10+3 nM TPT.
α C2 β kp21off p21total
α 1 -0.144 -0.885 0.338 0.811
C2 -0.144 1 0.202 -0.963 -0.368
β -0.885 0.202 1 -0.361 -0.694
kp21off 0.338 -0.963 -0.361 1 0.593
p21total 0.811 -0.368 -0.694 0.593 1
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The estimated correlation matrix for the well-determined parameters is given in Table 6.6.
From this table it is seen that the highest correlation is between α and β (-0.855), p21total
and α (0.811) and kp21off and C2 (-0.963). The high correlation of the logarithms of these
parameters indicates that it is the product or sum of the parameters that is important for the
fitting.
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Figure 6.23: Simulated output for the average number of γH2AX foci per nucleus from the 
model Equations (6.1), with parameters taking values in Tables 6.1 and 6.2 and the initial
dose D = 10×10+3 nM during one complete cell cycle.
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Figure 6.24: Simulated output for TPTH in the cytoplasm (Hc) from model Equations (6.1),
with parameters taking values in Tables 6.1 and 6.2 and the initial dose D = 10×10+3 nM
TPT during one complete cell cycle.
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Figure 6.23 represents the simulated output for the average number of γH2AX foci per 
nucleus during the complete cell cycle event of the cell (Figure 6.17) treated with 10×10+3
nM TPT, starting at tG1 = 640 (G1 phase of the newborn cell) min up to t3 = 2900 min. The
dsDNA breaks (induced by TPT) completely disappear at approximately time t = 1980 min
(i.e., the DNA is successfully repaired, see Figure 6.15). In addition, at approximately time
t = 1420 min, the drug (in both forms TPTL and TPTH) is totally flushed out of the cell,
directly (via passive diffusion) and indirectly (via the BCRP/ABCG2 transporter) as
illustrated in Figure 6.24, which demonstrates the potential significance of this transporter
in drug resistance mechanisms (see Chapters 3 and 4).
In comparison between the results obtained from the parameter estimation for the untreated
cell (see Chapter 5), the cell treated with 1×10+3 nM TPT (Table 6.3) and the cell treated
with 10×10+3 nM TPT (Table 6.5), the main difference is the extension in the IMT as a
result of the decrease in the effective rate at which the CKI p21CIP1/WAF1 is switched off,
i.e., C1kp21off/(1 + kdamγH2AX(t)). That is, the time required to complete the cell cycle
increases when the parameter kp21off decreases due to its inhibitory effect. These results
match the expected biological behaviour since both Cyclin B1/CDK1 and the CKI
p21CIP1/WAF1 are antagonist proteins (see Chapters 3 and 5). Additionally, the estimated
parameter values for the constant C2 (see Section 5.3) for the untreated cell, the cell treated
with 1×10+3 nM TPT and the cell treated with 10×10+3 nM TPT are 9.2038×10-1, 9×10-1
and 9.23×10-1, respectively. The estimated values for C2 (in the three different cells) are
relatively close since these cells are from the same cell type (U-2 OS cell line). However,
the slight variation among the values for C2 is caused by the different conditions (i.e.,
different treatment regimens) these cells are subject to (see Chapter 5). Similar to the
parameter C2, the estimated values for the parameter p21total are of the order of 10+2 nM in
the untreated cell and the treated cells. This confirms that the concentrations of the cell
cycle components are close for cells from the same cell type, however, the variations are
caused by the different conditions these cells are subject to. The estimated values for the
parameters α and β vary significantly between the untreated cell(s) (see Chapter 5) and the
treated cells (Tables 6.3 and 6.5) due to the differences in the experimental set up and the
resulting background intensities in the Cyclin B1-GFP data for the control cell (untreated
cell) and the treated cells.
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6.6 Sensitivity analysis of the coupled drug kinetics/cell cycle
response model
It was shown in Chapter 5 that the model variable CDC2CycBTP (the active form of Cyclin
B1 protein) exhibits a noticeable variation in simulations when varying the parameter
kp21off. In this section, the impact of varying the values for the parameter kdam is considered
with respect to the variable CDC2CycBTP in the coupled drug kinetics/dynamics model.
The impact of varying the values for the parameter kdam for one complete cycle starting at
tG1 = 280 min of the cell treated with 1×10+3 nM TPT is shown in Figure 6.25. The
parameter kdam was varied over the range 1.44×10-5 min-1-1.44×10+1 min-1. These values
are: (a) 1.44×10-5 min-1, (b) 1.44×10-2 min-1, (c) 1.44×10-1 min-1 and , (d) 1.44×10+1 min-1.
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Figure 6.25: Simulated output from the coupled drug kinetics/dynamics model at t = tG1 by
varying the parameter kdam in the range of 1.44×10-5-1.44×10+1 min-1.
As shown in Figure 6.25, the active form of Cyclin B1 exhibits noticeable variation in
simulations when varying the parameter kdam. That is, the activity of Cyclin B1/CDC2 is
sensitive to changes in the parameter kdam. Based on the results obtained in Figure 6.25, the
time required to complete a cell cycle event increases with an increase in the parameter
kdam. This is not surprising since the parameter kdam determines (implicitly) the rate at
which the CKI p21CIP1/WAF1 is switched off (kp21off). Therefore, an increase in the value of
kdam decreases the rate constant kp21off which results in an up-regulation of the CKI
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p21CIP1/WAF1. Further increase in the value of the parameter kdam can result in a cell cycle
arrest (see Chapter 3) as shown in Figure 6.25.
6.7 Summary
Chapter 6 presents a novel coupling of the extended drug kinetics model and the extended
cell cycle model to describe the response of the growth of single human osteosarcoma cells
in the presence of 1×10+3 and 10×10+3 nM TPT. Modelling the dynamic effect (response)
of TPT on human osteosarcoma cells was achieved by extending the drug kinetics model
presented in Chapter 4 by introducing an effect compartment to represent γH2AX which is 
linked to the CKI p21CIP1/WAF1 in the extended cell cycle model. The model proposed in
this experiment was found to be structurally globally identifiable with respect to the high
content screening experiments (DNA damage data) and Cyclin B1-GFP microscopy
experiments used to collect data. The corresponding simulations show a good qualitative
representation of the experimental data. However, the fits for the cell treated with 1×10+3
nM TPT does not show close reproduction of the data by simulated output from the
coupled model due to the noise in the data.
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7 Conclusions
In this final chapter, the significant outcomes of the work presented in this thesis will be
identified and discussed. In all models developed in this thesis, mathematical modelling of
biological systems has proven to be useful, particularly when investigating parts of the
system that are not directly measured (i.e., that are not physically accessible).
In Chapter 4, a state-space model of the in vitro kinetics of the anti-cancer agent TPT has
been extended from a previously published model. The postulated model takes into
account the effect of the ALDH enzyme and the elimination of the drug (TPTH) from the
cytoplasm via the efflux pump (ABCG2/BCRP drug transporter). The extended drug
kinetics model was reduced by assuming that the binding kinetics of both the ALDH
enzyme and the BCRP/ABCG2 transporter are saturable and therefore, PSSA applies.
Structural identifiability, which is an a priori analysis for parameter estimation, was
performed using the computer algebra system MATHEMATICA, this tool has proven useful
for symbolic computations mainly when they become algebraically complicated. The
identifiability analysis demonstrates that all of the unknown model parameters (of the
reduced drug kinetics model) are uniquely determined by the output structure
corresponding to the real experiment. This ensures that each model parameter can be
uniquely determined from perfect, noise-free and continuous observations.
Parameter estimation was performed using the commercial simulation software package
FACSIMILE. The optimisation method used in this computer-modelling tool to obtain
parameter estimates involves minimisation of the weighted least-square criterion. One
advantage of this tool is the robust and reliable numerical integrator that is capable of
handling extremely stiff systems efficiently. Initially, three different curve fittings were
conducted for average, low loading and high loading cells. Model simulations were
compared with live human breast cancer cell (MCF-7 cell line) data and found to give
good qualitative agreement. Based on the results obtained from the three curve fittings, the
averaged data from 13 individual cells, the high loading cell and the low loading cell, the
active pumping mechanism resulting from BCRP/ABCG2 transporter is a key factor in
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resisting the anti-cancer agent TPT. To ensure that the results are appropriate and to
investigate the heterogeneity in response to the drug, the kinetic model was fitted to a high
loading cell and a low loading cell simultaneously by assuming that variations across cells
are only due to differences between the parameter relating to the ALDH enzyme and
BCRP/ABCG2 transporter. Similar to the individual fittings, simulated output from the
drug kinetics model accurately reproduces the behaviour of the underlying biological
system being represented. In addition, the results obtained from the model confirm that the
efflux pumping mechanism plays a key role in the resistance of anti-cancer drugs. Further
analysis showed that model fits were sensitive to the binding affinity of the drug to the
transporter (ABCG2/BCRP) and to the binding affinity of the drug to the enzyme ALDH,
confirming that both the transporter and the enzyme resist TPT.
One of the motivations for mathematical modelling is the ability to perform in silico
estimations and predictions about future system behaviour in addition to the relationship
between the target binding and the dose. The impact of the dose was measured by
calculating the AUC (integral) of the model variable Ln (TPTL bound to DNA target)
corresponding to the initial dose over the first hour. It was found that the high loader and
low loader respond differently to the dose and therefore, this variable (i.e., Ln) is an
important factor in modelling the effect of the drug (dynamic modelling).
In Chapter 5, a mathematical model describing the growth of single human cells in the
absence of TPT was presented. The cell cycle model described in Chapter 5 is a novel
extension of a previously published model for Xenopus laevis embryos to account for the
inhibition effect of the CKI p21CIP1/WAF1 (under the transcriptional control of p53). For a
realistic cell cycle model, the effect of the CKI p21CIP1/WAF1 must be taken into account
since in eukaryotic cells, this inhibitor plays an important role in stabilising the G1 state. A
unique feature of the extended cell cycle model is that it takes into consideration the
variations (in the interaction rate constants and concentrations of the cell cycle
components) between different cell types of the same organism and within the same cell
type under different conditions. This feature was added by introducing the scaling factors
C1 and C2.
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The structural identifiability analysis of the extended cell cycle model demonstrates that all
of the unknown model parameters are uniquely determined by the output structure
corresponding to the real experiment. Similar to identifiability analysis of the drug kinetics
model, the structural identifiability analysis of the extended cell cycle model was
performed using MATHEMATICA. The unknown model parameters were estimated (using
FACSIMILE) from live human osteosarcoma cells (Cyclin B1-GFP data) of a control
(untreated cell) for one complete cell cycle event of a newborn cell starting at G1 of the
cycle, to investigate the effects of the CKI p21CIP1/WAF1 on the progression of the cell cycle
traverse. The model fit (of the untreated cell) shows that there is close reproduction of the
experimental data by simulated output from the extended cell cycle model. In addition, the
false peak (spike) in the experimental data (due to rounding up of cell in the final stages of
the cell cycle) is minimised by the extended model. Sensitivity analysis of the extended
cell cycle model showed that the model variable CDC2CycBTP (the active form of Cyclin
B1) is sensitive to small variations in the values for parameters relating to the CKI
p21CIP1/WAF1. That is, the increase in the activity of the CKI results in an extension in the
IMT and possible cell cycle arrest. Therefore, the CKI p21CIP1/WAF1 is an important protein
in regulating the cell cycle traverse.
Chapter 6 presents a novel coupling of the extended drug kinetics model (in Chapter 4) and
the extended cell cycle model (in Chapter 5) to describe the response of the growth of
single human osteosarcoma cells (U-2 OS cells) in the presence of TPT. Coupling the
models in this way, rather than using separate approaches, allows examination of how the
drug perturbs the cell cycle. Modelling the dynamic effect (response) of TPT on human
osteosarcoma cells was achieved by extending the drug kinetics model presented in
Chapter 4 by introducing an effect compartment to represent the DNA damage (γH2AX) 
which is linked to the CKI p21CIP1/WAF1 in the extended cell cycle model (presented in
Chapter 5).
The structural identifiability analysis for the coupled drug kinetics/dynamics model was
performed using MATHEMATICA. The state-space model proposed in this experiment was
found to be structurally globally identifiable with respect to the high content screening
experiments (DNA damage data) and Cyclin B1-GFP microscopy experiments used to
collect data. The predicted values (using FACSIMILE) for the number of γH2AX foci per 
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nucleus are identical to the experimental values. The results obtained from this chapter also
confirm drug resistance to TPT resulting from the BCRP/ABCG2 transporter and the
enzyme ALDH following the washout event. In addition, it has predicted that extension in
the IMT as a result of the DNA damage is due to the up-regulation of the CKI p21CIP1/WAF1.
It was illustrated that this coupling has proven to be useful in studying how the drug
perturbs the cell cycle. In addition, a robust and validated version of the current model
could be used to design drug treatment regimens, i.e., treatment plans that specify dosage,
schedule and duration of treatment.
7.1 Future work
The present drug kinetics model does not address inter-cellular heterogeneity across the
entire population of cells (i.e., the 13 individual cells) but the model was used to compare
two different responses to the drug. Future work can include an extension of the single-cell
model (presented in Chapter 4) to a multi-cell model to account for inter-cellular
heterogeneity which is similar to the approach used by Cheung et al. [48]. In recent years,
a wide assortment of BCRP inhibitors (chemosensitisers) have been identified, which can
also be considered in future research on the extended drug kinetics model.
The current extended cell cycle model includes the basic feature of the cell cycle
components. However, other components such as p53 tumour suppressor gene can be
incorporated into the model. One current limitation is the available microscopy data, and
suggestions in this respect include acquiring further data from the cell in addition to the
activity of Cyclin B1 protein.
The cell cycle dynamics data provided by the biological collaborators (at Cardiff) are for
live human osteosarcoma cells. The extended drug kinetics model has been validated to a
certain degree from live human breast cancer cells. For a more robust drug kinetics/cell
cycle response model, it is more appropriate to have coupling from the same cell type.
Future work includes extending the current in vitro drug kinetics/dynamics model for in
vivo applications using physiologically-based pharmacokinetic/pharmacodynamic
Conclusions 196
(PBPK/PD) modelling techniques. PBPK/PD modelling approaches are very powerful
tools which account for the anatomical and physiological structure of the body. In addition,
they assist in determining relationships between drug levels, dosing regimens and response
to drug in vivo which are critical to the success of clinical trials.
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Appendix A
Structural identifiability analysis of the single-cell model
Lm'[t_] := -(Kom + Kmi) Lm[t] + Kcm Hm[t] + Kmo v0 Le[t]
Hm'[t_] := Kom Lm[t] - (Kcm + Kmi) Hm[t] + Kmo v0 He[t]
Le'[t_] := Kmi/v0 Lm[t] - (Kmo + Kom + Ki) Le[t] + Kcm He[t]
+ Ke/v1 Lc[t]
He'[t_] := Kmi/v0 Hm[t] + Kom Le[t] - (Kcm + Kmo) He[t] +
(Vm1 /v1) ((v3 Hc[t])/(v3 Km1 + Hc[t]))
Lc'[t_] := Ki v1 Le[t] - (Ke + Koc) Lc[t] + Kcc Hc[t] + Kdl
v2 Ln[t] - Kb (Bt - Ln[t]) Lc[t] - (Vm2 Lc[t])/(Km2 + Lc[t])
Hc'[t_] := Koc Lc[t] - Kcc Hc[t] + Kdh v2 Ln[t] - (Vm1 v3
Hc[t])/(v3 Km1 + Hc[t]) + (Vm2 Lc[t])/(Km2 + Lc[t])
Ln'[t_] := Kb/v2 (Bt - Ln[t]) Lc[t] - (Kdl + Kdh) Ln[t]
Lm[0]= (1+v0) d;Hm[0]=0;Le[0]=0;He[0]=0;
Lc[0]=0;Hc[0]=0;Ln[0]=0;
y[t_]:= {Le[t] + He[t],Lc[t] + Hc[t],Ln[t]}
v1 = ( v0)/(1+v0);
y[0]
{0,0,0}
subst={KmiKmib, KmoKmob, KiKib, KeKeb, KbKbb,
KdlKdlb, KdhKdhb, BtBtb,v0v0b,Vm1 Vm1b, Km1Km1b, Vm2
Vm2b, Km2Km2b}
{KmiKmib,KmoKmob,KiKib,KeKeb,KbKbb,KdlKdlb,KdhKdhb,B
tBtb,v0v0b,Vm1Vm1b,Km1Km1b,Vm2Vm2b,Km2Km2b}
yDer=D[y[t], t];
yCoeff=yDer/.t0
{(d Kmi (1+v0))/v0,0,0}
eqn=yCoeff[[1]]-(yCoeff[[1]]/.subst);
newSoln=Simplify[Solve[eqn0, {Btb, v0b, Vm1b,Kmib,
Kmob,Kib,Keb, Kbb,Kdlb, Kdhb, Km1b, Vm2b, Km2b}]]
Solve::svars: Equations may not give solutions for all
"solve" variables. 
{{Kmib(Kmi (1+v0) v0b)/(v0 (1+v0b))}}
soln=newSoln[[1]]
{Kmib(Kmi (1+v0) v0b)/(v0 (1+v0b))}
yDer=D[yDer, t];
yCoeff=Simplify[yDer/.t0]
{-(d Kmi (Ki+Kmi+Kmo) (1+v0))/v0,d Ki Kmi ,0}
eqn=yCoeff-(yCoeff/.subst);
eqn=Simplify[eqn/.soln];
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newSoln=Simplify[Solve[eqn0,{Btb, v0b, Vm1b,Kmob,Kib,Keb,
Kbb,Kdlb, Kdhb, Km1b, Vm2b, Km2b}]]
Solve::svars: Equations may not give solutions for all
"solve" variables. 
{{Kmob(Ki (-v0+v0b))/((1+v0) v0b)+(Kmi v0+Kmo v0-Kmi
v0b+Kmo v0 v0b)/(v0+v0 v0b),Kib(Ki v0 (1+v0b))/((1+v0)
v0b)}}
soln=Simplify[soln/.newSoln[[1]]];
soln = Union [soln, newSoln [[1]]]
{Kib(Ki v0 (1+v0b))/((1+v0) v0b),Kmib(Kmi (1+v0) v0b)/(v0
(1+v0b)),Kmob(Ki (-v0+v0b))/((1+v0) v0b)+(Kmi v0+Kmo v0-Kmi
v0b+Kmo v0 v0b)/(v0+v0 v0b)}
yDer=D[yDer, t];
yCoeff=Simplify[yDer/.t0]
{(d Kmi (Ke Ki+Ki2+(Kmi+Kmo)2+Ki (Kmi+2 (Kmo+Kom)))
(1+v0))/v0,-d Ki Kmi (Bt Kb+Ke+Ki+Kmi+Kmo+2 Kom) ,(Bt d Kb
Ki Kmi )/v2}
eqn=yCoeff-(yCoeff/.subst);
eqn=Simplify[eqn/.soln];
newSoln=Simplify[Solve[eqn0,{Btb, v0b, Vm1b,Keb, Kbb,Kdlb,
Kdhb, Km1b, Vm2b, Km2b}]]
Solve::svars: Equations may not give solutions for all
"solve" variables. 
{{Btb(Bt Kb)/Kbb,KebKe,v0bv0}}
soln=Simplify[soln/.newSoln[[1]]];
soln = Union [soln, newSoln [[1]]]
{Btb(Bt Kb)/Kbb,KebKe,KibKi,KmibKmi,KmobKmo,v0bv0}
yDer=D[yDer, t];
yCoeff=Simplify[yDer/.t0]
{-1/(Km1 Km2 v0) d Kmi (1+v0) (Bt Kb Ke Ki Km1 Km2+Ke2 Ki
Km1 Km2+Ki3 Km1 Km2+Ki2 Km1 Km2 Kmi+Ki Km1 Km2 Kmi2+Km1 Km2
Kmi3+3 Ki2 Km1 Km2 Kmo+4 Ki Km1 Km2 Kmi Kmo+3 Km1 Km2 Kmi2
Kmo+3 Ki Km1 Km2 Kmo2+3 Km1 Km2 Kmi Kmo2+Km1 Km2 Kmo3+3 Kcm Ki
Km1 Km2 Kom+3 Ki2 Km1 Km2 Kom+3 Ki Km1 Km2 Kmi Kom+5 Ki Km1
Km2 Kmo Kom+3 Ki Km1 Km2 Kom2-Ki Km2 Koc Vm1-Ki Vm1 Vm2+Ke Ki
Km1 (2 Ki Km2+Km2 (Kmi+2 Kmo+Koc+2 Kom)+Vm2)),1/(Km1 Km2) d
Ki Kmi (Bt2 Kb2 Km1 Km2+Ke2 Km1 Km2+Ki2 Km1 Km2+Ki Km1 Km2
Kmi+Km1 Km2 Kmi2+2 Ki Km1 Km2 Kmo+2 Km1 Km2 Kmi Kmo+Km1 Km2
Kmo2+3 Kcm Km1 Km2 Kom+3 Ki Km1 Km2 Kom+3 Km1 Km2 Kmi Kom+3
Km1 Km2 Kmo Kom+3 Km1 Km2 Kom2-Km2 Koc Vm1-Vm1 Vm2+Bt Kb Km1
(Kdh Km2+Kdl Km2+2 Ke Km2+Ki Km2+Km2 Kmi+Km2 Kmo+Km2 Koc+2
Km2 Kom+Vm2)+Ke Km1 (2 Ki Km2+Km2 (Kmi+Kmo+Koc+2 Kom)+Vm2))
,-(Bt d Kb Ki Kmi (Bt Kb Km2+Kdh Km2+Kdl Km2+Ke Km2+Ki
Km2+Km2 Kmi+Km2 Kmo+Km2 Koc+2 Km2 Kom+Vm2) )/(Km2 v2)}
eqn=yCoeff-(yCoeff/.subst);
eqn=Simplify[eqn/.soln];
newSoln=Simplify[Solve[eqn0,{Vm1b, Kbb,Kdlb, Kdhb, Km1b,
Vm2b, Km2b}]];
Solve::svars: Equations may not give solutions for all
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"solve" variables. 
newSoln[[1]]
{KdlbKdh-Kdhb+Kdl+Vm2/Km2-Vm2b/Km2b,Vm1b(Km1b Km2 Km2b
Koc Vm1-Ke Km1 Km1b Km2b Vm2+Km1b Km2b Vm1 Vm2+Ke Km1 Km1b
Km2 Vm2b)/(Km1 Km2 Km2b Koc+Km1 Km2 Vm2b)}
soln=Simplify[soln/.newSoln[[1]]];
soln = Union [soln, newSoln [[1]]]
{Btb(Bt Kb)/Kbb,KdlbKdh-Kdhb+Kdl+Vm2/Km2-
Vm2b/Km2b,KebKe,KibKi,KmibKmi,KmobKmo,v0bv0,Vm1b(Km1b
Km2 Km2b Koc Vm1-Ke Km1 Km1b Km2b Vm2+Km1b Km2b Vm1 Vm2+Ke
Km1 Km1b Km2 Vm2b)/(Km1 Km2 Km2b Koc+Km1 Km2 Vm2b)}
yDer=D[yDer, t];
yCoeff=Simplify[yDer/.t0];
eqn=yCoeff-(yCoeff/.subst);
eqn=Simplify[eqn/.soln];
newSoln=Simplify[Solve[eqn0,{Kbb,Kdhb, Km1b, Vm2b,Km2b}]];
Solve::svars: Equations may not give solutions for all
"solve" variables. 
soln=Simplify[soln/.newSoln[[1]]];
soln = Union [soln, newSoln [[1]]]
{Btb(Bt
Kb)/Kbb,KdhbKdh,KdlbKdl,KebKe,KibKi,KmibKmi,KmobKmo,v
0bv0,Vm1b(Km1b Vm1)/Km1,Vm2b(Km2b Vm2)/Km2}
yDer=D[yDer, t];
yCoeff=Simplify[yDer/.t0];
eqn=yCoeff-(yCoeff/.subst);
eqn=Simplify[eqn/.soln];
newSoln=Simplify[Solve[eqn0,{Kbb,Km1b, Km2b}]]
Solve::svars: Equations may not give solutions for all
"solve" variables. 
{{KbbKb,Km2bKm2}}
soln=Simplify[soln/.newSoln[[1]]];
soln = Union [soln, newSoln [[1]]]
{BtbBt,KbbKb,KdhbKdh,KdlbKdl,KebKe,KibKi,Km2bKm2,Kmi
bKmi,KmobKmo,v0bv0,Vm1b(Km1b Vm1)/Km1,Vm2bVm2}
yDer=D[yDer, t];
yCoeff=Simplify[yDer/.t0];
eqn=yCoeff-(yCoeff/.subst);
eqn=Simplify[eqn/.soln];
newSoln=Simplify[Solve[eqn0,{Km1b}]]
{{Km1bKm1}}
soln=Simplify[soln/.newSoln[[1]]];
soln = Union [soln, newSoln [[1]]]
{BtbBt,KbbKb,KdhbKdh,KdlbKdl,KebKe,KibKi,Km1bKm1,Km2
bKm2,KmibKmi,KmobKmo,v0bv0,Vm1bVm1,Vm2bVm2}
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Structural identifiability analysis of the extended cell cycle
model
cyclin' [t_] := ksynth - kdest*(apcstar [t] + p21[t])*cyclin
[t] - ka*cdc2 [t]*cyclin [t] + kd*cdc2cyclin [t];
cdc2cyclin' [t_] := ka*cdc2 [t]*cyclin [t] - kd*cdc2cyclin
[t] - kdest*(apcstar [t] + p21[t])*cdc2cyclin [t] -
kwee1*wee1act [t]*cdc2cyclin [t]
- kwee1/factor*(C2*wee1tot - wee1act [t])*cdc2cyclin [t] +
kcdc25*cdc25act [t]*cdc2cyclinyp [t] +
kcdc25/factor*(C2*cdc25tot - cdc25act [t])*cdc2cyclinyp [t];
cdc2cyclinyp' [t_] := kwee1*wee1act [t]*cdc2cyclin
[t]+kwee1/factor*(C2*wee1tot - wee1act [t])*cdc2cyclin [t] -
kcdc25*cdc25act [t]*cdc2cyclinyp [t]
-kcdc25/factor*(C2*cdc25tot - cdc25act [t])*cdc2cyclinyp [t]
- kcak*cdc2cyclinyp [t] + kpp2c*cdc2cyclinyptp [t] -
kdest*(apcstar [t] + p21[t])*cdc2cyclinyp [t];
cdc2cyclinyptp'[t_] := kcak*cdc2cyclinyp [t] -
kpp2c*cdc2cyclinyptp [t] - kcdc25*cdc25act [t]*cdc2cyclinyptp
[t]
- kcdc25/factor*(C2*cdc25tot - cdc25act [t])*cdc2cyclinyptp
[t] + kwee1*wee1act [t]*cdc2cyclintp [t] +
kwee1/factor*(C2*wee1tot - wee1act [t])*cdc2cyclintp [t] -
kdest*(apcstar [t] + p21[t])*cdc2cyclinyptp [t];
cdc2cyclintp' [t_] := kcdc25*cdc25act [t]*cdc2cyclinyptp [t]
+ kcdc25/factor*(C2*cdc25tot - cdc25act[t])*cdc2cyclinyptp
[t]
- kwee1*wee1act [t]*cdc2cyclintp [t] -
kwee1/factor*(C2*wee1tot - wee1act [t])*cdc2cyclintp [t] -
kdest*(apcstar [t] + p21[t])*cdc2cyclintp [t];
cdc25act' [t_] := kcdc25on*(cdc2cyclintp
[t]^ncdc25/((C2*ec50cdc25)^ncdc25 + cdc2cyclintp
[t]^ncdc25))*(C2*cdc25tot - cdc25act [t]) -
kcdc25off*cdc25act [t];
wee1act' [t_] := - kwee1off*(cdc2cyclintp
[t]^nwee1/((C2*ec50wee1)^nwee1 + cdc2cyclintp
[t]^nwee1))*(wee1act [t])+kwee1on*(C2*wee1tot-wee1act [t]);
apc0' [t_] := - kapcon*(cdc2cyclintp
[t]^napc/((C2*ec50apc)^napc+cdc2cyclintp
[t]^napc))*(C2*apctot-apcstar [t])+kapcoff*apcstar [t];
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p21'[t_] := kp21on*(cdc2cyclintp
[t]^np21/((C2*ec50p21)^np21+cdc2cyclintp
[t]^np21))*(C2*p21tot-p21 [t]) - kp21off*p21 [t];
apcstar [t_]:= C2*apctot-apc0 [t];
cdc2 [t_]:= C2*cdc2tot-(cdc2cyclin [t]+cdc2cyclinyp
[t]+cdc2cyclinyptp [t]+cdc2cyclintp [t]);
cyclin [0]= C2*0.141396; cdc2cyclin[0]= C2*0.992654;
cdc2cyclinyp[0]= C2*1.4763; cdc2cyclinyptp[0]= C2*11.41023;
cdc2cyclintp [0]= C2*1.64121; cdc25act[0]= C2*1.54009;
wee1act[0]= C2*15; p21[0] = C2*3.8539; apc0[0] = C2*46.1461;
nwee1=4;
ncdc25=4;
napc = 5;
np21=5;
y[t_]:=  cdc2cyclintp[t] + ;
subst={b,b,C2C2b, kp21offkp21offb,p21totp21totb}
{b,b,C2C2b,kp21offkp21offb,p21totp21totb}
yCoeff=y[0]
1.64121 C2 +
eqn=yCoeff-(yCoeff/.subst)
newSoln=Simplify[Solve[eqn0, {b,C2b,b,kp21offb,p21totb}]]
1.64121 C2 -1.64121 C2b b+-b
Solve::svars: Equations may not give solutions for all
"solve" variables. 
{{b1.64121 C2 -1.64121 C2b b+1. }}
soln=newSoln[[1]]
{b1.64121 C2 -1.64121 C2b b+1. }
yDer=D[y[t], t];
yCoeff=yDer/.t0
(17.5728 C22 kcdc25+(11.4102 C2 (-1.54009 C2+C2 cdc25tot)
kcdc25)/factor) 
yCoeff
2.52518 C22 
eqn=yCoeff-(yCoeff/.subst);
newSoln=Simplify[Solve[eqn0, {b,C2b,kp21offb,p21totb}]]
Solve::svars: Equations may not give solutions for all
"solve" variables. 
{{b(1. C22 )/C2b2}}
soln=Simplify[soln/.newSoln[[1]]]
soln=Union[soln,newSoln[[1]]]
{b1.64121 C2 -(1.64121 C22 )/C2b+1. }
{b(C22 )/C2b2,b1.64121 C2 -(1.64121 C22 )/C2b+}
yDer=D[yDer, t];
yCoeff=Simplify[yDer/.t0]
(0.107836 -0.388901 C2) C22 
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eqn=Simplify[yCoeff-(yCoeff/.subst)];
eqn=Simplify[eqn/.soln];
newSoln=Simplify[Solve[eqn0,{C2b,kp21offb,p21totb}]]
Solve::svars: Equations may not give solutions for all
"solve" variables. 
{{C2b0. +1. C2}}
newSoln={{C2b1.` C2}}
{{C2b1. C2}}
(* First define the model’ s parameters. Concentration units
are nM; time units are min
ksynth defines the constant rate of cyclin synthesis
and
kdest defines the rate constant for cyclin destruction. *)
ksynth=1.2;
kdest=0.005;
(* ka is the association constant for Cdc2+cyclin. kd is the
dissociation constant. kd/ka should be less than 1 nM *)
ka=0.1;
kd=0.001;
(* kwee1 and kcdc25 are the rate constants for the
inactivation and activation of Cdc2/cyclin by Wee1 and Cdc25.
If Km=1 uM and kcat=1 reaction/min,
then kcat/Km would be 1 uM-1 min-1 or 0.001 nM-1 min-1. The
bigger the value for 'factor', the stronger the feedback. If
factor=1 then the mitotic and interphase forms of Cdc25 and
Wee1 do not differ in activity,and so there is no feedback
from Cdc2 to Cdc25 and Wee1. If it's 10,the feedback is
strong enough to give sustained, realistic-looking
oscillations. *)
factor = 20;
kwee1=0.1;
kwee1basal=kwee1/factor;
kcdc25=0.1;
kcdc25basal=kcdc25/factor;
(* cdc2tot, cdc25tot, wee1tot and apctot are total
concentrations in nM *)
cdc2tot=100;
cdc25tot=15;
wee1tot=15;
apctot=50;
(* Assuming that the dependence of Cdc25 and Wee1 on Cdc2
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activity is described by Hill functions with Hill
coefficients of nwee1 and ncdc25 and EC50's (in nM) of
ec50wee1 and ec50cdc25. *)
nwee1=4;
ncdc25=4;
napc=5;
np21 = 5;
ec50wee1=25;
ec50cdc25=25;
ec50apc=30;
ec50p21 = 30;
(* Define the rate constants for turning Cdc25 on (by Cdc2)
and off (by?) and for turning Wee1 off (by Cdc2) and on (by?)
*)
kcdc25on=0.8;
kcdc25off=0.08;
kapcon=0.8;
kapcoff=0.08;
kwee1on=0.8;
kwee1off=0.08;
kp21on = 0.8;
(* And define CAK activity and PP2C activity in nM-1 min-1 *)
kcak=0.8;
kpp2c=0.008;
newSoln
{{C2b1. C2}}
soln=Simplify[soln/.newSoln[[1]]]
soln=Union[soln,newSoln[[1]]]
{b1. ,b0. C2 +}
{C2b1. C2,b1. ,b0. C2 +}
soln={C2b C2,b ,b}
{C2bC2,b,b}
yDer=D[yDer, t];
yCoeff=Simplify[yDer/.t0]
0.0598942 (-0.0627616+C2) C22 (4.45049 +C2) 
eqn=Simplify[yCoeff-(yCoeff/.subst)];
eqn=Simplify[eqn/.soln];
newSoln=Simplify[Solve[eqn0,{kp21offb,p21totb}]]
{{}}
soln
yDer=D[yDer, t];
yCoeff=Simplify[yDer/.t0]
-0.00922425 (-0.0569411+C2) C22 (0.26181 +C2) (18.3566 +C2)

eqn=Simplify[yCoeff-(yCoeff/.subst)];
eqn=Simplify[eqn/.soln];
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newSoln=Simplify[Solve[eqn0,{kp21offb,p21totb}]]
{{}}
yDer=D[yDer, t];
yCoeff=Simplify[yDer/.t0]
C22 (-0.000310113+2.6964 C2-2.50228 C23+0.00142062 C24+C22
(0.0542277 +0.00507981 kp21off-5.16716×10-10 p21tot)) 
eqn=Simplify[yCoeff-(yCoeff/.subst)];
eqn=Simplify[eqn/.soln];
newSoln=Simplify[Solve[eqn0,{kp21offb,p21totb}]]
Solve::svars: Equations may not give solutions for all
"solve" variables. 
{{kp21offbkp21off-1.01719×10-7 p21tot+1.01719×10-7 p21totb}}
{C2bC2,b,b}
{C2bC2,kp21offbkp21off-1.01719×10-7 p21tot+1.01719×10-7
p21totb,b,b}
yDer=D[yDer, t];
yCoeff=Simplify[yDer/.t0]
C22 (0.0000343614 -0.80468 C2+27.7678 C24-0.000218788 C25+C23
(0.769495 -0.00674463 kp21off-3.28906×10-9 p21tot)+C22 (-
27.9778-0.00507981 kp21off2+kp21off (-0.00139704+5.16716×10-10
p21tot)+1.42106×10-10 p21tot)) 
eqn=Simplify[yCoeff-(yCoeff/.subst)];
eqn=Simplify[eqn/.soln];
newSoln=Simplify[Solve[eqn0,{p21totb}]]
{{p21totbp21tot}}
soln=Simplify[soln/.newSoln[[1]]]
soln=Union[soln,newSoln[[1]]]
{C2bC2,kp21offbkp21off+0. p21tot,b,b}
{C2bC2,kp21offbkp21off,p21totbp21tot,b,b}
Structural identifiability analysis of the coupled drug
kinetics/dynamics model
Structural identifiability analysis of the drug kinetics model including the
effect compartment
Lm'[t_] := -(Kom + Kmi) Lm[t] + Kcm Hm[t] + Kmo v0 Le[t]
Hm'[t_] := Kom Lm[t] - (Kcm + Kmi) Hm[t] + Kmo v0 He[t]
Le'[t_] := Kmi/v0 Lm[t] - (Kmo + Kom + Ki) Le[t] + Kcm He[t]
+ Ke/v1 Lc[t]
He'[t_] := Kmi/v0 Hm[t] + Kom Le[t] - (Kcm + Kmo) He[t] +
(Vm1 /v1) ((v3 Hc[t])/(v3 Km1 + Hc[t]))
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Lc'[t_] := Ki v1 Le[t] - (Ke + Koc) Lc[t] + Kcc Hc[t] + Kdl
v2 Ln[t] - Kb (Bt - Ln[t]) Lc[t] - (Vm2 Lc[t])/(Km2 + Lc[t])
Hc'[t_] := Koc Lc[t] - Kcc Hc[t] + Kdh v2 Ln[t] - (Vm1 v3
Hc[t])/(v3 Km1 + Hc[t]) + (Vm2 Lc[t])/(Km2 + Lc[t])
Ln'[t_] := Kb/v2 (Bt - Ln[t]) Lc[t] - (Kdl + Kdh) Ln[t]
H2AX'[t_] := k11*Ln [t] - k2tp*H2AX [t];
y[t_]:= H2AX[t]
H2AX [0] = 0;
Lm[0]= (1+v0) d;Hm[0]=0;Le[0]=0;He[0]=0;
Lc[0]=0;Hc[0]=0;Ln[0]=0;
v1 = ( v0)/(1+v0);
y[0]
0
subst={ k11k11b, k2tpk2tpb}
{k11k11b,k2tpk2tpb}
yDer=D[y[t], t]
yCoeff=yDer/.t0
-k2tp H2AX[t]+k11 Ln[t]
0
yDer=D[yDer, t]
yCoeff=Simplify[yDer/.t0]
-k2tp (-k2tp H2AX[t]+k11 Ln[t])+k11 ((Kb Lc[t] (Bt-
Ln[t]))/v2-(Kdh+Kdl) Ln[t])
0
yDer=D[yDer, t]
yCoeff=Simplify[yDer/.t0]
-k2tp (-k2tp (-k2tp H2AX[t]+k11 Ln[t])+k11 ((Kb Lc[t] (Bt-
Ln[t]))/v2-(Kdh+Kdl) Ln[t]))+k11 (-(Kdh+Kdl) ((Kb Lc[t] (Bt-
Ln[t]))/v2-(Kdh+Kdl) Ln[t])-(Kb Lc[t] ((Kb Lc[t] (Bt-
Ln[t]))/v2-(Kdh+Kdl) Ln[t]))/v2+(Kb (Bt-Ln[t]) (Kcc Hc[t]-
(Ke+Koc) Lc[t]-(Vm2 Lc[t])/(Km2+Lc[t])+(Ki v0 
Le[t])/(1+v0)-Kb Lc[t] (Bt-Ln[t])+Kdl v2 Ln[t]))/v2)
0
yDer=D[yDer, t]
yCoeff=Simplify[yDer/.t0]
(Bt d k11 Kb Ki Kmi )/v2
eqn=yCoeff-(yCoeff/.subst);
newSoln=Simplify[Solve[eqn0, {k11b,k2tpb}]]
Solve::svars: Equations may not give solutions for all
"solve" variables. 
{{k11bk11}}
soln=newSoln[[1]]
{k11bk11}
yDer=D[yDer, t];
yCoeff=Simplify[yDer/.t0];
Appendix A 231
eqn=yCoeff-(yCoeff/.subst);
eqn=Simplify[eqn/.soln];
newSoln=Simplify[Solve[eqn0,{k2tpb}]]
{{k2tpbk2tp}}
soln=Simplify[soln/.newSoln[[1]]];
soln = Union [soln, newSoln [[1]]]
{k11bk11,k2tpbk2tp}
Structural identifiability analysis of the full drug kinetics/dynamics
model
Lm'[t_] := -(Kom + Kmi) Lm[t] + Kcm Hm[t] + Kmo v0 Le[t]
Hm'[t_] := Kom Lm[t] - (Kcm + Kmi) Hm[t] + Kmo v0 He[t]
Le'[t_] := Kmi/v0 Lm[t] - (Kmo + Kom + Ki) Le[t] + Kcm He[t]
+ Ke/v1 Lc[t]
He'[t_] := Kmi/v0 Hm[t] + Kom Le[t] - (Kcm + Kmo) He[t] +
(Vm1 /v1) ((v3 Hc[t])/(v3 Km1 + Hc[t]))
Lc'[t_] := Ki v1 Le[t] - (Ke + Koc) Lc[t] + Kcc Hc[t] + Kdl
v2 Ln[t] - Kb (Bt - Ln[t]) Lc[t] - (Vm2 Lc[t])/(Km2 + Lc[t])
Hc'[t_] := Koc Lc[t] - Kcc Hc[t] + Kdh v2 Ln[t] - (Vm1 v3
Hc[t])/(v3 Km1 + Hc[t]) + (Vm2 Lc[t])/(Km2 + Lc[t])
Ln'[t_] := Kb/v2 (Bt - Ln[t]) Lc[t] - (Kdl + Kdh) Ln[t]
cyclin' [t_] := ksynth - kdest*(apcstar [t] + p21[t])*cyclin
[t] - ka*cdc2 [t]*cyclin [t] + kd*cdc2cyclin [t];
cdc2cyclin' [t_] := ka*cdc2 [t]*cyclin [t] - kd*cdc2cyclin
[t] - kdest*(apcstar [t] + p21[t])*cdc2cyclin [t] -
kwee1*wee1act [t]*cdc2cyclin [t]
- kwee1/factor*(C2*wee1tot - wee1act [t])*cdc2cyclin [t] +
kcdc25*cdc25act [t]*cdc2cyclinyp [t] +
kcdc25/factor*(C2*cdc25tot - cdc25act [t])*cdc2cyclinyp [t];
cdc2cyclinyp' [t_] := kwee1*wee1act [t]*cdc2cyclin
[t]+kwee1/factor*(C2*wee1tot - wee1act [t])*cdc2cyclin [t] -
kcdc25*cdc25act [t]*cdc2cyclinyp [t]
-kcdc25/factor*(C2*cdc25tot - cdc25act [t])*cdc2cyclinyp [t]
- kcak*cdc2cyclinyp [t] + kpp2c*cdc2cyclinyptp [t] -
kdest*(apcstar [t] + p21[t])*cdc2cyclinyp [t];
cdc2cyclinyptp'[t_] := kcak*cdc2cyclinyp [t] -
kpp2c*cdc2cyclinyptp [t] - kcdc25*cdc25act [t]*cdc2cyclinyptp
[t]
- kcdc25/factor*(C2*cdc25tot - cdc25act [t])*cdc2cyclinyptp
[t] + kwee1*wee1act [t]*cdc2cyclintp [t] +
kwee1/factor*(C2*wee1tot - wee1act [t])*cdc2cyclintp [t] -
kdest*(apcstar [t] + p21[t])*cdc2cyclinyptp [t];
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cdc2cyclintp' [t_] := kcdc25*cdc25act [t]*cdc2cyclinyptp [t]
+ kcdc25/factor*(C2*cdc25tot - cdc25act[t])*cdc2cyclinyptp
[t]
- kwee1*wee1act [t]*cdc2cyclintp [t] -
kwee1/factor*(C2*wee1tot - wee1act [t])*cdc2cyclintp [t] -
kdest*(apcstar [t] + p21[t])*cdc2cyclintp [t];
cdc25act' [t_] := kcdc25on*(cdc2cyclintp
[t]^ncdc25/((C2*ec50cdc25)^ncdc25 + cdc2cyclintp
[t]^ncdc25))*(C2*cdc25tot - cdc25act [t]) -
kcdc25off*cdc25act [t];
wee1act' [t_] := - kwee1off*(cdc2cyclintp
[t]^nwee1/((C2*ec50wee1)^nwee1 + cdc2cyclintp
[t]^nwee1))*(wee1act [t])+kwee1on*(C2*wee1tot-wee1act [t]);
apc0' [t_] := - kapcon*(cdc2cyclintp
[t]^napc/((C2*ec50apc)^napc+cdc2cyclintp
[t]^napc))*(C2*apctot-apcstar [t])+kapcoff*apcstar [t];
p21'[t_] := kp21on*(cdc2cyclintp
[t]^np21/((C2*ec50p21)^np21+cdc2cyclintp
[t]^np21))*(C2*p21tot-p21 [t]) - (kp21off*p21 [t] )/(1
+k2tp*H2AX[t]);
H2AX'[t_] := k11*Ln [t] - k2tp*H2AX [t];
apcstar [t_]:= C2*apctot-apc0 [t];
cdc2 [t_]:= C2*cdc2tot-(cdc2cyclin [t]+cdc2cyclinyp
[t]+cdc2cyclinyptp [t]+cdc2cyclintp [t]);
y[t_]:= { cdc2cyclintp[t] + }
cyclin [0]= C2*0.141396; cdc2cyclin[0]= C2*0.992654;
cdc2cyclinyp[0]= C2*1.4763; cdc2cyclinyptp[0]= C2*11.41023;
cdc2cyclintp [0]= C2*1.64121; cdc25act[0]= C2*1.54009;
wee1act[0]= C2*15; p21[0] = C2*3.8539; apc0[0] = C2*46.1461;
H2AX [0] = a8;
Lm[0]= a1;Hm[0]=a2;Le[0]=a3;He[0]=a4;
Lc[0]=a5;Hc[0]=a6;Ln[0]=a7;
v1 = (1 v0)/(1+v0);
subst={b,b,C2C2b, kp21offkp21offb,p21totp21totb}
{b,b,C2C2b,kp21offkp21offb,p21totp21totb}
nwee1=4;
ncdc25=4;
napc = 5;
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np21=5;
yCoeff=y[0]
{1.64121 C2 +}
eqn=yCoeff-(yCoeff/.subst)
newSoln=Simplify[Solve[eqn0, {b,C2b,b,kp21offb,p21totb}]]
{1.64121 C2 -1.64121 C2b b+-b}
Solve::svars : Equations may not give solutions for all
"solve" variables. 
{{b1.64121 C2 -1.64121 C2b b+1. }}
soln=newSoln[[1]]
{b1.64121 C2 -1.64121 C2b b+1. }
yDer=D[y[t], t];
yCoeff=yDer/.t0
{(17.5728 C22 kcdc25+(11.4102 C2 (-1.54009 C2+C2 cdc25tot)
kcdc25)/factor) }
yCoeff
eqn=yCoeff-(yCoeff/.subst);
newSoln=Simplify[Solve[eqn0, {b,C2b,kp21offb,p21totb}]]
Solve::svars : Equations may not give solutions for all
"solve" variables. 
{{b(C22 )/C2b2}}
soln=Simplify[soln/.newSoln[[1]]]
soln=Union[soln,newSoln[[1]]]
{b1.64121 C2 -(1.64121 C22 )/C2b+1. }
{b(C22 )/C2b2,b1.64121 C2 -(1.64121 C22 )/C2b+1. }
yDer=D[yDer, t];
yCoeff=Simplify[yDer/.t0]
{C22 kcdc25 (2.27363 kcak-27.0637 C2 kcdc25+(127.496
kcdc25off+17.5728 ec50cdc254 kcdc25off+127.496 kcdc25on-
82.7849 cdc25tot kcdc25on)/(7.25532 factor+ec50cdc254
factor)+((-127.496-17.5728 ec50cdc254) kcdc25off+(-
127.496+82.7849 cdc25tot) kcdc25on)/(7.25532 +ec50cdc254)+((-
1.54009+cdc25tot) (1.4763 kcak-17.5728 C2 kcdc25-11.4102
kpp2c))/factor-17.5728 kpp2c) }
eqn=Simplify[yCoeff-(yCoeff/.subst)];
eqn=Simplify[eqn/.soln];
newSoln=Simplify[Solve[eqn0,{C2b,kp21offb,p21totb}]]
Solve::svars : Equations may not give solutions for all
"solve" variables. 
{{C2b0. +1. C2}}
newSoln
soln=Simplify[soln/.newSoln[[1]]]
soln=Union[soln,newSoln[[1]]]
{b(C22 )/(0. +1. C2)2,b(1. C2 )/(0. +1. C2)}
{C2bC2,b,b}
yDer=D[yDer, t];
yCoeff=Simplify[yDer/.t0]
{0.0598942 (-0.0627616+C2) C22 (4.45049 +C2) }
eqn=Simplify[yCoeff-(yCoeff/.subst)]
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eqn=Simplify[eqn/.soln];
newSoln=Simplify[Solve[eqn0,{kp21offb,p21totb}]]
{0.0598942 (-0.0627616+C2) C22 (4.45049 +C2) -0.0598942 (-
0.0627616+C2b) C2b2 (4.45049 +C2b) b}
{{}}
eqn
yDer=D[yDer, t];
yCoeff=Simplify[yDer/.t0]
{-0.00922425 (-0.0569411+C2) C22 (0.26181 +C2) (18.3566 +C2)
}
eqn=Simplify[yCoeff-(yCoeff/.subst)];
eqn=Simplify[eqn/.soln];
newSoln=Simplify[Solve[eqn0,{kp21offb,p21totb}]]
{{}}
soln=Simplify[soln/.newSoln[[1]]]
soln=Union[soln,newSoln[[1]]]
(* First define the model’ s parameters. Concentration units
are nM; time units are min
ksynth defines the constant rate of cyclin synthesis
and
kdest defines the rate constant for cyclin destruction. *)
ksynth=1.2;
kdest=0.005;
(* ka is the association constant for Cdc2+cyclin. kd is the
dissociation constant. kd/ka should be less than 1 nM *)
ka=0.1;
kd=0.001;
(* kwee1 and kcdc25 are the rate constants for the
inactivation and activation of Cdc2/cyclin by Wee1 and Cdc25.
If Km=1 uM and kcat=1 reaction/min,
then kcat/Km would be 1 uM-1 min-1 or 0.001 nM-1 min-1. The
bigger the value for 'factor', the stronger the feedback. If
factor=1 then the mitotic and interphase forms of Cdc25 and
Wee1 do not differ in activity,and so there is no feedback
from Cdc2 to Cdc25 and Wee1. If it's 10,the feedback is
strong enough to give sustained, realistic-looking
oscillations. *)
factor = 20;
kwee1=0.1;
kwee1basal=kwee1/factor;
kcdc25=0.1;
kcdc25basal=kcdc25/factor;
(* cdc2tot, cdc25tot, wee1tot and apctot are total
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concentrations in nM *)
cdc2tot=100;
cdc25tot=15;
wee1tot=15;
apctot=50;
(* Assuming that the dependence of Cdc25 and Wee1 on Cdc2
activity is described by Hill functions with Hill
coefficients of nwee1 and ncdc25 and EC50's (in nM) of
ec50wee1 and ec50cdc25. *)
nwee1=4;
ncdc25=4;
napc=5;
np21 = 5;
ec50wee1=25;
ec50cdc25=25;
ec50apc=30;
ec50p21 = 30;
(* Define the rate constants for turning Cdc25 on (by Cdc2)
and off (by?) and for turning Wee1 off (by Cdc2) and on (by?)
*)
kcdc25on=0.8;
kcdc25off=0.08;
kapcon=0.8;
kapcoff=0.08;
kwee1on=0.8;
kwee1off=0.08;
kp21on = 0.8;
(* And define CAK activity and PP2C activity in nM-1 min-1 *)
kcak=0.8;
kpp2c=0.008;
yDer=D[yDer, t];
yCoeff=Simplify[yDer/.t0]
{1/(1. +a8 k2tp) C22 (-0.000310113-0.000310113 a8 k2tp+C23
(-2.50228-2.50228 a8 k2tp)+C24 (0.00142062 +0.00142062 a8
k2tp)+C2 (2.6964 +2.6964 a8 k2tp)+C22 (0.0542277 +0.00507981
kp21off+a8 k2tp (0.0542277 -5.16716×10-10 p21tot)-5.16716×10-10
p21tot)) }
eqn=Simplify[yCoeff-(yCoeff/.subst)];
eqn=Simplify[eqn/.soln];
newSoln=Simplify[Solve[eqn0,{kp21offb,p21totb}]]
Solve::svars : Equations may not give solutions for all
"solve" variables. 
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{{kp21offb(1.01719×10-7+1.01719×10-7 a8 k2tp) p21totb+1/(C24
) 196.858 (1. +a8 k2tp) ((0. C24 )/(1. +a8 k2tp)+(0. a8 C24
k2tp )/(1. +a8 k2tp)+(C22 (0. +0. a8 k2tp) )/(1. +a8
k2tp)+(C23 (0. +0. a8 k2tp) )/(1. +a8 k2tp)+(C25 (0. +0. a8
k2tp) )/(1. +a8 k2tp)+(C26 (0. +0. a8 k2tp) )/(1. +a8
k2tp)+(0.00507981 C24 kp21off )/(1. +a8 k2tp)-(5.16716×10-10
C24 p21tot )/(1. +a8 k2tp)-(5.16716×10-10 a8 C24 k2tp p21tot
)/(1. +a8 k2tp))}}
soln=Simplify[soln/.newSoln[[1]]]
soln=Union[soln,newSoln[[1]]]
{C2bC2,b,b}
{C2bC2,kp21offb(1.01719×10-7+1.01719×10-7 a8 k2tp)
p21totb+1/(C24 ) 196.858 (1. +a8 k2tp) ((0. C24 )/(1. +a8
k2tp)+(0. a8 C24 k2tp )/(1. +a8 k2tp)+(C22 (0. +0. a8 k2tp)
)/(1. +a8 k2tp)+(C23 (0. +0. a8 k2tp) )/(1. +a8 k2tp)+(C25
(0. +0. a8 k2tp) )/(1. +a8 k2tp)+(C26 (0. +0. a8 k2tp)
)/(1. +a8 k2tp)+(0.00507981 C24 kp21off )/(1. +a8 k2tp)-
(5.16716×10-10 C24 p21tot )/(1. +a8 k2tp)-(5.16716×10-10 a8
C24 k2tp p21tot )/(1. +a8 k2tp)),b,b}
yDer=D[yDer, t];
yCoeff=Simplify[yDer/.t0];
eqn=Simplify[yCoeff-(yCoeff/.subst)];
eqn=Simplify[eqn/.soln];
newSoln=Simplify[Solve[eqn0,{p21totb}]]
{{p21totbp21tot}}
newSoln={{p21totbp21tot}}
soln=Simplify[soln/.newSoln[[1]]]
soln=Union[soln,newSoln[[1]]]
{C2bC2,kp21offb(1.01719×10-7+1.01719×10-7 a8 k2tp)
p21tot+1/(C24 ) 196.858 (1. +a8 k2tp) ((0. C24 )/(1. +a8
k2tp)+(0. a8 C24 k2tp )/(1. +a8 k2tp)+(C22 (0. +0. a8 k2tp)
)/(1. +a8 k2tp)+(C23 (0. +0. a8 k2tp) )/(1. +a8 k2tp)+(C25
(0. +0. a8 k2tp) )/(1. +a8 k2tp)+(C26 (0. +0. a8 k2tp)
)/(1. +a8 k2tp)+(0.00507981 C24 kp21off )/(1. +a8 k2tp)-
(5.16716×10-10 C24 p21tot )/(1. +a8 k2tp)-(5.16716×10-10 a8
C24 k2tp p21tot )/(1. +a8 k2tp)),b,b}
{C2bC2,k11bk11,k2tpb1.
k2tp,kp21offbkp21off,p21totbp21tot,b,b}
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Parameter estimation for the hydrolysis model
* TPT in Buffer Parameter Estimation pH = 7.2 Sept. 2010 ;
*========================================================= ;
* Mohammed Isam Atari ;
*========================================================= ;
EXECUTE ;
OPEN 8 "Pstream1In.txt" ;
OPEN 9 "Pstream2In.txt" ;
OPEN 10 "Plot1.out";
OPEN 11 "Plot2.out";
OPEN 12 "Fit_Plot1_Data.txt";
OPEN 13 "Fit_Plot2_Data.txt";
**;
VARIABLE
x1a x2a x1b x2b
;
* Define the Parameters ;
PARAMETER
k12 1.8e-2 k21 9.36e-3 D 10
;
INTEGER #COUNT ;
* Assign intital conditions for variables ;
COMPILE INITIAL;
x1a = D ;
x2a = 0 ;
x1b = D ;
x2b = 0 ;
**;
COMPILE EQUATIONS ;
'x1a = -k21*x1a + k12*x2a ;
'x2a = k21*x1a - k12*x2a ;
'x1b = -k21*x1b + k12*x2b ;
'x2b = k21*x1b - k12*x2b ;
**;
SETPSTREAM 1 8;
**;
SETPSTREAM 2 9;
**;
* DATA relative error estimate default 0.05;
DATA 0.05 ;
TIME x1a x2a x1b x2b ;
RANGE 9.99 3.11 9.93 3.12;
1.00 9.99 0.00 9.93 0.05 ;
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2.00 9.89 0.09 9.85 0.11 ;
5.00 9.71 0.27 9.63 0.29 ;
10.00 9.36 0.60 9.26 0.71 ;
15.00 8.98 1.10 8.91 1.02 ;
30.00 7.96 2.01 8.40 1.52 ;
45.00 7.47 2.48 7.34 2.61 ;
60.00 7.10 3.07 6.86 3.08 ;
120.00 6.79 3.11 6.83 3.12 ;
**;
* Identify parameters to be varied;
SETVARY k12 k21 ;
BEGIN;
COMPILE INSTANT ;
WRITE 1=10, "PRINT STREAM NO." % ;
WRITE 1, "TIME La La(obs) Ha Ha(obs) " % ;
WRITE 1=11, "PRINT STREAM NO." % ;
WRITE 1, "TIME Lb Lb(obs) Hb Hb(obs) " % ;
WRITE 1=12, "PRINT STREAM NO." % ;
WRITE 1, "TIME La La(obs) Ha Ha(obs) " % ;
WRITE 1=13, "PRINT STREAM NO." % ;
WRITE 1, "TIME Lb Lb(obs) Hb Hb(obs) " % ;
#COUNT=0;
**;
COMPILE PRINT;
* Output routine called during the final phase;
#COUNT=#COUNT+1;
DO 10 FOR #2=#COUNT-1 ;
WRITE 1=10, ((E14,6)) TIME, x1a, VOBS<0,#2>, x2a, VOBS<1,#2> ;
WRITE 1=11, ((E14,6)) TIME, x1b, VOBS<2,#2>, x2b, VOBS<3,#2> ;
WRITE 1=12, ((E14,6)) TIME, x1a, VOBS<0,#2>, x2a, VOBS<1,#2> ;
WRITE 1=13, ((E14,6)) TIME, x1b, VOBS<2,#2>, x2b, VOBS<3,#2> ;
LABEL 10 ;
**;
SETNOFIT;
WHENEVER TIME = TOBS % CALL PRINT;
**;
BEGIN;
STOP;
Parameter estimation of the single-cell model
Averaged data
* Active Pump Parameter Fitting
*========================================================= ;
* Mohammed Isam Atari ;
*========================================================= ;
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EXECUTE ;
OPEN 8 "Pstream1In.txt";
OPEN 9 "Pstream2In.txt";
OPEN 10 "fplot.out";
OPEN 11 "fit_plot_data.txt";
**;
* Define the Variables ;
VARIABLE Lm Hm Le He Lc Hc Ln;
* Define the Parameters ;
PARAMETER
ki ke kb kmi kmo kom kcm koc kcc kdl kdh
v0 v1 v2 v3
D
Vm1 Km1 Vm2 Km2
alpha 2.4375e4
BT Med Cyt Nuc
;
* Open file, read in and assign parameters ;
COMPILE INSTANT;
OPEN 7 "pars.txt";
READ 7 kom ;
READ 7 kcm ;
READ 7 koc ;
READ 7 kcc ;
READ 7 ki ;
READ 7 ke ;
READ 7 kb ;
READ 7 kmi ;
READ 7 kmo ;
READ 7 kdl ;
READ 7 kdh ;
READ 7 v0 ;
READ 7 v2 ;
READ 7 v3 ;
READ 7 D ;
READ 7 Vm1 ;
READ 7 Km1 ;
READ 7 Vm2 ;
READ 7 Km2 ;
READ 7 BT ;
**;
COMPILE GENERAL ;
Med = Le + He ;
Nuc = Ln ;
Cyt = Lc + Hc ;
**;
INTEGER #COUNT ;
* Assign Intital Conditions for Variables ;
COMPILE INITIAL;
Lm = (1+v0)*D ;
Hm = 0 ;
Le = 0 ;
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He = 0 ;
Lc = 0 ;
Hc = 0 ;
Ln = 0 ;
v1 = alpha*v0/(1+v0) ;
**;
COMPILE EQUATIONS;
'Lm = -(kom + kmi)*Lm + kcm*Hm + kmo*v0*Le ;
'Hm = kom*Lm -(kcm + kmi)*Hm + kmo*v0*He ;
'Le = (kmi*Lm)/v0 -(kmo + kom + ki)*Le + kcm*He +
(ke*Lc)/v1 ;
'He = (kmi*Hm)/v0 + kom*Le -(kcm + kmo)*He +
(Vm1*v3*Hc)/((v1)*(v3*Km1 + Hc)) ;
'Lc = ki*v1*Le -(ke + koc)*Lc + kcc*Hc + kdl*v2*Ln - kb*(BT - Ln)*Lc
- (Vm2*Lc)/(Km2 + Lc) ;
'Hc = koc*Lc - kcc*Hc + kdh*v2*Ln - (v3*Vm1*Hc)/(v3*Km1 + Hc)
+ (Vm2*Lc)/(Km2 + Lc) ;
'Ln = kb*Lc*(BT - Ln)/v2 - (kdl + kdh)*Ln;
**;
SETPSTREAM 1 8;
**;
SETPSTREAM 2 9;
**;
DATA 0.05;
TIME Med Nuc Cyt ;
RANGE 10.7556 12.0667 9.2068 ;
5 3.4000 0.0632 0.1538 ;
10 5.8889 0.1932 0.2940 ;
15 6.9778 0.3453 0.4701 ;
20 7.5333 0.5385 0.6547 ;
25 7.9111 0.7915 0.8325 ;
30 8.2889 1.0496 1.0667 ;
35 8.5778 1.3265 1.3009 ;
40 8.7111 1.6188 1.5162 ;
45 8.8667 1.8684 1.7385 ;
50 9.0000 2.1641 1.9658 ;
55 9 2.4085 2.1863 ;
60 9.0222 2.6581 2.3829 ;
65 9.1778 2.9368 2.5590 ;
70 9.2222 3.1658 2.6889 ;
75 9.2 3.3658 2.9453 ;
80 9.2222 3.6137 3.0838 ;
85 9.2889 3.8291 3.2496 ;
90 9.3111 4.0547 3.4291 ;
95 9.3556 4.2462 3.5641 ;
100 9.4444 4.4479 3.6991 ;
105 9.3778 4.6222 3.8291 ;
110 9.4 4.8325 4.0291 ;
115 9.4444 4.9983 4.0547 ;
120 9.4222 5.147 4.1761 ;
125 9.4 5.3368 4.2034 ;
130 9.4444 5.4701 4.3726 ;
135 9.4667 5.653 4.4718 ;
140 9.5556 5.7658 4.6325 ;
145 9.5333 5.9487 4.6786 ;
150 9.6 6.1504 4.7932 ;
155 9.5556 6.2547 4.8427 ;
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160 9.6222 6.4496 4.9778 ;
165 9.7333 6.6222 5.0855 ;
170 9.7333 6.7094 5.2547 ;
175 9.8 6.8803 5.3128 ;
180 9.7778 7.0718 5.4821 ;
185 9.7778 7.1744 5.4872 ;
190 9.8667 7.3658 5.6256 ;
195 9.8667 7.465 5.7060 ;
200 9.7778 7.5658 5.7573 ;
205 9.7333 7.665 5.8256 ;
210 9.7556 7.7641 6.0239 ;
215 9.7556 7.935 5.9726 ;
220 9.8444 8.0581 6.0821 ;
225 9.8222 8.2359 6.1932 ;
230 9.7556 8.3248 6.2701 ;
235 9.8 8.4547 6.4222 ;
240 9.8889 8.5556 6.4667 ;
245 9.8444 8.6684 6.5675 ;
250 9.9111 8.7538 6.6376 ;
255 9.8889 8.8735 6.6957 ;
260 9.9333 8.9778 6.7538 ;
265 9.9556 9.0974 6.9060 ;
270 10 9.1966 6.9880 ;
275 10 9.3863 7.0889 ;
280 10.0222 9.4291 7.1111 ;
285 10.0222 9.5385 7.1658 ;
290 10.0889 9.6735 7.3282 ;
295 10.1556 9.7641 7.3077 ;
300 10.1333 9.8821 7.4222 ;
305 10.1778 9.9504 7.4803 ;
310 10.1778 10.0256 7.5470 ;
315 10.2889 10.1368 7.6650 ;
320 10.2222 10.1709 7.6906 ;
325 10.2222 10.2462 7.7521 ;
330 10.2444 10.3658 7.7179 ;
335 10.2222 10.453 7.8701 ;
340 10.2889 10.5197 7.9402 ;
345 10.2889 10.641 8.0137 ;
350 10.3333 10.8154 8.0803 ;
355 10.3111 10.788 8.0838 ;
360 10.3333 10.8427 8.1470 ;
365 10.3778 10.9402 8.2889 ;
370 10.4222 11.0547 8.2530 ;
375 10.4222 11.0496 8.3504 ;
380 10.3556 11.1145 8.3385 ;
385 10.4222 11.1556 8.4017 ;
390 10.4 11.241 8.5026 ;
395 10.3778 11.2342 8.6120 ;
400 10.4 11.3744 8.6325 ;
405 10.4 11.3214 8.5761 ;
410 10.4222 11.4496 8.8000 ;
415 10.4222 11.5829 8.7658 ;
420 10.5111 11.588 8.7897 ;
425 10.5111 11.6752 8.9077 ;
430 10.5111 11.735 8.8393 ;
435 10.6667 11.9436 9.0530 ;
440 10.7556 12.0291 9.0427 ;
445 10.7111 12.0667 9.2068 ;
450 10.6889 12.0376 9.0735 ;
**;
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* Identify Parameters to be Varied;
SETVARY ki ke kb kmi kmo kdl kdh v0 BT Vm1 Vm2 Km1 Km2;
BEGIN;
COMPILE INSTANT ;
WRITE 1=10, " PRINT STREAM NO. " % ;
WRITE 2=10, "TIME Med Med(obs) Nuc Nuc(obs) Cyt Cyt(obs)" % ;
WRITE 1=11, " PRINT STREAM NO. " % ;
WRITE 2=11, "TIME Med Med(obs) Nuc Nuc(obs) Cyt Cyt(obs)" % ;
#COUNT=0;
**;
COMPILE PRINT;
* Output routine called during the final phase;
#COUNT=#COUNT+1;
DO 10 FOR #2=#COUNT-1 ;
WRITE 1=10, ((E14,6)) TIME, Med, VOBS<0,#2> ,Nuc, VOBS<1,#2>
Cyt, VOBS<2,#2> ;
WRITE 1=11, ((E14,6)) TIME, Med, VOBS<0,#2> ,Nuc, VOBS<1,#2>
Cyt, VOBS<2,#2> ;
LABEL 10 ;
**;
SETNOFIT;
WHENEVER TIME = TOBS % CALL PRINT;
**;
BEGIN;
STOP;
High loading cell
* Active Pump Parameter Fitting
*========================================================= ;
* Mohammed Isam Atari ;
*========================================================= ;
EXECUTE ;
OPEN 8 "Pstream1In.txt";
OPEN 9 "Pstream2In.txt";
OPEN 10 "fplot.out";
OPEN 11 "fit_plot_data.txt";
**;
* Define the Variables ;
VARIABLE Lm Hm Le He Lc Hc Ln;
* Define the Parameters ;
PARAMETER
ki ke kb kmi kmo kom kcm koc kcc kdl kdh
v0 v1 v2 v3
D
Vm1 Km1 Vm2 Km2
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alpha 2.4375e4
BT Med Cyt Nuc
;
* Open file, read in and assign parameters ;
COMPILE INSTANT;
OPEN 7 "pars.txt";
READ 7 kom ;
READ 7 kcm ;
READ 7 koc ;
READ 7 kcc ;
READ 7 ki ;
READ 7 ke ;
READ 7 kb ;
READ 7 kmi ;
READ 7 kmo ;
READ 7 kdl ;
READ 7 kdh ;
READ 7 v0 ;
READ 7 v2 ;
READ 7 v3 ;
READ 7 D ;
READ 7 Vm1 ;
READ 7 Km1 ;
READ 7 Vm2 ;
READ 7 Km2 ;
READ 7 BT ;
**;
COMPILE GENERAL ;
Med = Le + He ;
Nuc = Ln ;
Cyt = Lc + Hc ;
**;
INTEGER #COUNT ;
* Assign Intital Conditions for Variables ;
COMPILE INITIAL;
Lm = (1+v0)*D ;
Hm = 0 ;
Le = 0 ;
He = 0 ;
Lc = 0 ;
Hc = 0 ;
Ln = 0 ;
v1 = alpha*v0/(1+v0) ;
**;
COMPILE EQUATIONS;
'Lm = -(kom + kmi)*Lm + kcm*Hm + kmo*v0*Le ;
'Hm = kom*Lm -(kcm + kmi)*Hm + kmo*v0*He ;
'Le = (kmi*Lm)/v0 -(kmo + kom + ki)*Le + kcm*He +
(ke*Lc)/v1 ;
'He = (kmi*Hm)/v0 + kom*Le -(kcm + kmo)*He +
(Vm1*v3*Hc)/((v1)*(v3*Km1 + Hc)) ;
'Lc = ki*v1*Le -(ke + koc)*Lc + kcc*Hc + kdl*v2*Ln - kb*(BT - Ln)*Lc
- (Vm2*Lc)/(Km2 + Lc) ;
'Hc = koc*Lc - kcc*Hc + kdh*v2*Ln - (v3*Vm1*Hc)/(v3*Km1 + Hc)
+ (Vm2*Lc)/(Km2 + Lc) ;
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'Ln = kb*Lc*(BT - Ln)/v2 - (kdl + kdh)*Ln;
**;
SETPSTREAM 1 8;
**;
SETPSTREAM 2 9;
**;
DATA 0.05;
TIME Med Nuc Cyt ;
RANGE 10.8 16.4 12.5 ;
5 3.4 0.1 0.5 ;
10 5.9 0.2 0.9 ;
15 7 0.4 1.3 ;
20 7.5 0.6 1.3 ;
25 7.9 1 1.5 ;
30 8.3 1.3 1.8 ;
35 8.6 1.6 2 ;
40 8.7 2 2.2 ;
45 8.9 2.3 2.7 ;
50 9 2.6 2.8 ;
55 9 3 2.7 ;
60 9 3.2 3.1 ;
65 9.2 3.5 3.5 ;
70 9.2 3.8 3.6 ;
75 9.2 4.2 4 ;
80 9.2 4.5 4.2 ;
85 9.3 4.8 4.5 ;
90 9.3 5 4.5 ;
95 9.4 5.2 4.4 ;
100 9.4 5.4 4.9 ;
105 9.4 5.7 5 ;
110 9.4 6 5.4 ;
115 9.4 6.2 5.3 ;
120 9.4 6.4 5.4 ;
125 9.4 6.7 5.3 ;
130 9.4 6.9 5.2 ;
135 9.5 7.2 5.9 ;
140 9.6 7.3 5.7 ;
145 9.5 7.5 6 ;
150 9.6 7.9 6.2 ;
155 9.6 8 5.8 ;
160 9.6 8.2 6.4 ;
165 9.7 8.4 6.6 ;
170 9.7 8.5 6.8 ;
175 9.8 8.9 6.8 ;
180 9.8 9 7.3 ;
185 9.8 9.2 7 ;
190 9.9 9.4 7.3 ;
195 9.9 9.6 7.5 ;
200 9.8 9.6 7.2 ;
205 9.7 9.7 7.5 ;
210 9.8 10.1 8.2 ;
215 9.8 10.4 7.8 ;
220 9.8 10.3 8.1 ;
225 9.8 10.8 8.1 ;
230 9.8 10.7 8.3 ;
235 9.8 11.2 8.7 ;
240 9.9 11.4 8.4 ;
245 9.8 11.2 8.7 ;
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250 9.9 11.3 8.8 ;
255 9.9 11.5 8.9 ;
260 9.9 11.8 8.9 ;
265 10 12 9.4 ;
270 10 12 9.2 ;
275 10 12.4 9.6 ;
280 10 12.3 9.2 ;
285 10 12.5 9.4 ;
290 10.1 12.9 9.3 ;
295 10.2 13 9.8 ;
300 10.1 12.9 10.1 ;
305 10.2 13.3 10.3 ;
310 10.2 13.1 9.7 ;
315 10.3 13.6 10.4 ;
320 10.2 13.6 10.2 ;
325 10.2 13.6 10.3 ;
330 10.2 13.7 10.4 ;
335 10.2 14 10 ;
340 10.3 14.2 10.8 ;
345 10.3 14.2 10.6 ;
350 10.3 14.4 10.9 ;
355 10.3 14.6 10.6 ;
360 10.3 14.6 10.6 ;
365 10.4 14.9 11.1 ;
370 10.4 14.8 10.9 ;
375 10.4 14.9 10.8 ;
380 10.4 14.8 11.1 ;
385 10.4 15.1 11.5 ;
390 10.4 15.1 11.2 ;
395 10.4 15.1 11.7 ;
400 10.4 15.5 11.5 ;
405 10.4 15.3 11.5 ;
410 10.4 15.4 12.4 ;
415 10.4 15.8 12.1 ;
420 10.5 15.5 11.6 ;
425 10.5 15.6 12 ;
430 10.5 16 12 ;
435 10.7 16.2 12.4 ;
440 10.8 16.4 12.5 ;
445 10.7 16.4 12.4 ;
450 10.7 16.2 11.6 ;
**;
* Identify Parameters to be Varied;
SETVARY ki ke kb kmi kmo kdl kdh v0 BT Vm1 Vm2 Km1 Km2;
BEGIN;
COMPILE INSTANT ;
WRITE 1=10, " PRINT STREAM NO. " % ;
WRITE 2=10, "TIME Med Med(obs) Nuc Nuc(obs) Cyt Cyt(obs)" % ;
WRITE 1=11, " PRINT STREAM NO. " % ;
WRITE 2=11, "TIME Med Med(obs) Nuc Nuc(obs) Cyt Cyt(obs)" % ;
#COUNT=0;
**;
COMPILE PRINT;
* Output routine called during the final phase;
#COUNT=#COUNT+1;
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DO 10 FOR #2=#COUNT-1 ;
WRITE 1=10, ((E14,6)) TIME, Med, VOBS<0,#2> ,Nuc, VOBS<1,#2>
Cyt, VOBS<2,#2> ;
WRITE 1=11, ((E14,6)) TIME, Med, VOBS<0,#2> ,Nuc, VOBS<1,#2>
Cyt, VOBS<2,#2> ;
LABEL 10 ;
**;
SETNOFIT;
WHENEVER TIME = TOBS % CALL PRINT;
**;
BEGIN;
STOP;
Low loading cell
* Active Pump Parameter Fitting
*========================================================= ;
* Mohammed Isam Atari ;
*========================================================= ;
EXECUTE ;
OPEN 8 "Pstream1In.txt";
OPEN 9 "Pstream2In.txt";
OPEN 10 "fplot.out";
OPEN 11 "fit_plot_data.txt";
**;
* Define the Variables ;
VARIABLE Lm Hm Le He Lc Hc Ln;
* Define the Parameters ;
PARAMETER
ki ke kb kmi kmo kom kcm koc kcc kdl kdh
v0 v1 v2 v3
D
Vm1 Km1 Vm2 Km2
alpha 2.4375e4
BT Med Cyt Nuc
;
* Open file, read in and assign parameters ;
COMPILE INSTANT;
OPEN 7 "pars.txt";
READ 7 kom ;
READ 7 kcm ;
READ 7 koc ;
READ 7 kcc ;
READ 7 ki ;
READ 7 ke ;
READ 7 kb ;
READ 7 kmi ;
READ 7 kmo ;
READ 7 kdl ;
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READ 7 kdh ;
READ 7 v0 ;
READ 7 v2 ;
READ 7 v3 ;
READ 7 D ;
READ 7 Vm1 ;
READ 7 Km1 ;
READ 7 Vm2 ;
READ 7 Km2 ;
READ 7 BT ;
**;
COMPILE GENERAL ;
Med = Le + He ;
Nuc = Ln ;
Cyt = Lc + Hc ;
**;
INTEGER #COUNT ;
* Assign Intital Conditions for Variables ;
COMPILE INITIAL;
Lm = (1+v0)*D ;
Hm = 0 ;
Le = 0 ;
He = 0 ;
Lc = 0 ;
Hc = 0 ;
Ln = 0 ;
v1 = alpha*v0/(1+v0) ;
**;
COMPILE EQUATIONS;
'Lm = -(kom + kmi)*Lm + kcm*Hm + kmo*v0*Le ;
'Hm = kom*Lm -(kcm + kmi)*Hm + kmo*v0*He ;
'Le = (kmi*Lm)/v0 -(kmo + kom + ki)*Le + kcm*He +
(ke*Lc)/v1 ;
'He = (kmi*Hm)/v0 + kom*Le -(kcm + kmo)*He +
(Vm1*v3*Hc)/((v1)*(v3*Km1 + Hc)) ;
'Lc = ki*v1*Le -(ke + koc)*Lc + kcc*Hc + kdl*v2*Ln - kb*(BT - Ln)*Lc
- (Vm2*Lc)/(Km2 + Lc) ;
'Hc = koc*Lc - kcc*Hc + kdh*v2*Ln - (v3*Vm1*Hc)/(v3*Km1 + Hc)
+ (Vm2*Lc)/(Km2 + Lc) ;
'Ln = kb*Lc*(BT - Ln)/v2 - (kdl + kdh)*Ln;
**;
SETPSTREAM 1 8;
**;
SETPSTREAM 2 9;
**;
DATA 0.05;
TIME Med Nuc Cyt ;
RANGE 10.8 7.4 6.2 ;
5 3.4 1e-36 0.1;
10 5.9 0.1 0.1;
15 7 0.2 0.2;
20 7.5 0.3 0.4;
25 7.9 0.5 0.6;
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30 8.3 0.6 0.6;
35 8.6 0.7 0.7;
40 8.7 0.9 0.9;
45 8.9 1.1 0.9;
50 9 1.2 1.1;
55 9 1.4 1.1;
60 9 1.5 1.3;
65 9.2 1.7 1.6;
70 9.2 1.8 1.7;
75 9.2 2.0 1.6;
80 9.2 2.1 1.7;
85 9.3 2.3 1.9;
90 9.3 2.5 1.9;
95 9.4 2.5 2.1;
100 9.4 2.6 2.2;
105 9.4 2.8 2.3;
110 9.4 2.9 2.4;
115 9.4 3.0 2.4;
120 9.4 3.1 2.4;
125 9.4 3.2 2.5;
130 9.4 3.3 2.7;
135 9.5 3.4 2.8;
140 9.6 3.5 2.9;
145 9.5 3.7 2.7;
150 9.6 3.7 3.0;
155 9.6 3.7 3.0;
160 9.6 3.9 3.1;
165 9.7 4.1 3.2;
170 9.7 4.1 3.2;
175 9.8 4.2 3.2;
180 9.8 4.3 3.4;
185 9.8 4.4 3.5;
190 9.9 4.5 3.4;
195 9.9 4.6 3.6;
200 9.8 4.6 3.9;
205 9.7 4.6 3.6;
210 9.8 4.7 4.0;
215 9.8 4.8 3.7;
220 9.8 5.0 3.7;
225 9.8 5.0 3.9;
230 9.8 5.1 4.0;
235 9.8 5.1 4.0;
240 9.9 5.0 4.3;
245 9.8 5.2 4.4;
250 9.9 5.3 4.3;
255 9.9 5.3 4.3;
260 9.9 5.4 4.5;
265 10 5.5 4.4;
270 10 5.6 4.4;
275 10 5.8 4.7;
280 10 5.7 4.5;
285 10 5.8 4.6;
290 10.1 5.8 4.5;
295 10.2 6.0 4.8;
300 10.1 6.0 4.8;
305 10.2 6.0 4.9;
310 10.2 6.1 4.9;
315 10.3 6.2 4.9;
320 10.2 6.2 5.1;
325 10.2 6.2 5.0;
330 10.2 6.2 5.1;
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335 10.2 6.4 5.2;
340 10.3 6.4 4.9;
345 10.3 6.3 5.3;
350 10.3 6.5 5.2;
355 10.3 6.6 5.2;
360 10.3 6.5 5.2;
365 10.4 6.6 5.3;
370 10.4 6.7 5.4;
375 10.4 6.7 5.3;
380 10.4 6.7 5.6;
385 10.4 6.8 5.2;
390 10.4 6.9 5.4;
395 10.4 6.9 5.7;
400 10.4 6.9 5.3;
405 10.4 6.8 5.5;
410 10.4 7.0 5.6;
415 10.4 7.1 5.7;
420 10.5 6.9 5.6;
425 10.5 7.0 5.9;
430 10.5 7.2 5.7;
435 10.7 7.3 6.0;
440 10.8 7.4 6.2;
445 10.7 7.4 5.9;
450 10.7 7.4 5.9;
**;
* Identify Parameters to be Varied;
SETVARY ki ke kb kmi kmo kdl kdh v0 BT Vm1 Vm2 Km1 Km2;
BEGIN;
COMPILE INSTANT ;
WRITE 1=10, " PRINT STREAM NO. " % ;
WRITE 2=10, "TIME Med Med(obs) Nuc Nuc(obs) Cyt Cyt(obs)" % ;
WRITE 1=11, " PRINT STREAM NO. " % ;
WRITE 2=11, "TIME Med Med(obs) Nuc Nuc(obs) Cyt Cyt(obs)" % ;
#COUNT=0;
**;
COMPILE PRINT;
* Output routine called during the final phase;
#COUNT=#COUNT+1;
DO 10 FOR #2=#COUNT-1 ;
WRITE 1=10, ((E14,6)) TIME, Med, VOBS<0,#2> ,Nuc, VOBS<1,#2>
Cyt, VOBS<2,#2> ;
WRITE 1=11, ((E14,6)) TIME, Med, VOBS<0,#2> ,Nuc, VOBS<1,#2>
Cyt, VOBS<2,#2> ;
LABEL 10 ;
**;
SETNOFIT;
WHENEVER TIME = TOBS % CALL PRINT;
**;
BEGIN;
STOP;
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Simultaneous fitting
* Active Pump Parameter Fitting
*========================================================= ;
* Mohammed Isam Atari ;
*========================================================= ;
EXECUTE ;
OPEN 8 "fplot_c.out";
OPEN 9 "fplot_r.out";
OPEN 10 "fplot_p1.out";
OPEN 11 "fplot_p2.out";
**;
* Define the Variables ;
VARIABLE Lmh Hmh Leh Heh Lch Hch Lnh
Lml Hml Lel Hel Lcl Hcl Lnl ;
* Define the Parameters ;
PARAMETER
ki ke kb kmi kmo kom kcm koc kcc kdl kdh
v0 v1 v2 v3
D
Vm1h Km1h Vm2h Km2h
Vm1l Km1l Vm2l Km2l
alpha 2.4375e4
BT Medh Cyth Nuch
Medl Cytl Nucl
;
* Open file, read in and assign parameters ;
COMPILE INSTANT;
OPEN 7 "pars.txt";
READ 7 kom ;
READ 7 kcm ;
READ 7 koc ;
READ 7 kcc ;
READ 7 ki ;
READ 7 ke ;
READ 7 kb ;
READ 7 kmi ;
READ 7 kmo ;
READ 7 kdl ;
READ 7 kdh ;
READ 7 v0 ;
READ 7 v2 ;
READ 7 v3 ;
READ 7 D ;
READ 7 Vm1h ;
READ 7 Km1h ;
READ 7 Vm2h ;
READ 7 Km2h ;
READ 7 Vm1l ;
READ 7 Km1l ;
READ 7 Vm2l ;
READ 7 Km2l ;
Appendix B 251
READ 7 BT ;
**;
COMPILE GENERAL ;
Medh = Leh + Heh ;
Nuch = Lnh ;
Cyth = Lch + Hch ;
Medl = Lel + Hel ;
Nucl = Lnl ;
Cytl = Lcl + Hcl ;
**;
INTEGER #COUNT ;
* Assign Intital Conditions for Variables ;
COMPILE INITIAL;
Lmh = (1+v0)*D ;
Hmh = 0 ;
Leh = 0 ;
Heh = 0 ;
Lch = 0 ;
Hch = 0 ;
Lnh = 0 ;
Lml = (1+v0)*D ;
Hml = 0 ;
Lel = 0 ;
Hel = 0 ;
Lcl = 0 ;
Hcl = 0 ;
Lnl = 0 ;
v1 = alpha*v0/(1+v0) ;
**;
COMPILE EQUATIONS;
'Lmh = -(kom + kmi)*Lmh + kcm*Hmh + kmo*v0*Leh ;
'Hmh = kom*Lmh -(kcm + kmi)*Hmh + kmo*v0*Heh ;
'Leh = (kmi*Lmh)/v0 -(kmo + kom + ki)*Leh + kcm*Heh +
(ke*Lch)/v1 ;
'Heh = (kmi*Hmh)/v0 + kom*Leh -(kcm + kmo)*Heh +
(Vm1h*v3*Hch)/((v1)*(v3*Km1h + Hch)) ;
'Lch = ki*v1*Leh -(ke + koc)*Lch + kcc*Hch + kdl*v2*Lnh
- kb*(BT - Lnh)*Lch - (Vm2h*Lch)/(Km2h + Lch) ;
'Hch = koc*Lch - kcc*Hch + kdh*v2*Lnh - (v3*Vm1h*Hch)/(v3*Km1h + Hch)
+ (Vm2h*Lch)/(Km2h + Lch) ;
'Lnh = kb*Lch*(BT - Lnh)/v2 - (kdl + kdh)*Lnh;
'Lml = -(kom + kmi)*Lml + kcm*Hml + kmo*v0*Lel ;
'Hml = kom*Lml -(kcm + kmi)*Hml + kmo*v0*Hel ;
'Lel = (kmi*Lml)/v0 -(kmo + kom + ki)*Lel + kcm*Hel +
(ke*Lcl)/v1 ;
'Hel = (kmi*Hml)/v0 + kom*Lel -(kcm + kmo)*Hel +
(Vm1l*v3*Hcl)/((v1)*(v3*Km1l + Hcl)) ;
'Lcl = ki*v1*Lel -(ke + koc)*Lcl + kcc*Hcl + kdl*v2*Lnl
- kb*(BT - Lnl)*Lcl - (Vm2l*Lcl)/(Km2l + Lcl) ;
'Hcl = koc*Lcl - kcc*Hcl + kdh*v2*Lnl - (v3*Vm1l*Hcl)/(v3*Km1l + Hcl)
+ (Vm2l*Lcl)/(Km2l + Lcl) ;
'Lnl = kb*Lcl*(BT - Lnl)/v2 - (kdl + kdh)*Lnl ;
**;
SETPSTREAM 1 8;
Appendix B 252
**;
SETPSTREAM 2 9;
**;
DATA 0.05;
TIME Medh Nuch Cyth Medl Nucl Cytl ;
RANGE 10.76 16.4 12.51 10.76 7.44 6.18;
5 3.40 0.07 0.51 3.40 0.04 0.11 ;
10 5.89 0.20 0.91 5.89 0.11 0.09 ;
15 6.98 0.44 1.29 6.98 0.20 0.22 ;
20 7.53 0.62 1.29 7.53 0.33 0.38 ;
25 7.91 0.96 1.49 7.91 0.47 0.56 ;
30 8.29 1.31 1.78 8.29 0.62 0.60 ;
35 8.58 1.62 2.00 8.58 0.73 0.73 ;
40 8.71 1.96 2.22 8.71 0.91 0.87 ;
45 8.87 2.31 2.69 8.87 1.09 0.93 ;
50 9.00 2.58 2.78 9.00 1.22 1.07 ;
55 9.00 2.96 2.71 9.00 1.42 1.11 ;
60 9.02 3.18 3.13 9.02 1.53 1.29 ;
65 9.18 3.53 3.51 9.18 1.73 1.56 ;
70 9.22 3.80 3.64 9.22 1.82 1.67 ;
75 9.20 4.22 4.04 9.20 2.00 1.64 ;
80 9.22 4.51 4.16 9.22 2.13 1.69 ;
85 9.29 4.76 4.51 9.29 2.31 1.91 ;
90 9.31 4.98 4.49 9.31 2.47 1.93 ;
95 9.36 5.20 4.42 9.36 2.49 2.07 ;
100 9.44 5.42 4.89 9.44 2.64 2.20 ;
105 9.38 5.69 4.96 9.38 2.78 2.29 ;
110 9.40 5.98 5.40 9.40 2.87 2.38 ;
115 9.44 6.18 5.31 9.44 3.02 2.42 ;
120 9.42 6.40 5.42 9.42 3.13 2.42 ;
125 9.40 6.71 5.27 9.40 3.20 2.51 ;
130 9.44 6.93 5.24 9.44 3.33 2.73 ;
135 9.47 7.16 5.93 9.47 3.38 2.76 ;
140 9.56 7.27 5.71 9.56 3.51 2.91 ;
145 9.53 7.47 6.00 9.53 3.69 2.67 ;
150 9.60 7.89 6.16 9.60 3.71 3.02 ;
155 9.56 7.98 5.78 9.56 3.73 3.04 ;
160 9.62 8.18 6.40 9.62 3.87 3.13 ;
165 9.73 8.38 6.60 9.73 4.07 3.18 ;
170 9.73 8.53 6.76 9.73 4.11 3.22 ;
175 9.80 8.91 6.84 9.80 4.18 3.20 ;
180 9.78 8.96 7.31 9.78 4.27 3.40 ;
185 9.78 9.16 7.04 9.78 4.38 3.47 ;
190 9.87 9.36 7.33 9.87 4.47 3.44 ;
195 9.87 9.62 7.49 9.87 4.62 3.62 ;
200 9.78 9.60 7.16 9.78 4.60 3.93 ;
205 9.73 9.67 7.49 9.73 4.62 3.58 ;
210 9.76 10.07 8.22 9.76 4.73 4.00 ;
215 9.76 10.38 7.82 9.76 4.76 3.67 ;
220 9.84 10.33 8.09 9.84 5.00 3.73 ;
225 9.82 10.80 8.11 9.82 5.02 3.91 ;
230 9.76 10.73 8.31 9.76 5.07 3.96 ;
235 9.80 11.18 8.69 9.80 5.11 4.04 ;
240 9.89 11.38 8.36 9.89 5.02 4.33 ;
245 9.84 11.18 8.71 9.84 5.22 4.42 ;
250 9.91 11.33 8.80 9.91 5.31 4.33 ;
255 9.89 11.53 8.93 9.89 5.33 4.31 ;
260 9.93 11.76 8.91 9.93 5.44 4.49 ;
265 9.96 12.00 9.44 9.96 5.53 4.42 ;
270 10.00 12.00 9.20 10.00 5.58 4.40 ;
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275 10.00 12.40 9.58 10.00 5.76 4.71 ;
280 10.02 12.33 9.22 10.02 5.71 4.53 ;
285 10.02 12.53 9.44 10.02 5.78 4.58 ;
290 10.09 12.87 9.27 10.09 5.82 4.49 ;
295 10.16 13.02 9.78 10.16 5.98 4.84 ;
300 10.13 12.93 10.13 10.13 5.96 4.78 ;
305 10.18 13.27 10.29 10.18 6.04 4.89 ;
310 10.18 13.09 9.69 10.18 6.13 4.89 ;
315 10.29 13.56 10.44 10.29 6.16 4.89 ;
320 10.22 13.56 10.16 10.22 6.22 5.13 ;
325 10.22 13.64 10.29 10.22 6.22 5.02 ;
330 10.24 13.67 10.44 10.24 6.20 5.09 ;
335 10.22 13.96 10.02 10.22 6.36 5.16 ;
340 10.29 14.24 10.78 10.29 6.38 4.87 ;
345 10.29 14.18 10.62 10.29 6.33 5.31 ;
350 10.33 14.40 10.93 10.33 6.49 5.20 ;
355 10.31 14.56 10.56 10.31 6.62 5.24 ;
360 10.33 14.56 10.56 10.33 6.53 5.24 ;
365 10.38 14.91 11.13 10.38 6.58 5.27 ;
370 10.42 14.76 10.93 10.42 6.73 5.42 ;
375 10.42 14.87 10.78 10.42 6.71 5.33 ;
380 10.36 14.84 11.09 10.36 6.73 5.56 ;
385 10.42 15.07 11.51 10.42 6.76 5.24 ;
390 10.40 15.11 11.22 10.40 6.93 5.36 ;
395 10.38 15.09 11.71 10.38 6.87 5.71 ;
400 10.40 15.51 11.51 10.40 6.93 5.29 ;
405 10.40 15.31 11.47 10.40 6.78 5.47 ;
410 10.42 15.42 12.38 10.42 7.00 5.62 ;
415 10.42 15.80 12.11 10.42 7.11 5.71 ;
420 10.51 15.53 11.60 10.51 6.93 5.56 ;
425 10.51 15.60 12.04 10.51 7.04 5.93 ;
430 10.51 16.02 11.96 10.51 7.16 5.71 ;
435 10.67 16.18 12.44 10.67 7.27 6.00 ;
440 10.76 16.40 12.51 10.76 7.36 6.18 ;
445 10.71 16.40 12.42 10.71 7.36 5.89 ;
450 10.69 16.16 11.64 10.69 7.44 5.87 ;
**;
* Identify Parameters to be Varied;
SETVARY ki ke kb kmi kmo kdl kdh v0 BT Vm1h
Vm2h Km1h Km2h Vm1l Vm2l Km1l Km2l;
BEGIN;
COMPILE INSTANT ;
WRITE 1=10, " PRINT STREAM NO. " % ;
WRITE 1, "TIME Medh Medh(obs) Nuch Nuch(obs) Cyth Cyth(obs) " % ;
WRITE 1=11, " PRINT STREAM NO. " % ;
WRITE 1, "TIME Medl Medl(obs) Nucl Nucl(obs) Cytl Cytl(obs)" % ;
#COUNT=0;
**;
COMPILE PRINT;
* Output routine called during the final phase;
#COUNT=#COUNT+1;
DO 10 FOR #2=#COUNT-1 ;
WRITE 1=10, ((E14,6)) TIME, Medh, VOBS<0,#2>, Nuch, VOBS<1,#2>,
Cyth, VOBS<2,#2> ;
WRITE 1=11, ((E14,6)) TIME, Medl, VOBS<3,#2>, Nucl, VOBS<4,#2>,
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Cytl, VOBS<5,#2> ;
LABEL 10 ;
**;
SETNOFIT;
WHENEVER TIME = TOBS % CALL PRINT;
**;
BEGIN;
STOP;
Parameter estimation of the extended cell cycle model
* Extended Cell Cycle Model Parameter Estimation;
EXECUTE ;
OPEN 8 "Pstream1In.txt" ;
OPEN 9 "Pstream2In.txt" ;
OPEN 10 "plot.out";
OPEN 11 "fit_plot_data.txt";
**;
VARIABLE cyclin cdc2cyclin cdc2cyclinyp cdc2cyclinyptp
cdc2cyclintp cdc2 cdc25act
wee1act apcstar apc0 p21 ;
* Define the Parameters ;
PARAMETER
ksynth kdest ka kd factor
kwee1 kcdc25
cdc2tot cdc25tot wee1tot apctot p21tot
ec50wee1 ec50cdc25 ec50apc ec50p21
kcdc25on kcdc25off kapcon kapcoff kwee1on kwee1off
kcak kpp2c C2 kp21on kp21off
alpha beta CycBact C1
;
INTEGER #nwee1 #ncdc25 #napc #np21 #COUNT ;
* Open file, read in and assign parameters ;
COMPILE INSTANT;
OPEN 7 "pars1.txt";
READ 7 ksynth ;
READ 7 kdest ;
READ 7 ka ;
READ 7 kd ;
READ 7 factor ;
READ 7 kwee1 ;
READ 7 kcdc25 ;
READ 7 cdc2tot ;
READ 7 cdc25tot ;
READ 7 wee1tot ;
READ 7 apctot ;
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READ 7 #nwee1 ;
READ 7 #ncdc25 ;
READ 7 #napc ;
READ 7 ec50wee1 ;
READ 7 ec50cdc25 ;
READ 7 ec50apc ;
READ 7 kcdc25on ;
READ 7 kcdc25off ;
READ 7 kapcon ;
READ 7 kapcoff ;
READ 7 kwee1on ;
READ 7 kwee1off ;
READ 7 kcak ;
READ 7 kpp2c ;
READ 7 C2 ;
READ 7 kp21on ;
READ 7 kp21off ;
READ 7 #np21 ;
READ 7 p21tot ;
READ 7 ec50p21 ;
READ 7 alpha ;
READ 7 beta ;
READ 7 C1 ;
**;
COMPILE GENERAL ;
CycBact = alpha*cdc2cyclintp + beta ;
**;
* Assign intital conditions for variables ;
COMPILE INITIAL;
cyclin = C2*0.141396 ;
cdc2cyclin = C2*0.992654 ;
cdc2cyclinyp = C2*1.4763 ;
cdc2cyclinyptp = C2*11.41023 ;
cdc2cyclintp = C2*1.64121 ;
cdc2 = C2*84.479606 ;
cdc25act = C2*1.54009 ;
wee1act = C2*15 ;
apc0 = C2*46.1461 ;
apcstar = C2*3.8539 ;
p21 = C2*3.8539 ;
**;
COMPILE EQUATIONS;
'cyclin = C1*ksynth - C1*kdest*(apcstar + p21)*cyclin -
C1*ka*cdc2*cyclin + C1*kd*cdc2cyclin ;
'cdc2cyclin = C1*ka*cdc2*cyclin - C1*kd*cdc2cyclin -
C1*kdest*(apcstar + p21)*cdc2cyclin -
C1*kwee1*wee1act*cdc2cyclin -
(C1*kwee1/factor)*(C2*wee1tot - wee1act)*cdc2cyclin +
C1*kcdc25*cdc25act*cdc2cyclinyp +
(C1*kcdc25/factor)*(C2*cdc25tot - cdc25act)*cdc2cyclinyp ;
'cdc2cyclinyp = C1*kwee1*wee1act*cdc2cyclin +
(C1*kwee1/factor)*(C2*wee1tot - wee1act)*cdc2cyclin -
C1*kcdc25*cdc25act*cdc2cyclinyp -
(C1*kcdc25/factor)*(C2*cdc25tot - cdc25act)*cdc2cyclinyp -
C1*kcak*cdc2cyclinyp + C1*kpp2c*cdc2cyclinyptp -
C1*kdest*(apcstar + p21)*cdc2cyclinyp ;
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'cdc2cyclinyptp = C1*kcak*cdc2cyclinyp -
C1*kpp2c*cdc2cyclinyptp -
C1*kcdc25*cdc25act*cdc2cyclinyptp -
(C1*kcdc25/factor)*(C2*cdc25tot - cdc25act)*cdc2cyclinyptp +
C1*kwee1*wee1act*cdc2cyclintp +
(C1*kwee1/factor)*(C2*wee1tot - wee1act)*cdc2cyclintp -
C1*kdest*(apcstar + p21)*cdc2cyclinyptp ;
'cdc2cyclintp = C1*kcdc25*cdc25act*cdc2cyclinyptp +
(C1*kcdc25/factor)*(C2*cdc25tot - cdc25act)*cdc2cyclinyptp -
C1*kwee1*wee1act*cdc2cyclintp -
(C1*kwee1/factor)*(C2*wee1tot - wee1act)*cdc2cyclintp -
C1*kdest*(apcstar + p21)*cdc2cyclintp ;
'cdc2 = C1*kd*cdc2cyclin - C1*ka*cdc2*cyclin +
C1*kdest*(apcstar + p21)*(cdc2cyclin + cdc2cyclinyp +
cdc2cyclinyptp + cdc2cyclintp) ;
'cdc25act = -C1*kcdc25off*cdc25act +
C1*kcdc25on*(C2*cdc25tot - cdc25act)*((cdc2cyclintp**#ncdc25)/
(C2*ec50cdc25**#ncdc25 + cdc2cyclintp**#ncdc25)) ;
'wee1act = C1*kwee1on*(C2*wee1tot - wee1act) -
wee1act*C1*kwee1off*((cdc2cyclintp**#nwee1)/
(C2*ec50wee1**#nwee1 + cdc2cyclintp**#nwee1)) ;
'apcstar = - C1*kapcoff*apcstar +
C1*kapcon*(C2*apctot - apcstar)*((cdc2cyclintp**#napc)/
(C2*ec50apc**#napc + cdc2cyclintp**#napc)) ;
'apc0 = C1*kapcoff*apcstar -
C1*kapcon*(C2*apctot - apcstar)*((cdc2cyclintp**#napc)/
(C2*ec50apc**#napc + cdc2cyclintp**#napc)) ;
'p21 = - C1*kp21off*p21 +
C1*kp21on*(C2*p21tot - p21)*((cdc2cyclintp**#np21)/
(C2*ec50p21**#np21 + cdc2cyclintp**#np21)) ;
**;
SETPSTREAM 1 8;
**;
SETPSTREAM 2 9;
**;
* DATA relative error estimate default 0.01;
DATA 0.1 ;
TIME CycBact ;
RANGE 345.05 ;
20 119.01 ;
40 97.085 ;
60 92.51 ;
80 85.175 ;
100 83.575 ;
120 80.4 ;
140 86.96 ;
160 86.86 ;
180 91.86 ;
200 92.44 ;
220 85.19 ;
240 88.53 ;
260 94.465 ;
280 114.77 ;
300 117.07 ;
320 125.82 ;
340 126.38 ;
360 142.12 ;
380 131.65 ;
Appendix B 257
400 147.84 ;
420 115.62 ;
440 118.81 ;
460 123.65 ;
480 130.54 ;
500 141.22 ;
520 134.5 ;
540 131.95 ;
560 145.21 ;
580 153.42 ;
600 148.16 ;
620 140.33 ;
640 140.84 ;
660 144.17 ;
680 155.25 ;
700 158.17 ;
720 167.97 ;
740 170.97 ;
760 170.87 ;
780 179.77 ;
800 174.8 ;
820 159.13 ;
840 160.6 ;
860 145.67 ;
880 143.03 ;
900 167.66 ;
920 166.83 ;
940 200.41 ;
960 197.27 ;
980 198.44 ;
1000 213.57 ;
1020 199.8 ;
1040 232.64 ;
1060 237.55 ;
1080 224.57 ;
1100 226.65 ;
1120 218.78 ;
1140 227.57 ;
1160 215.26 ;
1180 225.05 ;
1200 243.9 ;
1220 215.38 ;
1240 222.27 ;
1260 246.39 ;
1280 261.6 ;
1300 345.05 ;
**;
* Identify parameters to be varied, not more than 10;
SETVARY alpha C2 beta kp21off p21tot ;
BEGIN;
COMPILE INSTANT ;
WRITE 1=10, "PRINT STREAM NO." % ;
WRITE 1, "TIME CycBact CycBact(obs)" % ;
#COUNT=0;
**;
COMPILE PRINT;
* Output routine called during the final phase;
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#COUNT=#COUNT+1;
DO 10 FOR #2=#COUNT-1 ;
WRITE 1=10, ((E14,6)) TIME, CycBact, VOBS<0,#2> ;
WRITE 1=11, ((E14,6)) TIME, CycBact, VOBS<0,#2> ;
LABEL 10 ;
**;
SETNOFIT;
WHENEVER TIME = TOBS % CALL PRINT;
**;
BEGIN;
STOP;
Parameter estimation of the coupled drug kinetics/cell cycle
model
Parameter estimation before the washout event
*========================================================= ;
* Mohammed Isam Atari ;
*========================================================= ;
EXECUTE ;
OPEN 10 "cell.out";
OPEN 11 "cell.txt";
OPEN 12 "medium.out";
OPEN 13 "medium.txt";
OPEN 14 "H2AX.out";
OPEN 15 "H2AX.txt";
**;
SETHMAX 0.1;
* Define the Variables ;
VARIABLE Lm Hm Le He Lc Hc Ln H2AX;
* Define the Parameters ;
PARAMETER
ki ke kb kmi kmo kom kcm koc kcc kdl kdh
v0 v1 v2 v3
Vm1 Km1 Vm2 Km2
alpha 2.4375e4
BT Med Cyt Nuc
ktpt kdam
D
;
* Open file, read in and assign parameters ;
COMPILE INSTANT;
OPEN 7 "pars1wash.txt";
READ 7 kom ;
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READ 7 kcm ;
READ 7 koc ;
READ 7 kcc ;
READ 7 ki ;
READ 7 ke ;
READ 7 kb ;
READ 7 kmi ;
READ 7 kmo ;
READ 7 kdl ;
READ 7 kdh ;
READ 7 v0 ;
READ 7 v2 ;
READ 7 v3 ;
READ 7 D ;
READ 7 Vm1 ;
READ 7 Km1 ;
READ 7 Vm2 ;
READ 7 Km2 ;
READ 7 BT ;
READ 7 ktpt ;
READ 7 kdam ;
**;
* Assign Intital Conditions for Variables ;
COMPILE INITIAL;
Lm = (1+v0)*D ;
Hm = 0 ;
Le = 0 ;
He = 0 ;
Lc = 0 ;
Hc = 0 ;
Ln = 0 ;
H2AX = 0 ;
v1 = alpha*v0/(1+v0) ;
**;
COMPILE EQUATIONS;
'Lm = -(kom + kmi)*Lm + kcm*Hm + kmo*v0*Le ;
'Hm = kom*Lm -(kcm + kmi)*Hm + kmo*v0*He ;
'Le = (kmi*Lm)/v0 -(kmo + kom + ki)*Le + kcm*He +
(ke*Lc)/v1 ;
'He = (kmi*Hm)/v0 + kom*Le -(kcm + kmo)*He +
(Vm1*v3*Hc)/((v1)*(v3*Km1 + Hc)) ;
'Lc = ki*v1*Le -(ke + koc)*Lc + kcc*Hc + kdl*v2*Ln - kb*(BT - Ln)*Lc
- (Vm2*Lc)/(Km2 + Lc) ;
'Hc = koc*Lc - kcc*Hc + kdh*v2*Ln - (Vm1*v3*Hc)/(v3*Km1 + Hc)
+ (Vm2*Lc)/(Km2 + Lc) ;
'Ln = kb*Lc*(BT - Ln)/v2 - (kdl + kdh)*Ln;
'H2AX = ktpt*Ln - kdam*H2AX ;
**;
COMPILE INSTANT ;
WRITE 1=10, "PRINT STREAM NO." % ;
WRITE 1, "TIME Ln Lc Hc" % ;
WRITE 1=12, "PRINT STREAM NO." % ;
WRITE 1, "TIME Lm Hm Le He" % ;
WRITE 1=14, "PRINT STREAM NO." % ;
WRITE 1, "TIME H2AX" % ;
**;
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COMPILE PRINT;
WRITE 1=10, ((E14,6)) TIME, Ln, Lc, Hc % ;
WRITE 1=11, ((E14,6)) TIME, Ln, Lc, Hc % ;
WRITE 1=12, ((E14,6)) TIME, Lm, Hm, Le, He % ;
WRITE 1=13, ((E14,6)) TIME, Lm, Hm, Le, He % ;
WRITE 1=14, ((E14,6)) TIME, H2AX % ;
WRITE 1=15, ((E14,6)) TIME, H2AX % ;
**;
WHENEVER TIME = 0.0 + 2*1800 % CALL PRINT;
**;
BEGIN;
STOP;
Parameter estimation of the coupled model
* Coupled drug kinetics/cell cycle response TPT = 1 micromolar;
EXECUTE ;
OPEN 8 "Pstream1In.txt" ;
OPEN 9 "Pstream2In.txt" ;
OPEN 10 "CycBresults.out";
OPEN 11 "CycBresults.txt";
OPEN 12 "Cell.out";
OPEN 13 "Cell.txt";
OPEN 14 "H2AX.out";
OPEN 15 "H2AX.txt";
OPEN 16 "medium.out";
OPEN 17 "medium.txt";
**;
VARIABLE cyclin cdc2cyclin cdc2cyclinyp cdc2cyclinyptp
cdc2cyclintp cdc2 cdc25act
wee1act apcstar apc0 p21
Lm Hm Le He Lc Hc Ln H2AX;
* Define the Parameters ;
PARAMETER
ksynth kdest ka kd factor
kwee1 kcdc25
cdc2tot cdc25tot wee1tot apctot p21tot
ec50wee1 ec50cdc25 ec50apc ec50p21
kcdc25on kcdc25off kapcon kapcoff kwee1on kwee1off
kcak kpp2c C2 kp21on kp21off
alpha beta CycBact C1
ki ke kb kmi kmo kom kcm koc kcc kdl kdh
v0 v1 v2 v3
Vm1 Km1 Vm2 Km2
alphanew 2.4375e4
BT Med Cyt Nuc
ktpt kdam
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;
INTEGER #nwee1 #ncdc25 #napc #np21 #COUNT ;
* Open file, read in and assign parameters ;
COMPILE INSTANT;
OPEN 7 "pars1.txt";
READ 7 ksynth ;
READ 7 kdest ;
READ 7 ka ;
READ 7 kd ;
READ 7 factor ;
READ 7 kwee1 ;
READ 7 kcdc25 ;
READ 7 cdc2tot ;
READ 7 cdc25tot ;
READ 7 wee1tot ;
READ 7 apctot ;
READ 7 #nwee1 ;
READ 7 #ncdc25 ;
READ 7 #napc ;
READ 7 ec50wee1 ;
READ 7 ec50cdc25 ;
READ 7 ec50apc ;
READ 7 kcdc25on ;
READ 7 kcdc25off ;
READ 7 kapcon ;
READ 7 kapcoff ;
READ 7 kwee1on ;
READ 7 kwee1off ;
READ 7 kcak ;
READ 7 kpp2c ;
READ 7 kp21on ;
READ 7 #np21 ;
READ 7 ec50p21 ;
READ 7 C1 ;
READ 7 kom ;
READ 7 kcm ;
READ 7 koc ;
READ 7 kcc ;
READ 7 ki ;
READ 7 ke ;
READ 7 kb ;
READ 7 kmi ;
READ 7 kmo ;
READ 7 kdl ;
READ 7 kdh ;
READ 7 v0 ;
READ 7 v2 ;
READ 7 v3 ;
READ 7 Vm1 ;
READ 7 Km1 ;
READ 7 Vm2 ;
READ 7 Km2 ;
READ 7 BT ;
READ 7 ktpt ;
READ 7 kdam ;
READ 7 alpha ;
READ 7 beta ;
READ 7 kp21off ;
READ 7 C2 ;
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READ 7 p21tot ;
**;
COMPILE GENERAL ;
CycBact = alpha*cdc2cyclintp + beta ;
**;
* Assign intital conditions for variables ;
COMPILE INITIAL;
cyclin = C2*0.141396 ;
cdc2cyclin = C2*0.992654 ;
cdc2cyclinyp = C2*1.4763 ;
cdc2cyclinyptp = C2*11.41023 ;
cdc2cyclintp = C2*1.64121 ;
cdc2 = C2*84.479606 ;
cdc25act = C2*1.54009 ;
wee1act = C2*15 ;
apc0 = C2*46.1461 ;
apcstar = C2*3.8539 ;
p21 = C2*3.8539 ;
Lm = 5.844233E-02 ;
Hm = 4.573399E-02 ;
Le = 6.586645E-02 ;
He = 5.049545E+00 ;
Lc = 1.056672E-02 ;
Hc = 6.97E+03 ;
Ln = 1.971363E-02 ;
H2AX = 2.91 ;
v1 = alphanew*v0/(1+v0) ;
**;
COMPILE EQUATIONS;
'cyclin = C1*ksynth - C1*kdest*(apcstar + p21)*cyclin -
C1*ka*cdc2*cyclin + C1*kd*cdc2cyclin ;
'cdc2cyclin = C1*ka*cdc2*cyclin - C1*kd*cdc2cyclin -
C1*kdest*(apcstar + p21)*cdc2cyclin -
C1*kwee1*wee1act*cdc2cyclin -
(C1*kwee1/factor)*(C2*wee1tot - wee1act)*cdc2cyclin +
C1*kcdc25*cdc25act*cdc2cyclinyp +
(C1*kcdc25/factor)*(C2*cdc25tot - cdc25act)*cdc2cyclinyp ;
'cdc2cyclinyp = C1*kwee1*wee1act*cdc2cyclin +
(C1*kwee1/factor)*(C2*wee1tot - wee1act)*cdc2cyclin -
C1*kcdc25*cdc25act*cdc2cyclinyp -
(C1*kcdc25/factor)*(C2*cdc25tot - cdc25act)*cdc2cyclinyp -
C1*kcak*cdc2cyclinyp + C1*kpp2c*cdc2cyclinyptp -
C1*kdest*(apcstar + p21)*cdc2cyclinyp ;
'cdc2cyclinyptp = C1*kcak*cdc2cyclinyp -
C1*kpp2c*cdc2cyclinyptp -
C1*kcdc25*cdc25act*cdc2cyclinyptp -
(C1*kcdc25/factor)*(C2*cdc25tot - cdc25act)*cdc2cyclinyptp +
C1*kwee1*wee1act*cdc2cyclintp +
(C1*kwee1/factor)*(C2*wee1tot - wee1act)*cdc2cyclintp -
C1*kdest*(apcstar + p21)*cdc2cyclinyptp ;
'cdc2cyclintp = C1*kcdc25*cdc25act*cdc2cyclinyptp +
(C1*kcdc25/factor)*(C2*cdc25tot - cdc25act)*cdc2cyclinyptp -
C1*kwee1*wee1act*cdc2cyclintp -
(C1*kwee1/factor)*(C2*wee1tot - wee1act)*cdc2cyclintp -
C1*kdest*(apcstar + p21)*cdc2cyclintp ;
'cdc2 = C1*kd*cdc2cyclin - C1*ka*cdc2*cyclin +
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C1*kdest*(apcstar + p21)*(cdc2cyclin + cdc2cyclinyp +
cdc2cyclinyptp + cdc2cyclintp) ;
'cdc25act = -C1*kcdc25off*cdc25act +
C1*kcdc25on*(C2*cdc25tot - cdc25act)*((cdc2cyclintp**#ncdc25)/
(C2*ec50cdc25**#ncdc25 + cdc2cyclintp**#ncdc25)) ;
'wee1act = C1*kwee1on*(C2*wee1tot - wee1act) -
wee1act*C1*kwee1off*((cdc2cyclintp**#nwee1)/
(C2*ec50wee1**#nwee1 + cdc2cyclintp**#nwee1)) ;
'apcstar = - C1*kapcoff*apcstar +
C1*kapcon*(C2*apctot - apcstar)*((cdc2cyclintp**#napc)/
(C2*ec50apc**#napc + cdc2cyclintp**#napc)) ;
'apc0 = C1*kapcoff*apcstar -
C1*kapcon*(C2*apctot - apcstar)*((cdc2cyclintp**#napc)/
(C2*ec50apc**#napc + cdc2cyclintp**#napc)) ;
'p21 = - C1*kp21off*p21/(1 + kdam*H2AX) +
C1*kp21on*(C2*p21tot - p21)*((cdc2cyclintp**#np21)/
(C2*ec50p21**#np21 + cdc2cyclintp**#np21)) ;
'Lm = -(kom + kmi)*Lm + kcm*Hm + kmo*v0*Le ;
'Hm = kom*Lm -(kcm + kmi)*Hm + kmo*v0*He ;
'Le = (kmi*Lm)/v0 -(kmo + kom + ki)*Le + kcm*He +
(ke*Lc)/v1 ;
'He = (kmi*Hm)/v0 + kom*Le -(kcm + kmo)*He +
(Vm1*v3*Hc)/((v1)*(v3*Km1 + Hc)) ;
'Lc = ki*v1*Le -(ke + koc)*Lc + kcc*Hc + kdl*v2*Ln - kb*(BT - Ln)*Lc
- (Vm2*Lc)/(Km2 + Lc) ;
'Hc = koc*Lc - kcc*Hc + kdh*v2*Ln - (Vm1*v3*Hc)/(v3*Km1 + Hc)
+ (Vm2*Lc)/(Km2 + Lc) ;
'Ln = kb*Lc*(BT - Ln)/v2 - (kdl + kdh)*Ln;
'H2AX = ktpt*Ln - kdam*H2AX ;
**;
SETPSTREAM 1 8;
**;
SETPSTREAM 2 9;
**;
* DATA relative error estimate default 0.01;
DATA 0.2 ;
TIME CycBact ;
RANGE 66.2 ;
100 45.84 ;
120 48.09 ;
140 47.415 ;
160 40.76 ;
180 44.265 ;
200 40.35 ;
220 40.25 ;
240 41.19 ;
260 41.725 ;
280 39.32 ;
300 39.205 ;
320 37.78 ;
340 38.46 ;
360 38.63 ;
380 42.465 ;
400 44.06 ;
420 44.77 ;
440 38.765 ;
460 36.585 ;
480 36.48 ;
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500 36.41 ;
520 36.28 ;
540 32.495 ;
560 31.43 ;
580 34.665 ;
600 31.445 ;
620 39.95 ;
640 32.705 ;
660 41.46 ;
680 37.78 ;
700 37.13 ;
720 36.665 ;
740 38.85 ;
760 34.08 ;
780 36.3 ;
800 34.885 ;
820 34.675 ;
840 32.47 ;
860 27.225 ;
880 31.61 ;
900 30.385 ;
920 33.58 ;
940 31.985 ;
960 28.155 ;
980 25.32 ;
1000 28.315 ;
1020 32.325 ;
1040 32.315 ;
1060 37.47 ;
1080 33.83 ;
1100 35.965 ;
1120 37.545 ;
1140 36.095 ;
1160 34.005 ;
1180 32.175 ;
1200 30.405 ;
1220 23.295 ;
1240 23.905 ;
1260 25.115 ;
1280 24.065 ;
1300 24.975 ;
1320 22.775 ;
1340 24.035 ;
1360 24.54 ;
1380 26.23 ;
1400 26.99 ;
1420 44.21 ;
1440 43.805 ;
1460 39.7 ;
1480 46.37 ;
1500 45.89 ;
1520 43.035 ;
1540 47.805 ;
1560 48.91 ;
1600 66.2 ;
1620 16.62 ;
1640 15.375 ;
**;
* Identify parameters to be varied, not more than 10;
SETVARY alpha C2 beta kp21off p21tot ;
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BEGIN;
COMPILE INSTANT ;
WRITE 1=10, "PRINT STREAM NO." % ;
WRITE 1, "TIME CycBact CycBact(obs)" % ;
WRITE 1=12, "PRINT STREAM NO." % ;
WRITE 1, "TIME Ln Lc Hc" % ;
WRITE 1=14, "PRINT STREAM NO." % ;
WRITE 1, "TIME H2AX" % ;
WRITE 1=16, "PRINT STREAM NO." % ;
WRITE 1, "TIME Lm Hm Le He" % ;
#COUNT=0;
**;
COMPILE PRINT;
* Output routine called during the final phase;
#COUNT=#COUNT+1;
DO 10 FOR #2=#COUNT-1 ;
WRITE 1=10, ((E14,6)) TIME, CycBact, VOBS<0,#2> ;
WRITE 1=11, ((E14,6)) TIME, CycBact, VOBS<0,#2> ;
WRITE 1=12, ((E14,6)) TIME, Ln, Lc, Hc % ;
WRITE 1=13, ((E14,6)) TIME, Ln, Lc, Hc % ;
WRITE 1=14, ((E14,6)) TIME, H2AX % ;
WRITE 1=15, ((E14,6)) TIME, H2AX % ;
WRITE 1=16, ((E14,6)) TIME, Lm, Hm, Le, He % ;
WRITE 1=17, ((E14,6)) TIME, Lm, Hm, Le, He % ;
LABEL 10 ;
**;
SETNOFIT;
WHENEVER TIME = TOBS % CALL PRINT;
**;
BEGIN;
STOP;
